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Summary 
The aim of this PhD. thesis was to evaluate the potential of edible mushrooms as novel 
sources of natural hypocholesterolemic compounds to develop specific food products with 
cholesterol lowering properties. However, cholesterol levels are strictly regulated to maintain its 
homeostasis therefore, if it is not absorbed with the diet, the cholesterol biosynthetic pathway is 
enhanced and vice versa. Nowadays, the commonly prescribed therapeutic treatments for 
hypocholesterolemic patients are targeted toward the reduction of both cholesterol intestinal 
absorption and/or its endogenous biosynthesis. But, when hypercholesterolemia is still moderate 
the consumption of food products with cholesterol-lowering capacities are more desirable than 
drugs. The marketed food supplemented with hypocholesterolemic compounds are only inhibiting 
mechanisms for cholesterol absorption. Consequently, in this work experiments were conducted 
to design a specific food supplemented with fungal extracts able of modulating cholesterol levels 
by both strategies as pharmaceutical drugs.  
Previous reports suggested that some of the fungal hypocholesterolemic compounds 
exerted their activity via different mechanisms i.e. inhibiting the pancreatic lipase (PL) during 
digestion process or limiting the activity of the 3-hydroxy-3-methyl-glutaryl CoA reductase 
(HMGCR), the key enzyme in the cholesterol biosynthetic pathway (due to the presence of 
lovastatin) etc. However, when several mushroom extracts were tested using an in vitro digestion 
model that mimics the in vivo physiological conditions in gut, no interesting PL inhibition was 
noticed in strains that showed certain inhibitory capacity with in vitro enzymatic tests and therefore 
no further studies were performed. 
On the other hand, lovastatin was not detected in extracts of mushrooms showing high 
HMGCR inhibitory activity thus, further identification of the responsible compounds was carried 
out. Specific water soluble polysaccharides with different structures depending on the mushroom 
specie were pointed as HMGCR inhibitors. They could be extracted from mushrooms with 
traditional and advanced technologies (such as pressurized liquid extraction, PLE or supercritical 
fluid extraction, SFE) and depending on the mushroom specie, their fragments could also retain 
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their inhibitory activity at least until molecular weights of 1 KDa. When digested (in vitro) and 
applied to cell cultures resembling the enterocytic barrier (Caco2), they were detected at the 
basolateral compartment indicating that they were partly bioavailable and when the bioavailable 
fraction was applied to hepatic cell cultures (HepG2), they were able of modulating the expression 
of genes related to the cholesterol metabolism. However, the transcriptomic response was not 
directed toward a specific metabolic pathway suggesting that the changes observed in mRNAs 
profiles might be an indirect result of post-transcriptional events then, in vivo experiments were 
carried out using Lentinula edodes extracts. 
Other compounds investigated for their potentially as hypocholesterolemic molecules 
were the fungal dietary fibers (DF). DF-fractions obtained by classical and advanced methods 
such as pressurized water extraction (PWE) containing mainly β-glucans and lower levels of 
chitins and α-glucans. They were acting as scavengers of bile acids during an in vitro digestion 
model with only a slightly lower effectivity than β-glucans extracted from cereals. When applied to 
Caco2 cells they modulated a few cholesterol-related genes but differently depending on the 
studied mushroom specie. DF-fraction from Pleurotus ostreatus was selected and further tested 
to elucidate in vivo hypocholesterolemic influence. 
Fungal sterols were also studied in detail because of their structural similarity with plant 
sterols (phytosterols/phytostanols). They could be extracted from mushroom fruiting bodies and 
from their by-products by PLE and SFE although sterol yields were higher in the latter. Obtained 
fractions contained mainly ergosterol although other derivatives were also found in quantities 
specie-dependent. Ergosterol and particularly SFE extracts obtained from Agaricus bisporus 
displaced cholesterol from dietary mixed micelles (DMM) more effectively than β-sitosterol using 
an in vitro digestion model where DMMs were isolated. The mixture of ergosterol-enriched extracts 
with fungal β-glucans reduced even more the presence of cholesterol in DMMs. When applied to 
Caco2 cell cultures they modified the transcriptional pattern of genes related to the cholesterol 
metabolism and also later on, the pattern of HepG2 cells. SFE-extracts were further used for animal 
trials. 
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    In vivo studies using normo- and hypercholesterolemic mice models were carried out 
following different experimental settings depending on the mushroom extract investigated. None 
of the tested fungal extracts were able to lower significantly cholesterol levels in plasma and only 
some of them reduced triglycerides levels in liver. However, fungal sterols down-regulated genes 
involved in the cholesterol homeostasis (such as Srebf2 and Nr1h4 (FXR)) and the other mentioned 
extracts also stimulated transcriptional profiles similar to simvastatin or ezetimibe (two 
hypocholesterolemic drugs). Therefore, the three extracts were separately or pooled together into 
a high-lipid containing food matrix (simulating unhealthy dietary habits) and given in higher doses 
to mice during 4 weeks together with a high-cholesterol diet. All the extracts lowered cholesterol 
levels in serum particularly the β-glucan extracts, but the modulated transcriptomic response was 
different than the one noticed by direct administration of the extracts. This and other observations 
suggested that the hypocholesterolemic effect of mushrooms extracts could be due to post-
transcriptional changes being the observed modulations result of indirect effects. Moreover, the 
supplemented food including the mixture of the extracts showed similar hypocholesterolemic 
activities than the separate extracts indicating no positive synergies.  
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Resumen 
El objetivo de esta tesis ha sido la evaluación de hongos comestibles, como nueva fuente 
de compuestos naturales hipocolesterolemicos, para el desarrollo de productos alimenticios 
específicos con propiedades reductoras de los niveles de colesterol. Sin embargo, con el fin de 
mantener la homeostasis del colesterol los niveles del mismo se encuentran estrictamente 
regulados, de tal manera que si el colesterol no es absorbido con la dieta, la vía de síntesis 
endógena se ve reforzada y viceversa. Hoy en día, los tratamientos terapéuticos comúnmente 
prescritos, a pacientes que sufren de hipocolesterolemia, están dirigidos hacia la reducción de 
la absorción intestinal de colesterol y/o su biosíntesis endógena. Sin embargo, en casos de 
hipercolesterolemia moderada, el consumo de alimentos beneficiosos para la salud y con 
capacidad de reducir los niveles de colesterol podría  ser más adecuado que el uso de fármacos. 
La comercialización de productos alimenticios suplementados con compuestos 
hipocolesterolemicos se centran en la inhibición de los mecanismos de absorción del colesterol. 
En consecuencia, en este trabajo se detallan los experimentos llevados a cabo para diseñar un 
alimento suplementado con extractos naturales de origen fúngico, capaces de modular ambas 
estrategias, tal y como actúan las drogas farmacéuticas. 
Informes anteriores al presente trabajo sugirieron que los compuestos fúngicos 
hipocolesterolemicos  pueden ejercer dicha actividad por diversos mecanismos de acción, 
mediante la inhibición de la lipasa pancreática (PL) durante el proceso de digestión o limitando 
la actividad de la 3-hidroxi-3-metil-glutaril CoA reductasa (HMGCR), enzima clave de la 
biosíntesis de colesterol (debido a la posible presencia de lovastatina), etc…Sin embargo, la 
capacidad inhibidora de la PL que mostraron determinadas cepas de hongos tras su evaluación 
con test químicos in vitro, no mostraron ningún efecto sobre la actividad de la PL una vez 
sometidos a un modelo de digestión in vitro que simula las condiciones fisiológicas in vivo del 
intestino. Por tanto, no se realizaron estudios adicionales. 
De manera adicional, no se detectó la presencia de lovastatina en aquellos extractos de 
hongos con capacidad inhibidora de la actividad HMGCR; por tanto, se llevó a cabo la 
Summary/Resumen 
 
10 
 
identificación de los compuestos responsables de dicha actividad inhibitoria; señalándose como 
inhibidores de la HMGCR a polisacáridos solubles en agua, estructuralmente dependientes de la 
especie de hongo. La extracción de dichos polisacáridos se puede realizar mediante el uso de 
tecnologías tradicionales y avanzadas (como puede ser la extracción con líquidos presurizados, 
PLE o la extracción con fluidos supercríticos, SFE) y, dependiendo de la especie de hongo, 
distintos tipos de fragmentos conservan su actividad inhibidora, al menos hasta pesos 
moleculares de 1KDa. Un una vez digeridos (in vitro) y aplicados a cultivos celulares que 
asemejan a la barrera entérica (Caco2), se detectaron dichas estructuras en el compartimento 
basolateral indicando que, al menos parcialmente, son biodisponibles. Posteriormente, células 
hepáticas (HepG2) tratadas con dicha fracción biodisponible mostraron cierta modulación en la 
expresión de genes relacionados con el metabolismo del colesterol. Sin embargo, la respuesta 
transcriptómica no se centró de forma específica en una vía metabólica en concreto, sugiriendo 
que los cambios observados en los perfiles de ARNm pueden ser resultado indirecto de eventos 
post-transcripcionales. Por consiguiente, se evaluó el efecto de los extractos obtenidos a partir 
de L. edodes en modelos experimentales in vivo. 
Las fibras dietéticas (DF) de origen fúngico resultan un grupo ampliamente investigado 
debido a su potencial hipocolesterolemico. Las fracciones DF obtenidas mediante el uso de 
métodos de extracción tradicionales y avanzados, como extracción con agua presurizada (PWE), 
contienen principalmente β-glucanos y, en menor proporción, quitinas y α-glucanos. Dichas 
fracciones actuaron como captadores de ácidos biliares tras ser sometidos a un modelo de 
digestión in vitro con tan sólo una ligera reducción respecto a la efectividad mostrada por β-
glucanos extraídos de cereales. Los extractos aplicados a las células Caco2 modularon ciertos 
genes relacionados con el metabolismo del colesterol aunque este efecto resultó ser diferente 
dependiendo de la especie estudiada. La fracción DF de P. ostreatus se seleccionó y 
posteriormente se evaluó su influencia hipocolesterolemica en condiciones in vivo. 
A su vez, se llevó a cabo un estudio en detalle de los esteroles de origen fúngico debido 
a su similitud estructural con los esteroles vegetales (fitosteroles/fitostanoles). Dichos compuestos 
se pudieron extraer tanto del cuerpo fructífero así como de los productos de desecho de los 
Summary/Resumen 
 
11 
 
hongos mediante el empleo de tecnologías de extracción como PLE y SFE, aunque esta última 
técnica permitió elevados rendimientos en cuanto a porcentaje de esteroles referidos a extracto. 
Las fracciones obtenidas contuvieron principalmente ergosterol seguido de derivados del mismo 
en cantidades que dependieron de la especie de partida. Las micelas mixtas de digestión (DMM) 
aisladas del resto de componentes de la digestión in vitro de extractos obtenidos por tecnología 
SFE (así como ergosterol), mostraron capacidad de desplazamiento el colesterol de dichas 
micelas de una forma más efectiva que el β-sitosterol. La mezcla de extractos enriquecidos en 
ergosterol con  β-glucans de origen fúngico redujo aún más la presencia de colesterol en las 
DMM. Los extractos enriquecidos en esteroles fúngicos demostraron capacidad moduladora en 
el patrón de trascripción de genes relacionados con el metabolismo del colesterol en células 
Caco2, extendiendo su efecto en células hepáticas (HepG2). Las fracciones obtenidas mediante 
el uso de tecnología SFE fueron seleccionadas para los ensayos con animales. 
 
Posteriormente, se llevaron a cabo estudios in vivo con modelos de ratones normo- e 
hipercolesterolemicos, siguiendo diferentes parámetros experimentales en función del extracto 
de hongo. Ninguno de los extractos de hongos analizados fueron capaces de disminuir los niveles 
de colesterol en el plasma de manera significativa y sólo algunos de ellos redujeron los niveles 
de triglicéridos en el hígado. Sin embargo, los esteroles de origen fúngico fueron capaces de 
disminuir la trascripción de genes involucrados en la homeostasis del colesterol (como Srebf2 y 
Nr1h4 (FXR)); en cuanto a los otros extractos mencionados dieron lugar a perfiles de transcripción 
similares a aquellos obtenidos tras la administración de simvastatina y ezetimibe (dos fármacos 
hipocolesterolemicos). Por lo tanto, los tres extractos por separado y la mezcla de los mismos se 
adicionaron a una matriz alimentaria de alto contenido lipídico (simulando hábitos alimentarios 
poco saludables) y se administraron a los ratones en dosis superiores a las utilizadas en los 
ensayos in vivo, anteriormente mencionados, durante 4 semanas junto con una dieta alta en 
colesterol. Todos los extractos y en especial los extractos de  β-glucanos, redujeron 
significativamente los niveles de colesterol en suero sin embargo, la modulación en la respuesta 
transcriptómica fue diferente a la obtenida tras la aplicación directa de éstos. A partir de éstas, y 
de otras observaciones detalladas en la presente memoria, se sugirió que el efecto 
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hipocolesterolemico de los extractos de hongos podría deberse a cambios post-
transcripcionales, siendo las modulaciones génicas observadas resultado de efectos indirectos. 
Sumando a esto, el producto alimenticio suplementado con la mezcla de los tres extractos mostró 
efectos hipocolesterolémicos similares a cada una de las fracciones de manera individual, 
indicando la ausencia de sinergias positivas. 
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Although cardiovascular diseases (CVDs) incidence is decreasing over the last decades 
due to medical advances and advise, they are still the second leading cause of premature death 
in Western world after cancer (Figure 1)  [1, 2].   
CVD risks are influenced by genetic factors such as specific tendencies to obesity, 
hypertension, etc., gender or age however, many risk factors are also modulated by life style 
habits such as smoking, sedentary/sporting or in/adequate diets [3] and this is the reason that 
CVDs are considered as multifactorial diseases.  
 
Figure 1. Mortality trends of vascular disease of males and females in a range of age 35-69 years (Spain). 
Source: www.mortality-trends.org. 
The decreasing CVD tendency might be partially due to the combined interest of 
physicians, nutritionists and food scientists. Already for many years, health authorities are 
reinforcing efforts to inform and advice people about what CVD are, their main symptoms, their 
health consequences and the way to decrease the risk of suffering them [2, 4]. Moreover, food 
scientists are focusing their studies on the precise cause and influence of those CVD risks in a 
`CVD-high risk population´ in order to maintain a healthy life, avoiding critical problems such as 
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heart attacks or coronary thrombosis.  In these terms, one of the most interesting scientific area is 
the development of food supplemented by bioactive compounds from natural sources providing 
health benefits such as hypocholesterolemic effects, despite its own nutritional value. In fact, the 
food industry is exploring the possibility of increasing components in the diet with cholesterol-
lowering effects and nowadays there are already marketed products with EFSA, FDA, FOSHU etc. 
approved health claims [5-7]. 
All the marketed products claiming a reduction in the cholesterol levels in serum are able 
to perform their beneficial effect by reducing cholesterol absorption. However, it has been shown 
that in subjects who were administered some of them (depending on genetic polymorphisms), the 
cholesterol biosynthetic pathway was stimulated compared with control subjects  [4]. Thus, in 
order to design a novel hypocholesterolemic food, it could be convenient to combine inhibitors of 
the cholesterol absorption with inhibitors of the cholesterol synthesis to increase the product 
efficiency. 
 
I. Metabolism of cholesterol 
Cholesterol is a lipid-like molecule present in all vertebrates.  The relative amphiphilic 
character of this sterol makes it an essential compound for the biological membranes. Cholesterol, 
together with phospholipids, modulate the fluidity of the membrane influencing transport through 
membranes, permeability, and configuration of membrane proteins or enzyme activities. 
Furthermore, cholesterol is involved in many metabolic pathways since it is a precursor of a wide 
range of biological molecules such as bile acids (i.e. cholic acid), steroids hormones (i.e. 
testosterone) and lipophilic vitamins (i.e. vitamin D3) [8]. This sterol is synthetized mainly in the 
liver, besides other organs such as adrenals glands, intestine or ovaries. But, it can also be 
incorporated from the diet after the digestion process. 
Well-balanced mechanisms of cholesterol synthesis, bile acids catabolism, cholesterol 
intake and excretion through feces will maintain healthy stable values of cholesterol in serum 
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(homeostasis). Until few years ago, liver was considered the main control center of cholesterol 
homeostasis however, more recent studies pointed intestine as a tissue highly involved in the 
regulation of plasma cholesterol levels and homeostasis [9-11]. 
I.1. Exogenous cholesterol absorption 
The exogenous cholesterol is coming from 3 different sources: diet, bile and intestinal 
epithelial sloughing. In diets of people from industrialized areas the average daily intake is 
approximately 300 – 500 mg. Bile provides 800 – 1200 mg cholesterol per day to the intraluminal 
pool. The turnover of intestinal mucosal epithelium is the third source of intraluminal cholesterol, 
and it is estimated to contribute with 300 mg cholesterol per day [12, 13]. 
I.1.1. Molecular events occurring during cholesterol intake 
Although food digestion in humans starts in mouth with the mechanical chewing and 
starch degradation by salivary enzymes (mastication process), fatty contain remains undigested 
until it reaches the stomach (only in case of babies, lingual lipase plays an important role in the 
oral lipid degradation). Gastric digestion is mainly oriented toward protein degradation however, 
some lipid-degraded enzymes are also active at this step. Afterwards, the main lipid degradation 
takes place at the beginning of the intestine where cholesterol and rest of lipid molecules are 
micellated prior to their assimilation [14].  
So, hydrophobic molecules i.e cholesterol once they arrive to the intestine, and in order 
to be available for the enterocyte brush border before the absorption step, they should firstly 
undergo the a few transitions such as emulsification and solubilization.  
I.1.1.1. Partial fat digestion and emulsification in the stomach 
At the stomach, the presence of gastric acids reduce the pH until approx. 2 generating 
a special environment where some lipolytic enzymes such as lingual and gastric lipases, are 
activated. These enzymes are capable of breaking down some ester linkages of tri-, di- or 
monoacylglycerols. The generated free fatty acids in the presence of co-lipases produce an 
optimal emulsification of fat-like compounds and the rest of partially degraded proteins and 
carbohydrates becoming the “gastric bolus”. However, the activity of those enzymes is low 
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therefore, most of lipid digestion process take place in the intestine. The gastric bolus is delivered 
by peristaltic movements to the first part of the gut, the duodenum. 
I.1.1.2. Micellar solubilization (micellar structure formation) in the duodenum  
Further on along the intestinal track, the presence of lipids in the duodenum (the small 
intestine area nearest to the stomach) stimulates the secretion of taurocholic and deoxycholic salts 
(bile acids), phosphatidylcholine and cholesterol from the gall bladder and lipases/co-lipases from 
from the pancreas. The real fat digestion take place in duodenal lumen where cholesterol and lipid 
compounds from diet and desquamated cells together with the secreted fluids, form small 
emulsified particles. The hydrolytic activity of pancreatic lipase, phospholipase A2 and cholesterol 
esterase transform the emulsified particles in a series of colloidal structures including emulsion 
droplets, vesicles, micelles and dietary mixed micelles (DMM) [15]. Lipophilic compounds are 
absorbed by intestinal cells (enterocytes) only if they are inside or forming part of the latter 
structures. The micellated cholesterol molecule should pass the mucoid barrier of enterocytes and 
enter by protein binding inside the cell. Then, it will be further transformed, processed and 
immediately transported to lymph. 
I.1.2. Molecular events occurring during cholesterol absorption 
Most of the micellated lipid-like compounds are incorporated into the organism through 
the second part of small intestine (jejunum), except bile acids that can be absorbed also along 
ileum´s area [16]. Once DMMs diffused across the unstirred mucous layer of enterocyte brush 
border-membrane, the absorption process of the lipid-like molecules will take place.  
I.1.2.1. Lipid uptake through enterocyte membrane (Figure 2) 
Each compound integrated in the DMMs i.e. fatty acid, cholesterol, lysophosphatidic acid 
(LPA) acid or monoacylglycerols (MGA), request a particular transport mechanism through the 
membrane. For instance, part of the bile acids are absorbed by passive diffusion when reaching 
the upper intestine but, most of them (95%) are incorporated through the ileal enterocytes by an 
apical sodium-dependent bile acid transporter (ABTS) [16, 17]. LPA as well as MGA can cross  
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the 
membrane 
by 
Figure 2. Fat digestion and absorption pathway. BA: bile acids, CL: cholesterol, TAG: triacylglycerol, PL: phospholipids, FA: fatty acids, MAG: 
monoacylglycerols, LPA: lysophosphatidic acid, CE: cholesterol esters, CoA: coenzyme A, acylCoA: acyl coenzyme A, PA: phosphatidic acid, DAG: 
diacylglycerol, ABCG5, ABCG8 and ABCA1: ABC membrane transporters, NPC1L1: Niemann-Pick C1-like protein, SOAT: Sterol-O 
acetyltransferase, MTTP: microsomal triglyceride transfer protein large subunit, DAGT: diacylglycerol O-acyltransferase, ApoB48: apolipoprotein B 
and ApoA1: apolipoprotein A-I. 
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passive diffusion but,  fatty acids need the aminotransferase FABPpm (plasma membrane fatty 
acid binding protein) and several scavenging membrane-receptors such as      SR-B1 and CD36 
to enter into the cytoplasm [16, 18].  
SR-B1 scavenger receptor (encoded by SCARB1 gen in humans) is mainly located at 
both apical and basolateral membranes [11, 19] of adrenals glands, hepatocytes and enterocytes. 
This receptor is involved in the regulation of the endocrine metabolism, vitamin absorption or bile 
secretion.  It plays a role in the cholesterol transport through membranes as a receptor of           
HDL-cholesterol but not in the small intestine absorption context [19, 20]. SR-B1 transport allows 
a passive bi-directional cholesterol flux depending of concentration gradients [21] pointing SR-B1 
as an important modulator of reverse cholesterol transport (RCT) (described later) [19]. However, 
although SR-B1 contribute to enterocytic lumen cholesterol absorption, recent studies 
demonstrated that Niemann-Pick C1-like protein (NPC1L1) is the main sterol transporter from the 
intestinal lumen to the enterocyte cytoplasm, being imperative for non-esterified cholesterol 
absorption [22].  
NPC1L1 is involved in this transmembrane sterol efflux due to a sterol-sensing domain 
(SSD) and it is co-localized at the cellular and intracellular vesicular membranes [23]. The 
distribution of non-esterified cholesterol determines the main location of NPC1L1 protein, at low 
intracellular amounts, NPC1L1 protein will be mostly dispose in the brush-border enterocyte 
membrane and it will be translocate inside the cell at high levels of non-esterified cholesterol [24]. 
In human, NPC1L1 genes are not only expressed in enterocytes of small intestine but also in liver 
where they are expressed in large amounts. According to Dikkers and Tietge (2010) [19] 
suggestions, human hepatocytic NPC1L1 protein is located at the canalicular membrane  
facilitating the uptake of newly secreted biliary cholesterol and therefore, showing a similar role 
that intestinal NPC1L1. Transcriptional regulation of NPC1L1 is not yet elucidated but, it seems to 
be influenced by sterol regulatory element-binding protein or SREBP2 (encoded by SREBF2 gene 
in humans) that are sensors activating different answers depending on the intracellular amounts 
of cholesterol. At low cholesterol levels, SCAP (integral membrane protein) goes along with 
SREBP2 from endoplasmic reticulum (ER) to Golgi body (GB) for subsequent processing and 
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activation. On contrary, at high or enough cholesterol levels SCAP-SREBP2 complex is retained 
by INSIG proteins (Insulin induced gene 1 protein located in ER membrane) to avoid SREBP2 
maturation impairing its transcription [25]. Moreover, other reports pointed PPARδ (peroxisome-
proliferator-activated receptor δ) as another NPC1L1 modulator since down-regulation of the 
cholesterol transporter has been induced by PPARδ  activation in mice [26]. 
Intracellular non-esterified cholesterol concentrations could also be modulated by              
3 ATP-binding cassette (ABC) transporters, ABCG5/ABCG8 and ABCA1, located respectively at 
apical and basolateral enterocyte sides. ABCG5 and ABCG8 proteins, expressed in liver and 
small intestine, are involved in the reverse cholesterol transport (RCT) of sterols, from intracellular 
environment to lumen. Independent expression of both genes is necessary for the proper function 
of this heterodimer [27]. Over-expression of ABCG5/8 heterodimer increases non-esterified 
cholesterol excretion to the lumen reducing its internal concentration and consequently inducing 
activation of cholesterol synthesis rate [28]. In small intestine, the ABCG5/8 gene expression 
seems to be regulated by a LXR-dependent member of nuclear receptor family named RXR 
(retinoid X receptor) [27-29] while in liver, the heterodimer is directly modulated by LXR [30]. 
Apparently, the latter receptor along with PPARδ are also modulators of the ABCA1 expression 
[15, 27]. ABCA1 is a transport protein directly involved in excretion of exceeding non-esterified 
cholesterol into HDL. LXR agonist administration or high cholesterol concentrations in the cytosol 
stimulated a direct effect on the transcriptional modulation of these transport proteins although its 
specific regulatory mechanisms remains still unclear. A protein-protein interaction with another 
transcription factor affecting the transcription rate of the ABC proteins have been hypothesized 
[31]. 
I.1.2.2. Intracellular cholesterol transformation and enterocyte secretion 
Once non-esterified cholesterol reaches the cytoplasm and after esterification by 
transferase proteins, more than a half of these molecules are assembled in pre-chylomicrons and 
further transformed into chylomicrons through an ER and GB biosynthetic pathway. Then, the 
formed structures are secreted from the basolateral membrane of enterocytes into the lymph 
system and blood stream. 
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ACAT vs SOAT controversy (AvS) 
 
Due to confusions noticed in several publications, it is worthy to define the 
specific role of two widely mentioned enzymes involved in the transferring of acyl groups 
within the cholesterol metabolism. Acetyl-Coenzime A transferase (ACAT) and Sterol O-
acyltransferase (SOAT) are two enzymes belonging to the acyltransferases family 
however, they do not catalyze the same reaction (Table 1). These enzymes are encoded 
by genes located in different chromosomes.  
Table 1. Chemical reaction as well as metabolism pathway step and cellular gene location of ACAT 
and SOAT enzymes involved in cholesterol metabolism. 
   ACAT/SOAT are involucrate in   
 
  Cholesterol 
synthesis 
Cholesterol 
absorption 
 
 Reaction 
 Pre-
HMGCR 
Post-
HMGCR 
Small 
intestine  
 Cellular gene 
location 
ACAT 
     
 yes no no  Mitochondrion 
SOAT 
 
 
no yes yes 
 
Endoplasmic 
reticle 
 
ACAT isoforms (ACAT1/ACAT2) are responsible of the reversible formation of 
acetoacetyl-CoA from two molecules of acetyl-CoA. The ACAT1 and ACAT2 genes are 
respectively located in chromosome 11 (11q22.3) and chromosome 6 (6q25.3) [32, 33]. 
However, SOAT isoforms (SOAT1/SOAT2) catalyze the formation of fatty acid-cholesterol 
esters from cholesterol and acyl-CoA molecules and are encoded by two genes located 
respectively in loci 1q25.2 and 12q13.13 [34, 35].  
Therefore, in those mentioned works where ACAT is wrongly referred as SOAT, 
a personal advice (AvS superscript mark) was added pointing attention where required.  
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ACAT2(AvS)   isoform is an integral membrane protein mainly expressed in small intestine 
and liver responsible of cholesterol esterification. ACAT2(AvS)   decreased cytoplasmic amounts of 
non-esterified cholesterol promoting its integration into the ER pre-chylomicrons and modulating 
the cholesterol transmembrane absorption rate from intestinal lumen [36]. It also plays an 
important role maintaining the dynamic equilibrium (homeostasis) between free-cholesterol and 
esterified-cholesterol [37]. More than 50% of sterols esterification within the enterocytes is carried 
out by ACAT2(AvS) with a higher affinity for cholesterol esterification rather than other non-
cholesterol sterols.  
The internal ER triglycerides re-assemblage is carried out by several enzymes such as 
lysophosphatidate acyltransferase (AGPAT), phosphatidate phosphatase (LPAP), 2-acylglycerol 
O-acyltransferase 2 (MGAT2) and diacylglycerol O-acyltransferase 1 (DGAT1). Then, esterified-
cholesterol is also packed by the microsomal triglyceride transfer protein (MTTP) and the 
apolipoprotein B-48 (an isoform derived from APOB gene characteristic of enterocytes).  MTTP 
and APOB-48 proteins constitute an active heterodimeric complex joined by ionic interactions with 
a particular feedback assembly and secretion system i.e. the longer the APOB-48 subunit is, the 
lower joining capacity with MTTP is noticed and less APOB-48 is secreted. Therefore, the APOB48-
MTTP binding process plays an important role in lipoprotein biogenesis [38-40].  
The combined regulatory effect of NPC1L1, ABCA1, ABCG5/8 and ACAT2(AvS) activities 
play a critical role in modulating the amount of esterified cholesterol that will be integrated in the 
prechylomicrons with the assistance of the apolipoporotein B48 (ApoB48), the microsomal 
triglyceride transfer protein (MTTP) and the diacylglicerol-o-acyltransferase (DGAT1/2) [41]. 
Once prechylomicrom structure is assembled, it is further transformed into chylomicron 
in the GB and excreted by exocytosis into the lymph system through enterocyte basolateral 
membrane. On the other hand, the non-esterified cholesterol remaining in the cytoplasm could 
bind to APOA1 protein for a further transport to the lymphatic vessels leading to nascent HDL 
lipoproteins. Thus, HDL as well as chylomicroms are released free into the blood stream and 
transported to the liver and peripheral organs such as adrenal glands [26]. 
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I.2. Endogenous cholesterol synthesis 
Total blood stream cholesterol levels are not only modulated by exogenous cholesterol 
absorption but also by cholesterol endogenous synthesis. Several structures are involucrated in 
de novo cholesterol synthesis i.e. enterocytes, adrenal glands, ovaries or testicles but, mostly it is 
generated by hepatic cells. In fact, liver´s main role is the production of the bile salts from 
cholesterol as constitutive compounds of biliary fluids needed for the digestion processes while 
the cholesterol synthetized in adrenals glands or intestine is used respectively as hormone 
precursor and cholesterolemia modulator [26]. Cholesterol biosynthesis is carry out by a 
combination of mevanolate and steroid biosynthetic pathways. After more than two tens of 
chemical changes, acetyl-coenzyme A (Acetyl-CoA) (considered as initial precursor)  promotes 
the synthesis of a widely range of compounds, including cholesterol, by i.e. oxidation, reduction, 
decarboxylation or transfer molecules reactions (Figure 3) [42]. 
I.2.1. Molecular events occurring during cholesterol synthesis 
The 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) is considered the key 
enzyme of cholesterol synthesis although the activities of many enzymes involved in the 
biosynthetic pathway such as ACAT2, hydroxymethylglutaryl-CoA synthase (HMGCS), Delta24-
sterol reductase (DHCR24), farnesyl-diphosphate farnesyltransferase (FDFT1/SQS) or                      
7-dehydrocholesterol reductase (DHCR7), are susceptible of modulation. Recently, Gill et al 
(2011) suggested that squalene monoxygenase (SQLE) might be the second critical modulatory 
point despite its lower specificity within the cholesterol metabolism compared to HMGCR (after in 
vitro experiments) [43]. In fact, several natural compounds with cholesterol lowering effects such 
as resveratrol and gallocatechins from red wine [44], or  theasinensin A  [45]  from green tea were 
described as SQLE inhibitors.  
Nowadays, the SQS is also gaining attention as a potential stop-point of cholesterol 
synthesis since it is involved in the transformation of farnesyl pyrophosphate into squalene, being 
the first specific reaction at the branching point between sterol and non-sterol biosynthesis. SQS 
transcriptional product and protein are modulated by cholesterol since low levels of this sterol 
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activate the SQS promoter by sterol regulatory element binding proteins (mostly SREBP2). On the 
contrary, SQS mRNA concentration decreases as response of cholesterol excess. 
 
 
Figure 3. Cholesterol synthesis pathway from glycolysis product  acetyl coenzyme A and acetoacetyl 
coenzyme A. Ac-CoA: Acetyl coenzyme A; AcAc-CoA: Acetoacetyl coenzyme A; CoA: coenzyme A;            
HMG-CoA: 3-Hydroxy-3-methylglutaryl-CoA; ; A: Cholesta-7,24-dien-3β-ol; B: Cholesta-8-en-3β-ol;               
C: 7-Dehydro-desmosterol; D: Lathosterol; E: Desmosterol; F: 7-Dehydrocholesterol; ACAT2: acetyl-CoA 
acetyltransferase 2; HMGCS: hydroxymethylglutaryl-CoA synthase; HMGCR: 3-hydroxy-3-methylglutaryl 
coenzyme A reductase; SQS: farnesyl-diphosphate farnesyltransferase or squalene synthetase;             
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SQLE: squalene monooxygenase; DHCR24: delta24-sterol reductase; DHCR7: 7-dehydrocholesterol 
reductase; SOAT: Sterol O-acyltransferase. 
SQLE is a monoxygenase (also named squalene epoxidase) that catalyzes the next step 
after squalene transformation by SQS, a crucial oxygenation procees yielding squalene                  
2,3-epoxide (Figure 3). Modulation of SQLE activity seems also cholesterol-dependent and 
apparently regulation is mediated by proteasome activity [43].  In vitro studies indicated that SQLE 
activity is controlled at post-transcriptional level through its N-terminal region (100 amino acids 
fragment).  In the presence of high cholesterol levels, this regulatory domain is separated from the 
catalytic region by ubiquitin-proteosome activity. SQLE ubiquitylation is carried out by a 
membrane-associated ring finger (C3HC4) 6, MARCH6 (in humans it is also named DOA10, 
MARCH-VI, RNF176 or TEB4). Higher amounts of MARCH6 were associated with low SQLE 
transcriptional rates. However, MARCH6 is not transcriptionally regulated by cholesterol levels 
therefore, at the present, the precisely mechanism inducing SQLE degradation by cholesterol is 
still unclear [43]. Other studies suggested that both altered membrane conditions and cholesterol 
interactions could affect SQLE transcriptional modulation [25, 46].  
Since HMGCR was firstly purified in ‘70s by Marvin Siperstein´s laboratory many studies 
have been carried out increasing the knowledge about the molecular biology of the enzyme, 
mechanisms of action and control points [47]. The HMGCR includes seven domains inserted in 
ER membrane with an active carboxyl chain located at the cytosol. HMGCR is ubiquitously 
expressed i.e. immune (white blood cells), nervous, muscle, small intestine or reproductive (ovary 
cells) human tissues [48]. HMGCR transcription and degradation depends of a sterol/non-sterol 
feedback regulation but not directly controlled by cholesterol molecule. Under cholesterol 
depleted conditions, SREBP-SCAP complex is formed in ER membrane (without any INSIG 
interaction), then it is transported to GB where SREBP is activated by proteolytic events facilitating 
its translocation into the nucleus to activate HMGCR transcription (Figure 4a). On the contrary, in 
excess cholesterol sterol conditions, high amount of oxysterols are synthetized by the 
mitochondrial sterol 27-hydroxylase (CYP27A) and several mechanisms decreasing HMGCR 
transcriptional rates are activated [49].  A high oxysterols concentration is also reached by intake 
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of cholesterol-enriched food stored for a long time or submitted to heat treatments [50]. The 
HMGCR regulatory mechanisms could be classified in INSIG-dependent (modulating at 
transcriptional and post-transcriptional levels), or INSIG-independent.  
INSIG-dependent HMGCR regulation mechanisms (figure 4b): 
- INSIG can disrupt SREBP activation by binding to SCAP when high sterol 
concentrations are noticed in the cytosol. Once INSIG-SCAP complex is formed, SCAP 
is structurally altered impairing the SREBP recognition and stopping the assembly of 
SREBP-SCAP complex for his further transport from ER to AB. In consequence, SREBP 
is not translocated to the nucleus and HMGCR transcription is inactivated [11, 47].  
- Under similar conditions, INSIG can also binds to the N-terminal region of HMGCR and 
conjugate it with ubiquitin. Ubiquitation is carried out by gp78 (membrane-bound 
ubiquitin E3 ligase) assisted by Ubc7 (an E2 ubiquitin conjugating enzyme) providing 
active ubiquitins and a few other enzymes. Then, ubiquitinated HMGCR is rejected to 
cytosol and subsequently proteasome-degraded with the participation of p97/VCP 
(ATPase associate to membrane). However, the presence of high levels of sterols is not 
mandatory for the ubiquitination process but its stimulate HMGCR degradation by 
enhancing INSIG-HMCR bindings  [47]. 
 
INSIG-independent HMGCR regulation mechanisms (figure 4b): 
- HMGCR activity could be also modulated in situations of cellular stress (low ATP levels) 
by AMPkinase (AMP-activated protein kinase). In this case, HMGCR is inactivated by 
a serine phosphorylation due to the AMPkinase activity. It is a reversible reaction and 
HMGCR can also be activated by a protein phosphatase 2A (PP2A)  [47, 51]. 
- Non-sterol isoprenoids might also modulate HMGCR translation by a  mechanism still 
unclear Burg et al. (2011) [47].   
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I.3. Molecular events occurring during cholesterol excretion 
For several decades, classical reverse cholesterol transport (RCT) have been considered 
the main mechanism to eliminate cholesterol however, recent studies suggest an alternative 
pathway, the so called transintestinal cholesterol excretion (TICE) [11]. 
RCT is a derivative branch of the hepatobiliary pathway. Lipoproteins such as HDL or 
LDL makes available cholesterol for hepatic absorption as esterified or non-esterified molecules. 
Esterified cholesterol is transformed by the hepatic cholesteryl ester hydrolase (NCEH1) into the 
non-esterified form after hydrolysis of the ester linkage. Thus, the generated forms are directly 
excreted through the ABCG8/5 heterodimer protein or transformed into bile salts [52]. CYP7A1 
(cholesterol 7alpha-monooxygenase) is the enzyme responsible for cholesterol transformation into 
primary bile salts (cholic and chenodeoxycholic acid) within the neutral bile acids pathway in liver. 
Synthetized bile salts are secreted to bile canaliculus by the bile salt export pump (BSEP) or the 
multidrug resistance-associated protein 2 (MRP2) and become part of bile fluids. Recent in vivo 
studies have suggested the involvement of other cholesterol transporters such as NPC1L1 in RCT. 
According to Temel et al (2007)[53] overexpression of NPC1L1 in transgenic mice resulted in a 
10-20 fold decrease in biliary cholesterol concentration. Dikkers and Tietge (2010) [19] noticed a 
90% decrease in biliary cholesterol in knockout NPC2 subjects and in both cases no quantitative 
changes in bile acids or phospholipids bile content were observed. The role of NPC1L1 in biliary 
cholesterol excretion is not yet elucidated but, it might involve adjustments in cholesterol balance 
to avoid excessive loss of the metabolite through the intestinal track. 
TICE have been suggested as an alternative cholesterol excretion mechanism where the 
sterol is directly eliminated from blood through the intestinal mucosa and excreted via feces [11]. 
The hypothesis was drawn after the unexpected results obtained by several authors that noticed 
an unwarranted balance between cholesterol inputs and outputs in mouse models. They showed 
a higher amount of fecal cholesterol than the sum of dietary intake and biliary secretion [54] or an 
unaltered cholesterol excretion rate in knockout NPC1L1 mice with a decreasing of 90% biliary 
excretion [55]. 
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Figure 4a. Molecular regulatory pathway of HMGCR transcription under low intracellular cholesterol levels. 
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Figure 4b. Molecular regulatory pathway of HMGCR transcription under high intracellular cholesterol levels. 
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These results questioned the complete RTC classical concept [56] as well as the 
contribution of biliary or non-biliary cholesterol to its RCT excretion [57].  Although the involvement 
of several membrane transports in TICE have been studied (i.e. SR-B1 [58], NPC1L1 [59], ApoA1 
[60], LDLR or ABCG5/8 [61]), it is still unknown whether  TICE is carried out through the basolateral 
or apical transporters  or whether HDLs are involved [62] therefore, the mechanism is not yet 
elucidated. There is scientific controversy about the importance of TICE, some authors suggest 
that it could be only a compensatory cholesterol excretion mechanism in case of biliary cholesterol 
depletion but, other authors pointed it as the main mechanism in cholesterol excretion. Van der 
Velde et al (2007, 2010) estimated TICE contribution as 70 and 30% of total cholesterol excretion 
respectively in mice and humans [54, 62].  
I.4. Maintenance of cholesterol transport 
To ensure a dynamic blood-tissue cholesterol transport and to avoid related diseases, 
rates of cholesterol absorption, synthesis and excretion should be balanced. Thus, an effective 
communication mainly between liver and small intestine (also adrenals glands) is necessary. HDL, 
IDL, LDL and VLDL are the connecting structures responsible for transporting of cholesterol 
molecules through the blood stream from one tissue to another until they are detected by cellular 
membrane receptors such as SR-B1 for HDL or LDLr (LDL-receptor) for the latter two.  
After the enterocyte absorption process, the non-esterified cholesterol eliminated by 
ABCA1 through the basolateral membrane is bound to apoA-1 generating nascent-HDL and the 
esterified cholesterol is similarly assembled with apoB-48 in ER synthetized prechylomicrons 
further transformed into chylomicrons in GA and excreted by exocytosis to intracellular space. 
Therefore, both structures become cholesterol transporters and they distribute it via the blood 
stream to the rest of the organism.  
Nascent HDL is transformed into mature HDL by accumulation of non-esterified 
cholesterol molecules secreted by hepatocyte and enterocyte ABCA1 protein (also by ABCG1 
transporter in gland adrenal cells). Once mature HDLs are formed, some cholesterol molecules 
are esterified by action of lecithin—cholesterol acyltransferase (LCAT) along it blood transport. 
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Esterified and non-esterified cholesterol is detected by the SR-B1 located in the basolateral 
membrane of cells from liver, small intestine or gland adrenals allowing the incorporation of 
esterified cholesterol inside the cell. Intracellular esterified cholesterol is transformed into non-
esterified cholesterol (SOAT action) and HDL is turned into LDL. The non-esterified cholesterol 
can be used for bile salts synthesis and their further intestinal secretion by BSEP or to be directly 
excreted via ABCA1 (basolateral membrane) and ABCG5/ABCG8 (apical membrane) activity. In 
turn, ejected non-esterified cholesterol again could be attached to nascent HDL to create mature 
HDL and continue with cholesterol transport. 
LDL molecules are recognized by liver, intestine and gland adrenal LDLR as esterified 
cholesterol suppliers. LDL particles can be generated not only by VLDL transformation (by SR-B1 
activity) but also by addition of esterified cholesterol to apoB-100 (apolipoprotein isoform 
characteristic of hepatocytes) leading very low density lipoproteins (VLDL). These structures are 
secreted to blood stream by hepatocytes.   VLDL lipids are used by the muscle and peripheral 
tissues as they pass through the blood stream generating IDL and LDL by lipoprotein lipases 
activity (LPL). Moreover, esterified cholesterol of chylomicron structures is also recognized by 
LDLR providing to the hepatocyte those cholesterol molecules assembled in enterocytic ER after 
digestion process.  
The difficult cholesterol biosynthesis enginery, the complexity of ABCA1, ABCG5/8, SR-
B1 and LDLR activities and the multifactorial regulation system make the control of cholesterol 
metabolism a large challenge for the scientific community. Particularly because some of the 
involved compounds are also intermediates of other metabolic pathways i.e LXR modulates 
ABCG5/8 activity but also DIO1, a selenoprotein involved in the thyroid hormone metabolism. 
However, these facts are also making it a flexible system that could be modulate from different 
critical points.   
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II. Strategies to lower serum cholesterol 
Moderate to severe hypercholesterolemia is usually treated with several drugs acting as 
inhibitors of endogenous cholesterol biosynthesis or impairing exogenous cholesterol absorption. 
These pharmacological compounds lower cholesterol levels in serum following different 
mechanisms of actions.  
Similarly, many natural compounds are able of performing the same effect than those 
drugs although for some, more studies are needed because so far the experiments  were only 
carried out using in vivo test. Drugs and natural extracts might follow several potential cholesterol-
lowering strategies. 
II.1. Inhibitors of the pancreatic lipase 
At the present, the pancreatic lipase (PL) inhibitor more frequently consumed is 
tetrahydrolipstatin (commercially named orlistat), a natural compound from Streptomyces 
toxytricini. Orlistat is acting by binding to a serine located in the active site preventing the lipase 
activity. It is widely accepted by physitians but induced unpleasant gastrointestinal side-effects 
[63]. 
Many natural extracts from plant, microorganism and marine algae showed PL inhibitory 
activity such as alcoholic fractions from Cudrania tricuspidata [64], Dioscorea niponica, Nelumbo 
nucifera [65], Hygrocybe conica, Laetiporus sulphureus, Tylopilus felleus or Caulerpa taxifolia  
but the responsible compounds still remain undetermined. However, catequines, saponines, 
triterpenoids, flavonoids, carnosic acid, manno-oligosacharides, ε-polylysine, crocin, caffeine, 
vibrolactones, lipistatin or flavan dimers from different sources were pointed as PL inhibitors [63].  
II.2. Cholesterol and bile acids scavengers  
Bile acid scavengers reduce cholesterol absorption via interruption of the enterohepatic 
circulation of bile acids and results in a secondary increase in the hepatic LDL receptor activity. 
A few synthetic compounds are used as bile acids scavengers such as cholestyramine. 
Cholestyramine is an ion exchange resin that could reduce total cholesterol and LDL-cholesterol 
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in a 9-25% and 15-33% by impairing total or partial bile acid absorption [66]. Treatment with this 
drug induced similar cholesterol-lowering effects than other molecules such as statins, fibers or 
ezetimibe (described below) and when combined with other drugs the reduction is enhanced 
because of synergistic effects [67, 68] [69].. For example, cholestyramine-statins treatments 
improve blood cholesterol levels an additional 20% more than only statins [66].  
Dietary fibers from several sources are also described as cholesterol bile acid binders 
but they will be further described elsewhere (paragraph III.2). 
II.3. Displacers or cholesterol from DMMs   
Nowadays, plant sterols (phytosterols and phytostanols) are considered the most potent 
cholesterol competitors for their inclusion into DMMs since no chemically synthetized compound 
have been designed so far to act at this strategic step. They will be described more in detail further 
on paragraph III.1.  In fact, any lipid compound that has to be integrated in the DMMs such as 
phosphatidylcholine, tocopherols, bile acids etc. will modify the DMM composition modulating its 
hydrophobicity and therefore the amount of cholesterol that will be included per DMM [70]. 
II.4. Inhibitiors of NPC1L1 and ABC transporters 
Another cholesterol lowering strategy is by impairing its transport through the plasmatic 
membranes using several NPC1L1 and ABC transporters inhibitors.  Stimulation or silencing of 
NPC1L1 gene expression respectively facilitated or inhibited the free cholesterol uptake [24] in a 
mechanism that seems to involve a deficient ACAT2(AvS) activity [23, 71],and apparently, NPC1L1 
is the molecular target of ezetimibe (a non-acylated β-lactam family member [72]). In vitro and in 
vivo studies indicated that NPC1L1 and ezetimibe are involved in the same pathway [73-76]. 
However, there is certain controversy about NPC1L1 inhibition mechanism, some hypothesis 
suggested that ezetimibe inhibition action is due to the blocking of NPC1L1 movement from 
cytosol to brush border membrane and vice versa [22]. Other publications indicated that 
ezetimibe undergoes glucuronidation to a single metabolite with higher affinity to brush border 
membrane NPC1L1 impairing the correct cholesterol absorption and enterohepatic recirculation 
[76]. However, ezetimibe was able of decreasing hepatic oxysterols levels, which are endogenous 
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agonists of liver X receptor (LXR), reducing hepatic lipogenic gene expression of a few enzymes 
such as stearoyl-CoA desaturase-1 (SCD1) [77]. 
Others compounds were described as potential NPC1L1 inhibitior such as 
spiroimidazolidinone derivates (they showed high NPC1L1 binding affinity) [78], novel amino          
β-lactams derivates [79] or curcuminoids polyphenols (acting by indirect influence on SREBP-1) 
[39]. 
Atorvastatine, a synthetic statin with high HMGCR inhibitory capacity, was also able of 
decreasing ABCG5/8 mRNA levels in enterocytes of hyperlipidemic animals. Similar effect was 
reported for an endotoxine in murine liver [80]. Posttranscriptional regulations were also described 
for spironolactones or polyphenols from Aronia Melanocarpa [80, 81]. In the latter case, specific 
miRNAs could be the responsible compounds.  
II.5. Inhibitors of cholesterol transport and assembling in the endoplasmic reticle 
Some compounds from natural sources have been reported as ACAT(AvS) inhibitors 
reducing cholesterol esterification rates such as alkamides from Piper nigrum [82], shikonin 
derivatives from Lithospermum erythrorhizon [83], an isoprenyl flavonoid identified as grabol from 
licorice roots [84], ursolic acid (via (PPAR)-α activation) [85] or flucoxanthin from marine plants  
[86].  
However, until now, only drugs obtained by chemical synthesis are been tested in clinical 
trials such as certain xanthone sulfamides [77], efluzimibe [78] or avasimibe. Recent studies 
indicated that avasimibe was not only involved in ACAT(AvS)  inhibition but also in the blocking of 
APOB-48 secretion (in HepG2 cells) [87]. Several compounds are also described as apoB-48 
blockers such as atorvastatin [88], adrenocorticotropic hormones [66] [89] [69] etc.  
 Other cholesterol regulating procedures included MTTP inhibition. Apparently, MTTP 
was the target of lomitapide [39]. This compound impaired TG, phospholipids and cholesteryl 
esters transferring from ER to the nascent APOB, leading a lower loading of this lipoprotein, 
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inhibition of VLDLs assembly and chylomicrons secretion [67] resulting in a fat and fat-soluble 
vitamins malabsorption [39, 68]. 
II.6. Inhibitors of enzymes involved in cholesterol biosynthesis 
From several decades, statins were considered the most effective compounds for 
HMGCR inhibition and considered safe and ideal as primary treatment for most of 
hypercholesterolemic patients. Many natural and synthetic statins are nowadays prescribed such 
as lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, etc. They 
all act as substrate competitors showing different binding affinities for the enzyme but always 
higher than the 3-hydroxy-3methylglutryl-Coenzime A (HMGcoA) [90].  
On the other hand, HMGCR inhibition is also mediated by an AMP kinase via 
phosphorylation and green and black tea polyphenols induced a direct increase of HMGCR 
phosphorylation possibly via AMP kinases phosphorylation. Their precise mechanism of action is 
still unclear but, it seems to involve activation of regulatory factors such as PPAR [91, 92].  
Only a few compounds are still nowadays pointed as potential inhibitors of the SQS such 
as resveratrol, quinuclidine, 4, 1-benzoxazepine-3-acetic acid derivatives such as TAK-475 (or 
Lapaquistat) or morpholine derivates. The SQS inhibition by two 2-biphenylmorpholine derivatives 
showed multiple consequences in lipid metabolism i.e. inhibition of triglyceride biosynthesis, 
increasing of LDLR gene expression and LDL uptake or lower apoB synthesis rate. Thus, 
modulation of this enzyme could also affect cholesterol metabolism at several levels [44-46, 78, 
82, 93].  
24(S), 25-epoxycholesterol was also pointed as inhibitor of the DHCR24 activity. This 
enzyme catalyze the transformation of desmosterol into cholesterol. The inhibitor did not modify 
DHCR24 protein levels, but increased desmosterol accumulation decreasing cholesterol levels 
in in vitro studies due to its structural similarity with desmosterol [94]. 
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III.  Marketed supplemented foods containing           
hypocholesterolemic compounds 
People with incipient hypercholesterolemia can prevent, delay or enhance the 
pharmaceutical treatment by taking a few functional foods already available at the supermarkets. 
At the present, many supplements are indicated by herbalists because they might help against 
CVD such as garlic extracts, soy preparations, ω3 oils, etc. However, only two types of compounds 
are nowadays authorized by the competent institutions from most of the industrialized countries to 
bear the health claim ¨ hypocholesterolemic properties¨ in their labels and they are marketed under 
many different brands by the food industry: plant sterols and polysaccharides (β-glucans and 
chitins derivatives). 
III.1. Phytosterols 
This group of compounds gained much attention in the last decade since, in 1999 a 
sitostanol-containing margarine was launched in the market [95, 96]. A few years later, other 
sterols such as esterified phytosterols and not free sterols were utilized to functionalize foods 
because the esterification increases their solubility in fat and improved their bioavailability [97, 
98].  
Although more than 40 plant sterols and derivatives have been identified (Figure 5), only 
stigmasterol, campesterol and β-sitosterol are present in most of vegetables (0.1-0.5% w/w). 
Brassicasterol is also present in large quantities but only in Brassica sp. Other derivatives such 
as stanols (campestanol, sitostanol etc.) are also present in lower amounts although after some 
culinary treatments their composition increase [99]. The amount of phytosterols and derivatives 
depend on the type of plant being those rich in oils and lipidic compounds the food with higher 
sterol contents (Table 2) [100-102]. 
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Figure 5. Structural similarities of cholesterol, β-sitosterol and fungal sterols molecules. 
 
Table 2. Plant sterols composition (mg/g edible portion) obtained from several food sources. 
 
Plant-derived 
food 
Campesterol β-sitosterol Stigmasterol Campestanol Sitostanol 
Sacha inchi Oil 0.42 1.47 0.48 nd nd 
Soybean 
Oil 0.42 1.47 0.48 nd nd 
Seed 0.07 0.17 0.08 0.1 x 10-2 0.7 x 10-2 
Corn Oil 2.20 4.45 0.61 nd nd 
Carrot Vegetable 0.02 0.10 0.03 nd 0.6  x 10-3 
Peanut Oil 0.10 0.82 0.07 nd nd 
    nd: non-detected compounds. 
III.1.1. Physiological changes modulated by plants sterols  
Cholesterol absorption from dietary and biliary sources is significantly reduced in the 
presence of plant sterols. Their mechanism of action is related to their structural similarity since 
they appear to compete with dietary cholesterol absorption displacing it from the dietary mixed 
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micelles formed during intestinal digestion and then, the unabsorbed cholesterol is excreted in 
the feces [15]. According to both static and dynamic studies, phytosterols become more efficiently 
incorporated into micelles in the intestinal lumen, displace the cholesterol and lead to its 
precipitation with other non-solubilized phytosterols [12, 103-105] but, the specific mechanisms 
remains still unclear. 
Cholesterol solubilization in DMMs was lowered by β-sitosterol because both compounds 
competed for the DMMs binding sites specific for steroid interactions [106]. When comparing 
between phytosterols (β-sitosterol and sitostanol) micelles of different size and composition were 
obtained depending on the sterol solubilized [103, 105]. 
Furthermore, sterols are also described as promotors of cholesterol co-crystallization at 
gastric duodenal levels and compounds stimulating their competition for their transfer through the 
brush border membrane and within chylomicron assembly[103]. Their effect on the SOAT activity 
have also been studied although it remains partially unclear. Some reports indicated that 
cholesterol enterocytic esterification by ACAT(AvS) decreased by sterols competition although the 
enzyme showed lower esterification efficiency for plant sterol than cholesterol. Other reports 
suggested plant sterols influence on MTTP and APOB48 lipoprotein. APOB48 inhibitory effect was 
noticed by stigmanterol, campesterol and β-sitosterol in cell cultures but not in an animal model. 
More recent publications suggested other mechanism of actions involving modulations at the 
molecular level.  
III.1.2. Molecular events modulated by plants sterols 
 Transcription of some ABC transporters (ABCG5/8 etc.) was induced by LXR factor in 
enterocytes (but not in hepatocytes) [103] although, there is a controversy about it influence on 
other transporters (ABCA1). Oxysterols such as 22(R)-hydroxycholesterol, 24(S),25-
epoxycholesterol or  27-hydroxycholesterol etc., are considered as endogenous natural LXR 
agonist however, plant sterols derivatives showed higher LXR agonist activity. Brasicasterols from 
unicellular algae and Brassiceas sp (i.e. rapeseed) induced large variations in the gene 
expression of ABC transporters due to their ability to act as the LXR factor in mice. Moreover, 
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sitostanol (in mice), sitosterol (in Caco2 cells) and a few 4-desmethylsterol derivatives were also 
able of inducing ABCA1 up-regulation using their LXR agonist activity [9, 26, 103, 107]. However, 
no direct effects of phytoesterols was noticed on the transcriptional levels of the transporters 
because in ABCA1 and ABCG5/8-deficient mice decreasing of cholesterol intestinal absorption 
was also noticed indicating that  ABC transporters were not their direct targets. 
Other reports indicated that phytosterol/stanols modulated HMGCR expression via 
ACAT(AvS)  inhibition. Apparently, lower ACAT(AvS)  activity led to higher free cholesterol amounts, 
inhibiting the cholesterol biosynthetic pathway and HMGCR expression beside others. It also 
reduced chylomicron assembling, and promoted the back efflux of non-esterified sterols to the 
lumen [26, 103, 108]. However, their influence on SOAT seemed to be by chemical inhibition more 
than by molecular modulation.  
Several in vitro studies pointed out that SREBP-2, NPC1L1 and SR-B1 gene expression 
is modulated by plant sterols such as stigmasterol and β-sitosterol toward the reduction of 
cholesterol absorption. Surprisingly, HepG2 cells treated with these sterols showed simultaneous 
down-regulation of NPC1L1 and SR-B1 when a opposite effect on this two molecules could be 
expected . Studies using homozygous and heterozygous knockout mice (NPC1L1-/- and NPC1L1+/-
) showed a lower cholesterol absorption in homozygous animals however, heterozygous mice 
showed higher HMGCR mRNA levels in gut and liver tissues than wild-type animals without 
changes in ABC transporters expression rates. Authors explained their results by compensatory 
effects: difficulties for cholesterol absorption were compensated by a stimulation of endogenous 
cholesterol synthesis to maintain physiological plasma levels [23, 73]. Moreover, when the 
knockout mice were treated with plant sterols or ezetimibe, the wild-type and heterozygous 
animals showed a reduction in cholesterol and TG levels. Absorption of campesterol and                  
β-sitosterol was reduced in NPC1L1+/- and almost absent in NPC1L1-/- mice indicating that certain 
modulation of NPC1L1 took place [23, 73].  
β-Sitosterol addition to Caco2 cultures induced down-regulation of HMGCR expression 
although this effect was not noticed in mice. Only sitosterolemic individuals showed reduction in 
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HMGCR activity in ileum so apparently only large amounts of plan sterols or  long-term 2% (w/w) 
plant sterol administration can induce such effect [26, 109].  
Other reports indicated that phytosterols might modulate the expression of other closely 
related genes such as those encoding the hepatic cholesterelogenic farnesyl phosphate synthase 
(FFPS), liver CYP7A1 (cytochrome P450 family 7 subfamily A polypeptide 1)  or  anexin 2-Caveolin 
1 (ANXA2-CAV1) protein complex [26]. 
III.2. β-Glucans 
More recently, β-glucans containing foods such as oat or barley products have also been 
launched in the market claiming up to 15% cholesterol reduction after regular consumption [4]. 
Many epidemiological studies have demonstrated a reduced CVD risk for consumers of high 
amounts of dietary fiber. The (13),(14)-β-glucans are believed to perform many biological 
functions and one of them is the ability to lower serum cholesterol (LDL) levels [110].  
Cereals are the main source of β-glucans and other dietary fibers with 
hypocholesterolemic properties (Table 3) being oat and barley glucans those pointed as more 
effective in lowering cholesterol and glucose levels or increasing immunity against infection. 
Table 3. β-Glucan composition (mg/100mg dry weight) obtained from several food sources [111]. 
Cereal Total β-glucan Soluble β-glucan 
Oats 10.37 1.73-5.7 
Barley 10.87-19.7 1.87-5.37 
Wheat 8.48-16.19 0.19-0.67 
Rye 7.45 2.26 
 
Until a few years ago, the term dietary fiber included a wide range of polysaccharides 
that could not be digested by human track becoming substrates for microbiota fermentation. 
Nowadays, a precise definition is more complicated because of the multiple different structures 
and biological activities ascribed. 
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III.2.1. Physiological changes provoked by dietary fibers or β-glucans  
Apparently the cholesterol-lowering mechanisms of dietary fibers are dependent of their 
solubility and can be distinguished as water-insoluble (WIF) or water-soluble (WSF) fibers 
(although some authors divide them depending on the extraction solvent utilized i.e. alkalis-soluble 
etc.). The mechanism of actions proposed for WSF are [112, 113]:  
- WSF might provoke changes in the properties of digestion fluids i.e. high viscosity. 
Higher water binding capacity on the chime might lead to a bad diffusion of 
cholesterol and bile acids for their proper incorporation into the DMMs and further 
absorption/reabsorption.  
- WSF presence during digestion might decrease the glycemic response stimulating 
hepatocytic cholesterol synthesis. 
- Products generated from WSF after colonic fermentation by microbiota such as 
propionate etc. (generally called short chain fatty acids, SCFAs) might act as 
hypocholesterolemic compounds by modulating cholesterol-related gene 
expression.  
The cholesterol reducing properties of WIF appeared to be more related to their ability to 
act as bile acid scavengers following a similar mechanism as previously described for 
cholestyramine by direct specific bindings when passing the small intestine [112]. This 
mechanism impair bile acids re-absorption stimulating the hepatic synthesis of new bile acids from 
cholesterol reducing its blood concentration [15, 89, 114].  
Although the above described mechanisms have been propose to explain 
hypocholesterolemic fiber effects, it is still hard to define them properly due to wide variety of 
fibers from different natural sources and their different extraction and study protocoles [115]. 
Moreover, despite the indicated properties, their hypocholesterolemic effects (in particular for       
β-glucans) might be due to a combination of several mechanisms including potential modulation 
of cholesterol-related gene expresions [116].  
 
General Introduction 
 
43 
 
III.2.2. Molecular events modulated by β-glucans  
At the present, not many investigations have been carried out concerning the molecular 
effect of dietary fibers. High viscosity oat or barley β-glucan extracts demonstrated their ability to  
down-regulate SREBF2 gene expression in intestinal cells (NCl-H716) [116] but no with in vivo 
testing. However, according to  Hu et al (2008) corn bran dietary fiber up-regulated the expression 
of other genes such as FXR in ileum intestinal cells or PPAR in liver [117]. 
Hepatic HMGCR up-regulation was observed after administration of 
hydroxylpropylmethycellulose or inulin-oligofructose (1:1) to animal models [118, 119] however 
barley β-glucans administration induced no changes on HMGCR expression [113]. Jones (2008) 
noticed hepatic SREBF2 up-regulation when soluble dietary fiber (guar gum, a galactomannan) 
was administrated to pigs. In consequence, LDLr expression was enhanced and reduced the 
LDLs from the blood stream. Hepatic ABCG5/8 gene expression was also enhanced by guar gum 
consumption leading a higher cholesterol efflux from the liver to intestinal lumen [120].  
Other studies indicated that the scavenging of bile acids by fiber (β-glucans) activated 
CYP7A1 to convert cholesterol into new bile acids [4, 117] provoking an hepatic cholesterol 
decrease that up-regulated LDLr expression and reduced cholesterol blood levels. Due to these 
changes the biosynthetic pathway was also activated via HMGCR up-regulation to compensate 
the lack of hepatic cholesterol [4, 113].  
III.3. Chitosan 
Chitosan, a de-N-acetylated derivative of chitin, is a heteropolysaccharide (considered 
as DF) consisting of linear β-(14)-linked glucosamine and N-acetyl-D-glucosamine units and it 
is included in the list of approved health claims according to FOSHU regulations with the claim 
¨helps lower cholesterol level¨. At the present (2011) in Japan, there are more than one hundred 
marketed products including powdered or soft drinks containing chitosan. This compound is 
obtained from chitins extracted from crustacean shell wastes, insect skeletons, mushrooms and 
other fungi or bacteria [121]. A particular enterprise is conducting double-blind studies with 
animals and it is scheduled to begin with human clinical tests next year to submit a specific 
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preparation for FOSHU approval. The preparation includes a mushroom-derived chitosan 
combined with β-glucans. 
The hypocholesterolemic action of chitosan might be due to its ability to decrease 
cholesterol absorption and interfere with bile acid absorption following a mechanism similar to 
those explained for the other above mentioned β-glucans [122] since both the water-soluble and 
water-insoluble chitosan fractions were able to lower cholesterol in a clinical trial with 60 elderly 
hyperlipidemic patients. Total cholesterol significantly declined by 7.5% in the water-soluble and 
by 8.9% in the water-insoluble chitosan groups over 8 weeks [123]. Other studies carried out on 
rat groups fed on a diet rich in cholesterol found that chitosan hydrolysates with different molecular 
weights and viscosity were also effective and that the lower the molecular weight, the better its 
cholesterol-lowering potential [124, 125]. 
 
IV. Evidences of the hypocholesterolemic properties of mushrooms 
Edible mushrooms should also contain compounds able to lower cholesterol levels in 
serum since already for years, many works have been published pointing some mushrooms 
species as source of hypocholesterolemic compounds. However, many of them did not identified 
the responsible molecules due to most of the studies were animal or clinical tests using the 
complete fruiting body (sporophore) or certain specific extracts or fractions. 
IV.1. Evidences supported by animal trials  
In vivo studies in Wistar rats, Syrian hamsters and Chinchilla rabbits demonstrated the 
ability of oyster mushrooms (Pleurotus ostreatus) to lower the cholesterol levels. Rats with 
hereditary enhanced sensitivity to alimentary cholesterol were fed with 4% fruiting bodies in a diet 
containing 1% cholesterol. Mushroom consumption prevented serum cholesterol increase after 4 
weeks and after 7 weeks the cholesterolemia was lowered by 40% compared with control animals. 
This effect was due to a decrease in the concentrations of very low density lipoproteins (VLDL) 
and LDL [126] and to an induced delay in cholesterol absorption [127, 128]. A 50% increase in 
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the HDL and activation of antioxidative enzymes was also observed [129]. Similar results were 
observed using Chinchilla rabbits (fed with 10% P. ostreatus) where a decrease in total serum 
cholesterol was also detected primarily affected by the reduction (70%) of the VLDL-cholesterol. 
An increase by a factor of 3 in the HDL was also observed [130]. However, the 
hypocholesterolemic effect was dependent on the amount of dietary oyster mushroom 
administrated, 1% was ineffective while doses of 5% induced a significantly reduction in normal 
rats [131].The ethanol extracts obtained from the same mushroom were less efficient with 
increasing concentrations of ethanol than the whole body or its water extract. The latter and the 
extracts including 30 and 60% ethanol were also able to reduce the cholesterol and triacylglycerol 
levels in hamsters serum and liver (reduction of 34% cholesterol and 48% triacylglycerols). The 
consumption of the water and 30% ethanol extracts reduced the VLDL fraction [127]. Another 
extract obtained from its mycelium with dichloromethane and 95% ethanol lowered cholesterol 
levels in liver of normal rats [132] but, a β-glucan fraction extracted from the fruiting bodies was 
unable to affect cholesterols levels in both serum and liver [129]. 
Supplementation of a high-fat-diet given to hyperlipidemic rats with Pleurotus 
citrinopileatus fruiting bodies, a hot-water extract and two specific fractions obtained by eluting 
from a silica gel column with ethyl acetate and methanol at different doses showed that serum 
triglycerides and total cholesterol levels were significantly lower and HLD significantly higher in 
the groups supplemented with the highest dosage of the two eluted fractions as compared with 
the control groups with no mushroom addition. The major constituents of the eluted fractions were 
ergosterol in one of them and nicotinic acid in the other [133]. 
Other species from the same genera such as Pleurotus eryngii reduced the plasma total 
cholesterol, triglyceride, LDL, total lipid, phospholipids and LDL/HDL ratio by 24, 46.3, 62.5, 24.6, 
19.2 and 57.1% respectively and showed no adverse effects when they were added as 
supplement (5%) to hypercholesterolemic Sprague-Dawley albino rats. Feeding mushrooms 
increased total lipid and cholesterol excretion in feces [134]. Its water extracts showed 
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hypolipidemic and hypocholesterolemic effects in fat-loaded mice. The low fat absorption 
provoked was due to its lipase inhibitory activity. Apparently, the water extract might prevent the 
interactions between lipid emulsions and pancreatic lipase [135]. The remarkably reduction of 
lipid levels, total cholesterol, total triglyceride and LDL-cholesterol and increase in HDL-
cholesterol was because of its water-soluble polysaccharides [136]. 
Ganoderma lucidum is considered by the Asiatic culture as a medicinal mushroom 
because of its many different beneficial properties. Several of these properties have been 
confirmed by scientific studies [137, 138] including its hypocholesterolemic effects in hamsters 
and minipigs [139]. The organic fractions containing oxygenated lanosterol derivatives inhibited 
cholesterol synthesis in T9A4 hepatocytes. In hamsters, 5% supplementation did not affect LDL 
but decreased 9.8% total cholesterol, 11.2% HDL and had effects on several faecal neutral sterols 
and bile acids. It also reduced hepatic microsomal ex-vivo HMGCoA reducase activity but not its 
gene expression [140]. In minipigs, 2.5% supplementation decreased 20% total cholesterol, 27% 
LDL and 18% HDL-cholesterol and increased faecal cholestanol and coprostanol and decreased 
cholate. Results also indicated that G. lucidum reduced LDL cholesterol in vivo through various 
mechanisms [139]. 
Similar studies with the white button mushroom (Agaricus bisporus) indicated that they 
were able to lowers blood glucose and cholesterol levels in diabetic and hypercholesterolemic 
Sprague-Dawley rats fed with hypercholesterolemic diets for 3 or 4 weeks [141]. 
Hypercholesterolemic rats significantly decreased their levels of plasma total cholesterol and LDL 
(22.8 and 33.1% respect.) and their hepatic levels of cholesterol and triglycerides (36.2 and 20.8% 
respect.) increasing significantly their plasma HDL concentrations. Apparently, these effects 
might have been induced by the presence of A. bisporus fibers because when rats were fed with 
these compounds, the serum total cholesterol, VLDL, IDL (intermediate density lipoprotein) and 
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LDL were lower than control rats while the HDL were lower. These observations could be caused 
by the overexpression of the hepatic LDL receptor since its mRNA level was significantly higher 
than in the control rats [142]. 
After these results, the fiber fraction from other edible mushrooms was also investigated. 
Rats were fed with the fiber fraction from Grifola frondosa (maitake), Lentinula edodes (Shiitake) 
and Flammulina velutipes (enokitake mushrooms) for 4 weeks and compared with cellulose as 
control. The total cholesterol in serum was significantly lower in rats fed with G. frondosa and F. 
velutipes than in those rats fed with cellulose. The VLDL, IDL and LDL levels were also lower when 
the rats ate any of the three mushrooms whereas only the HDL of the F. velutipes group was 
significantly lower than the others. The LDL receptor mRNA levels were only significantly higher in 
the F. velutipes group, thus, F. velutipes lowered cholesterol in serum by enhancement of hepatic 
LDL receptor mRNA while the other mushroom fibers enhanced the faecal cholesterol excretion 
[143]. Hericium erinaceus (hot water and ethanol extracts) also induced transcriptional changes 
but affecting to the PPARα gene, this modulation influenced others such as ACAT, ApoA1, LPL or 
SREBP1 in mice fed a high-fat diet [144]. Other authors indicated that this mushroom was also 
inducing the up-regulation of many genes involved in the fatty acid transport but repressed 
SREBP1 and ACAT [144]. Moreover, G. frondosa and two other mushroom species such as            
P. eryngii, and particularly Hypsizygus marmoreus also showed antiatherosclerotic effects in 
atherosclerosis-susceptible C57BL/6J, apolipoprotein E–deficient (apoE−/−) mice [145]. The 
effect of G. frondosa and H. marmoreus together with P. ostreatus were also investigated in 
feeding experiments using normal mice where a DNA microarray analysis of liver indicated 
differences of gene expression patterns among mushrooms. CTP1A and FABP families were 
upregulated in the P. ostreatus-fed group, which were considered to promote lipid transport and 
β-oxidation. In the G. frondosa-fed group, not only the gene involved in signal transduction of 
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innate immunity via TLR3 and interferon but also virus resistance genes, such as MX1, RSAD2 
and OAS1 were upregulated [146]. 
Auricularia auricular (tree-ear mushroom) and Tremella fuciformis (white jelly-leaf 
mushroom) fruiting bodies were also capable of reducing total cholesterol in serum (5% fed 
Sprague-Dawley rats) after 4 weeks (17 and 19% reduction respect.) by decreasing the              
LDL-cholesterol levels but with no significant differences in the HDL levels nor total lipids or 
cholesterol in liver [147]. However, the hypocholesterolemic properties of the mushrooms were 
effective when the animals consumed the fruiting bodies in regular basis and for long terms 
because when the cholesterol levels were determined 3 or 6 h after in taking, although the 
glycemic levels were decreased no statistical differences were observed in cholesterol levels in 
Wistar rats administrated with water or methanol extracts obtained from Lentinula lepideus, 
Calvatia cyathiformis and Ganoderma applantum [148]. 
IV.2. Evidences supported by clinical trials 
In a clinical investigation carried out on 17 diabetic subjects eating Pleurotus ostreatus 
for 24 days, it was concluded that mushrooms significantly reduced blood glucose, blood 
pressure, triglycerides and cholesterol of diabetic subject without any deleterious effect on liver 
and kidney. The mushroom diet modified particularly the total cholesterol leaving unaffected the 
HDL levels [149]. A similar trial was performed by Schneider et al. (2011) but using healthy 
volunteers [150]. They drank an oyster mushroom soup as part of a diet followed by 20 subjects 
(9 male, 11 female 20-34 years old) during 21 days. After the treatment, the volunteers showed a 
significant decrease in triacylglycerol concentrations and oxidized-LDL and a tendency in 
lowering total cholesterol values with no effect on HDL or LDL levels. They attributed the beneficial 
effects to the presence of linoleic acid, ergosterol and ergosta-derivatives showing antioxidant 
activities. 
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A few more edible mushrooms were tested with human trials such as Ganoderma 
lucidum (Lingzhi or reishi mushroom) [151] and Cordyceps sp. [152] to investigate, besides other 
parameters, their hypocholesterolemic effects. Both were double-blinded, placebo-controlled 
studies and results indicated that those mushrooms could help treating hyperlipidemia. Specific 
extracts obtained from L. edodes also induced significant decrease in serum cholesterol in young 
women and people older than 60 years in Japan [121]. Recently, Poddar et al. (2013) 
demonstrated that substitution of meat by mushrooms (Agaricus bisporus) improved energy 
intake, reduced body weight and improved the lipid (including LDL) and inflammatory profile 
among 73 obese adults in a short and 1 year long trials [153]. 
 
V. Fungal compounds potentially able to impair cholesterol absorption 
After the above mentioned studies it seems possible to hypothesize that edible 
mushrooms should contain bioactive compounds responsible for the observed 
hypocholesterolemic effects. Some of them have been already investigated in detail, however for 
some others, results are still inconclusive, contradictory or with no physiological significance 
although their in vitro tests were promising. 
V.1. Ergosterol and other derivative fungal sterols 
Edible mushrooms are good sources of cholesterol-like structures such as ergosterol, 
(ergosta-5,7,22-trien-3β-ol), fungisterol (ergosta-7-en-3-ol), ergosterol peroxides and many other 
derivatives [154-157] so these molecules could also act as plant sterols or even better because 
some of them are more hydrophobic (Figure 5).  The major fungal sterol, ergosterol, is abundant 
in all mushrooms species (micellium and sphorophore) since it is a constitutive compound of the 
hyphae membranes and it is known as a Vitamin D2 (ergocalciferol) precursor. This compound 
might represent 53 up to 98% of the fungal sterols (w/w) followed by ergosterol derivatives such 
as ergosta-5,8,22-trien-3-ol, ergosta-7,22-dien-3-ol, ergosta-5,7dien-3-ol and ergosta-7-en-3-ol 
(fungisterol). Some mushroom species such as Chantharellus cibarius and Craterellus 
cornucopioides showed almost exclusively ergosterol, other species showed more                        
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ergosta-5,7-dienol than fungisterol (i.e. Russula foetens, Pleurotus ostreatus etc.) (Table 4), other 
showed specific derivatives such as Flammulina velutipes which according to some reports 
contained high amount of ergosta 5,8,22-trien3β-ol, etc. Ergosterol concentrations ranged from 
0.2 up to almost 10 mg/g dw being the most commonly cultivated mushrooms the species with 
the highest levels. This is probably because mushroom growers cultivate them with specific 
substrates containing all the nutritive requirements and harvest the fruiting bodies at their optimal 
developmental stage while when they grow wild in the woods they do not always flush at the 
optimal environmental conditions. Ergosterol is utilized as a biomarker of optimal fungal growth 
since high production of this constituent by the fungal hyphae indicates that the mycelia are 
elongated and the mushroom is properly growing [121]. 
Moreover, besides the influence of the different analytical methodologies utilized, the 
observed differences between publications are normal because of the typical variability 
depending on the mushroom strain, mushroom variety and other cultivation parameters such as 
flush number, type of casing soil and developmental stages. For instance, in species such as C. 
cibarius, C. tubaeformis and L. trivialis the ergosterol levels were higher in the gills except for B. 
edulis with similar ergosterol concentrations in the cap and gills. Mushroom from the first flush 
contained higher amount of fungal sterols than second or latter flushes since the substrate 
nutrients disappear during the cultivation [154]. 
Table 4. Fungal sterol content in mushroom species (mg/g dw). A: ergosterol, B: fungisterol, C: ergosta-7,22-
dienol, D: ergosta-5,7-dienol, E: ergosta-5,8,22-trien-β3ol, F: lanosterol, G: lanosta-8,24-dienol, H: 4α-
methylzymosterol. * in the original article the value was expressed in fresh weigh (value between bracket in 
mg/100g fw) but it is here converted into dry weight assuming an average 95% R.H. 
Mushroom specie A B C D E F G H Ref. 
Agaricus bisporus 8.92 
(44.6*) 
0.18 
(0.9*) 
0.38 
(1.9*) 
0.38 
(1.9*) 
    [155] 
6.42        [158] 
7.8        [159] 
6.54 0.26 0.15 0.94     [154] 
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Mushroom specie A B C D E F G H Ref. 
Amanita caesarea 8.25   1.75     [160] 
Boletus edulis 
 
4.89        [154] 
38.4 
(192.2*) 
3.28 
(16.4*) 
2.24 
(11.2*) 
2.5 
(12.5*) 
    [155] 
4.00        [158] 
Calocybe gambosa 3.61        [158] 
Clitocybe maxima 6.42        [161] 
Clitocybe nebularis 6.38 1.04       [156] 
Catathelasma 
ventricosum 
6.51        [161] 
Cantharellus cibarius 
 
3.04        [154] 
4.94 
(24.7*) 
0.04 
(0.2*) 
0.08 
(0.4*) 
0.08 
(0.4*) 
    [155] 
0.23        [158] 
Cantharellus tubaeformis 
 
1.73        [156] 
3.36 
(16.8*) 
0.24 
(1.2*) 
0.36 
(1.8*) 
0.9 
(4.5*) 
    [155] 
3.77        [154] 
Craterellus 
cornucopioides 
3.27        [161] 
0.44        [158] 
Coprinus atramentarius 2.45   7.55     [160] 
Flamulina  velutipes 0.68        [159] 
4.53  1.41 1.05 3.01    [160] 
Ganoderma lucidum 0.705        [162] 
Ganoderma sinense 0.0801        [162] 
Grifola frondosa 
 
0.32        [158] 
1.85 
(9.25*) 
0.204 
(1.02*) 
0.104 
(0.52*) 
0.01 
(0.05*) 
 
0.01 
(0.05*) 
0.011 
(0.56*) 
0.004 
(0.02*) 
[163] 
Lactarius sangruifluus 
 
3.6  
(18*) 
0.26 
(1.32*) 
0.19 
(0.97*) 
0.008 
(0.04*) 
 
0.008 
(0.04*) 
0.102 
(0.51*) 
0.008 
(0.04*) 
[163] 
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Mushroom specie A B C D E F G H Ref. 
Lactarius 
semisanguifluus 
2.12 
(10.58*) 
0.26 
(1.3*) 
0.174 
(0.87*) 
0.012 
(0.06*) 
 
0.014 
(0.07*) 
0.11 
(0.57*) 
0.01 
(0.05*) 
[163] 
Lactarius trivialis 2.96        [154] 
Lampteromyces 
japonicus 
4.56   5.44     [160] 
Laccaria amethystea 6.37        [161] 
Lentinula edodes 21.58 
(107.9*) 
1.82 
(9.1*) 
1.7 
(8.5*) 
1.4 
(7.0*) 
    [155] 
3.64        [158] 
6.05        [159] 
6.79 0.63 0.17 0.28     [154] 
Leucopaxillus giganteus 8.59   0.73     [160] 
Hydnum repandum 6.28 0.85       [156] 
Hygrophorus marzuolus 6.81        [158] 
Hypsizygus marmoreus 10.56 
(52.8*) 
       [145] 
Hygrocybe punicea 7.88   2.12     [160] 
Pleurotus ostreatus 12.14 
(60.7*) 
1.24 
(6.2*) 
0.64 
(4.7*) 
1.18 
(5.9*) 
    [155] 
 3.31        [158] 
 4.4        [159] 
 6.74 0.18 0.15 0.83     [154] 
Pleurotus eryngii 9.1 
(45.5*) 
       [145] 
Pleurotus cystidus 
 
4.35        [159] 
 9.86 
(49.3*) 
       [145] 
Russula cyanoxantha 6.32 1.28       [156] 
Russula xerampelina 6.55 1.12       [156] 
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Mushroom specie A B C D E F G H Ref. 
Russula delica 
 
2.5 
(12.51*) 
0.38 
(1.90*) 
0.266 
(1.33*) 
0.034 
(0.17*) 
 
0.048 
(0.24*) 
0.12 
(0.61*) 
0.014 
(0.07*) 
[163] 
Russula foetens 7.09   2.91     [160] 
Russula senecis 8.45        [160] 
Russula nigricans 8.38   1.62     [160] 
Suillus granulatus 7.02 0.8       [156] 
Suillus luteus 6.62 0.83       [156] 
Suillus bellinii 2.46 
(12.31*) 
0.298 
(1.49*) 
0.14 
(0.70*) 
0.076 
(0.38*) 
 
0.094 
(0.47*) 
0.054 
(0.27*) 
0.01 
(0.05*) 
[163] 
Stropharia rugoso-
annulata 
7.89        [161] 
        Empty boxes indicate non-detected compound. 
Many of these compounds showed interesting bioactive properties such as antioxidant, 
antimicrobial or antitumor activities  [157]. But, two of their biological activities can be particularly 
interesting because of their relation with the cholesterol metabolism such that the ability of 
ergosterol derivatives (ergost-22-ene-1,3-diol, ergosta-5,7-dien-3b-ol, (22E)-ergosta-1,4,6,22-
tetraen-3-one, etc.) that were pointed as a potent agonists for LXR able to induce the expression 
of ABC transporters [107]. Moreover, ergosterol was a competitive inhibitor (showing Ki values = 
36.8 µM) of the enzyme that catalyzes the reduction of the double bond at C-24 in the cholesterol-
biosynthesis pathway (DHCR24, delta24-sterol reductase). Ergosterol together with other sterols 
such as stigmasterol and brassicasterol were efficient because of its double bond at C-22 in the 
side chain of their structure [164].  
V.2. Dietary fibers (soluble polysaccharides, β-glucans and chitins) 
Edible mushrooms also contain interesting polysaccharides such as β-glucans (Figure 
6). Their molecular structure is different than those present in cereals but they share many 
biological activities such as antioxidant, antitumoral and immunomodulatory activities including 
the capability of lowering serum cholesterol levels [110, 147, 165] and those are the reason for 
the detailed studies carried out on many particular fungal β-glucans such as lentinan from shiitake 
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mushrooms (Lentinula edodes), schizophyllan from Schizophyllum commune, grifolan from            
G. frondosa, and other from Agaricus blazei, G. lucidum, P. ostreatus as well as the                           
(13)-β-glucans and glucuronoxylomannans from Auricularia polytricha and Tremella fuciformis 
[166, 167]. Mushroom β-glucans, despite characteristic residues and special branches, share a 
similar structure including a main chain of (13)-β-linked glucoses to which some side chains 
were connected by (16)-β-glicosidic linkages randomly or following a pattern with a DB range 
(degree of branching) approx. of 0.2-0.3. Obviously, the tertiary structure varies with the linkage 
degree because β-glucans with few or no β-(16)-linkages mainly have a single helix structure 
while those with higher degrees of β-(16)-glycosidic bonds form a triple helix [168]. Other 
reports indicated that triple helix structure together with the molecular mass positively affected the 
biological activity of the β-glucans [169]. However, the more polysaccharides are studied the least 
correlation between structure and functiona can be drawn [15]. 
 
Figure 6. Typical fungal β-glucans molecular structures (including chitin). 
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The main problem with finding the correlations between structures and functions within 
the β-glucans are the different extraction procedures followed to obtain polysaccharides enriched 
extracts. For instance, traditional β-glucan extraction protocols included: hot water extraction, 
ethanol precipitation, alkali/acid treatments, enzymatic degradations, washing with Sevag or other 
reagents etc., yielding fractions with completely different composition difficult to characterize or 
quantify [170-172]. However, several publications indicated that β-glucan contents ranged from 
0.14 to 0.53 mg/100 mg in similar strains such as Pleurotus pulmonarius, P. ostreatus, P. eryngii, 
B. edulis, A. aegerita and L. edodes. Other more recent publications estimated the total β-glucan 
levels between 2.6 - 13.4 mg/100mg dw for A. bisporus, F. Velutipes, L. edodes, P. ostreatus and 
P. eryngii using other analytical determinations [169, 173]. An example of these wide quantitative 
differences can be noticed in the Table 5. 
A particular type of β-glucans which is lately getting interest is chitin and chitins 
derivatives such as the previously mentioned chitosans and their degradation products (low 
molecular weight polymers generated from chitin/chitosan hydrolysis (LMWC) or 
chitooligosaccharides). Chitin is a water-insoluble β-(14)-glucan of N-acetylglucosamine 
monomers and chitosan can be obtained from chitin by de-N-acetylation, both are considered as 
dietary fiber [122]. The immunomodulatory and antitumor properties seemed to be more related 
to the water soluble fraction including the oligomers and low molecular weight polymers generated 
from chitin hydrolysis (LMWC) [174] while their effect as prebiotic and hypocholesterolemic 
compounds might be due to their water-insoluble β-glucans (chitins and protein-bound glucans) 
[165] although as previously indicated for other type of β-glucans, results are largely different 
depending on report [124]. Some indicated that chitin itself was unable of lowering cholesterol 
levels in serum if it is not transformed into chitosan or degraded in smaller products [122]. β-
Glucan enriched fractions obtained from P. ostreatus reduced total cholesterol levels of Winstar 
mice that were administrated simultaneously with a hypercholesterolemic diet for 4 weeks [175]. 
Thus, perhaps, the presence of other polysacharides (which are not chitins, could be 
proteoglucans) might enhance their hypocholesterolemic effect or stimulated certain synergy 
between fungal polysaccharides.  
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Chitin concentrations were more similar between different publications than those values 
described for β-glucans if the same or similar analytical methods were utilized (Table 5). Many 
authors determined chitin by the amount of N-glucosamine residues present in the samples [176] 
while others quantify them by the amount of non-protein nitrogen content detected with Keldar 
[173, 177, 178]. 
Table 5. Fungal β-glucan content in mushroom species (mg/100mg dw) according to different authors 
indicating those that were quantified as chitins (mg/100 mg dw). Empty boxes indicate non-detected compound. 
Mushroom  specie 
β-glucan   Chitin  
mg/100mg dw Ref.  mg/100mg dw Ref. 
Agaricus bisporus 58.2 [179]  4.69 [169] 
   8.68-6.17 [176] 
Agaricus blazei              
 (or A. brasiliensis) 
22.8 [179]    
Pleurotus ostreatus 0.38-0.24 [170]  0.76 [169] 
   5.46-2.42 [176] 
Pleurotus eryngii 0.38-0.29 [170]  3.16 [169] 
Lentinula edodes 0.2 [170]  1.87 [169] 
   8.07-5.36 [176] 
Flammulina veluttipes 3.2 [173]  9.83 [169] 
Ganoderma lucidum 1.2 [179]    
Grifola frondosa 33.5 [173]    
Pholiota nameko 32.8 [173]    
Phellinus linteus 21.8 [179]    
Pleurotus pulmonarius 0.53 [170]    
Panellus serotinus 19.6 [173]    
Hypsizygus marmoreus 13.7 [173]    
Pleurotus cornucopiae 7.5 [173]    
Armillaria mellea 5.8 [173]    
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V.3. Inhibitors of the Pancreatic Lipase 
Inhibiting the pancreatic lipase (PL) during digestion can be considered as an indirect 
mechanism of lowering cholesterol because if this enzyme cannot generate properly the DMMs, 
less lipids are absorbed as well as less cholesterol since this molecule should also be included in 
the micelles for enterocyte absorption. 
A few different PL inhibitors were isolated from edible fungi, two of them were β-lactones 
with unusual configurations named percyquinin (obtained from Stereum complicatum) and 
vibralactone (Boreostereum vibrans) with similar IC50 (0.4 μg/mL) (Figure 7). Several publications 
and particularly Slanc et al [177, 180, 181] screened more than 60 edible and non-edible fungi 
species and found that some of them exhibited PL inhibitory activities ranging from 1% till 97% 
depending on the specie considered. However, only the report from Mizutani et al [135] managed 
to record PL inhibitory activity in vivo (for P. eryngii).  
 
 
Figure 7. Vibralactone and percyquinin structures. 
Other authors pointed to other compounds such as chitin oligosaccharides derivatives 
(and chitosan) as molecules involved not only in a direct inhibition of pancreatic lipase during the 
digestion process but also as modulators of the PPAR gene expression [182]. 
 
VI. Fungal compounds potentially able to inhibit cholesterol metabolism 
Actually, no functional food able to inhibit the cholesterol synthesis have been designed, 
there are only drugs prescribed for people with cholesterol levels in serum reaching pathological 
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levels. However, it seems that edible mushrooms might contain several types of compounds able 
to perform such a task via different mechanisms. 
VI.1. Inhibitors of the HMGCR and other enzymes involved in the cholesterol    
synthesis 
According to several authors, oyster mushrooms species such as P. ostreatus,                    
P. sapidus, P. eryngii and P. cornucopiae, contain mevinolin (lovastatin) (Figure 8) [183-185]. In 
lower quantities, statins were also described in other species such as A. bisporus, B. edulis, 
Clitocybe maxima, Hipsizigus marmoreus etc. [136, 185]. The statin levels were high in the spores 
and widely distributed through the complete fruiting body and they were present during all the 
developmental stages [183]. Statins or vastatins were in fact isolated for the first time from fungi 
by the pharmaceutical industry. However, other authors found no statins [139, 150] but other 
compounds such as lanosteroids, ganoderols etc. in G. lucidum able to reduce the mRNA 
expression of the HMGCoA reducase.  
 
 
Figure 8. Mevinolin structure. 
Inhibitors of this key enzyme (i.e. synthetic statins) are well tolerated, having little 
collateral effects. However, when this enzyme is blocked, other important metabolic pathways are 
affected such as ubiquinone, dolichol and isoprenylated protein synthesis [186, 187]. Thus, new 
hypocholesterolemic drugs are at the present being developed to inhibit other enzymes down-
stream in the cholesterol biosynthetic pathway such as the squalene synthase. This enzyme also 
named farnesyl-diphosphate:farnesyl-diphosphate farnesyl transferase catalyzes the reductive 
dimerization of two molecules of farnesyl pyrophosphate to form squalene at the final branch point 
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of the cholesterol biosynthetic pathway (Figure 3). Inhibition of squalene synthase could therefore 
avoid any potential adverse effect associated with reduced synthesis of isoprenylated metabolites 
by the inhibitors of HMG-CoA reductase. 
Only a few inhibitors of this enzyme have been studied in detail, one is the synthetic     
RPR 107393 compound (3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo [2-2-2]octane 
dihydrochloride) [188] but others are called zaragozic acids and they are obtained from the liquid 
broth of certain ascomicetes able to form macroscopic fruiting bodies [189]. These types of 
compounds might also be found in the basidiomycota family where most of the macrofungi are 
included (together with the ascomycota).  
Moreover and as previously indicated, ergosterol was able to inhibit another enzyme 
related with the cholesterol metabolic pathway such as the C24-reductase, the enzyme that 
catalyzes the reduction of the double bond at C-24 (Figure 3) [164]. 
Bobek et al., (1998) also suggested that the reduction in the cholesterol biosynthesis 
found in rats was not only due to the suppression of the hepatic HMGCoA reducase activity but 
also by accelerating the cholesterol catabolism by up-regulating hepatic cholesterol                         
7α-hydroxylase  [128, 131]. 
VI.2. Modulators of the phospholipid metabolism 
Lentinula edodes was able to induce hypocholesterolemia and reduce the triacylglycerol 
levels in rats due to its content in eritadenine (2(R), 3(R),-dihydroxy-4-(9-adenyl)-butyric acid, 
lentinacin or lentysine) a specific compound with S-adenosylhomocysteine hydrolase (SAHH) 
inhibitory activity able to modify the hepatic phospholipid metabolism (Figure 9) [190].  
 
Figure 9. Eritadenine molecule. 
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Rats supplemented with eritadenite significantly decreased the phosphatidylcholine: 
phosphatidylethanolamine ratio in liver microsomes and the S-adenosylmethionine:S-
adenosylhomocysteine ratio in the liver in addition to the plasma cholesterol concentration 
suggesting that the hypocholesterolemic action of this compound might be associated with a 
modification of hepatic phospholipid metabolism [191]. Moreover, eritadenine also decreased in 
a dose-dependent manner levels of VLDL, LDL and HDL, increased the hepatic                                     
S-adenosylhomocysteine (SAH) level and decreased the ratio of S-adenosylmethionine (SAM) to 
SAH indicating that the hypocholesterolemic action of eritadenine might be elicited through an 
alteration of the hepatic phospholipid metabolism that resulted from an inhibition of 
phosphatidylethanolamine N-methylalion due to a decreased SMA/SAH ratio in the liver [191]. 
VI.3. Modulators of the thyroid hormones metabolism 
Another important factor in the cholesterol regulation is via thyroid. Triiodothyronine (T3) 
is a thyroid hormone directly involved in the regulation of LDLR gene expression. A 20% of this 
hormone is secreted directly by thyroid but the major amount is produced from thyroxine (T4) 
(produced exclusively in the thyroid) by 5´-deiodination in peripheral tissues. This reaction is 
catalyzed by the selenoprotein, type-I 5´-iodothyronine deiodinasein (DIO1 and 2). Other related 
selenoprotein is the glutathione peroxidase (GSH-Px) since the reduced expression of GSH-Px 
has been shown to increase cell-mediated oxidation of LDL [192]. 
Mushrooms contain selenium and can be easily Se-fortified by addition of sodium selenite 
to their cultivation substrates. This supplementation can modify their biological properties [193]. 
Moreover, selenium supplementation combined with statins therapy was proved to be significantly 
beneficial to lipid therapy. The observed upregulation of LDLR expression by selenium 
supplementation might have offered more receptor sites for LDL binding and its clearance from 
the circulation. One ppm Se supplementation on rats decreased the total cholesterol and LDL 
levels, increased T3 levels due to increased DIO2 expression, decreased the apoB and             
HMG-CoA reductase mRNAs expression [192].Thus, it could be assumed that if an statin-
producer mushroom strains could be Se-fortified during its cultivation, it might enhance their 
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hypocholesterolemic effect. However, up to the date, no studies about this posibility have been 
carried out yet. 
VII.   The use of pressurized technologies to obtain                   
bioactive fungal extracts 
In the past, most of the potential bioactive compounds described for edible mushrooms 
were obtained by traditional extraction systems or simple solid-liquid extraction using cold or hot 
water or others such as chloroform, hexane, methanol, ethanol or their mixtures. However, the use 
of the organic solvents to extract non-polar compounds can be toxic for humans and dangerous 
for the environment. Moreover, the extraction conditions and solvent removing from obtained 
fraction could be laborious and expensive. In consequence, environmentally friendly technologies 
have been optimized to extract bioactive fractions from mushrooms and many other sources 
ensuring that there are safer for human consumption (food grade labeling) than most of the 
standardized methods. 
VII.1. Pressurized liquid extraction 
 Pressurized solvent extraction (PLE) is an extraction technology utilized in the food 
industry to obtain bioactive fractions from solid or semi-solid material using nontoxic and/or GRAS 
(generally recognized as safe) solvents such as ethanol, limonene, lactic acid, glycerine or their 
mixtures. A particular PLE method named SWE (subcritical water extraction) is also utilized for the 
extraction of bioactive compounds using water as solvent under specific combinations of high 
pressures and temperatures below supercritical conditions [194]. Despite the obvious ecological 
interest of PLE technology, it is applied in the food industry because of the technological 
advantages described bellow [195-198]: 
- The use of elevated temperatures (50 °C to 200 °C) increases the kinetics of extraction 
process and consequently decreases the extraction time making possible a high 
solubility and diffusion rates. 
- Solvent polarity can be modulated since temperature is involved in its dielectric constant. 
At higher temperatures the dielectric constant decreases, consequently the solvent 
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polarity is reduced. Thus, higher temperatures could improve the extraction capacities 
of non-toxic solvents. 
- The high pressures applied (such as 10.34 MPa) allows a quick extraction vessel filling 
and force liquid into the solid matrix.  
- High pressures-temperatures combinations enables maintenance of the solvent liquid 
state preserving it extraction properties.  
Thus, this technology allows a fast extraction of a wide variety of compounds from 
different nature by the use of less amounts of solvent and obtaining higher yield rates in 
comparison with traditional solid-liquid extractions. Moreover, PLE is automated and the sample 
remains in an oxygen and light free environment avoiding oxidation and polymerization processes 
(Figure 10). 
 
Figure 10. Example of pressurized liquid extraction (ASE) equipment. 
At the present, only a few studies using PLE technology to obtaining fractions enriched 
in potential bioactive compunds from mushrooms have been reported. PLE was used to obtain 
certain fatty acids from Cordyceps spp. [199]. or polysaccharides from several fungal species 
[200-203]. High content β-glucans extracts could be obtained from mushrooms such as                    
G. lucidum and B. edulis using water as extraction solvent and 200 ºC, 5 cycles of 5 min each at 
10.3 MPa. The crude polysaccharide (PSC) fractions, isolated from the PWE extracts contained 
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mainly β-glucans (including N-glucosamine-containing compounds deriving from chitin 
hydrolysis), β-glucans and other PSCs (hetero-/proteo-glucans) depending on the extraction 
temperature and mushroom strain considered [201, 204]. The same solvent submitted to                    
10.1 MPa for 70 min at 28 °C was also used to isolate α-(14) and β-(16) glucans mixture from 
L. edodes [203]. 
VII.2. Supercritical fluid extraction 
Supercritical fluids extraction (SFE) is another pressurized extraction technology also 
utilized for the extraction or removal of specific fractions of interest for the food industry [205] 
(Figures 11,12). It is based on the transition that suffer a substance when it is submitted to a 
temperature and pressure above its critical point. At this state, its liquid and gas status are 
identical since it is turned into a supercritical fluid (SF). Thus, a supercritical fluid maintain both 
liquid and gas specific properties such as liquid density and gas viscosity [196].  
The advantages of this technology are many such as high selectivity (higher even than 
PLE), shorter extraction times of than those neccesary for solid-liquid extractions and the use of 
non-toxic organic solvents [196]. Many compounds are brought to the supercritical state in order 
to extract specific compounds from food matrix such as methane or nitrogen but, carbone dioxide 
(CO2) is more frequently used because it is considered more safe and cheap despite 
nonexplosive, nontoxic, inexpressive and ease to be removed from the obtained fraction [206]. 
Moreover, CO2 is considered GRAS by FDA (Food and Drug Administration) and EFSA (European 
Food Safety Authority) and with the ability to extract lipophilic compounds, although for polar 
molecules is not so effective. The CO2 extraction capacity can be increased to improve the poor 
solubility of polar compounds in this fluid by combine this solvent with small quantities of others. 
Then, the selectivity of the extraction process is also improved with the named co-solvent effect 
[207]. Specific percentages of hexane, methanol, isopropanol, acetonitrile or ethanol are widely 
used as co-solvents/modifiers in combination with CO2 but, the latter solvent is specifically 
recommended by many authors for its lower toxicity, high CO2miscibility [208]  and low 
environmental impact [209]  
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Studies using SF for the extraction of specific fungal metabolites are limited. This 
advanced technology was utilized to obtain triterpenoids from G. lucidum, carboxylic and fatty 
acids from Agaricus spp., antioxidant and antimicrobial compounds from the fruiting bodies of           
L. edodes and A. brasiliensis, ergothineine and polyphenols from P. ostreatus, antitumoral 
fractions from Cordyceps sinensis mycelia and immune-modulators polysaccharides from                 
G. lucidum [206, 210-216]. 
 
Figure 11. Example of supercritical fluid extraction equipment. 
               
Figure 12. SFE equipment details. CO2 tank and extraction cell even collecting cells (separators) details from 
left to right. 
General Introduction 
 
65 
 
VIII. References 
[1]. Araújo, F., et al., Trends in cardiovascular diseases and cancer mortality in 45 countries from five continents 
(1980–2010). European Journal of Preventive Cardiology, 2013. 
[2]. Uemura, K. and Z. Pisa, Trend in cardiovascular disease mortality in industrialized countries since 1950. World 
Health Statistics Quarterly, 1988. 41: p. 155-178. 
[3]. Graham, I., European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. 
Atherosclerosis, 2007. 194(1): p. 1-45. 
[4]. Chen, J. and X.-F. Huang, The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. 
Journal of Clinical Lipidology, 2009. 3(3): p. 154-158. 
[5]. EFSA Panel on Dietetic Products, N.a.A.N., Scientific Opinion on the substantiation of a health claim related to 3 
g/day plant sterols/stanols and lowering blood LDL-cholesterol and reduced risk of (coronary) heart disease 
pursuant to Article 19 of Regulation (EC) No 1924/2006. EFSA Journal 2012. 10(5): p. 2693-2708. 
[6]. EFSA Panel on Dietetic Products, N.a.A.N., Scientific Opinion on the substantiation of a health claim related to oat 
beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 
of Regulation (EC) No 1924/2006. EFSA Journal 2010. 8(12): p. 1885-1900. 
[7]. EFSA Panel on Dietetic Products, N.a.A.N., Scientific Opinion on the substantiation of a health claim related to 
barley beta-glucans and lowering of blood cholesterol and reduced risk of (coronary) heart disease pursuant to 
Article 14 of Regulation (EC). No 1924/2006. EFSA Journal 2011. 9(12): p. 2471-2484. 
[8]. Rozner, S. and N. Garti, The activity and absorption relationship of cholesterol and phytosterols. Colloids and 
Surfaces A: Physicochemical and Engineering Aspects, 2006. 282–283(0): p. 435-456. 
[9]. Sudhop, T., D. Lütjohann, and K. von Bergmann, Sterol transporters: targets of natural sterols and new lipid 
lowering drugs. Pharmacology & Therapeutics, 2005. 105(3): p. 333-341. 
[10]. Kruit, J.K., et al., Emerging roles of the intestine in control of cholesterol metabolism. World Journal of 
Gastroenterology, 2006. 12(40): p. 6429-6439. 
[11]. van der Wulp, M.Y.M., H.J. Verkade, and A.K. Groen, Regulation of cholesterol homeostasis. Molecular and 
Cellular Endocrinology, 2013. 368(1–2): p. 1-16. 
[12]. Wilson, M.D. and L.L. Rudel, Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. 
Journal of Lipid Research, 1994. 35(6): p. 943-55. 
[13]. Ginter PhD, D.E., Cardiovascular disease prevention in eastern Europe. Nutrition, 1998. 14(5): p. 452-457. 
[14]. Porter, C.J.H., et al., Enhancing intestinal drug solubilisation using lipid-based delivery systems. Advanced Drug 
Delivery Reviews, 2008. 60(6): p. 673-691. 
[15]. Gil-Ramírez, A. and C. Soler-Rivas, The use of edible mushroom extracts as bioactive ingredients to design novel 
functional foods with hypocholesterolemic activities, in Mushrooms: Cultivation, Antioxidant Properties and Health 
Benefits, G. Pesti, Editor. 2014, Nova Science Publishers: New York. p. 43-73. 
[16]. Chiang, J.Y., Bile acids: regulation of synthesis. J Lipid Res, 2009. 50(10): p. 1955-66. 
General Introduction 
 
66 
 
[17]. Geyer, J., T. Wilke, and E. Petzinger, The solute carrier family SLC10: more than a family of bile acid transporters 
regarding function and phylogenetic relationships. Naunyn Schmiedebergs Arch Pharmacol, 2006. 372(6): p. 
413-31. 
[18]. Silverstein, R.L. and M. Febbraio, CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, 
and behavior. Sci Signal, 2009. 2(72). 
[19]. Dikkers, A. and U.J. Tietge, Biliary cholesterol secretion: more than a simple ABC. World Journal of 
Gastroenterology, 2010. 16: p. 5936-5945. 
[20]. van Bennekum, A., et al., Class B scavenger receptor-mediated intestinal absorption of dietary beta-carotene and 
cholesterol. Biochemistry, 2005. 44(11): p. 4517-25. 
[21]. Turley, S.D. and J.M. Dietschy, Sterol absorption by the small intestine. Curr Opin Lipidol, 2003. 14(3): p. 233-40. 
[22]. Jia, L., J.L. Betters, and L. Yu, Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol 
transport. Annu Rev Physiol, 2011. 73: p. 239-59. 
[23]. Davis, H.R., Jr., et al., Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter 
and a key modulator of whole-body cholesterol homeostasis. J Biol Chem, 2004. 279(32): p. 33586-92. 
[24]. Yu, L., et al., Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. 
J Biol Chem, 2006. 281(10): p. 6616-24. 
[25]. Sharpe, L.J., et al., The UPS and downs of cholesterol homeostasis. Trends in Biochemical Sciences, 2014. 
39(11): p. 527-535. 
[26]. Calpe-Berdiel, L., J.C. Escolà-Gil, and F. Blanco-Vaca, New insights into the molecular actions of plant sterols 
and stanols in cholesterol metabolism. Atherosclerosis, 2009. 203(1): p. 18-31. 
[27]. Kusuhara, H. and Y. Sugiyama, ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch, 2007. 453(5): 
p. 735-44. 
[28]. Yu, L., et al., Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional 
absorption of dietary cholesterol. J Clin Invest, 2002. 110(5): p. 671-80. 
[29]. Berge, K.E., et al., Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC 
transporters. Science, 2000. 290(5497): p. 1771-1775. 
[30]. Cummins, C.I. and D.J. Hangelsdorf, Liver X receptors and cholesterol homeostasis: spotlight on the adrenal 
gland. Biocheistry Society Transcations, 2006. 34: p. 1110-1113. 
[31]. Repa, J.J., et al., Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X 
receptors alpha and beta. J Biol Chem, 2002. 277(21): p. 18793-800. 
[32]. Acetyl-CoA Acetyltransferase 1 in  The GeneCards Human. Weizmann Institute of Science, Rehovot, Israel. 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=ACAT1 16/10/2014. 
[33]. Acetyl-CoA Acetyltransferase 2, The GeneCards Human. Weizmann Institute of Science, Rehovot, Israel. 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=ACAT2 16/10/2014. 
[34]. Sterol O-Acyltransferase 1, The GeneCards Human. Weizmann Institute of Science, Rehovot, Israel. 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=SOAT1 16/10/2014 
General Introduction 
 
67 
 
[35]. Sterol O-Acyltransferase 2, The GeneCards Human. Weizmann Institute of Science, Rehovot, Israel. 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=SOAT2 16/10/2014 
[36]. Chang, T.-Y., et al., Acyl-coenzyme A:cholesterol acyltransferases. 2009. 297(1): p. E1-E9. 
[37]. Tabas, I., Cholesterol in health and disease. Journal of Clinical Investigation, 2002. 110(5): p. 583-590. 
[38]. Hussain, M.M., J. Shi, and P. Dreizen, Microsomal triglyceride transfer protein and its role in apoB-lipoprotein 
assembly. Journal of Lipid Research, 2003. 44(1): p. 22-32. 
[39]. Sahebkar, A., G.T. Chew, and G.F. Watts, Recent advances in pharmacotherapy for hypertriglyceridemia. 
Progress in Lipid Research, 2014(0). 
[40]. Mahmood Hussain, M., A proposed model for the assembly of chylomicrons. Atherosclerosis, 2000. 148(1): p. 1-
15. 
[41]. Lammert, F. and D.Q.H. Wang, New insights into the genetic regulation of intestinal cholesterol absorption. 
Gastroenterology, 2005. 129(2): p. 718-734. 
[42]. Plana, N., Peroxidacion lipidica y factores de riesgo cardiovascular, in Departamento de Medicina y Cirujia de la 
Facultad de Medicina de la Universidad de Roivira I Virgili. 1993, Universidad Roivira y Vigili: Reus. 
[43]. Gill, S., et al., Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol 
synthesis beyond HMG-CoA reductase. Cell Metabolism, 2011. 13(3): p. 260-273. 
[44]. Laden, B.P. and T.D. Porter, Resveratrol inhibits human squalene monooxygenase. Nutrition Research, 2001. 
21(5): p. 747-753. 
[45]. Abe, I., et al., Green tea polyphenols: Novel and potent inhibitors of squalene epoxidase. Biochemical and 
Biophysical Research Communications, 2000. 268(3): p. 767-771. 
[46]. Hulce, J.J., et al., Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Meth, 2013. 
10(3): p. 259-264. 
[47]. Burg, J.S. and P.J. Espenshade, Regulation of HMG-CoA reductase in mammals and yeast. Progress in Lipid 
Research, 2011. 50(4): p. 403-410. 
[48]. 3-Hydroxy-3-Methylglutaryl-CoA Reductase, The GeneCards Human. Weizmann Institute of Science, Rehovot, 
Israel. http://www.genecards.org/cgi-bin/carddisp.pl?gene=HMGCR. 15/10/2014. 
[49]. Ikonen, E., Mechanisms for cellular cholesterol transport: Defects and human disease. Vol. 86. 2006. 1237-1261. 
[50]. Derewiaka, D. and E. Molińska, Cholesterol transformations during heat treatment. Food Chemistry, 2015. 171(0): 
p. 233-240. 
[51]. Lee, J.P., et al., The TRC8 ubiquitin ligaseis sterol regulated and Iinteracts with lipid and protein biosynthetic 
pathways. Molecular Cancer Research, 2010. 8(1): p. 93-106. 
[52]. Norlin, M. and K. Wikvall, Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med, 2007. 7(2): p. 
199-218. 
[53]. Temel, R.E., et al., Hepatic Niemann-Pick C1–like 1 regulates biliary cholesterol concentration and is a target of 
ezetimibe. The Journal of Clinical Investigation, 2007. 117(7): p. 1968-1978. 
General Introduction 
 
68 
 
[54]. van der Velde, A.E., et al., Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol 
excretion in mice. Gastroenterology, 2007. 133(3): p. 967-975. 
[55]. Tang, W., et al., Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann–Pick C1-Like 1 only 
in liver. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2011. 1811(9): p. 549-555. 
[56]. Brufau, G., A.K. Groen, and F. Kuipers, Reverse cholesterol transport revisited: Contribution of biliary versus 
intestinal cholesterol excretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011. 31(8): p. 1726-1733. 
[57]. Temel, R.E. and J. Mark Brown, A new framework for reverse cholesterol transport: Non-biliary contributions to 
reverse cholesterol transport. World Journal of Gastroenterology, 2010. 16(47): p. 5946-5952. 
[58]. Bura, K.S., et al., Intestinal SR-BI does not impact cholesterol absorption or transintestinal cholesterol efflux in 
mice. Journal of Lipid Research, 2013. 54(6): p. 1567-1577. 
[59]. de Boer, J.F., et al., Inhibition of NPC1L1 increases transintestinal cholesterol excretion (tice) dependent on 
Abcg5/g8 but independent of plasma Apob-containing lipoproteins. Atherosclerosis, 2014. 235(2): p. e47. 
[60]. Danielsen, E.M., et al., Apolipoprotein A-1 (apoA-1) deposition in, and release from, the enterocyte brush border: 
A possible role in transintestinal cholesterol efflux (TICE)? Biochimica et Biophysica Acta (BBA) - Biomembranes, 
2012. 1818(3): p. 530-536. 
[61]. Vrins, C.L.J., From blood to gut: Direct secretion of cholesterol via transintestinal cholesterol efflux. World Journal 
of Gastroenterology, 2010. 16(47): p. 5953-5957. 
[62]. van der Velde, A.E., G. Brufau, and A.K. Groen, Transintestinal cholesterol efflux. Current Opinion in Lipidology, 
2010. 21(3): p. 167-171 10.1097/MOL.0b013e3283395e45. 
[63]. Yun, J.W., Possible anti-obesity therapeutics from nature – A review. Phytochemistry, 2010. 71(14–15): p. 1625-
1641. 
[64]. Jeong, J.Y., et al., Optimization of pancreatic lipase inhibition by Cudrania tricuspidata fruits using response 
surface methodology. Bioorganic & Medicinal Chemistry Letters, 2014. 24(10): p. 2329-2333. 
[65]. Liu, S., et al., Inhibition of pancreatic lipase, α-glucosidase, α-amylase, and hypolipidemic effects of the total 
flavonoids from Nelumbo nucifera leaves. Journal of Ethnopharmacology, 2013. 149(1): p. 263-269. 
[66]. Xu, N., U. Ekstrom, and P. Nilsson-Ehle, ACTH decreases the expression and secretion of apolipoprotein B in 
HepG2 cell cultures. J Biol Chem, 2001. 276(42): p. 38680-4. 
[67]. Cuchel, M., et al., Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J 
Med, 2007. 356(2): p. 148-56. 
[68]. Chen, H.C. and R.V. Farese, Jr., Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons 
from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol, 2005. 25(3): p. 482-6. 
[69]. Karimian Pour, N. and K. Adeli, Insulin silences Apolipoprotein B mRNA translation by inducing intracellular traffic 
into cytoplasmic RNA granules. Biochemistry, 2011. 50(32): p. 6942-6950. 
[70]. Cohen, D.E. and M.C. Carey, Rapid (1 hour) high-performance gel-filtration chromatography resolves coexisting 
simple micelles, mixed micelles and vesicles in bile. Journal of Lipid Research, 1990. 31(11): p. 2103-2112. 
General Introduction 
 
69 
 
[71]. Temel, R.E., et al., Intestinal cholesterol absorption is substantially reduced in mice deficient in both ABCA1 and 
ACAT2. J Lipid Res, 2005. 46(11): p. 2423-31. 
[72]. Kluge, A.F. and R.C. Petter, Acylating drugs: redesigning natural covalent inhibitors. Current Opinion in Chemical 
Biology, 2010. 14(3): p. 421-427. 
[73]. Altmann, S.W., et al., Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004. 
303(5661): p. 1201-1204. 
[74]. Garcia-Calvo, M., et al., The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A, 
2005. 102(23): p. 8132-7. 
[75]. Ge, L., et al., The cholesterol absorption inhibitor Ezetimibe acts by blocking the sterol-induced internalization of 
NPC1L1. Cell Metabolism, 2008. 7(6): p. 508-519. 
[76]. Davis, H.R. and E.P. Veltri, Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol 
absorption and treat hyperlipidemia. J Atheroscler Thromb, 2007. 14(3): p. 99-108. 
[77]. Sugizaki, T., et al., The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via 
decreased liver X receptor (LXR) activity in liver of obese male mice. Endocrinology, 2014. 155(8): p. 2810-9. 
[78]. Arya, N., et al., Some molecular targets for antihyperlipidemic drug research. European Journal of Medicinal 
Chemistry, 2014. 85(0): p. 535-568. 
[79]. Dražić, T., et al., Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors. European Journal 
of Medicinal Chemistry, 2014. 87(0): p. 722-734. 
[80]. Yu, X.-H., et al., ABCG5/ABCG8 in cholesterol excretion and atherosclerosis. Clinica Chimica Acta, 2014. 428(0): 
p. 82-88. 
[81]. Dieter, M.Z., et al., Expression and regulation of the sterol half-transporter genes ABCG5 and ABCG8 in rats. 
Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 2004. 139(4): p. 209-218. 
[82]. Kourounakis, A.P., A.N. Matralis, and A. Nikitakis, Design of more potent squalene synthase inhibitors with multiple 
activities. Bioorganic & Medicinal Chemistry, 2010. 18(21): p. 7402-7412. 
[83]. An, S., et al., Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon. Bioorganic 
& Medicinal Chemistry Letters, 2007. 17(4): p. 1112-1116. 
[84]. Choi, J.H., et al., Glabrol, an acyl-coenzyme A: Cholesterol acyltransferase inhibitor from licorice roots. Journal of 
Ethnopharmacology, 2007. 110(3): p. 563-566. 
[85]. Jia, Y., et al., Ursolic acid is a PPAR-α agonist that regulates hepatic lipid metabolism. Bioorganic and Medicinal 
Chemistry Letters, 2011. 21(19): p. 5876-5880. 
[86]. Woo, M.N., et al., Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose 
concentration in high-fat fed C57BL/6N mice. Chemico-Biological Interactions, 2010. 186(3): p. 316-322. 
[87]. Taghibiglou, C., et al., Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis 
and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase 
(ACAT) inhibitor. Biochemical Pharmacology, 2002. 63(3): p. 349-360. 
General Introduction 
 
70 
 
[88]. Hogue, J.-C., et al., Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 
and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism, 2008. 57(2): p. 
246-254. 
[89]. Skoog, M., et al., ACTH reduces the rise in ApoB-48 levels after fat intake. Atherosclerosis, 2007. 191(2): p. 433-
439. 
[90]. Nieto-Ramirez, I.J., et al. (2013) Las estatinas: química, técnicas analíticas, biosíntesis y farmacocinética. Vitae 
20, 49-63. 
[91]. Singh, D.K., S. Banerjee, and T.D. Porter, Green and black tea extracts inhibit HMG-CoA reductase and activate 
AMP kinase to decrease cholesterol synthesis in hepatoma cells. The Journal of Nutritional Biochemistry, 2009. 
20(10): p. 816-822. 
[92]. Zang, M., et al., Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated 
atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 2006. 55(8): p. 2180-91. 
[93]. Tavridou, A., et al., Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene 
synthase and lipid biosynthesis. European Journal of Pharmacology, 2006. 535(1–3): p. 34-42. 
[94]. Zerenturk, E.J., et al., The endogenous regulator 24(S),25-epoxycholesterol inhibits cholesterol synthesis at 
DHCR24 (Seladin-1). Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012. 1821(9): 
p. 1269-1277. 
[95]. Ling, W.H. and P.J.H. Jones, Dietary phytosterols: A review of metabolism, benefits and side effects. Life 
Sciences, 1995. 57(3): p. 195-206. 
[96]. Thurnham, D.I., Functional foods: cholesterol-lowering benefits of plant sterols. Br J Nutr, 1999. 82(4): p. 255-6. 
[97]. Miettinen, T.A., et al., Reduction of serum cholesterol with sitostanol-ester margarine in a mildly 
hypercholesterolemic population. New England Journal of Medicine, 1995. 333(20): p. 1308-1312. 
[98]. Heinemann, T., O. Leiss, and K. von Bergmann, Effect of low-dose sitostanol on serum cholesterol in patients with 
hypercholesterolemia. Atherosclerosis, 1986. 61(3): p. 219-223. 
[99]. Wong, A., Chemical and microbiological considerations of phytosterols and their relative efficacies in functional 
foods for the lowering of serum cholesterol levels in humans: A review. Journal of Functional Foods, 2014. 6(0): 
p. 60-72. 
[100]. Jonnala, R.S., N.T. Dunford, and K.E. Dashiell, Tocopherol, phytosterol and phospholipid compositions of new 
high oleic peanut cultivars. Journal of Food Composition and Analysis, 2006. 19(6–7): p. 601-605. 
[101]. Martins, C.M., et al., Common sources and composition of phytosterols and their estimated intake by the 
population in the city of São Paulo, Brazil. Nutrition, 2013. 29(6): p. 865-871. 
[102]. Chirinos, R., et al., Sacha inchi (Plukenetia volubilis): A seed source of polyunsaturated fatty acids, tocopherols, 
phytosterols, phenolic compounds and antioxidant capacity. Food Chemistry, 2013. 141(3): p. 1732-1739. 
[103]. Trautwein, E.A., et al., Proposed mechanisms of cholesterol-lowering action of plant sterols. European Journal of 
Lipid Science and Technology, 2003. 105(3-4): p. 171-185. 
General Introduction 
 
71 
 
[104]. Mel’nikov, S.M., J.W.M. Seijen ten Hoorn, and A.P.A.M. Eijkelenboom, Effect of phytosterols and phytostanols on 
the solubilization of cholesterol by dietary mixed micelles: an in vitro study. Chemistry and Physics of Lipids, 
2004. 127(2): p. 121-141. 
[105]. Matsuoka, K., et al., Competitive solubilization of cholesterol and β-sitosterol with changing biliary lipid 
compositions in model intestinal solution. Chemistry and Physics of Lipids, 2012. 165(1): p. 7-14. 
[106]. Matsuoka, K., et al., NMR study on solubilization of sterols and aromatic compounds in sodium taurodeoxycholate 
micelles. Bulletin of the Chemical Society of Japan, 2007. 80(12): p. 2334-2341. 
[107]. Kaneko, E., et al., Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X 
receptor agonist. J Biol Chem, 2003. 278(38): p. 36091-8. 
[108]. García-Llatas, G. and M.T. Rodríguez-Estrada, Current and new insights on phytosterol oxides in plant sterol-
enriched food. Chemistry and Physics of Lipids, 2011. 164(6): p. 607-624. 
[109]. Nguyen, L.B., et al., Deficient ileal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in sitosterolemia: 
Sitosterol is not a feedback inhibitor of intestinal cholesterol biosynthesis. Metabolism, 1994. 43(7): p. 855-859. 
[110]. Schepetkin, I.A. and M.T. Quinn, Botanical polysaccharides: Macrophage immunomodulation and therapeutic 
potential. International Immunopharmacology, 2006. 6(3): p. 317-333. 
[111]. Havrlentová, M., et al., Cereal β-glucans and their significance for the preparation of functional foods - a review. 
Czech Journal of Food Sciences, 2011. 29(1): p. 1-14. 
[112]. Jeon, Y.-J., F. Shahidi, and S.-K. Kim, Preparation of chitin and chitosa oligomers and their applications in 
physiological functional foods. Food Reviews International, 2000. 16(2): p. 159-176. 
[113]. Kaczmarczyk, M.M., M.J. Miller, and G.G. Freund, The health benefits of dietary fiber: Beyond the usual suspects 
of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism, 2012. 61(8): p. 1058-1066. 
[114]. Zacherl, C., P. Eisner, and K.-H. Engel, In vitro model to correlate viscosity and bile acid-binding capacity of 
digested water-soluble and insoluble dietary fibres. Food Chemistry, 2011. 126(2): p. 423-428. 
[115]. Gohil, D.D. and S.S. Lele, Insoluble vegetable fiber as a potential functional ingredient: in vitro studies on 
hypoglycemic and hypocholesterolemic effect. American Journal of Food Science and Technology, 2014. 2(2): 
p. 48-52. 
[116]. Drozdowski, L.A., et al., β-Glucan extracts inhibit the in vitro intestinal uptake of long-chain fatty acids and 
cholesterol and down-regulate genes involved in lipogenesis and lipid transport in rats. The Journal of Nutritional 
Biochemistry, 2010. 21(8): p. 695-701. 
[117]. Hu, Y.-B., Z. Wang, and S.-Y. Xu, Corn bran dietary fibre modified by xylanase improves the mRNA expression of 
genes involved in lipids metabolism in rats. Food Chemistry, 2008. 109(3): p. 499-505. 
[118]. Parnell, J.A. and R.A. Reimer, Effect of prebiotic fibre supplementation on hepatic gene expression and serum 
lipids: a dose–response study in JCR:LA-cp rats. The British journal of nutrition, 2010. 103(11): p. 
10.1017/S0007114509993539. 
General Introduction 
 
72 
 
[119]. Bartley, G.E., et al., Hypocholesterolemic effects of hydroxypropyl methylcellulose are mediated by altered gene 
expression in hepatic bile and cholesterol pathways of male hamsters. The Journal of Nutrition, 2010. 140(7): p. 
1255-1260. 
[120]. Jones, P.J.H., Dietary agents that target gastrointestinal and hepatic handling of bile acids and cholesterol. 
Journal of Clinical Lipidology, 2008. 2(2): p. S4-S10. 
[121]. Cheung, P.C.K., Mushrooms as functional foods, P.C. Cheung, Editor. 2008, John Wiley & Sons, Inc., publications: 
New Jersey. 
[122]. Harish Prashanth, K.V. and R.N. Tharanathan, Chitin/chitosan: modifications and their unlimited application 
potential—an overview. Trends in Food Science & Technology, 2007. 18(3): p. 117-131. 
[123]. Liao, F.-H., et al., Chitosan supplementation lowers serum lipids and maintains normal calcium, magnesium, and 
iron status in hyperlipidemic patients. Nutrition Research, 2007. 27(3): p. 146-151. 
[124]. Sugano, M., et al., Hypocholesterolemic action of chitosans with different viscosity in rats. Lipids, 1988. 23(3): p. 
187-191. 
[125]. Ylitalo, R., et al., Cholesterol-lowering properties and safety of chitosan. Arzneimittel-Forschung, 2002. 52(1): p. 
1-7. 
[126]. Bobek, P., et al., Cholesterol-lowering effect of the mushroom Pleurotus ostreatus in hereditary 
hypercholesterolemic rats. Annals of Nutrition and Metabolism, 1991. 35(4): p. 191-195. 
[127]. Bobek, P., L. Kuniak, and L. Ozdín, The mushroom Pleurotus ostreatus reduces secretion and accelerates the 
fractional turnover rate of Very-Low-Density Lipoproteins in the rat. Annals of Nutrition and Metabolism, 1993. 
37(3): p. 142-145. 
[128]. Bobek, P., L. Ozdin, and L. Kuniak, Mechanism of hypocholesterolemic effect of oyster mushroom (Pleurotus 
ostreatus) in rats: reduction of cholesterol absorption and increase of plasma cholesterol removal. Zeitschrift für 
Ernährungswissenschaft, 1994. 33(1): p. 44-50. 
[129]. Bobek, P., Ĺ. Ozdín, and Ĺ. Kuniak, Effect of oyster mushroom and isolated β-glucan on lipid peroxidation and on 
the activities of antioxidative enzymes in rats fed the cholesterol diet. The Journal of Nutritional Biochemistry, 
1997. 8(8): p. 469-471. 
[130]. Bobek, P. and Š. Galbavý, Hypocholesterolemic and antiatherogenic effect of oyster mushroom (Pleurotus 
ostreatus) in rabbits. Food / Nahrung, 1999. 43(5): p. 339-342. 
[131]. Bobek PhD, P., L. Ozdín PhD, and Š. Galbavý Md, Dose- and time-dependent hypocholesterolemic effect of 
Oyster Mushroom (Pleurotus ostreatus) in rats. Nutrition, 1998. 14(3): p. 282-286. 
[132]. Opletal, L., et al., Evidence for the anti-hyperlipidaemic activity of the edible fungus Pleurotus ostreatus. British 
Journal of Biomedical Science, 1997. 54(4): p. 240-243. 
[133]. Hu, S.H., et al., Antihyperlipidemic and antioxidant effects of extracts from Pleurotus citrinopileatus. Journal of 
Agricultural and Food Chemistry, 2006. 54(6): p. 2103-2110. 
[134]. Alam, N., et al., Dietary effect of Pleurotus eryngii on biochemical function and histology in hypercholesterolemic 
rats. Saudi Journal of Biological Sciences, 2011. 18(4): p. 403-409. 
General Introduction 
 
73 
 
[135]. Mizutani, T., et al., Hypolipidemic effect of Pleurotus eryngii extract in fat-loaded mice. Journal of Nutritional 
Science and Vitaminology, 2010. 56(1): p. 48-53. 
[136]. Chen, S.-Y., et al., Contents of lovastatin, γ-aminobutyric acid and ergothioneine in mushroom fruiting bodies and 
mycelia. LWT - Food Science and Technology, 2012. 47(2): p. 274-278. 
[137]. Kabir, Y. and S. Kimura, Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). 
Journal of Nutritional Science and Vitaminology, 1989. 35(1): p. 91-94. 
[138]. R. Russell M, P., Ganoderma – A therapeutic fungal biofactory. Phytochemistry, 2006. 67(18): p. 1985-2001. 
[139]. Berger, A., et al., Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and 
minipigs. Lipids in Health and Disease, 2004. 3(1): p. 2. 
[140]. Seto, S., et al., Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) 
mice. Phytomedicine, 2009. 16: p. 426 - 436. 
[141]. Jeong, S.C., et al., White button mushroom (Agaricus bisporus) lowers blood glucose and cholesterol levels in 
diabetic and hypercholesterolemic rats. Nutrition Research, 2010. 30(1): p. 49-56. 
[142]. Fukushima, M., et al., Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (Agaricus bisporus) 
fiber and sugar beet fiber. The Journal of Nutrition, 2000. 130(9): p. 2151-2156. 
[143]. Fukushima, M., et al., Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) 
fiber, and enokitake (Flammulina velutipes) fiber in rats. Experimental Biology and Medicine, 2001. 226(8): p. 
758-765. 
[144]. Hiwatashi, K., et al., Yamabushitake mushroom (Hericium erinaceus) improved lipid metabolism in mice fed a 
high-fat diet. Bioscience, Biotechnology, and Biochemistry, 2010. 74(7): p. 1447-1451. 
[145]. Mori, K., et al., Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa 
(Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E–deficient mice. Nutrition Research, 
2008. 28(5): p. 335-342. 
[146]. Sato, M., et al., Profiling of hepatic gene expression of mice fed with edible Japanese mushrooms by DNA 
microarray analysis: comparison among Pleurotus ostreatus, Grifola frondosa, and Hypsizigus marmoreus. 
Journal of Agricultural and Food Chemistry, 2011. 59(19): p. 10723-10731. 
[147]. Cheung, P.C.K., The hypocholesterolemic effect of two edible mushrooms: Auricularia auricula (tree-ear) and 
Tremella fuciformis (white jelly-leaf) in hypercholesterolemic rats1. Nutrition Research, 1996. 16(10): p. 1721-
1725. 
[148]. Tamez de la O, E.J., et al., Hypoglycemic and hypocholesterolemic effects of aqueous and methanolic extracts 
of Lentinus lepideus, Calvatia cyathiformis and Ganoderma applanatum, from Northeastern Mexico, in Wistar 
rats. Journal of Medicinal Plants Research, 2013. 7: p. 661-668. 
[149]. Khatun, K., et al., Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. Mymensingh 
medical journal : MMJ, 2007. 16(1): p. 94-99. 
[150]. Schneider, I., et al., Lipid lowering effects of oyster mushroom (Pleurotus ostreatus) in humans. Journal of 
Functional Foods, 2011. 3(1): p. 17-24. 
General Introduction 
 
74 
 
[151]. Wachtel-Galor, S., B. Tomlinson, and I.F.F. Benzie, Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal 
mushroom: biomarker responses in a controlled human supplementation study. British Journal of Nutrition, 2004. 
91(02): p. 263-269. 
[152]. Shao, G., Treatment of hyperlipidemia with cultivated Cordyceps--a double-blind, randomized placebo control 
trial. Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine / Zhongguo 
Zhong xi yi jie he yan jiu hui (chou), Zhong yi yan jiu yuan, zhu ban, 1985. 5(11): p. 652-4, 642. 
[153]. Poddar, K.H., et al., Positive effect of mushrooms substituted for meat on body weight, body composition, and 
health parameters. A 1-year randomized clinical trial. Appetite, 2013. 71(0): p. 379-387. 
[154]. Mattila, P., et al., Sterol and vitamin D-2 contents in some wild and cultivated mushrooms. Food Chemistry, 2002. 
76(3): p. 293-298. 
[155]. Teichmann, A., et al., Sterol and vitamin D-2 concentrations in cultivated and wild grown mushrooms: Effects of 
UV irradiation. Lwt-Food Science and Technology, 2007. 40(5): p. 815-822. 
[156]. Kalač, P., Chemical composition and nutritional value of European species of wild growing mushrooms: A review. 
Food Chemistry, 2009. 113(1): p. 9-16. 
[157]. Kobori, M., et al., Ergosterol peroxide from an edible mushroom suppresses inflammatory responses in RAW264.7 
macrophages and growth of HT29 colon adenocarcinoma cells. British Journal of Pharmacology, 2007. 150(2): 
p. 209-219. 
[158]. Villares, A., et al., Storage temperature and UV-irradiation influence on the ergosterol content in edible 
mushrooms. Food Chemistry, 2014. 147(0): p. 252-256. 
[159]. Jasinghe, V.J. and C.O. Perera, Distribution of ergosterol in different tissues of mushrooms and its effect on the 
conversion of ergosterol to vitamin D2 by UV irradiation. Food Chemistry, 2005. 92(3): p. 541-546. 
[160]. Yokokawa, H. and T. Mitsuhashi, The sterol composition of mushrooms. Phytochemistry, 1981. 20(6): p. 1349-
1351. 
[161]. Liu, Y.-T., et al., Chemical composition of five wild edible mushrooms collected from Southwest China and their 
antihyperglycemic and antioxidant activity. Food and Chemical Toxicology, 2012. 50(5): p. 1238-1244. 
[162]. Lv, G.-p., et al., Comparison of sterols and fatty acids in two species of Ganoderma. Chemistry Central Journal, 
2012. 6(1): p. 10. 
[163]. Kalogeropoulos, N., et al., Bioactive microconstituents and antioxidant properties of wild edible mushrooms from 
the island of Lesvos, Greece. Food and Chemical Toxicology, 2013. 55(0): p. 378-385. 
[164]. Fernández, C., et al., Inhibition of cholesterol biosynthesis by Delta22-unsaturated phytosterols via competitive 
inhibition of sterol Delta24-reductase in mammalian cells. Biochem. J., 2002. 366(1): p. 109-119. 
[165]. Aida, F.M.N.A., et al., Mushroom as a potential source of prebiotics: a review. Trends in Food Science & 
Technology, 2009. 20(11–12): p. 567-575. 
[166]. Gonzaga, M.L.C., et al., Isolation and characterization of polysaccharides from Agaricus blazei Murill. 
Carbohydrate Polymers, 2005. 60(1): p. 43-49. 
General Introduction 
 
75 
 
[167]. Zhang, M., P.C.K. Cheung, and L. Zhang, Evaluation of mushroom dietary fiber (nonstarch polysaccharides) from 
sclerotia of Pleurotus tuber-regium (Fries) singer as a potential antitumor agent. Journal of Agricultural and Food 
Chemistry, 2001. 49(10): p. 5059-5062. 
[168]. Synytsya, A. and M. Novák, Structural diversity of fungal glucans. Carbohydrate Polymers, 2013. 92(1): p. 792-
809. 
[169]. Nitschke, J., et al., A new colorimetric method to quantify β-1,3-1,6-glucans in comparison with total β-1,3-glucans 
in edible mushrooms. Food Chemistry, 2011. 127(2): p. 791-796. 
[170]. Manzi, P. and L. Pizzoferrato, Beta-glucans in edible mushrooms. Food Chemistry, 2000. 68(3): p. 315-318. 
[171]. Manzi, P., A. Aguzzi, and L. Pizzoferrato, Nutritional value of mushrooms widely consumed in Italy. Food 
Chemistry, 2001. 73(3): p. 321-325. 
[172]. Manzi, P., et al., Commercial mushrooms: nutritional quality and effect of cooking. Food Chemistry, 2004. 84(2): 
p. 201-206. 
[173]. Lee, J.-S., et al., Immunomodulatory effect of mushrooms on cytotoxic activity and cytokine production of intestinal 
lamina propria leukocytes does not necessarily depend on β-glucan contents. Food Chemistry, 2011. 126(4): p. 
1521-1526. 
[174]. Rop, O., J. Mlcek, and T. Jurikova, Beta-glucans in higher fungi and their health effects. Nutr Rev, 2009. 67(11): 
p. 624-31. 
[175]. Caz, V., C. Soler-Rivas, and M. Tabernero. Oyster mushroom (Pleurotus ostreatus) decreases blood cholesterol 
levels in diet-induced hypercholesterolemic mice. in 20th Congress of Nutrition. 2013. Granada, Spain. 
[176]. Vetter, J., Chitin content of cultivated mushrooms Agaricus bisporus, Pleurotus ostreatus and Lentinula edodes. 
Food Chemistry, 2007. 102(1): p. 6-9. 
[177]. Liu, D.-Z., et al., Vibralactone:  A lipase inhibitor with an unusual fused β-Lactone produced by cultures of the 
Basidiomycete Boreostereum vibrans. Organic Letters, 2006. 8(25): p. 5749-5752. 
[178]. Cheung, Y.-C., et al., Molecular properties and antioxidant activities of polysaccharide–protein complexes from 
selected mushrooms by ultrasound-assisted extraction. Process Biochemistry, 2012. 47(5): p. 892-895. 
[179]. Kozarski, M., et al., Antioxidative and immunomodulating activities of polysaccharide extracts of the medicinal 
mushrooms Agaricus bisporus, Agaricus brasiliensis, Ganoderma lucidum and Phellinus linteus. Food 
Chemistry, 2011. 129(4): p. 1667-1675. 
[180]. Birari, R.B. and K.K. Bhutani, Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug 
Discovery Today, 2007. 12(19–20): p. 879-889. 
[181]. Slanc, P., et al., Screening of wood damaging fungi and macrofungi for inhibitors of pancreatic lipase. 
Phytotherapy Research, 2004. 18(9): p. 758-762. 
[182]. Kumar, S.G., et al., Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan 
oligosaccharides in ob/ob mice. PROTEOMICS, 2009. 9(8): p. 2149-2162. 
[183]. Gunde-Cimerman, N., A. Plemenitas, and A. Cimerman, Pleurotus fungi produce mevinolin, an inhibitor of 
HMGCoA reductase. FEMS Microbiology Letters, 1993. 113(3): p. 333-337. 
General Introduction 
 
76 
 
[184]. Gunde-Cimerman, N., A. Plemenitaš, and A. Cimerman, A hydroxymethylglutaryl-CoA reductase inhibitor 
synthesized by yeasts. FEMS Microbiology Letters, 1995. 132(1–2): p. 39-43. 
[185]. Gunde-Cimerman, N., et al., Screening fungi for the production of an inhibitor of HMG CoA reductase: Production 
of mevinolin by the fungi of the genus Pleurotus. FEMS Microbiology Letters, 1993. 111(2-3): p. 203-206. 
[186]. Folkers, K., et al., Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of 
Sciences of the United States of America, 1990. 87(22): p. 8931-8934. 
[187]. Willis, R.A., et al., Lovastatin decreases coenzyme Q levels in rats. Proceedings of the National Academy of 
Sciences of the United States of America, 1990. 87(22): p. 8928-8930. 
[188]. Amin, D., et al., RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: 
Comparison with inhibitors of HMG-CoA reductase. Journal of Pharmacology and Experimental Therapeutics, 
1997. 281(2): p. 746-752. 
[189]. Hosoya, T., et al., Zaragozic acids production from discomycetes. Mycoscience, 1997. 38(3): p. 305-311. 
[190]. Yamada, T., et al., Structure and function of eritadenine and its 3-deaza analogues: Potent inhibitors of S-
adenosylhomocysteine hydrolase and hypocholesterolemic agents. Biochemical Pharmacology, 2007. 73(7): p. 
981-989. 
[191]. Sugiyama, K., T. Akachi, and A. Yamakawa, Eritadenine-induced alteration of hepatic phospholipid metabolism 
in relation to its hypocholesterolemic action in rats. The Journal of Nutritional Biochemistry, 1995. 6(2): p. 80-87. 
[192]. Dhingra, S. and M.P. Bansal, Modulation of hypercholesterolemia-induced alterations in apolipoprotein B and 
HMG-CoA reductase expression by selenium supplementation. Chemico-Biological Interactions, 2006. 161(1): p. 
49-56. 
[193]. Spolar, M.R., et al., Selenium-enriched Agaricus bisporus mushrooms suppress 7,12-dimethlybenz[a]anthracene 
bioactivation in mammary tissue. Cancer Letters, 1999. 138(1–2): p. 145-150. 
[194]. Martinez Aguda, R., Modeling the solubility of sclareol in organic solvents using solubility parameters, in Chemical 
engineering. 2007, Faculty of North Carolina State University Raleigh, North Carolina  
[195]. Dunford, N.T., S. Irmak, and R. Jonnala, Pressurised solvent extraction of policosanol from wheat straw, germ and 
bran. Food Chemistry, 2010. 119(3): p. 1246-1249. 
[196]. Joana Gil-Chávez, G., et al., Technologies for extraction and production of bioactive compounds to be used as 
nutraceuticals and food ingredients: An Overview. Comprehensive Reviews in Food Science and Food Safety, 
2013. 12(1): p. 5-23. 
[197]. Abboud, J.L.M. and R. Notari, Critical compilation of scales of solvent parameters. Part I. Pure, non-hydrogen 
bond donor solvents, in Pure and Applied Chemistry. 1999. p. 645. 
[198]. Miron, T.L., et al., Chemical composition of bioactive pressurized extracts of Romanian aromatic plants. Journal 
of Chromatography A, 2011. 1218(30): p. 4918-4927. 
[199]. Yang, F.Q., et al., Analysis of sterols and fatty acids in natural and cultured Cordyceps by one-step derivatization 
followed with gas chromatography–mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 
2009. 49(5): p. 1172-1178. 
General Introduction 
 
77 
 
[200]. Fan, X., et al., Optimization of technology for pressurized solvent extraction of lentinan by response surface 
method. Journal of Chinese Institute of Food Science and Technology, 2012. 12(2): p. 98-104. 
[201]. Aldars-Garcia, L., M. Palanisamy, and A. Gil-Ramírez. Extracción acelerada con disolventes (ASE) de 
polisacáridos de Boletus edulis. in VI Reunión de Expertos en Tecnología de Fluidos Comprimidos (FLUCOMP). 
2013. Madrid, Spain. 
[202]. Di, X., et al., Fingerprint profiling of acid hydrolyzates of polysaccharides extracted from the fruiting bodies and 
spores of Lingzhi by high-performance thin-layer chromatography. Journal of Chromatography A, 2003. 1018(1): 
p. 85-95. 
[203]. Lo, T.C.T., et al., Pressurized water extraction of polysaccharides as secondary metabolites from Lentinula 
edodes. Journal of Agricultural and Food Chemistry, 2007. 55(10): p. 4196-4201. 
[204]. Palanisamy, M., A. Gil-Ramírez, and L. Aldars-Garcia. Pressurized water extraction of bioactive b-glucans from 
the medicinal mushroom Ganoderma lucidum. in XVI Jornadas Nacionales de Nutrición Práctica. 2012. Madrid, 
Spain. 
[205]. Mendiola, J.A., et al., Use of compressed fluids for sample preparation: Food applications. Journal of 
Chromatography A, 2007. 1152(1–2): p. 234-246. 
[206]. Wang, B.J., et al., Free radical scavenging and apoptotic effects of Cordyceps sinensis fractionated by 
supercritical carbon dioxide. Food and Chemical Toxicology, 2005. 43(4): p. 543-552. 
[207]. Daintree, L.S., A. Kordikowski, and P. York, Separation processes for organic molecules using SCF Technologies. 
Advanced Drug Delivery Reviews, 2008. 60(3): p. 351-372. 
[208]. Liza, M.S., et al., Supercritical carbon dioxide extraction of bioactive flavonoid from Strobilanthes crispus (Pecah 
Kaca). Food and Bioproducts Processing, 2010. 88(2–3): p. 319-326. 
[209]. Wang, L. and C.L. Weller, Recent advances in extraction of nutraceuticals from plants. Trends in Food Science 
& Technology, 2006. 17(6): p. 300-312. 
[210]. Huang, S.-q. and Z.-x. Ning, Extraction of polysaccharide from Ganoderma lucidum and its immune enhancement 
activity. International Journal of Biological Macromolecules, 2010. 47(3): p. 336-341. 
[211]. Hsu, R.C., B.H. Lin, and C.W. Chen, The study of supercritical carbon dioxide extraction for Ganoderma Lucidum. 
Industrial & Engineering Chemistry Research, 2001. 40(20): p. 4478-4481. 
[212]. Ibrahim Abdullah, M., J.C. Young, and D.E. Games, Supercritical fluid extraction of carboxylic and fatty acids 
from Agaricus spp. mushrooms. Journal of Agricultural and Food Chemistry, 1994. 42(3): p. 718-722. 
[213]. Kitzberger, C.S.G., et al., Antioxidant and antimicrobial activities of shiitake (Lentinula edodes) extracts obtained 
by organic solvents and supercritical fluids. Journal of Food Engineering, 2007. 80(2): p. 631-638. 
[214]. Kitzberger, C.S.G., et al., Supercritical fluid extraction of shiitake oil: Curve modeling and extract composition. 
Journal of Food Engineering, 2009. 90(1): p. 35-43. 
[215]. Bhattacharya, M., P.P. Srivastav, and H.N. Mishra, Optimization of process variables for supercritical fluid 
extraction of ergothioneine and polyphenols from Pleurotus ostreatus and correlation to free-radical scavenging 
activity. The Journal of Supercritical Fluids, 2014. 95(0): p. 51-59. 
General Introduction 
 
78 
 
[216]. Mazzutti, S., et al., Supercritical fluid extraction of Agaricus brasiliensis: Antioxidant and antimicrobial activities. 
The Journal of Supercritical Fluids, 2012. 70(0): p. 48-56. 
 
 
  
 
 
 
 
   Objectives/Objetivos 
 
 
                  
 
 
 
 
 
 
                                            
Objectives/Objetivos 
 
81 
 
Objectives 
Edible mushrooms hold an interesting potential to develop specific food products with 
beneficial health properties because they contain many bioactive compounds showing not only 
hypocholesterolemic properties but many other health beneficial activities. Several cholesterol- 
lowering mechanisms have been postulate for specific fungal compounds including impairing of 
both endogenous cholesterol biosynthesis and exogenous cholesterol absorption. Therefore, this 
work was aimed to study the hypocholesterolemic properties of specific extracts obtained from 
commonly consumed edible mushrooms by advanced technologies. Experimental assays were 
planned in order to point out the compounds responsible for the hypocholesterolemic activities 
and define their different mechanisms of action using in vitro and in vivo tests including their effect 
as modulators of cholesterol-related gene expression. Results are expected to indicate whether 
the fungal extracts could be used as ingredients to design novel hypocholesterolemic food with 
higher effectivity than those actually marketed.  
Thus, in order to achieve this ambitious objective, the work plan is divided in several 
specific secondary objectives focused on the different potentially hypocholesterolemic fungal 
compounds such as: 
1. Evaluation of mushrooms polysaccharides as compounds able of impairing exogenous 
cholesterol absorption: 
 Screening of polysaccharides content in several mushroom species. 
 Optimization of selective polysaccharide extraction methods using environmentally 
friendly technologies from selected mushrooms. 
 Determination of the bile acids scavenging properties of specific mushrooms extracts 
during an in vitro digestion model.  
 Modulatory effect of specific polysaccharide extracts on cholesterol-related gene 
expression using in vitro models. 
 Hypocholesterolemic activity and modulatory effect on the expression of genes related 
to cholesterol metabolism using animal models. 
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2. Evaluation of fungal sterols as compounds able of impairing exogenous cholesterol 
absorption: 
 Identification and screening of the main fungal sterols present in several mushroom 
species. 
 Influence of cultivation parameters on the sterols content of several commercially 
available strains. 
 Optimization of pressurized extraction methods to obtain fungal sterols-enriched 
fractions. 
 Evaluation of the ability of fungal sterols as cholesterol displacers from dietary mixed 
micelles during an in vitro digestion model. 
 In vitro studies of fungal sterols as modulators of cholesterol-related gene expression.  
 Hypocholesterolemic activity and modulatory effect on the expression of genes related 
to cholesterol metabolism using animal models. 
 
3. Evaluation of mushroom extracts as pancreatic lipase inhibitors influencing diet lipid 
absorption: 
 Screening of several mushroom species with pancreatic lipase inhibitory activity. 
 Testing extraction processes to obtain lipase inhibitory extracts from mushrooms. 
 Study of the lipase inhibitory activities of specific mushroom extracts using an in vitro 
digestion model. 
 
4. Evaluation of mushroom extracts with HMGCR inhibitory activity able of impairing 
endogenous cholesterol biosynthesis: 
 Screening of the HMGCR inhibitory activities of mushrooms species and commercial 
varieties. 
 Selection of the optimal extraction method to obtain HMGCR inhibitors-enriched 
fractions. 
 Isolation and identification of the compounds responsible for HMGCR inhibition. 
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 Bioavailability study and influence on the cholesterol-related gene expression of 
mushrooms extracts with HMGCR inhibitory properties using in vitro models. 
 Hypocholesterolemic activity and modulatory effect on the expression of genes related 
to cholesterol metabolism using animal models. 
 
5. Evaluation of the hypocholesterolemic effect of a food matrix supplemented with specific 
mushroom extracts using animal trials: 
 Determination of the blood cholesterol lowering capacity of several supplemented food 
products.  
 Study of cholesterol-related gene modulation of supplemented food products. 
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Objetivos 
Los hongos comestibles constituyen una fuente potencialmente interesante para el 
desarrollo de productos alimenticios de uso específico para la salud debido a su amplio 
contenido en compuestos bioactivos, responsables no solo de sus propiedades 
hipocolesterolemicas sino de otros efectos beneficiosos. Son varios los mecanismos de reducción 
de colesterol que han sido vinculados a determinados compuesto fúngicos, incluyendo 
estrategias tanto de inhibición de síntesis endógena como de absorción exógena del mismo. Por 
tanto, este trabajo tuvo como objetivo estudiar las propiedades hipocolesterolemicas de extractos 
específicos obtenidos mediante el uso de tecnologías avanzadas a partir de hongos comestibles 
más comúnmente consumidos. Los ensayos experimentales se planearon con el fin de indicar los 
compuestos fúngicos responsables de las actividades hipocolesterolemicas y definir sus 
mecanismos de acción mediante el uso de ensayos in vitro e in vivo, así como su capacidad 
reguladora en la expresión de genes relacionados con el metabolismo del colesterol. Se espera 
que los resultados obtenidos indiquen si dichos extractos fúngicos pueden ser considerados 
como ingredientes para el diseño de nuevas matrices alimentarias con mayor capacidad 
hipocolesterolemica que aquellas disponibles actualmente en el mercado. 
 
Por lo tanto, con el fin de lograr este objetivo tan ambicioso, el plan de trabajo se divide 
en varios objetivos secundarios específicamente centrados en diferentes compuestos fúngicos 
considerados potencialmente hipocolesterolemiantes, descritos a continuación: 
1. Evaluación de polisacáridos fúngicos como compuestos capaces de impedir la absorción 
exógena de colesterol: 
 Análisis del contenido de polisacáridos en varias especies de hongos. 
 Optimización del proceso de extracción de polisacáridos fúngicos de varios hogos 
seleccionados mediante el uso de tecnologías respetuosas con el medio ambiente.  
 Determinación de la capacidad de captura de ácidos biliares por parte de extractos 
fúngicos específicos tras su aplicación a un modelo de digestión in vitro.  
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 Efecto modulador de polisacáridos específicos presentes en extractos fúngicos sobre 
la expresión de genes relacionados con el metabolismo del colesterol en modelos in 
vitro. 
 Actividad hipocolesterolemica y efecto modulador en la expresión de genes 
relacionados con el metabolismo del colesterol mediante el uso de modelos animales. 
  
2. Evaluación de polisacáridos fúngicos como compuestos capaces de impedir la absorción 
de colesterol exógeno. 
 Identificación y análisis de los principales esteroles fúngicos de varias especies de 
hongos. 
 Influencia de los parámetros de cultivo en el contenido de esteroles de diversas cepas 
de hongos comercialmente disponibles. 
 Optimización de un método de extracción presurizada para la obtención de fracciones 
enriquecidas en esteroles fúngicos. 
 Evaluación de la habilidad de desplazamiento del colesterol de las micelas mixtas de 
digestión por parte de esteroles fúngicos siguiendo un modelo de digestión in vitro. 
 Estudio in vitro de esteroles fúngicos como moduladores de la expresión de genes 
relacionados con el metabolismo del colesterol.  
 Actividad hipocolesterolemica y efecto modulador en la expresión de genes 
relacionados con el metabolismo del colesterol mediante el uso de modelos animales. 
 
3. Evaluación de la influencia de extractos fúngicos en la absorción de lípidos dietéticos por 
su potencial inhibidor de la lipasa pancreática: 
 Análisis de diversas especies de hongos con actividad inhibidora de la lipasa 
pancreática. 
 Evaluación de varios procesos de extracción para la obtención de fracciones fúngicas 
inhibidoras de la lipasa pancreática. 
 Estudio de la actividad inhibidora de la lipasa pancreática de extractos fúngicos 
seleccionados mediante su aplicación a un modelo de digestión in vitro. 
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4. Evaluación de extractos fúngicos con actividad inhibidora de la HMGCR capaces de impedir 
la biosíntesis endógena de colesterol: 
 Evaluación de la actividad inhibidora de la HMGCR de una amplia variedad de 
especies de hongos y variedades comerciales. 
 Selección del método óptimo de extracción para la obtención de fracciones 
enriquecidas con inhibidores de la HMGCR. 
 Aislamiento e identificación de los compuestos responsables de la inhibición de la 
HMGCR. 
 Estudio de biodisponibilidad e influencia moduladora de extractos fúngicos con 
actividad inhibidora de la HMGCR, sobre la expresión de genes relacionados con el 
metabolismo del colesterol mediante el uso de modelos in vitro e in vivo. 
 Actividad hipocolesterolemica y efecto modulador en la expresión de genes 
relacionados con el metabolismo del colesterol mediante el uso de modelos 
animales. 
 
5. Evaluación de la capacidad hipocolesterolemica de una matriz alimentaria 
suplementada con extractos fúngicos seleccionados en ensayos con modelos animales: 
 Determinación de la eficacia de varios productos alimenticios suplementados en la 
disminución de los niveles de colesterol en sangre.  
 Estudio de la capacidad moduladora de productos alimenticios suplementados en 
genes involucrados en el metabolismo del colesterol. 
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Abstract 
Coronary heart disease (CHD) is the leading cause of death in the Western world after 
cancer according to World Health Organization. Many studies have established that high           
total-cholesterol levels and low-density lipoprotein (LDL) cholesterol levels are risk factors for CHD 
and mortality.  
Many investigations have been carried out to explore the possibility of increasing 
components which have hypocholesterolemic effects in the diet. Two particular groups of 
substances phytosterols and β-glucans gained much attention in the last decade and there are 
already commercialized functional food products supplemented with plant sterols and/or 
derivatives (sterol-esters, stanols, etc) and specific polysaccharides mainly obtained from cereals 
which are able to inhibit the absorption of exogenous cholesterol.  
Edible mushrooms are good sources of phytosterol-like structures such as ergosterol, 
fungisterol and other derivatives since they were present in all mushrooms because they are 
constitutive compounds of the hyphae membranes. On the other hand, edible mushrooms 
contained polysaccharides and depending on the specie, they showed high levels of β-glucans. 
Apart from these compounds, some mushroom species included certain molecules that were 
different than lovastatin (since statins were not detected) able to impair the synthesis of 
endogenous cholesterol by inhibiting the HMGCR (3-hydroxy-3-methyl-glutaryl CoA reductase) 
the key enzyme in the cholesterol metabolism.  
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Introduction 
Maintenance of cholesterol homeostasis is one of the major issues in the human body 
since it is a key constituent of the cell membranes. Thus, if the molecule is not obtained from diet 
liver synthesizes it by a specific metabolic pathway. When cholesterol enters the lumen of the 
small intestine is coming from 3 different sources: diet, bile and intestinal epithelial sloughing. 
Nowadays in industrialized countries, the average daily intake is approximately 300 – 500 mg. Bile 
provides 800 mg – 1200 mg cholesterol per day to the intraluminal pool. The turnover of intestinal 
mucosal epithelium is approximately 300 mg cholesterol per day. The synthesized cholesterol can 
reach ca. 1000-1600 mg per day. When an excess of exogenous cholesterol is absorbed and 
reach the liver, it induces several regulation effects such as inhibition of cholesterol biosynthetic 
pathway and of the LDLR (low density lipoproteins-receptor) gene expression [1, 2].  
Nutritionists have given wide range of dietary recommendations (fruit, vegetables, fish 
etc.) but with limited success. Only the novel foods products (yogurt, breakfast cereals etc.) 
offered in the market claiming hypocholesterolemic effects have got a little higher acceptance by 
consumers. At present there are two types of functional foods recognized by EFSA as able to 
reduce the risk of CVD because of their ability to reduce cholesterol absorption [3, 4]. One is those 
products including plant sterols (phytosterols) or derivatives (sitostanol esters etc.). Apparently, 
intaking of 1.5 g/day of these compounds reduced LDL-cholesterol in hypercholesterolemic 
patients by 10 and 15% within 3 - 4 weeks [5]. The other type of functional foods is those containing 
β-glucans, mainly obtained from cereal products and able to reach 15% cholesterol reduction [6]. 
Both functional products are able to lower cholesterol in serum by reducing its 
absorption. However, it has been shown that in subjects who were administered β-glucan, the 
cholesterol biosynthetic pathway was stimulated compared with control subjects [6]. Thus, in 
order to increase treatment efficiency, it could be necessary to combine inhibitors of the 
cholesterol absorption with inhibitors of the cholesterol synthesis.    
Edible mushrooms are good sources of phytosterol-like structures such as ergosterol, 
fungisterol and many other derivatives. The major fungal sterol, ergosterol (9.61-1.28 mg/g dw), is 
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abundant in all mushrooms species since it is a constitutive compound of the hyphae membranes 
and it is known as a vitamin D2 (ergocalciferol) precursor [7-9]. These molecules might act as plant 
phytosterols and reduce cholesterol absorption by displacement of the molecule from the dietary 
mixed micelles formed during intestinal digestion.  
Beside oat bran, pectin, guar gum etc. edible mushrooms also contains β-glucans such 
as lentinan from shiitake, schizophyllan from splitgill, grifolan from maitake mushrooms, α- and    
β-glucans from sun, reishi and oyster mushrooms, glucuronoxylomannans from tree-ear and white 
jelly-leaf mushroom etc. [10] and some of them were able to effectively lower serum cholesterol 
levels [11-13]. Apparently, the viscous and gel-forming properties of these compounds could 
lower the cholesterol absorption by inhibiting the formation of micelles in the small intestine and 
perhaps they might also interact with the bile acids similarly as explained for bran β-glucans, 
leading to an increase in fecal bile acids excretion and increasing of hepatic conversion of 
cholesterol into bile acids [12].  
However, if cholesterol is not obtained from the diet, it enhanced the de novo synthesis 
in the liver. Statins or vastatins are the most potent drugs available for reducing plasma low density 
lipoproteins (LDL)-cholesterol concentrations [14]. According to previous reports, several oyster 
mushrooms strains showed lovastatin (mevinolin) a compound able to lower cholesterol levels by 
inhibiting the 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR), a key-enzyme in the 
cholesterol metabolism [15]. However, other compounds such as lanosteroids, ganoderols etc., 
obtained from other mushrooms are also able to perform such an inhibition [11].   
Thus, in this work a preliminary screening of these potentially active compounds is 
carried out as an attempt to design new functional foods based on mushrooms extracts able to 
effectively reduce the cholesterol levels in serum by impairing both the synthesis and the 
absorption of cholesterol.  
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Materials and Methods 
Biological material and samples preparation 
Mushroom strains used in this investigation were Cantharellus cibarius (Fr.), Agaricus 
bisporus L. (Imbach), Pleurotus ostreatus (Jacq.Ex Fr.) Kummer, Lentinus edodes S. (Berkeley), 
Boletus edulis (Bull. Ex Fr.), Amanita caesarea (Scop. Ex Fri.) Pers. Ex Schw., Lactarius deliciosus 
(Fr.), Lyophyllum Shimeji (Kawam.), Agrocybe aegerita (Briganti) Singer, Ganoderma lucidum 
(Curtis) P.Karst., Craterellus cornucopioides (L. Ex Fr.) Pers, Marasmius oreades (Bolt. Ex Fr.) Fr., 
Pleurotus eryngii (D.C. Ex Fr.) Quel, Lepiota procera (Scop. Ex Fr.) Singer, Agaricus blazei Murill 
ss. (Heinem), Amanita ponderosa Malençon & R. Heim, Grifola frondosa (Dicks.) Gray and 
Flammulina velutipes (Curt. Ex Fr.) Singer. 
Fruiting bodies from wild mushrooms were purchased on season from the local market 
in Madrid (Spain) and the cultivated strains were harvested from the cultivation rooms at CTICH 
(Autol, Spain) facilities. Fruiting bodies were dehydrated and ground into fine powder as 
described by Ramirez-Anguiano et al. (2007) [16]. Dried mushroom powders were stored at              
-20 ºC until further use.  
Reagents 
Ascorbic acid and KOH (potassium hydroxide) were obtained from Sigma-Aldrich. 
Ethanol was purchased from Panreac (Barcelona, Spain), 2,6 di-tert-butyl-p-cresol (BHT) from 
Fluka (Madrid, Spain), ergosterol from Alfa Aesar GmbH & Co KG (Karlsruhe, Germany),  
pravastatin, lovastatin, simvastatin and atorvastatin  from Cinfa (Navarra, Spain). 
Determination of sterols levels in mushrooms 
Freeze-dried mushroom powders (0.2 g) and 0.3 g of ascorbic acid were mixed with      
15 ml of 11.5% KOH in ethanol:water (55:45, v/v) and vigorously stirred for 15 min at 80 ºC. 
Afterwards, the mixture was cooled down and 10 ml of 0.01% (w/v) BHT in hexane were added. 
The mixture was shacked during 2 min and left at room temperature (5 min) until complete 
separation of the phases. Organic fraction was collected and 5 ml BHT solution were added to 
the aqueous fraction for a second extraction. Both organic phases were pooled together in a round 
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bottom flask and evaporated on a rotary vacuum extractor at 30 ºC until dryness. Dry extracts 
were dissolved in a ClCH3: MeOH (2:1, v/v) solution including hexadecane as internal standard 
and submitted to GC analysis.  
Mushroom extracts were injected into a GC column (Zebron ZB-5 30m x 0.25 mm,         
0.25 µm, Phenomenex, France) from a CP-3380 gas chromatography (Varian, Spain) with a flame 
ionization detector (FID). Split was set 1:10. The injector was set at 260 ºC, the detector at 350 ºC 
and the oven temperature was maintained at 60 ºC for 1 min, then increased with a rate of                
40 ºC/min until a final temperature (310 ºC) that was maintained during 30 min (modification of the 
method proposed by Teichman et al. (2007) [8]).   
A standard curve of ergosterol was used to develop and validate the GC method 
(linearity, LOD, LOQ, precision and reproducibility were determined using standardized protocols) 
and to quantify ergosterol and derivatives.  
Determination of β-glucans levels in mushrooms  
The beta-glucan content of the selected mushroom powders (50 mg) was determined 
according to the protocol described at the user´s manual of the Megazyme assay for mushroom 
and yeast β-glucan determination (Megazyme, Barcelona, Spain).  
Determination of HMGCR inhibitors in mushrooms  
Mushroom powders (50 mg/ml) were dissolved in methanol, water or combined mixtures. 
Suspensions were shacked in a Vortex for 1 min and centrifuged at 12000 × g for 2 min. 
Supernatants (10 µl) were applied into a 96 wells-plate according to the user´s manual of the 
HMG-CoA Reductase Assay Kit (Sigma, Madrid). Absorbance at 340 nm was monitored at 37 ºC 
using a microplate reader (Tecan Group Lt, Männedorf, Switzerland). 
Several extraction methods were tested to isolate statins such as mixture of 200 mg 
mushroom powder with methanol:water (1:1, v/v), methanol or water and 20 mM phosphate buffer 
(pH 7.7):acetonitrile (1:1, v/v) following the procedures before described for lovastatin 
determination [15, 17, 18]. Depending on experiment, mushroom extracts and lovastatin solutions 
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were centrifuged (12000 × g, 2 min) and the obtained supernatants filtered through 0.45 µm filters 
(Millipore, Madrid, Spain). Filtrates were injected into a Sep-Pak® C18 cartridge (Waters, 
Milford, MA, United States) (preconditioned with acetonitrile and washed with water) and eluted 
using acetonitrile. Acetonitrile fraction was vacuum concentrated and injected into an HPLC 
system. Lovastatine and sample preparations were also treated according to Yang & Hwang 
(2006) [19] to transform lovastatin-lactone into its hydroxy acid form. 
 Mushroom extracts showing higher HMGCR inhibitory activity (20 µl) and statins were 
injected in an HPLC system (Agilent, Madrid, Spain) equipped with a column (Zorbax SB-C18              
0.3 x 150 mm, 5 µm particle size, Agilent, Madrid, Spain) and developed using an isocratic mixture 
of CH3CN:0.5% CH3COOH (60:40, v/v) and a at a flow of 1 ml/min. Peaks were detected with a 
Diode array detector and identified comparing the spectra and retention times with those of a few 
statins.   
The same samples and lovastatin solutions (20 µL) were also injected in an LC-MS 
(Agilent 6410A Triple Quadrupole LC/MS system coupled with an Agilent 1200 Series Rapid 
Resolution (RRLC) system) with a C18 column (ACE 3 C18-AR, 150 x 4.6 mm particle size 3 µm) 
and developed on isocratic conditions using CH3CN:0.5% CH3COOH (60:40, v/v) as mobile phase 
and a flow rate of 0.5 ml/min. The column eluent was introduced into the electrospray ionization 
source. The nebulizing gas flow-rate was 9 mL/min, drying gas temperature was 350 °C and the 
capillary voltage was 3500 V. The samples responses from the column were monitored in the 
positive as well as in the negative ionization mode with full scan from (m/z: 90-1200).  
Results and discussion 
Ergosterol-derivatives in mushrooms  
Ergosterol (ergosta-5,7,22-trien-3β-ol) and its derivatives are compounds structurally 
similar to plant phytosterols however, only a few reports studied their influence on the cholesterol 
metabolism. Ergosterol was pointed as a potent agonist for liver X receptor (a factor involved in 
the regulation of cholesterol homeostasis) and as inducer of ABC-transporters expression 
(promoters of the active efflux of cholesterol and plant sterols from the enterocyte into the intestinal 
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lumen for excretion). It was also described as a potent C24-reductase inhibitor, an enzyme which 
catalyzes the reduction of the double bond at C-24 in the cholesterol-biosynthesis pathway [20].  
Ergosterol was the major sterol found in all the analyzed samples (Figure 1) except for 
Ganoderma lucidum which showed similar concentrations of ergosterol and ergosta-7,22-dienol. 
The distribution of ergosterol derivatives was strain dependent (Table 1). Some mushroom species 
such as Chantharellus cibarius and Craterellus cornucopioides showed almost exclusively 
ergosterol, other species showed more ergosta-5,7-dienol than fungisterol (ergosta-7-enol) 
(Lyophyllum shimeji, Pleurotus ostreatus), other lacked one or two of the derivatives or presented 
similar concentrations of the three identified ergosterol-derivatives. 
 
Figure 1. GC chromatogram of the unsaponifiable fraction of Amanita caesarea. a) ergosterol,                          
b) ergosta-7,22-dienol, c) ergosta-5,7-dienol, d) fungisterol. 
 Ergosterol concentrations in the selected strains ranged from 0.7 up to 5.7 mg/g dw 
being Boletus edulis the specie with the highest levels and Craterellus cornucopioides the specie 
with the lowest concentration of total sterols. These results were in concordance with values 
previously reported for some of the strains for instance, B. edulis was also pointed as the 
mushroom with the largest ergosterol content with concentrations estimated between                       
9.61-4.89 mg/g depending on authors, C. cibarius showed 2.78-3.04 mg/g, Agaricus bisporus,   
P. ostreatus and Lentinula edodes 7.8-4.4 mg/g. Other mushroom species such as Suillus 
granulatus showed 7.02 mg/g ergosterol and 0.8 mg/g fungisterol (ergosta-7-enol), Russula 
 
 
a 
b 
c d 
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cyanoxantha and Clitocybe nebularis contained 1.28 and 1.04 mg/g fungisterol too [8, 9, 21, 22]. 
However, no previous information concerning the ergosterol content was found for other 
mushroom species indicated in this study such as for instance Lepiota procera, Marasmius 
oreades, Agrocybe aegerita, Lyophyllum shimeji etc.    
Table 1.Sterols concentration (mg/g dw) in several mushroom species. 
 
β-Glucans in mushrooms 
At present, fungal polysaccharides are the subject of several studies because their 
specific carbohydrate composition and structure appears to confer many important biological 
activities as antitumor, antioxidant, antiviral, immumodulatory activities etc. [10]. Many of the 
polysaccharides responsible for those activities are β-glucans including hypocholesterolemic 
activities [6, 13, 23]. 
Mushroom specie 
Ergosta-5,7,22-trien-3-ol 
(ergosterol) 
Ergosta-
7,22-dienol 
Ergosta-5,7-
dienol 
Ergosta-7-enol 
(fungisterol) 
Total 
Cantharellus cibarius 2,61 ND ND ND 2,61 
Agaricus bisporus 3,06 0,65 0,67 0,67 5,05 
Pleurotus ostreatus 3,75 0,79 0,98 0,51 6,04 
Lentinula edodes 5,51 0,40 ND 0,43 6,34 
Boletus edulis 5,69 1,21 0,93 0,87 8,71 
Amanita caesarea 3,81 1,05 1,15 1,09 7,09 
Lactarius deliciosus 1,60 0,36 ND ND 1,96 
Lyophyllum shimeji 4,64 ND 1,55 0,68 6,87 
Agrocybe aegerita 5,11 ND 1,01 ND 6,12 
Ganoderma lucidum 0,69 0,59 0,17 0,25 1,70 
Craterellus cornucopioides 0,79 ND ND ND 0,79 
Marasmius oreades 3,85 0,54 0,59 0,57 5,55 
Pleurotus eryngii 1,40 0,20 0,25 0,22 2,06 
Lepiota procera 2,57 0,67 ND 0,64 3,88 
Agaricus blazeii 1,73 1,06 0,60 0,75 4,13 
Amanita ponderosa 1,65 ND 0,60 0,62 2,87 
Grifola frondosa 3,24 0,57 ND 0,61 4,42 
ND: Not detectable 
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β-Glucans were also quantified in the same mushroom species than above described 
and similarly, their β-glucan content was strain dependent (Figure 2). Some of them showed a 
high β-glucan concentration such as for instance G. Lucidum, P. ostreatus, L. edodes, Agrocybe 
aegerita and Lactarius deliciosus. However, mushrooms such as L. procera, Agaricus blazeii and 
A. bisporus showed low levels compared to the others.  
 
Figure 2. β-glucan concentration in several mushroom species. 
These values were higher than those previously reported by few publications from the 
the same research group [24-26] since the described  β-glucan contents ranged from 0.14 to 0.53 
mg/100 mg in similar strains such as Pleurotus pulmonarius, P. ostreatus, P. eryngii, B. edulis,   
A. aegerita and L. edodes. Differences between results could be due to values expression since 
in their first publication they express their results on ´dry matter´ basis and later for similar values 
they indicate that they were referred to their ´edible portion´ which for raw mushrooms could be 
considered as ´fresh weight´. Moreover, in their β-glucan extraction procedure fresh fruiting 
bodies were utilized while dry mushroom powder was used to determine the β-glucan content of 
the samples presented in Figure 2.   
A more recent publication estimating the total β-glucan levels by a completely different 
method indicated concentrations between 2.6 - 13.4 mg/100mg dw for A. bisporus, F. velutipes, 
L. edodes, P. ostreatus and P. eryngii [27] and Lee et al. (2011) [28] ranged the β-glucan contents 
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from 3.2 mg/100mg for F. velutipes to 33.5 mg/100mg for Grifola frondosa with other intermediate 
values for other species including Pholliota nameko. Those values are more in concordance with 
the presented results. 
HMGCR inhibitors in Oyster mushrooms 
Nowadays, there are many in vivo evidences indicating the capability of Pleurotus spp. 
fruiting bodies to lower cholesterol levels in serum [29, 30]. Apparently, this activity could be 
partially due to the presence of lovastatin, a statin detected in mycelia culture broths as well as in 
mushroom fruiting bodies in all the developmental stages and tissues [15, 17, 18].  
 A few Pleurotus ostreatus strains were screened for HMGCR inhibitors using different 
extraction procedures such as a mixture of methanol:water (1:1, v/v), water or methanol with not 
or overnight incubation at 30 ºC and applying different extract concentrations.  
According to previous publications, overnight incubation (30 ºC) of the fruiting bodies 
with methanol:water (1:1, v/v) was the best method to extract lovastatine from fresh Oyster 
mushrooms [15, 17, 18].  When the dry mushroom powders were tested, the three selected       P. 
ostreatus strains showed significant HMGCR inhibitory activity (54.4, 37.7 and 18.8 %) and their 
inhibitory activity was increasing with increasing extracts concentrations (Figure 3). However, no 
significant differences were found when the extracts were freshly prepared and applied or after 
overnight incubation.  
When 100 % methanol or water were tested as solvents no significant inhibitory activity 
was found in the methanol extracts but for some strains, the water extracts showed a remarkable 
HMGCR inhibitory activity (Figure 3). Extraction in 20 mM phosphate buffer (pH 7.7) showed 
slightly higher HMGCR values than water and its mixture with acetonitrile did not change the value 
indicating that water was the best solvent to extract HMGCR inhibitors. 
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Figure 3. HMGCR activity in the presence of several Pleurotus ostreatus extracts prepared under different 
conditions. Pravastatin was used as positive inhibitory activity. 
Mushroom samples and statin standards were injected in HPLC-DAD and developed 
with two different mobile phases, the one reported by Gunde-Cimerman & Cimerman (1995) [15] 
and one including acetonitrile and 0.5 % acetic acid. The later method showed narrower peaks 
than the previously reported and proper separation of the 4 selected statins and their hydroxy acid 
forms therefore it was further utilized to detect and quantify statins in mushrooms (Figure 4).  
 
 
Figure 4. HPLC chromatograms at 240 nm of a) Pleurotus ostreatus concentrated extract and b) a mixture of 
statins including pravastatin (RT=1.4 min), atorvastatin (RT=3.3 min), lovastatin (RT=9.9 min) and simvastatin 
(RT=14.4 min). 
P. ostreatus water, methanol:water (with positive HMGCR inhibitory activity) or methanol 
extracts yielded no detectable peak at the retention time of lovastatin. Neither compatible peak 
 
a) 
b) 
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was detected when the samples were treated to generate lovastatin-hydroxy acid form. Only when 
the samples were concentrated using the SPE (Solid phase extraction) column, two peaks were 
observed at 8.9 and 9.9 min with similar spectra than lovastatin since they both showed a 
maximum at 240 nm (Figure 5). 
       
 
 
 
 
Figure  5. UV-VIS spectra of a) peak eluting at 8.9 min and b) 9.9 min from the P. ostreatus extract and c) 
lovastatin spectrum (9.9 min). 
Nevertheless, since many different compounds could also show similar UV-VIS spectra 
at that maximum, a standard of lovastatin and a P. ostreatus extract were injected into a LC-MS in 
order to determine and compare their mass. Lovastain injected in an LC-MS showed a single peak 
with a retention time of 8.2 min and a single mass peak of 405.1 undoubtedly corresponding to 
the 404.55 gram/mol assigned by the literature (Figure 6a). However, the peak from the                     
P. ostreatus extract eluting at similar R.T. showed a mass of 522.3 indicating that they were 
different compounds (Figure 6b). Moreover, none of the other detectable peaks showed a mass 
similar to neither lovastatin nor other statins.   
a) b) 
c) 
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Figure 6. UV-VIS and mass spectra of a) lovastatin (eluting at 8.2 min) and b) of P. ostreatus (peak with    
RT= 8.2 min).  
Conclusions 
Mushrooms fruiting bodies or their extracts might be considered as a new source of 
compounds with potential hypocholesterolemic activity because they are rich in ergosterol-
derivatives, β-glucans and HMGCR inhibitors. Since not a single mushroom strain showed the 
highest levels of the three type of compounds, a mixture of a few of them could be used to prepare 
bioactive supplements to functionalize foods potentially able to reduce levels of cholesterol in 
serum.  
Although lovastatin was not detected in oyster mushrooms, water extracts showed remarkable 
HMGCR inhibitory activity. Therefore, further investigations are at the present being carried out to 
optimize these supplements and to identify the responsible for the HMGCR inhibitory capacity 
observed.  
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Preface 
Edible mushrooms are considered as good source of dietary fibers (DF) because their 
hyphae membranes contained large amounts of non-digestible polysaccharides. They show many 
different structural conformations but mostly are composed by large chains of glucose joined by 
α- , β- or mixed α, β-glucose branches. However, those pointed by the literature as related to the 
hypocholesterolemic properties (not only for mushrooms but also for other food products) are 
constituted by D-glucose monomers linked by β-glycosidic bonds with β-branching after a few 
monomers. The hypocholesterolemic β-glucans from cereals showed β-(1→3),(1→4)-glucan 
linkages while mushrooms β-glucans combined β-(1→3)- and β-(1→3),(1→6)-linkages in 
different degrees depending on the mushroom specie. Apparently, their molecular size, branching 
degree, monomer composition or structure conformation modulated their biological properties as 
they enhance or impair their water-solubility. However, their precise mechanism for lowering 
cholesterol remains still unclear. Several hypothesis have been drawn including their ability for 
increasing their faecal excretion by a direct bile acid and cholesterol bindings or by their mobility 
impairing in a high gelled digestive bolus. Added to this, SCFA (short chain fatty acids) generated 
after mushroom fiber degradation by the intestinal microbiota have been pointed as HMGCR 
inhibitor. Moreover, modulation of lipid-related gene expression i.e SREBF1, SREBF2 or NR1H4 
by β-glucans was also observed, as previously indicated (see Introduction section). 
Other fungal carbohydrate structures related to hypocholesterolemic compounds are 
chitins (β-(1→4)-glucan linkages of N-acetylglucosamine monomers) derivative products, i.e. 
chitosans, molecules that showed lowering-cholesterol capabilities after in vivo animal model 
experiments.  
In addition to commented variability in the chemical properties i.e. water solubility of 
mushrooms DF, one of the main reasons for the diversity in results or conclusions when correlating 
structures and functions of polysaccharides is partially due to the wide range of extraction 
methods utilized before biological analysis. Both traditional and advanced technologies, i.e. 
boiling water, alkali, ultrasonic- or microwave- assisted, pressurized solvent extractions etc., have 
been used to isolate them. Thus, this chapter describes the experimental settings followed for 
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optimizing an extraction method to obtain specific β-glucan-enriched DF fractions from selected 
mushrooms and compare it with a more traditional extraction method. The influence of the 
obtained fractions as bile acid scavengers during an in vitro digestion model is also studied as 
well as their effect on the expression of genes related with the cholesterol metabolism using cell 
cultures and animal models. 
Initially, a screening through several species was carried out in order to select the edible 
mushrooms with higher levels of total β-glucans and according to the results obtained (previously 
described in the preliminary studies section) a high quantitative variability was found among the 
tested species. Thus, P. ostreatus was selected as raw material to obtain β-glucan-enriched DF 
fractions because it was one of the strains with higher levels and easier to cultivate than others 
such as Ganoderma lucidum. However, since the biological properties described are highly 
dependent on the β-glucan structural conformation and each mushroom synthetize its own 
particular polysaccharide mixture, two other species were also selected. A. bisporus was selected 
because it is widely cultivated and their fruiting bodies fiber extracts were already pointed as the 
responsible for the hypocholesterolemic and hypoglucemic properties found in vivo and L. 
edodes because a specific polysaccharides structure (lentinan), different from the other two 
species, was also pointed as bioactive compound. Thus, in the work titled Pressurized water 
extraction of β-glucans enriched fractions with bile acids-binding capacities obtained from edible 
mushroom, the steps followed to optimize an isolation process for fungal polysaccharides are 
described using an advanced environmentally friendly technology (pressurized water extraction, 
PWE). Several extraction procedures and parameters such as temperature, static extraction time 
etc., were tested to detect a possible structural selectivity of fungal fiber compounds according 
to different extraction conditions.  The three mushroom species were also submitted to a more 
standardized extraction (STD) procedure to compare with PWE, finding out their fiber composition 
as well as advantages and disadvantages of each extraction method. After DF-enriched-extracts 
were obtained, both STD and selected PWE fractions were submitted to an in vitro digestion 
process to quantify their bile acid-binding capacity. The amount of free bile acids in the digestates, 
when different polysaccharides of     DF-fractions were present, was evaluated by HPLC. A cereal 
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DF-enriched fraction and cholestyramine were used as controls to compare with the fungal DF 
extracts.  
On the other hand, DF are by definition, those polysaccharides that cannot be digested 
by humans and are left for colonic microbial degradation until excreted in feces. Due to their 
complex and polymeric structures DF are not absorbed by enterocytes but they, together with 
their degradation products (fragments resulting from their partial digestion/transformation), might 
get in contact with intestinal cells during digestion process. The chances of interaction increases 
when digestion reduce their molecular size enabling their solubilization in physiological media 
such as the lumen, stimulating cellular responses (as observed for instance for the enterocytic 
cytokine-activation mechanisms induced by β-glucans triggering an immune response). Thus, in 
order to study whether DF-fractions from A. bisporus, L. edodes and P. ostreatus could induce 
an enteric response, digestates obtained after theirs in vitro digestion  were administrated to 
Caco2 cell line. Enterocytes mRNAs were extracted 1 and 24h after the administration, 
transformed into cDNA and analyzed by qPCR to observe whether the DF-fractions might 
modulate the cholesterol-related gene expression of enterocytes. The results of the DF effects at 
the transcriptional level are described in the work entitled Modulation of cholesterol-related gene 
expression by dietary fiber fractions from edible mushrooms, and they were used to select one 
mushroom specie for further in vivo experiments. Animal interventions were carried out following 
two different experimental designs using male C57BL/6JRj mice. In the first one, 
hypercholesterolemia was firstly induced using diets with high cholesterol and cholic acid 
concentrations for 4 weeks and afterwards mice were treated for 4 more weeks with simvastatin 
or ezetimibe (as standardized hypocholesterolemic drugs) or a DF-fraction obtained from                 
P. ostreatus. In the second one, the hypercholesterolemic diet was administrated simultaneously 
with one of the two drugs or the DF-fraction for 4 weeks.  Biochemical parameters at final 
experimental time such as total cholesterol, HDL, LDL and triglycerides in serum and liver and 
sterols content in feces were determined. The mRNA expression pattern in four tissues (jejunum, 
ileum, cecum and liver) was also evaluated.  
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Abstract 
A pressurized water extraction (PWE) method was developed in order to extract β-
glucans with bile acids-binding capacities from cultivated mushrooms (Agaricus bisporus, 
Lentinula edodes, and Pleurotus ostreatus) to be used as supplements to design novel foods with 
hypocholesterolemic properties. Extraction yields were higher in individual than sequential 
extractions being the optimal extraction parameters: 200 °C, 5 cycles of 5 min each at 10.3 MPa. 
The crude polysaccharide (PSC) fractions, isolated from the PWE extracts contained mainly            
β-glucans (including chitooligosaccharides deriving from chitin hydrolysis), α-glucans, and other 
PSCs (hetero-/proteo-glucans) depending on the extraction temperature and mushroom strain 
considered. The observed bile acids-binding capacities of some extracts were similar to a              
β-glucan enriched fraction obtained from cereals.  
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Introduction 
Certain polysaccharides (PSC) present in plants and particularly those from cereals have 
recently gained attention because of their potential beneficial effects for human health. The 
(1→3),(1→4)-β-glucans are believed to perform many biological functions such as i.e. modeling 
of immune response [1] or reducing of cholesterol levels in serum [2].  
Direct binding of bile acids and cholesterol (from ingested food) and increasing their 
faecal excretion has been hypothesized as a possible mechanism by which the water-insoluble 
PSCs lower cholesterol [3]. By binding bile acids, they prevent their reabsorption and stimulate 
plasma and liver cholesterol conversion to additional bile acids [4, 5]. The cholesterol-lowering 
effect of water-soluble dietary fibers seems to be due to several mechanisms being the increase 
in viscosity (water binding capacity in the 119ydra) the main effect. This leads to a reduced 
diffusion rate of bile acids, which cannot be reabsorbed by the body being then excreted [3].  
Edible mushrooms also contain interesting PSCs [6] such as other β-glucans, which are 
structurally different from plants since their branches are (1→3) and (1→3),(1→6) but share 
biologically important properties including hypocholesterolemic effects [7], and chitin, a water-
insoluble β-(1→4)-glucan of N-acetylglucosamine monomers, also considered as dietary fiber. 
However, not all the fungal β-glucans show all the beneficial biological activities, the 
119ydrazine119latory and antitumor properties seemed to be more related to the water soluble 
fraction [8] including the oligomers and low molecular weight polymers generated from chitin 
hydrolysis (LMWC or chitooligosaccharides) [9] while their effect as prebiotic might be due to their 
water-insoluble β-glucans (chitins and protein-bound glucans) [10]. Obviously, their solubility in 
water depends, above all, on their molecular structure largely influenced by their monomer 
composition, type and degree of branching, conformation (single or triple helix), molecular weight, 
N-acetylation degree etc. [11] and, according to recent review, there is insufficient information to 
establish a broad generalization correlating structure with function [12]. 
A wide variety of PSCs with different structures and biological activities have been 
obtained from edible mushrooms using different extraction processes. The traditional methods 
include the use of boiling water, sodium hydroxide, ammonium oxalate, and more complex 
protocols [13], while the more advanced technologies included ultrasonic-assisted [14, 15] and 
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microwave assisted [16] extractions or combinations [17], supercritical carbon dioxide [18] and 
pressurized solvent extraction using water [19] or ethanol [20] as extraction solvents. 
The work presented in this article, describes the optimization of a specific procedure to 
obtain β-glucan enriched fractions from the three most commonly consumed edible mushrooms 
using an accelerated solvent extraction (ASE) device, which enable the use of pressurized water 
as extraction (PWE) solvent. Several PWE conditions and procedures were tested to investigate 
whether the mushrooms could be fractionated separating in one/some fraction/s those β-glucans 
with bile acid-binding activities to use them as food-grade supplements to design novel foods with 
hypocholesterolemic properties. Then, the obtained fractions were submitted to an in vitro 
digestion model to determine whether they are able to bind bile acids as the β-glucans from a 
cereal foodstuff. 
Materials and Methods 
 Biological material  
Mushroom strains used in this investigation were Agaricus bisporus L. (Imbach), Lentinus 
edodes S. (Berkeley), and Pleurotus ostreatus (Jacq.Ex Fr.) Kummer. Mushroom strains were 
cultivated at CTICH (Research Center for Mushroom Science and Technology, Autol, Spain) and 
harvested at the optimal developmental stage for consumption. Fruiting bodies were dehydrated 
and ground into fine powder as described by Ramírez-Anguiano et al. [21] and stored at -18 °C 
until further use.  
Commercially available breakfast cereals containing oat, rice, wheat, and barley                
β-glucans bearing the claim containing β-glucans able to reduce cholesterol levels were obtained 
from a local supermarket. All the experiments were performed from the same package.  
Reagents  
Ethylenediaminetetraacetic acid, sea sand, and methanol HPLC grade were purchased 
from Panreac (Barcelona, Spain). D(1)-glucose, ferric chloride, ammonium sulfamate, sodium 
nitrite, 3-methyl-2-benzothiazolone 120ydrazine hydrochloride, phenol, chitin (from shrimp), 
glucose, pancreatin, standard bile acids, and porcine bile extract, cellulose, cholestyramine, and 
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bovine serum albumin (BSA) were procured from Sigma-Aldrich. (Steinheim, Germany). All other 
reagents and solvents were used of analytical grade.  
Pressurized water extractions to obtain PSC enriched fractions  
Mushroom powder (1 g) were mixed with washed sea sand (4 g) and submitted to 
pressurized water extraction (PWE) at 10.68 Mpa using an ASE (Dionex Corporation, ASE 350, 
Sun-nyvale, CA). Extraction procedure per cycle was as follows: firstly, the sample was loaded 
into 11 ml extraction cells. Then, the cell was filled with solvent (MilliQ water), heat-up time applied 
and static extraction was carried out with all system valves closed. Afterwards, the cell was rinsed, 
solvent was purged from cell with N2 gas and depressurization took place. Several parameters 
such as solvent, static extraction time, or cycles number and temperature were changed in order 
to optimize the extraction method.  
A sequential extraction procedure was also tested by mixing the mushroom powders      
(1 g) with sea sand (4 g) into the ASE extraction cells. Then, the samples were submitted to                     
5 extraction cycles of 5 min each at 25 °C. Afterwards, the solvent was removed and another 
extraction was carried out for 5 cycles of 5 min each at 50 °C. These processes were repeated at 
100, 150, and 200 °C.  
Obtained fractions were immediately frozen, lyophilized, and stored at -18 °C until further 
analysis. Extracted dry matter content was measured to calculate the extraction yields. A minimum 
of two fractions were collected from each type of sample.   
Standardized extraction method to obtain PSC enriched fractions  
Mushroom powders (1 g) and powdered dehydrated cereals (1 g) were mixed with MilliQ 
water (100 ml), heated at 120 °C for 20 min and cooled down to 4 °C following the method reported 
by Jeurink et al. [22]. The crude PSC fraction was isolated as described below. 
Isolation of the PSC fractions  
The from the extracts obtained by both standardized and PWE methods were isolated by 
adding two volumes of cold ethanol, vigorous stirring, and allowing PSC precipitation overnight at 
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4 °C. The precipitated PSCs were collected by centrifugation (10,000g for 30 min at 4 °C) (Thermo 
Scientific Heraeus Multifuge, Fisher scientific, Madrid, Spain), suspended in   Milli-Q water and 
dialyzed with membrane tubing (MWCO 3.5 Kda; Medicell International Ltd. London, UK) against 
distilled water to remove low molecular weight (LMW) compounds during 24 h at 5 °C with three 
or four changes of the distilled water. After the dialysis, the fraction remaining inside the membrane 
(MW >3.5 kDa) was lyophilized, weighed, and stored at -18 °C until further use [22]. This extract 
was called crude PSC fraction.  
Total polysaccharide determination  
The PSC concentration of the obtained extracts was evaluated as their total carbohydrate 
content with the modified phenol–sulfuric acid method as described by Fox and Robyt [23]. 
Glucose was used as standard for quantification.  
Determination of β-glucans  
The β-glucan content of the obtained mushroom extracts (50 mg) was evaluated by a      
β-glucan determination kit specific for mushrooms and yeasts (Megazyme, Barcelona, Spain) 
following the instructions of the user’s manual. Absorbance at 510 nm was measured using a 
spectrophotometer (Evolution 600, Fisher scientific, Madrid, Spain).  
The procedure calculates the β-glucan concentration directly from mushroom powder by 
subtracting the values obtained from a first assay in which the content of total glucans                       
(α-glucan + β-glucan), D-glucose in oligosaccharides, sucrose and free D-glucose are quantified, 
to a second assay in which the content of α-glucans (glycogen and starch),                                              
D-glucose in sucrose and free D-glucose are quantified. Therefore, if these assays are carried out 
using the isolated crude PSC fractions (obtained after dialysis), mono-, di-, and oligosaccharides 
as well as broken or small PSCs are lacking. Thus, the values obtained by carrying out the first 
assay should be mainly due to the total glucans and in the second assay to α-glucans. Therefore, 
in these types of samples total, α-, and β-glucans can be quantified.  
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Determination of chitin and chitooligosaccharides  
The N-glucosamine containing β-glucans were determined in the crude PSC fractions 
following the method described by Vetter [24] adjusted from a previous method [25]. This method 
is usually utilized to determine chitin; however, if it is applied to extracts obtained with water (or 
pressurized water) where chitin is not extracted, it evaluates the amount of                                                
N-glucosamine-containing residues present in the fraction determining in this case, the amount of 
chitooligosaccharides, also referred as LMWC (low molecular weight chitin-hydrolysis products), 
which are depolymerized fractions showing values of n > 20 (n=monomers number) with 
increased water solubility [9]. Chitin from shrimp was used as standard for quantification. 
Determination of total protein  
The total protein concentration of the samples (2 mg/ml) was determined using the 
Bradford method reagents (cat. Num. B6916, Sigma-Aldrich, Madrid, Spain) according to the 
Instruction Manual. BSA was used as standard for protein quantification.  
In vitro digestion of the PSC fractions  
Mushroom PSC fractions (isolated after PWE or the standard extraction methods), cereal 
PSC fractions, cellulose (negative control for bile acid-binding properties), and cholestyramine 
(positive control) were submitted to in vitro digestion following the procedure described by Kahlon 
et al. [4] with a few modifications. Briefly, the PSC extracts were digested in 1 ml of 0.01M HCl for 
1 h at 37 °C with gentle agitation (Orbital incubator S150, Stuart, Stone, UK). Afterwards, the 
sample pH was adjusted to 6.3 with 0.1 ml of 0.1M NaOH. Then, 4 ml of bile extract (14.3 mg in 
Tris-maleate buffer pH 6.3) and 5 ml of pancreatin (10 mg in Tris-maleate buffer pH 6.3) were 
added and the mixture was incubated for 1 h at 37 °C. After digestion, the samples were filtered 
through filter paper and the bile acids isolated from the filtrate. A control sample was prepared 
following the same digestion protocol but without the addition of PSC fractions.  
Quantification of bile acids by HPLC  
Isolation of the bile acids was carried out using C18 Seppak cartridges and resulting 
extracts were injected (20 μl) in a HPLC system (Varian Pro-star 330, Madrid, Spain) equipped 
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with a C18 column (Microsorb-MV 100-5 Varian, 25 cm × 4.6 mm and 5 μm particle size) and a 
PDA detector according to Pang et al. [26]. 
The chromatograms from the utilized bile extract (before and after digestion) showed four 
major peaks in concordance with those described by Qiao et al. [27] for pig bile extract and 
identified as glycoursodeoxycholic acid (RT=7.3 min) (GUDCA), glycohyodeoxycholic acid         
(RT=7.7 min) (GHDCA), taurochenodeoxycholic acid (RT=10.9 min) (TCDCA), and 
taurohyodeoxycholic acid (RT=11.8 min) (THDCA). The bile acid-binding capacity of the PSC 
extracts was determined by subtracting the total bile acid concentration found in the control 
samples (digestion with no PSC fractions) and the digested PSC-containing samples. The total 
bile acid concentration considered was the sum of the four major bile acids present in the utilized 
porcine bile extract accounting for almost 93% of the total bile acids [27].   
Statistical analysis  
One way analysis of variance (ANOVA) was performed using a Statgraphics®Plus 3.1 for 
Windows software (Statis-tical Graphics Corporation, Rockville, MD). The mean comparison test 
used was Fisher’s least significant differences procedure (LSD).  
Results and discussion 
The PWE procedure was initially optimized for only one of the mushroom species 
(Lentinula edodes) in order to define the parameters inducing larger variations in the extraction 
yields to be taking into consideration for the extractions of the other mushroom species. 
Extractions of L. edodes PSC using different temperatures  
The temperature of the extraction water could be the most critical parameter to define 
the distribution of the extracted β-glucans within the fractions obtained at different temperatures 
since their solubility in water depends on their molecular structure and it increases with 
temperature [8]. Indeed, the extraction yields of the PWE extracts and of the crude PSC fraction 
obtained from these extracts exponentially increased with the temperature (Table 1). However, 
when the results of the PWE extractions were compared with those obtained after a standard PSC 
extraction method, the latter yielded higher crude PSC fraction (48.6%) than the best PWE 
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condition at 200 °C (28.3%) but, it contained 39% PSCs while the PWE extract (at 200 °C) almost 
doubled the amount of PSCs (74.2%) pointing PWE as a more selective procedure to extract PSCs. 
Extractions of L. edodes PSC using different extraction times  
There are two parameters that can be adjusted in PWE to modify the extraction time, one 
is the time that the solvent is in contact with the sample in the extraction cell and the other is the 
number of cycles of extraction. Therefore, temperature was fixed at 200 °C and the influence of 
both parameters in the extraction yields was investigated.  
No significant differences were found neither in the levels of material extracted by PWE                                  
(~80% of dry weight) nor in the levels of the crude PSC fraction extracted (219–285 mg/g 
mushroom powder) if the extraction time of each cycle was set from 1 to 5 min (with a total of           
5 cycles). However, the amount of extracted PSCs slightly increased after 4 min (from on average 
187.7 mg/g after 1, 2, or 3 min up to 206.9 mg/g) pointing 5 min as the best extraction time        
(255.7 mg/g). Moreover, 1, 5, 10, and 15 cycles of 5 min each one at 200 °C extracted from 627.6 
to almost 890 mg dry matter with a concomitant increase of the crude PSC fraction (from 215 up 
to 303.4 mg/g); however, no significant PSC increase was observed from 5 to 15 cycles, 
apparently all the extractable PSCs were already obtained after 5 cycles.  
Sequential extractions of L. edodes PSC  
A sequential extraction of L. edodes powder was carried out by gradually increasing 
temperatures from 25 to 200 °C (Figure 1). The first extraction carried out at 25 °C extracted only 
5.6% of dry weight and the second extraction (at 50 °C) yielded higher amount (9.7%); however, 
apparently in these extractions mostly low molecular weight material was extracted since their 
PSC content was very low. The third extraction showed a low yield thus most of the extracted PSCs 
were obtained after the forth (150 °C) and particularly the fifth (200 °C) extraction where 30.3% of 
material was extracted containing only 5.4% of PSCs. Thus, sequential extractions did not improve 
the yields obtained by individual extractions and if the data from the complete set of obtained 
fractions were added together, by sequentially performing the extractions not all the mushroom 
PSCs were extracted.  
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Thus, sequential extraction was discarded as a method to fractionate the β-glucans from 
mushrooms.  
 
 
 
 
 
 
 
Figure 1. Extraction yields (PWE extracts and crude PSC fractions) and PSC concentration obtained 
after a PWE sequential extraction of Lentinula edodes (5 cycles, 5 minutes). 1st ext: extraction at 25 
ºC; 2nd ext: extraction at 50 ºC; 3rd ext: extraction at 100 ºC; 4th ext: extraction at 150 ºC and             
5th ext: extraction at 200 ºC. 
Table 1. Extraction yields (total dry matter extracted in the PWE extracts and in the crude PSC fractions isolated 
from those PWE extracts) and PSC concentrations obtained after submitting Lentinula edodes powder to 
pressurized water extractions at different temperatures.  
Extraction 
temperature 
(°C) 
PWE 
extract (mg/g 
mushroom dw) 
Extraction  
yield 
(%) 
 
Crude PSC 
fraction obtained 
in PWE extracts 
(mg/g mushroom) 
Extraction 
yield 
(%) 
 
Crude PSC 
fraction in 
PWE extracts 
(%) 
Total PSCs 
obtained in 
PWE extracts 
(mg/g mushroom) 
Extraction  
yield 
(%) 
 
Total PSCs 
in the crude 
PSC fraction 
(%) 
Total  
PSCs in  
PWE  
extract      
 (%) 
25 201 ± 35a 20.1 48.0 ± 20.4a 4.8 23.9 15.1 ± 1.2a 1.51 31.5 7.5 
50 291 ± 48a 29.1 42.6 ± 19.0a 4.3 14.7 12.1 ± 1.8a 1.21 28.5 4.2 
100 248 ± 92a 24.8 44.0 ± 14.2a 4.4 17.7 19.6 ± 4.1a 1.96 44.6 7.9 
150 301 ± 48a 30.1 85.7 ± 13.7b 8.6 28.5 47.1 ± 17.8b 4.71 54.9 15.6 
200 823 ± 34b 82.3 282.7 ± 73.8c 28.3 34.4 209.7 ± 28.0c 21.0 74.2 25.5 
Std PSC ext. method  485.5 ± 72.8d 48.6  189.2 ± 27.5c 18.9 39.0  
a,b,c,d Denotes statistically significant differences (P < 0.05) among values from the same column. 
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Table 2. Extraction yields (total dry matter extracted in the PWE extracts and in the crude PSC fractions isolated 
from those PWE extracts) and PSC concentrations obtained after submitting Agaricus bisporus powder to 
pressurized water extractions at different temperatures.  
Extraction 
temperature 
(°C) 
PWE 
extract (mg/g 
mushroom dw) 
Extraction 
yield 
(%) 
 
Crude PSC 
fraction obtained 
in PWE extracts 
(mg/g mushroom) 
Extraction 
yield 
(%) 
 
Crude PSC 
fraction in 
PWE 
extracts (%) 
Total PSCs 
obtained in 
PWE extracts 
(mg/g mushroom) 
Extraction 
 yield 
(%) 
 
Total PSCs in 
the crude 
PSC fraction 
(%) 
Total 
PSCs in 
PWE 
extract 
(%) 
25 267 ± 20a 26.7 48.5 ± 12a 4.8 18.2 14.8 ± 3.3a 1.5 30.6 5.6 
50 240 ± 12a 24.0 42.5 ± 4.9a 4.3 17.7 6.9 ± 3.3a 0.7 16.2 2.9 
100 317 ± 21b 31.7 36.0 ± 11a 3.6 11.4 14.1 ± 2.1a 1.4 39.1 4.4 
150 597 ± 19c 59.7 89.5 ± 12b 9.0 15.0 30.9 ± 3.5b 3.1 34.5 5.2 
200 783 ± 88d 78.3 211 ± 38.2c 21.1 26.9 103 ± 7.1c 10.4 49.2 13.2 
Std PSC ext. method  290 ± 83.4 c 29.0  83.5 ± 6.1c 8.4 28.8  
a,b,c,d Denotes statistically significant differences (P < 0.05) among values from the same column. 
Extractions of PSC from other mushroom species  
The results obtained after submitting L. edodes to PWE extractions indicated that the 
highest PSC yields were obtained by carrying out individual extractions, setting 5 cycles of 5 min 
as extraction time and 200 °C being the extraction temperature the most crucial parameter. 
Therefore, PWE extractions of two other cultivated mushrooms such as Agaricus bisporus and 
Pleurotus ostreatus were carried out at different temperatures maintaining other parameters as 
described above.  
The observed increase in extraction yields with the temperature for both mushroom 
species was similar to the one observed for L. edodes being 200 °C the optimal temperature to 
obtain ~78% of the dry matter for both A. bisporus (Table 2) and P. ostreatus (Table 3). Also from 
these two other species, a higher amount of the crude PSC fractions could be extracted using the 
standard PSCs extraction method; however, they contained less PSCs than those obtained using 
PWEs at 200 °C pointing PWE also for these mushrooms as a more specific method for fungal 
PSC extraction.  
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Table 3. Extraction yields (total dry matter extracted in the PWE extracts and in the crude PSC fractions isolated 
from those PWE extracts) and PSC concentrations obtained after submitting Pleurotus ostreatus powder to 
pressurized water extractions at different temperatures 
 
Extraction 
temperature 
(°C) 
PWE 
extract (mg/g 
mushroom dw) 
Extraction 
yield 
(%) 
 
Crude PSC 
fraction obtained 
in PWE extracts 
(mg/g mushroom) 
Extraction 
yield 
(%) 
 
Crude PSC 
fraction in 
PWE extracts 
(%) 
Total PSCs 
obtained in 
PWE extracts 
(mg/g mushroom) 
Extraction 
yield 
(%) 
 
Total PSCs in 
the crude 
PSC fraction 
 (%) 
Total  
PSCs  in  
PWE 
 extract (%) 
25 154 ± 26a 15.4 36.0 ± 5.7a 3.6 23.4 19.9 ± 4.4a 2.0 55.2 12.9 
50 148 ± 36a 14.8 48.5 ± 6.4a 4.9 32.8 28.9 ± 8.7a 2.9 59.6 19.5 
100 198 ± 31a 19.8 58.0 ± 17.0a 5.8 29.3 40.5 ± 12a 4.1 70.0 20.5 
150 293 ± 87a 29.3 75.0 ± 26.9a 7.5 25.6 43.5 ± 9.3a 4.4 58.0 14.8 
200 786 ± 272b 78.6 187 ± 78b 18.8 23.9 153 ± 30b 15.3 81.6 19.5 
Std PSC ext. method  494 ± 28.3c 49.4  209 ± 58b 21.0 42.4  
a,b,c Denotes statistically significant differences (P < 0.05) among values from the same column 
 
PWE have already been utilized to extract PSC enriched fractions from mushrooms such 
as Ganoderma sp. [19] using a similar ASE device and conditions (120 °C, 10.7 Mpa, and 2 cycles 
of 5 min) because the total amount of extracted PSC was higher than those using sonication (water 
100 °C for 30 min). But, no optimization of the extraction process was carried out and no more 
detailed information was given about the obtained yield. Moreover, the filtrate obtained from the 
culture broth where L. edodes mycelium was growing was also submitted to PWE in order to 
isolate bioactive fractions [20]. However, precipitation of the PSCs from the filtrates with ethanol 
was carried out before PWE was applied thus in this case, PWE was not used for extraction but to 
further fractionate isolated PSCs obtained by a standard method therefore, no previous information 
on the yields of fungal PSC extractions by PWE was found in the literature. But, PWE of β-glucans 
from barley using temperatures from 135 to 180 °C (15–75 min total extraction times) generated 
fractions with 23–54% β-glucans being the optimal condition at 157.5 °C (45 min) [28]. These 
values indicated that the yields obtained for fungal PSCs at 150 °C were similar to those obtained 
from barley. However, if higher temperatures were utilized, barley β-glucans were partially 
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hydrolyzed therefore, the presence of hydrolyzed β-glucans in the obtained PWE extracts and the 
presence of other compounds was determined.   
Composition of the PWE extracts  
As expected, the obtained PWE extracts showed higher amounts of proteins and 
peptides in the fractions obtained at temperatures below 100 °C and higher PSC concentrations 
above that temperature. However, a different distribution was observed depending on the 
mushroom specie considered (Figure 2). The PWE extracts obtained from L. edodes and                 
A. bisporus at 50 °C showed the largest protein concentrations while more proteins were extracted 
from P. ostreatus with only 25 °C. The fraction of the latter mushroom obtained at 200 °C also 
showed high protein levels. Since proteins precipitate at temperatures close to 100 °C these 
values might be due to proteins or fragments tightly bound to PSCs forming proteoglucans, 
glucoproteins, or other protein-glucan complexes.  
A. bisporus PWE extracts contained less PSCs and β-glucans than L. edodes and           
P. ostreatus (Figure 2b) probably because this mushroom contained significantly lower levels of 
these compounds (respect. 12.30 mg β-glucans/100 mg A. bisporus, 38.18 mg/100 mg                     
L. edodes, and 41.79 mg/100 mg P. ostreatus mushroom powders dw).  
L. edodes PWE extractions carried out at low temperatures (Figure 2a) yielded larger 
amounts of hydrolyzed β-glucans (or β-glucan oligomers, with monomers number (n) between       
2 and 10, molecular weight < 3.5 kDa) than the other two mushroom species. Their concentration 
was increasing with the temperature up to 100 °C, above that temperature β-glucans of higher 
molecular weight were extracted. At 200 °C other PSCs beside β-glucans were also extracted 
since the total PSC concentration was significantly higher than the amount of higher molecular 
weight β-glucans (> 3.5 kDa, β-glucan polymers). The distinction between β-glucan oligomers 
and polymers could be calculated because the β-glucan levels were determined in the complete 
PWE extracts and in the separated (though a dialysis membrane with a MWCO 3.5 kDa) crude 
PSC fractions obtained from them.  
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The A. bisporus and P. ostreatus PWE extracts obtained at temperatures higher than   
100 °C showed β-glucan oligomer concentrations that were absent at lower temperatures 
suggesting that in these cases, degradation of the β-glucan polymers might have occurred 
probably as effect of the pressure and temperature as occurred with barley β-glucans [28].  
The P. ostreatus extracts obtained at 200 °C contained other PSC that were not                    
β-glucans (Figure 2c) as it was previously observed for L. edodes. Thus, a more detailed study 
on the type of PSCs present in the PWE extracts was carried out. 
Polysaccharides in the crude PSC fractions  
The composition of the crude PSC fractions (> 3.5 kDa) obtained from PWE extracts was 
as compared with the crude fraction obtained from a standard PSC extraction method and results 
indicated that they contained different type of PSCs (Figure 3). 
To distinguish between β-glucans derived from chitin hydrolysis (chitooligosaccharides) and other 
type of β-glucans, the N-glucosamine concentration was determined in the fractions. Chitins levels 
in the selected mushrooms were 4.6, 4.9, and 3.3 mg/100 mg for respectively L. edodes,                   
A. bisporus and P. ostreatus mushrooms so these values were in concordance with previous 
determinations [24]. However, these molecules cannot be present in the PWE fractions because 
they are not soluble in water and they request heavy extraction methods to solubilize them [29]. 
Thus, the N-glucosamine levels measured in the PWE fractions corresponded to the so called 
chitooligosaccharides or LMWC (low molecular weight chitin derivatives obtained after its 
hydrolysis), which were pointed as water soluble compounds with therapeutic properties [9].  
The amount of chitooligosaccharides in the crude PSC fractions obtained from the PWE 
extracts of L. edodes (Figure 3a) was increasing with the temperature up to 150 °C following a 
similar tendency than the β-glucan oligomers determined in the same PWE extracts (Figure 2a), 
suggesting that these fractions might be rich in monomers and oligomers considered as 
immunomodulators, with antimicrobial, antitumor activities etc [9]. Indeed, the crude PSC fraction 
from the PWE extract obtained at 50 °C showed very interesting immunomodulatory activities in 
macrophages that were lacking in the fraction obtained at 200 °C [30]. 
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Figure 2. Proteins (and peptides), polysaccharides and β-glucans (oligomers and polymers) of the PWE 
extracts obtained at different temperatures (5 cycles of 5 min) from a) Lentinula edodes b) Agaricus 
bisporus and c) Pleurotus ostreatus. 
The reason could be because in the latter fraction, the major PSCs were other β-glucans 
rather than those chitooligosaccharides (Figure 3a). Most of these β-glucans and a few α-glucans 
(glycogen and starch) were also present in the crude fraction obtained using the standard PSC 
extraction method. However, besides these glucans, the fraction obtained from the PWE extract 
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at 200 °C contained other PSCs probably with different structures since they were only detected 
by the total PSCs determination test, thus, they might be heteroglucans, proteoglucans, or others 
with specific configurations [11]. These other PSCs were extracted in larger concentrations with 
the increase of temperature and they were the responsible for the higher PSC extraction yield 
obtained in the PWE extracts at 200 °C (74.2%) as compared to the one obtained using the 
standard method (39%). 
The PSC composition of the crude fractions obtained from PWE extracts isolated from 
the other two mushroom species showed higher amount of chitooligosaccharides than the 
fractions obtained by the standard PSC extraction method but similar content of other β-glucans 
and α-glucans (Figures 3b,c). The main difference between these mushrooms was that                      
P. ostreatus contained larger amounts of other PSCs while in A. bisporus most of the extracted 
PSC were β-glucans as in the fraction obtained using the standard PSC extraction method. Since, 
the protein concentration in the P. ostreatus PWE extract at 200 °C was so high (Figure 2c) these 
other PSCs might be proteoglucans or other protein-PSC complexes. 
Bile acid-binding capacity by crude PSC fractions  
Direct binding or scavenging (because of their gel forming properties) of bile acids 
during digestion have been postulated as the main mechanisms of action for respectively the 
water-insoluble and water-soluble cereal β-glucans to reduce cholesterol from serum [3] and even 
some reports indicate that the cholesterol-reducing effect of water-insoluble fraction is rather low 
compared to the water-soluble PSCs [3]. However, since the crude PSC fractions obtained from 
both the PWE extracts and the fractions obtained using the standard PSC extraction method 
contained both water-soluble and –insoluble material (depending on the water temperature 
utilized for their extractions), the fractions were submitted to an in vitro digestion model and their 
bile acid-binding capacity determined by quantifying the bile acids, which were not retained by 
the PSC fractions independently whether this retention was by binding or scavenging of the bile 
acids. Thus, the PSCs effect will be referred as their “bile-acid binding activity” since some studies 
also suggested that direct binding forces between soluble PSCs and bile acids might also take 
place [3, 31].  
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Figure 3. Polysaccharides distribution within the crude PSC fractions obtained after PWE at different 
temperatures (5 cycles of 5 min) and after extraction using a standard PSC extraction method from              
a) Lentinula edodes b) Agaricus bisporus and c) Pleurotus ostreatus. 
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The crude PSC fractions were digested in the presence of bile extracts in ratios              
1:10 (bile extract: PSC extract), 1:30, 1:50, 1:75, and 1:100 but, although a slight reduction of 
GUDCA, GHDCA, TCDCA, and THDCA were observed as compared to the control digestion with 
increasing concentrations of the cereal and mushroom PSCs, they were only significant when the 
ratio was 1:100. Digestion of cellulose showed no reduction at any of the selected concentrations 
while the positive control, cholestyramine, showed a remarkable binding capacity already at ratios 
1:10 (w/w).  
Thus, the crude PSC fraction obtained from the cereals mixture (as positive control) and 
applied at ratio 1:100 was able to bind almost 40% of the four major bile acids showing no 
preference or binding affinity for any of the specific bile acids since their concentrations were 
almost equally reduced. The crude PSC fractions isolated from the PWE extracts obtained using 
temperatures lower than 200 °C showed none or insignificant bile acid-binding capacity; however, 
those obtained from the PWE extracts at 200 °C of A. bisporus and L. edodes showed similar 
binding capacity than the cereal. P. ostreatus showed lower binding capacity (23%) although still 
significantly higher than the negative control (Figure 4). When the crude PSC fractions obtained 
by the standard PSC extraction method were similarly digested (ratio 1:100) no significant 
differences were observed respect to their corresponding PWE extracts except for L. edodes.        
A slight reduction on the binding capacity of L. edodes and A. bisporus extracts (std. method) 
respect to the cereal fraction could be noticed.  
Chitin and their chitooligosaccharides enhanced excretion of triglycerides in feces but 
showed no cholesterol-lowering properties [9] thus, the fact that the crude PSC fractions from the 
PWE extracts obtained at 25–150 °C showed no bile acid-binding properties was not surprising 
since most of the β-glucans present in these fractions were the water-soluble 
chitooligosaccharides deriving from chitin hydrolysis. Only chitosan (a de-N-acetylated derivative 
of chitin) and its generated chitooligosaccharides, showed hypocholesterolemic action [32]; 
however, no acid/alkaline treatments were given to the PWE extracts to induce chitin deacetylation 
or transformation into chitosan hydrolysis products and therefore the chitooligosaccharides 
detected were probably deriving only from chitin. Moreover, the fractions obtained from PWE 
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extracts at 200 °C from L. edodes and P. ostreatus showing bile  acid-binding activities contained 
very low chitooligosaccharides levels pointing to the rest of PSCs as the responsible for the 
observed activities.  
 
 
 
 
 
 
Figure 4. Bile acid binding capacity of cellulose, cholestyramine and crude PSC fractions obtained from a 
cereals mixture and mushrooms by a standard PSC extraction method and by PWE at    200 ºC after an in 
vitro digestion model (mixed in a ratio 1:100 bile extract: PSC fractions except for cholestyramine which was 
1:10). * Denotes statistically significant differences (P < 0.05) between samples extracted by PWE and the 
standard PSC extraction method. 
Within these other PSCs, the fraction from  P. ostreatus PWE extract at 200 °C showed 
similar concentration of “nonchitooligosaccharides or chitins”(or deaminated β-glucans, named in 
the figures as “other β-glucans”) than the fraction obtained using the standard PSC extraction 
method and higher amount of other PSCs (tentatively proteo-glucans) but both fractions showed 
the same bile acid-binding capacity pointing those deaminated β-glucans as the responsible for 
the activity as occurred in cereals [28]. The crude PSC fraction obtained from cereals using the 
standard method and used as control contained 47.9 mg β-glucans/100 mg PSC fraction, the one 
obtained from L. edodes PWE extract at 200 °C contained 41.7 mg deaminated β-glucans/100 
mg and the one obtained using the standard extraction method 29.3 mg/100 mg PSC fraction. 
The bile acid-binding capacity of the latter fraction was lower than the PWE extract and the cereal 
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extract suggesting again that these compounds could be the responsible for the observed 
activities.  
However, apparently not all the β-glucans from the three species were equally efficient 
in the binding capacity since both A. bisporus extracts (obtained from the PWE and standard 
method) contained respect. 24.6 and 19.21 mg/100 mg PSC fraction while L. edodes extracts 
almost double their β-glucan content and still both mushroom extracts showed bile acid-binding 
activities similar to each other and to those observed for the cereal extract. 
Conclusions 
It can be concluded that PWE can be used to obtain β-glucans-rich fractions from edible 
mushrooms with different biological activities and compositions depending on the selected 
temperature. If the extraction is carried out at 200 °C (5 cycles of 5 min) the obtained fractions 
contain higher percentage of PSC than those usually obtained by a standardized PSC extraction 
method facilitating their incorporation into food matrices for their technological manufacture (faster 
extraction, higher PSC concentration can be added with less extract, more homogeneous 
chemical composition etc.). Their bile acid-binding capacities were similar to the fractions 
obtained by the standard PSC extraction method and they were also in the range of the β-glucans 
obtained from a cereal foodstuff commercially available and claiming to be able of reducing 
cholesterol levels. Thus, the obtained mushrooms extracts will further be tested to define whether 
they can be used as bioactive ingredients to functionalize foods with hypocholesterolemic 
properties.  
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Abstract 
Edible mushrooms are an interesting source of biological compounds such as dietary 
fiber with different structures but similar hypocholesterolemic properties than cereal β-glucans. 
However, their underlying mechanisms are still poorly understood. The effect of β-glucan enriched 
fractions obtained from 3 mushroom species on cholesterol-related expression was studied in 
vitro by low density arrays (LDA) and the Pleurotus ostreatus DF-fraction selected for two animal 
trials in order to assess its potential palliative or preventive effect against diet-induced 
hypercholesterolemia. Plasma and liver lipids and fecal cholesterol of mice fed with high-
cholesterol diet were examined. LDA assays were analyzed in jejunum, ileum, cecum and liver. 
Upon in vitro digestion, the P. ostreatus DF-fraction up-regulated FXR mRNA after 1 h and FDFT1 
and NPC1L1 after 24 h in Caco2 cells, suggesting a possible cholesterol-lowering effect. In the 
palliative setting, the DF-fraction reduced hepatic triglyceride likely by inhibition of synthesis since 
mRNA Dgat1 was down-regulated. Plasma and liver biochemical data of mice fed the DF-fraction 
showed no changes in cholesterol and no relation with transcriptional modulation. The highest 
transcriptional modulation was induced in the jejunum. Simvastatin also failed reducing cholesterol 
once the hypercholesterolemia was induced. In the preventive setting, no changes in plasma and 
liver biochemical data were induced by the DF-fraction but in the liver modulated cholesterol-
related genes expression similarly to simvastatin and ezetimibe. Thus, DF-fraction may be useful 
limiting hepatic steatosis but not diet-induced hypercholesterolemia in mice although its similar 
effect to hypocholesterolemic drugs on hepatic genes involved in cholesterol homeostasis 
warrants further dose-dependent studies.  
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Introduction 
An extensive number of studies in human and animal models have evidenced that in 
taking of dietary fibers (DF) has benefits for health maintenance and disease prevention including 
diabetes, cancer, and cardiovascular diseases. The term ´dietary fiber´ usually includes those 
carbohydrates that resist digestion and cannot be absorbed in the small intestine being partial or 
completely fermented in the large intestine [1].  
The mechanisms involved in the hypocholesterolemic effects of dietary fiber remain still 
unclear. Satiation and satiety effects or direct binding of bile acids within their structure underlie 
the cholesterol-lowering properties of insoluble DF while soluble DF could possibly use their water 
binding capabilities to increase chyme viscosity reducing the diffusion rate of bile acids [2]. Both 
mechanisms induce significant changes on hepatic cholesterol metabolism and on the synthesis, 
processing (in the intravascular compartment) and catabolism of lipoproteins because they lower 
hepatic cholesterol pools as a result of cholesterol being diverted to bile acid synthesis and less 
cholesterol delivery to the liver through chylomicron remnants [3]. At the molecular level, DF from 
cereals were able to down-regulate the expression of several genes involved in the lipid 
metabolism including SREBF1 (gene encoding two sterol regulatory element binding transcription 
factors: SREBP-1a and SREBP-1c) and the expression of SREBF2 gene involved in the regulation 
of cholesterol synthesis in NCI-H716 intestinal cell line [4] while in mice, hamster or rats, only some 
specific DFs were able to increase the hepatic expression of the Hmgcr gene (3-hydroxy-3-
methylglutaryl-CoA reductase) [5-7]. The Hmgcr up-regulation could be due to a depletion of 
cholesterol pools resulting from an increased excretion of bile cholesterol. The induced cholesterol 
reduction also led to up-regulation of the low-density lipoprotein receptor (Ldlr) synthesis and 
thereby accelerated the transportation of LDL-cholesterol from the blood into hepatocytes [7]. 
Other reports noticed decrease in the ileal level of ApoB mRNA (apolipoprotein B) after 3 weeks 
supplementation of rats with beet-DF plus low-fat diets [8], or up-regulation of ileal Nr1h4 mRNA 
(encoding the nuclear receptor FXR, farnesoid X receptor) simultaneously with its hepatic down-
regulation after modified corn-DF administration [9]. 
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Besides legumes, fruits, vegetable and particularly cereals, edible mushrooms are also 
an interesting source of DFs showing similar beneficial effects including hypocholesterolemic 
effects [10, 11]. DF extracts obtained from edible mushrooms such as Agaricus bisporus, Lentinus 
edodes, Flammulina velutipes and Grifola frondosa were able to lower cholesterol levels in rats 
fed with a cholesterol-free diet during 4 weeks [12, 13]. The hepatic Ldlr mRNA level in the groups 
supplemented with F. velutipes or A. bisporus was significantly higher than the control group. 
Similar up-regulation was observed after supplementation with P. ostreatus fruiting bodies [14]. 
Thus, this molecular effect and the enhancement of fecal cholesterol excretion were pointed as 
the responsible mechanisms for the observed reduction of total cholesterol levels in serum. Other 
studies carried out using other mushroom species such as Grifola frondosa mentioned hepatic 
up-regulation of the Abcg5/8 genes (genes encoding cholesterol transporters: ATP-binding 
cassette sub-family G proteins, involved in the reverse cholesterol transport (enterocytic 
cholesterol efflux)) [15]. Mushrooms DF fractions are constituted mainly by water-insoluble 
polysaccharides (PSC), with β-glucans and chitins being the most representatives, while the level 
of water-soluble PSC is usually lower than 10% (depending on specie) [1]. 
However, the described molecular studies on edible mushroom DFs were carried out 
using cholesterol-free or standard diets, therefore animals showed no hypercholesterolemia or 
altered cholesterol-related biochemical parameters. Functional foods with hypocholesterolemic 
properties (such as products enriched in phytosterols, cereal β-glucans, etc.) are usually 
recommended by physicians/nutritionists to people with slight to moderate hypercholesterolemia, 
thus, if a new functional product (based on mushroom DFs) is intended to be developed, the effect 
of such a fraction should be tested on individuals with certain level of hypercholesterolemia. 
Moreover, other reports indicated that when hypercholesterolemic animals were regularly fed with 
whole fruiting bodies, lowering of cholesterol in serum was noticed [16]. 
Thus, in order to study whether the dietary fiber fraction (DF-fraction) of edible 
mushrooms can be used as hypocholesterolemic ingredient to design novel functional foods and 
study their influence at the molecular level under cholesterol-altered physiological conditions, the 
modulation of mRNA expression of genes related to the cholesterol metabolism was investigated 
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on two models of hypercholesterolemic mice using low-density arrays (LDA). Firstly, a preliminary 
in vitro study was carried out using Caco2 cell cultures to select one DF-fraction out of the three 
most consumed mushrooms (Agaricus bisporus, Pleurotus ostreatus and Lentinus edodes) to 
reduce the number of mice and assays. Then, the two different in vivo experiments were carried 
out in order to compare the effect of a mushroom DF-fraction with two hypocholesterolemic drugs.  
Materials and Methods 
 Raw material and preparation of the dietary fiber-enriched extracts  
Mushroom strains Fresh fruiting bodies of Agaricus bisporus L. (Imbach) ¨Fungisem H-
15¨, Pleurotus ostreatus (Jacq.Ex Fr.) Kummer strain ¨Gurelan H-107¨ and Lentinus edodes S. 
(Berkeley) from ¨Sylvan 4312¨ from the first flush were harvested, cut in slices, lyophilized and 
ground until a dry powder was obtained following the procedure described by [16]. Resulting 
mushroom powders were utilized as starting material to extract the dietary fibers (DF). Dietary 
fiber-enriched fractions from the three mushroom species were prepared according to the method 
of [17].  
Standards and reagents 
Solvents as hexane (95%), chloroform (HPLC grade) and methanol (HLPC grade) were 
obtained from LAB-SCAN (Gliwice, Polland) and absolute ethanol and sea sand from Panreac 
(Barcelona, Spain). Potassium hydroxide, ascorbic acid, BHT (2,6-Di-tert-butyl-p-cresol), 
cholesterol, cholic acid, ergosterol, congo red as well as hexadecane were purchased from 
Sigma-Aldrich Química (Madrid, Spain). Simvastatin was obtained from Cinfa Laboratories (Spain) 
and ezetimibe (Ezetrol) from Merck Sharp & Dohme (Spain). Schizophyllan was pursached from 
Contripo Biotech s.r.o. (Czech Republic). All other reagents and solvents were used of analytical 
grade. 
β-glucans content of DF-fractions 
The β-glucan content of the obtained DF-fractions (50 mg) was evaluated in duplicate by 
a β-glucan determination kit specific for mushrooms and yeasts (Megazyme, Barcelona, Spain) 
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following the instructions of the user’s manual and as described in [18]. The amount of                       
β-(13),(16)-glucans was also determined following the method of [19] using a red congo 
concentration of 0.08% (w/v) and a schizophyllan as standard curve and chitins were determined 
as described in [18]. 
In vitro digestion 
Obtained DF-fractions were submitted to an in vitro digestion according to [18]. Briefly, 
the extracts were digested in 1 ml of 0.01 M HCl for 1 h at 37 ºC with gentle agitation (Orbital 
incubator S150, Stuart, Stone, UK). Afterwards, the sample pH was adjusted to 6.3 with 0.1 ml of 
0.1 M NaOH. Then, 4 ml of bile extract (14.3 mg in Tris-maleate buffer pH 6.3) and 5 ml of 
pancreatin (10 mg in Tris-maleate buffer pH 6.3) were added and the mixture was incubated for 
1 h at 37 ºC. After digestion, the samples were added to differentiated Caco2 cultures. A control 
sample was prepared following the same digestion protocol but without the addition of DF 
fractions. 
Caco2 cell cultures  
Human colorectal adenocarcinoma cell line Caco2 (ATCC HTB-37) obtained from the 
Americam Type Culture Collection (Rockville, MD, USA) were maintained in  Dulbecco´s Modified 
Eagle’s Medium (DMEM) with high glucose content (4.5 g/l) and supplemented with 10% fetal 
bovine serum, 1% penicillin-streptomycin, and 1% non-essential amino acids at 37 ºC in at 
humidified atmosphere containing 5% CO2.  
Firstly, the cytotoxicity was evaluated using 3-(4,5-dimethylthiazol)-2,5-diphenyl 
tetrazolium bromide (MTT) according the method published by Mosmann (1983) [20].  
Then, cells were seeded onto a 9.5 cm2 grown area 6 well flat bottom plate (Costar, 
Corning, USA) at a density of 5 × 105 cell per insert (3.3 × 105 cell/mL). Culture medium was 
replaced every three days and cells were allowed to generate a monolayer for 21 days before 
experiments. The digested DF fractions were applied at subtoxic concentrations (4 μl/ml) and left 
incubating at 37 ºC and 5% CO2 for 1 h or 24 h. Afterwards, cells were separated from the 
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membranes by incubation at 37 ºC during 30 min with Triton 0.1% (200 μl) and submitted to RNA 
extraction. Four replicates per sample were carried out. 
Animals and diets 
Male C57BL/6JRj mice were purchased from Janvier SAS (Le Genest Saint Isle, France). 
Mice were maintained four per cage in temperature-, humidity- and light-controlled conditions (24 
± 2  ºC, 40%-60% humidity, 12:12 hour light: dark cycle) and had free access to water and food. 
They were randomly divided into five groups, 2 control groups and 3 treated groups. Normal 
control group (NC, n=6) was fed a standard diet (Safe Rodent Diet A04, Augy, France) and the 
hypercholesterolemic control group (HC, n=8) was fed a high-cholesterol diet. The treated groups 
(n=8) were given high-cholesterol diet supplemented with their corresponding mushroom extract 
or control drug and were identified as follows: PE (Pleurotus ostreatus DF-fraction), SV 
(simvastatin, as a positive control for inhibition of cholesterol biosynthesis), and EZ (ezetimibe as 
a positive control for inhibition of cholesterol absorption). The animal intervention was carried out 
following two experimental settings in order to evaluate whether the P. ostreatus DF-fraction might 
act as a palliative (experiment 1: sequential supplementation) or as preventive agent (experiment 
2: simultaneous supplementation) against diet-induced hypercholesterolemia. In the experiment 
1 (sequential supplementation) mice were fed high-cholesterol diet for 4 weeks (from 5 to 9 weeks 
of age) followed by another 4 weeks of high-cholesterol diet plus mushroom extract (from 10 to 13 
weeks of age) while in the experiment 2 (simultaneous supplementation), mice were 
simultaneously fed high-cholesterol diet and the mushroom extract for 4 weeks (from 10 to 13 
weeks of age). The composition of diets, the dose per day of mushroom extract, drug or β-glucans, 
as well as the energy that received the mice daily are shown in Table 1. Body weight was 
registered for all mice before the experimental feeding period and at the end of the experiments. 
Wet mass of the liver was also registered. Animal studies were approved by our institution’s Animal 
Welfare and Ethics Committee and were carried out according to Spanish and European 
legislation (RD 53/2013, 2010/63/EU, respectively). 
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Feces, plasma and liver lipid analyses, tissue collection 
Following the experimental feeding period, mice were sacrificed by intracardiac 
exsanguination under anesthesia with 1.5% isoflurane, and plasma was collected and stored at -
80 ºC before use. Jejunum, ileum, cecum, and liver samples were removed and immediately 
frozen in liquid nitrogen and stored at -80 ºC. Feces were collected at the beginning and at the 
end of the experimental feeding period, and maintained at -20 ºC until further use. Cholesterol 
extraction from the stored feces (300 mg) and analysis by GC-MS were carried out as described 
in [16]. Plasma levels of total cholesterol, triglyceride, HDL and LDL were measured in duplicate 
for each sample using a Covas C311 Autoanalyzer (Roche, Spain). The lipids of the liver were 
extracted according to the manufacturer’s protocol. The cholesterol and triglycerides in the 
extracts of the liver were measured in duplicate for each sample by colorimetric methods using 
kits (BioVision Inc., CA, USA). 
Table 6. Composition of diets. 
 
Components NC HC PE SV EZ 
Carbohydrates (%) 59.9 59.9 59.9 59.9 59.9 
Proteins (%) 16.1 16.1 16.1 16.1 16.1 
Lipids (%) 3.1 3.1 3.1 3.1 3.1 
Fibres* (%) 3.9 3.9 3.9 3.9 3.9 
Mineral mixture** (%) 5.1 5.1 5.1 5.1 5.1 
Moisture (%) 11.9 8.9 7.4 8.9 8.9 
Cholesterol (%) 0.0 2.0 2.0 2.0 2.0 
Cholic acid (%) 0.0 1.0 1.0 1.0 1.0 
Mushroom extract or drug (%) 0.0 0.0 1.5 0.025 0.005 
Mushroom extract or drug 
(mg/mouse/day) 
0.0 0.0 60.0 1.0 0.2 
-glucans (%) nm nm 0.6 nm nm 
-glucans (mg/mouse/day) nm nm 24.0 nm nm 
Energy (Kcal/mouse/day) 13.37 14.39 14.39 14.39 14.39 
NC, normal control; HC, hypercholesterolemic control; PE: Pleurotus extract; SV: simvastatin; EZ: 
ezetimibe; *-glucans excluded; **A04 mineral mixture; n.m.: not measured. 
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Statistical analysis for biochemical data 
All values were expressed as mean ± SD. The SPSS software, version 15.0 (Lead 
Technologies, Chicago, IL, USA), was used to determine whether the variables differed among 
treatment groups in the in vivo experiments. The effects of treatments were assessed by one-way 
ANOVA followed by Tukey’s test when the ANOVA identified significant treatment effects. 
Differences with P < 0.05 were considered statistically significant. 
RNA extraction from cells and mice tissues and quantitative real-time PCR for LDA 
Total RNA from cell cultures or mice tissues was extracted by magnetic bead technology 
using a pureLinkTM Total RNA kit TRIzol® Plus RNA Kit (Invitrogen, Carlsbad, CA, USA) in an 
iPrepTM Purification Instrument (Invitrogen) programmed with an iPrepTM total RNA card 
(Invitrogen) according to manufacturer instructions. The RNA concentration was determined by 
spectrophotometry at 260 nm and the purity of the extracted RNA was calculated from ratio of 
absorbance at 260:280 nm and 260:230 nm in a NanoDrop ND-1000 (NanoDrop Technologies 
Inc., Wilmington, DE, USA). 
An amount of 400 ng of total RNA from each sample was reversed transcribed using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Framinghan, MA, USA). The 
obtained cDNA (100 μl per port) were loaded into micro-fluid cards designed for low-density array 
(LDA). Before sealing them, the cards were centrifuged twice on a Sorvall centrifuge at 1200 rpm 
for 1 min. Finally, the micro- fluid cards were run in a 7900HT Fast Real-Time PCR system (Applied 
Biosystems). Amplification conditions were 50 ºC for 2 min, 94.5 ºC for 10 min, followed by 40 
cycles with 97 ºC with 30 s and 59.7 ºC for 1 min. 
The micro-fluid card was constructed using respectively human and mouse commercial 
available assays (Applied Biosystems) for several genes related to the cholesterol metabolism, 
some internal standard and housekeeping gene that are described in detail elsewhere [21]. The 
cholesterol-related genes were ABCA1 (ATP-Binding Cassette, Sub-Family A, Member 1), ABCG5 
and  ABCG8 (ATP-binding cassette, sub-family G (WHITE), members 5 and 8), ACAT1 and ACAT2 
(Acetyl-CoA acetyltransferase 1 and 2), APOB (Apolipoprotein B), DGAT1 and  DGAT2 
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(Diacylglycerol O-acyltransferase 1 and 2), FDFT1 (Farnesyl-diphosphate farnesyltransferase 1), 
HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), LDLR (Low density lipoprotein receptor), 
MTTP (Microsomal triglyceride transfer protein), NPC1L1 (NPC1 (Niemann-Pick disease, type C1 
like 1), NR1H3 and NR1H4 (Nuclear receptor subfamily 1, group H, member 3 and 4), SOAT1 and  
SOAT2 (Sterol O-acyltransferase 1 and 2), SREBF1 and SREBF2 (Sterol regulatory element 
binding transcription factor 1 and 2). Comparative analysis of each of these genes was performed 
using specialized computer programs SDS2.3 and RQ 2.1 (Applied Biosystems). 
Gene expression statistical data analysis 
The expression of each gene was measured at least in duplicate and each biological 
group included a minimum of 3 replicates. In order to control for potential outliers, Grubb’s test 
was applied to technical replicates with a threshold of 0.05. Biological replicates were quality 
controlled using the Median Absolute Deviation test (MAD test). Samples of the same biological 
group with a MAD score higher than 3 were removed from the analysis. Genorm algorithm [22] 
was used to identify the most stable reference genes for normalization. Genes GUSB and HPRT1 
were found to be the most stably expressed in Caco2 cell cultures and in the mouse tissue 
samples, genes Hprt1 and Polr2a were the most stably expressed in cecum and liver tissues, 
Gusb and Polr2a in jejunum and ileum tissues. Relative gene expression levels were calculated 
by using the 2-ΔΔCT method [23], using these identified most stable genes as internal control genes 
in each group. Statistical significance of the results was assessed using a Limma test, and 
Benjamini-Hochberg false discovery rate procedure was subsequently applied.  Adjusted p-
values lower than 0.05 were considered significant. All these calculations were carried out with 
Real Time StarMiner 4.5® (Integromics S.L, Spain). 
Results 
Modulation of the mRNA expression pattern in Caco2 cell cultures   
Firstly, three mushroom species (A. bisporus, L. edodes, and P. ostreatus) were selected 
because they showed in vitro bile acid-binding capacity and this ability could be related to 
hypocholesterolemic activities [18]. Then, digestates obtained after in vitro digestion of the 
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mushroom DF-fractions were applied to Caco2 cell cultures to investigate whether they were able 
of modulating changes in the mRNA expression profile of genes related to the cholesterol 
metabolism. Results indicated that one hour after application, only the digestion products obtained 
from two mushrooms (A. bisporus and P. ostreatus) were able to induce significant overexpression 
of NR1H4 (gene encoding farnesoid X receptor, FXR) (Figure 1a). Moreover, the digestate of the 
A. bisporus DF-fraction up-regulated ACAT2 gene and down-regulated MTTP and SOAT2 genes. 
a) 
 
b) 
 
Figure 2. Relative mRNA expression (Log10) of Caco2 cells cholesterol-related genes after a) 1 h and b) 24 
h application of the digested DF-fraction obtained from A. bisporus, L. edodes or P. ostreatus. Indicated 
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
ACAT2 DGAT1 FDFT1 LDLR MTTP NPC1L1 NR1H4 SOAT1 SOAT2 SREBF1
Lo
g1
0R
Q
A. bisporus
L. edodes
P. ostreatus
-0.2
-0.1
0
0.1
0.2
0.3
0.4
ACAT2 DGAT1 FDFT1 LDLR MTTP NPC1L1 NR1H4 SOAT1 SOAT2 SREBF1
Lo
g1
0R
Q
A. bisporus
L. edodes
P. ostreatus
Chapter 1- Manuscript 2 
 
150 
 
genes are only those pointed as significant (P<0.05) compared with their controls (addition of the digestion 
product without DF addition). The expression of each gene was measured at least in duplicate and each 
biological group included a minimum of 3 replicates. 
However, when the treated cells were incubated for a longer period (24 h), 
overexpression of other genes were induced by the digestates obtained from the DF-fractions of 
L. edodes and particularly of P. ostreatus (Figure 1b) acting differently than those of A. bisporus 
that showed no effect. Both digestates were able to induce significant overexpression of the 
NPC1L1 (Niemann-Pick C1-like 1), gene directly involved in the cholesterol absorption. Digestates 
from the DF-fraction of L. edodes induced mRNA LDLR expression while those from P. ostreatus 
induced mRNA expression of other cholesterol-related genes such as DGAT1, FDFT1, SOAT1, 
and SREBF1 and inhibited mRNA expression of SOAT2. 
The fractions of the 3 mushroom species contained similar polysaccharide compositions 
[18] including lower α-glucan and chitin contents than β-glucans.  However, those β-glucans 
apparently showed different solubilities and conformations (Table 2). The DF-fraction of A. 
bisporus contained less β-(1→3),(1→6)-glucans than the other two DF-fractions and they were 
not soluble in KOH. Most of the β-glucans from the L. edodes DF-fraction showing conformation 
in triple helix (those with β-(1→3),(1→6) branching) were mainly soluble in alkalis while those of 
the P. ostreatus DF-fraction were more soluble in KOH than in NaOH.  
Table 7. Total β-glucan concentrations of the DF fractions obtained from the 3 mushroom species and their 
distribution as β-(1→3),(1→6)-glucans (conformation in triple helix) or chitins. 
 
 
DF fractions 
Total  
β-glucans 
mg/100mg 
dw 
β-(1→3),(1→6)-glucans 
(mg/100mg dw) 
Chitins 
mg/100mg 
dw 
KOH 
fraction 
HCl 
fraction 
NaOH 
fraction Total 
A. bisporus 25.87 ± 7.87 0.0 ± 0.01 1.01 ± 0.03 1.04 ± 0.06 2.05 ± 0.14 6.67 ± 2.23 
L. edodes 38.41 ± 6.50 2.54 ± 0.44 0.76 ± 0.11 2.89 ± 0.17 6.19 ± 1.01 9.13 ± 1.76 
P. ostreatus 39.87 ± 11.53 2.94 ± 0.54 0.00 ± 0.00 2.57 ± 0.60 5.51 ± 1.61 6.10 ± 3.56 
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Effect of mushroom extract on body and liver weight and fecal cholesterol excretion 
Food intake was approximately 4 g/d per mouse throughout the experimental feeding 
period in all groups, with no significant difference among groups (data not shown). All mice 
adapted immediately to the experimental diets. No differences were also noticed in initial body 
weight (Table 3). The normal control group gained weight over the feeding period in the sequential 
and simultaneous experiments. As expected, the remaining groups showed a slight tendency to 
lose weight since diets supplemented with cholate and cholesterol induced even higher weight 
loss in C57BL/6J mice [24]. No significant differences in final body weight of the treated groups 
were noticed compared with the hypercholesterolemic control group either in the sequential or 
simultaneous experiment, except for the simvastatin group where a significantly lower final body 
weight was recorded compared to all other groups, including the hypercholesterolemic control 
group. In the sequential experiment, liver weight was significantly increased in the 
hypercholesterolemic controls and the treated groups, except the simvastatin group, compared 
with the normal control group. Similar results for liver-to-body-weight ratio were observed, with a 
significant increase in all groups with respect to the normal control group. In the simultaneous 
experiment, liver weight was significantly increased in the hypercholesterolemic controls 
compared with the normal control group, and liver-to-body-weight ratio was significantly increased 
in the hypercholesterolemic controls and the PE group. The simvastatin and ezetimibe groups 
showed a significantly lower liver weight compared with hypercholesterolemic controls. Similar 
results for liver-to-body-weight ratio were observed, although only the ezetimibe group reached 
statistical significance. 
No cholesterol was detected in feces of normal controls but hypercholesterolemic 
controls significantly increased their cholesterol excretion either in the sequential or simultaneous 
supplementation compared with normal controls. In the sequential experiment, there was no 
significant difference in cholesterol excretion between hypercholesterolemic controls and the 
treated groups, except for mice fed the P. ostreatus DF-fraction extract where a significantly lower 
cholesterol excretion was observed. In the simultaneous experiment, the slight higher cholesterol 
excretion was significant for the ezetimibe group compared with hypercholesterolemic controls 
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but not for mice fed with the P. ostreatus DF-fraction. No differences were noticed in mice treated 
with simvastatin with respect to hypercholesterolemic controls. 
Table 8. Effect of mushroom extract on body and liver weight and fecal cholesterol excretion. 
 
Modulation of the lipid profile of plasma and liver in the animal intervention 
Sequential supplementation 
Plasma cholesterol levels increased 3.3-fold in hypercholesterolemic controls compared 
with normal controls (Table 4). In mice fed the P. ostreatus DF-fraction or treated with simvastatin, 
plasma cholesterol levels remained unchanged compared with those in hypercholesterolemic 
controls, while a reduction reaching normal levels was observed in the ezetimibe group. There 
was no significant difference in the plasma HDL levels between normal controls and 
hypercholesterolemic controls. No significant differences between mice fed the mushroom          
DF-fraction or treated with simvastatin and hypercholesterolemic controls were observed, 
 Sequential supplementation 
Variable NC HC PE SV EZ 
Initial BW (g) 19.2 ± 0.84 20.0 ± 0.71 19.3 ± 0.54 19.3 ± 0.60 19.8 ± 0.92 
Final BW (g) 25.0 ± 0.69 18.9 ± 1.07a 18.6 ± 1.18a,c 15.4 ± 1.52a,b,d 19.5 ± 0.93a 
LW (g) 1.25 ± 0.15 1.6 ± 0.13a 1.83 ± 0.15a,c,d 1.46 ± 0.31 1.56 ± 0.22a 
LW/BW (%) 4.99 ± 0.62 8.5 ± 0.56a 9.80 ± 0.63a,d 9.43 ± 1.34a,d 7.99 ± 1.15a 
Cholesterol  
(mg/g feces) 
nd 61.8 ± 0.47a 52.3 ± 4.62a,b 65.4 ± 7.41a 60.2 ± 14.74a 
 Simultaneous supplementation 
Initial BW (g) 23.4 ± 0.65 23.2 ± 0.50 23.1 ± 0.62 23.2 ± 0.58 23.2 ± 0.68 
Final BW (g) 24.7 ± 0.54 21.8 ± 0.57a 20.2 ± 1.22a,c 14.9 ± 0.73a,b,d 20.3 ± 1.66a 
LW (g) 1.27 ± 0.15 1.68 ± 0.31a 1.53 ± 0.14c 0.96 ± 0.10b 1.26 ± 0.20b 
LW/BW (%) 5.14 ± 0.63 7.69 ± 1.44a 7.54 ± 0.59a,d 6.41 ± 0.44 6.18 ± 0.63b 
Cholesterol  
(mg/g feces) 
nd 58.4 ± 2.10a 64.1 ± 8.41a 59.5 ± 7.96a 65.1 ± 2.58a,b 
NC, normal control; HC, hypercholesterolemic control; PE: Pleurotus extract; SV: simvastatin; EZ: ezetimibe. 
BW, body weight; LW, liver weight; nd, not detected. aP<0.05 vs. NC; bP<0.05 vs. HC; cP<0.05 vs. SV; 
dP<0.05 vs. EZ. 
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although interestingly, the mushroom DF-extract slightly increased HDL levels by another 9.3% as 
compared with hypercholesterolemic controls. Ezetimibe induced a significant reduction. The LDL 
levels were markedly increased by 6.6-fold in hypercholesterolemic controls compared with 
normal controls but remained unchanged in mice fed the mushroom DF-fraction or treated with 
simvastatin with respect to hypercholesterolemic controls. Reduction was noticed with the 
administration of ezetimibe as compared with hypercholesterolemic controls. In addition to the 
plasma lipid profile, two atherogenic indexes were calculated: total cholesterol/HDL and LDL/HDL 
ratios. Compared with normal controls, the total cholesterol/HDL and the LDL/HDL ratios were 
significantly increased in hypercholesterolemic controls by 2.1- and 5.3-fold, respectively. It is 
noteworthy that, although slight and no significantly, that negative balance in both indexes was 
improved in mice fed the P. ostreatus DF-fraction compared with hypercholesterolemic controls, 
mainly due to the increase in HDL levels. A significant reduction in both indexes was noticed in 
the ezetimibe group but not in the simvastatin group. Hypercholesterolemic controls and treated 
groups showed a reduction in plasma triglyceride levels with respect to normal controls. 
Compared with hypercholesterolemic controls, treated groups showed quite similar plasma 
triglyceride levels. 
Liver cholesterol levels were significantly increased by 4.9-fold in hypercholesterolemic 
controls compared with normal controls. In contrast with the lack of effect of the mushroom DF-
fraction on total plasma cholesterol, a 21.4% reduction in liver cholesterol levels with respect to 
hypercholesterolemic controls was observed, although it did not reach statistical significance. 
Simvastatin had no effect while ezetimibe produced a significant reduction compared with 
hypercholesterolemic controls. No significant differences in liver triglyceride levels were detected 
between hypercholesterolemic and normal controls. Treated groups showed a significant 
reduction with respect to normal and hypercholesterolemic controls and mice treated with 
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simvastatin or ezetimibe showed significant lower values compared with those of mice fed the P. 
ostreatus DF-fraction.  
Table 9. Plasma and liver lipid profile in mice treated for 4 weeks with the P. ostreatus DF-fraction, simvastatin 
or ezetimibe simultaneously with high-cholesterol diet after 4 weeks of high-cholesterol diet alone (sequential 
supplementation). 
 
 
Simultaneous supplementation 
Plasma cholesterol levels increased 1.9-fold in hypercholesterolemic controls compared 
with normal controls (Table 5). There was no significant difference between the mushroom             
DF-fraction and hypercholesterolemic control groups. Simvastatin and ezetimibe produced a 
significant reduction with ezetimibe the most effective. Plasma HDL levels were increased in 
hypercholesterolemic controls compared with normal controls. There was no significant 
differences in plasma HDL levels between the mushroom DF-fraction and hypercholesterolemic 
control groups while treatment with simvastatin or ezetimibe induced a significant reduction. 
Variable 
Plasma level (mg/dl) 
NC HC PE SV EZ 
TC 65.33 ± 26.63 214.2 ± 97.30a 207.1 ± 36.71a,d 156.2 ± 31.80a,d 59.43 ± 19.03b 
HDL 59.80 ± 25.07 89.70 ± 27.97 98.06 ± 17.93d 81.90 ± 21.92 47.91 ± 10.49b 
LDL 23.40 ± 11.03 155.0 ± 77.38a 152.6 ± 28.07a,d 102.5 ± 24.01a,d 23.40 ± 14.94b 
TC/HDL 1.10 ± 0.07 2.31 ± 0.38a 2.12 ± 0.16a,d 1.95 ± 0.21a,d 1.22 ± 0.16b 
LDL/HDL 0.31 ± 0.13 1.65 ± 0.35a 1.57 ± 0.17a,d 1.35 ± 0.22a,d 0.46 ± 0.23b 
TG 72.00 ± 20.00 47.25 ± 8.41a 39.43 ± 10.05a 46.29 ± 11.04a 43.43 ± 8.30a 
 Liver level (mg/g liver) 
TC 0.22±0.09 1.09±0.23a 0.86±0.46a 1.44±0.43a,d 0.45±0.20b 
TG 4.49±0.87 3.72±0.61 2.29±0.60a,b,c,d 0.78±0.18a,b 0.88±0.52a,b 
NC, normal control; HC, hypercholesterolemic control; PE: Pleurotus extract; SV: simvastatin; EZ: ezetimibe. TC, total 
cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride. aP<0.05 
vs. NC; bP<0.05 vs. HC; cP<0.05 vs. SV; dP<0.05 vs. EZ. 
The results are mean ± SD of six (NC group) or eight (remaining groups) mice on each diet and were analyzed by one-way 
ANOVA and the Tukey’s procedure. The assays were performed in duplicate for each sample. 
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 A 16-fold increase in plasma LDL levels was observed in hypercholesterolemic controls 
compared with normal controls. Mice fed with mushroom DF-fraction showed no significant 
changes compared with hypercholesterolemic controls while simvastatin and ezetimibe groups 
showed significant reductions. The total cholesterol/HDL ratio was moderately increased 
(P=0.071) in hypercholesterolemic controls compared with normal controls. No significant 
differences in total cholesterol/HDL ratio were detected between hypercholesterolemic controls 
and treated groups. A 10.3-fold increase in the LDL/HDL ratio was observed in 
hypercholesterolemic controls compared with normal controls. Similar values were observed in 
treated groups except for the ezetimibe group where a significant reduction compared with 
hypercholesterolemic controls was observed. Plasma triglyceride levels were reduced in 
hypercholesterolemic controls with respect to normal controls. Compared to hypercholesterolemic 
controls, similar plasma triglyceride levels were observed in the treated groups.  
Table 10. Plasma and liver lipid profile in mice treated for 4 weeks with the P. ostreatus DF-fraction, 
simvastatin or ezetimibe simultaneously with high-cholesterol diet (simultaneous supplementation). 
 
 
Variable 
Plasma level (mg/dl) 
NC HC PE SV EZ 
TC 120.8 ± 18.58 226.57 ± 16.64a 209.00 ± 40.33a,c,d 132.00 ± 13.37b 95.00 ± 14.14b 
HDL 84.69 ± 17.11 118.11 ± 13.07a 97.50 ± 21.36c,d 64.35 ± 9.81b 64.35 ± 17.57b 
LDL 10.03 ± 3.81 160.46 ± 25.42a 143.00 ± 29.46a,c,d 91.65 ± 17.30a,b,d 34.13 ± 16.11b 
TC/HDL 1.45 ± 0.15 1.93 ± 0.20 2.16 ± 0.18a,d 2.10 ± 0.44a 1.58 ± 0.51 
LDL/HDL 0.12 ± 0.04 1.36 ± 0.13a 1.48 ± 0.11a,d 1.47 ± 0.43a,d 0.62 ± 0.57b 
TG 
161.43 ± 
49.42 
50.29 ± 3.73a 38.00 ± 4.20a 42.00 ± 12.54a 68.50 ± 14.88a 
 Liver level (mg/g liver) 
TC 0.65 ± 0.23 0.98 ± 0.38 1.39 ± 0.21a,d 1.94 ± 0.64a,b,d 0.59 ± 0.42 
TG 3.03 ± 0.85 2.35 ± 0.69 3.47 ± 0.97c,d 0.38 ± 0.18a,b 1.03 ± 0.51a,b 
NC, normal control; HC, hypercholesterolemic control; PE: Pleurotus extract; SV: simvastatin; EZ: ezetimibe. TC, 
total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride. 
aP<0.05 vs. NC; bP<0.05 vs. HC; cP<0.05 vs. SV; dP<0.05 vs. EZ. 
The results are mean ± SD of six (NC group) or eight (remaining groups) mice on each diet and were analyzed by 
one-way ANOVA and the Tukey’s procedure. The assays were performed in duplicate for each sample. 
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There was no significant difference in liver cholesterol levels between normal and 
hypercholesterolemic controls. Liver cholesterol levels in the simvastatin group were significantly 
higher than those in the hypercholesterolemic control group but no significance differences in the 
mushroom DF-fraction or ezetimibe groups were observed compared with hypercholesterolemic 
controls. No significant differences in liver triglyceride levels were detected between normal 
controls and hypercholesterolemic controls or between the mushroom DF-fraction group and 
hypercholesterolemic controls. Liver triglyceride levels in mice treated with simvastatin or 
ezetimibe were significantly lower than those in hypercholesterolemic controls. 
 
Modulation of the mRNA expression pattern in the animal intervention 
Sequential supplementation 
In the jejunum, treatment with either simvastatin or ezetimibe inhibited the expression of 
Srebf1 and Srebf2 and simvastatin further inhibited other genes such as Fdft1, Hmgcr (involved 
in synthesis), Ldlr (involved in transport), Npc1l1 (involved in absorption) and Nr1h3 and Nr1h4 
(genes encoding respect. liver X receptor (LXR) and farnesoid X receptor (FXR), two nuclear 
receptors involved in regulation of lipid homestasis) (Figure 2a).  
In addition, administration of the P. ostreatus DF-fraction induced significant over-
expression of 10 genes related to the cholesterol metabolism with the higher levels for Fdft1 (100 
fold), and Abca1 and Npc1l1 (10 fold). On the contrary, it inhibited the expression of Nr1h4 and 
Srebf2 (regulatory genes) in a similar degree than simvastatin and ezetimibe. Slight transcriptional 
changes by the DF-fraction or the two drugs were observed in the ileum, not reaching statistical 
significance (data not shown). However, a higher transcriptional regulation was found in the 
cecum being the DF-fraction the most effective and simvastatin the least showing no effect, 
suggesting a response for the accumulation of the indigestible DF-fraction in the large intestine 
(Figure 2b).   
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Ezetimibe induced up-regulation of Abcg5 gene and down-regulation of ApoB and Fdft1. 
DF-fraction induced up-regulation of 5 genes and down-regulation of 2 genes. Particularly, the 
expression of Abcg5, Acat1, Ldlr, and Srebf1 were increased while the expression of Hmgcr and 
Nr1h4 were slightly decreased. In liver, simvastatin inhibited the expression of genes such as 
Abcg8, Ldlr and Nr1h4, and those related to the lipid metabolism such as both diacylglycerol        
O-acyltransferases (Dgat1/2) (Figure 2c). Ezetimibe inhibited expression of Abcg8 and Dgat1.    
DF-fraction was also able of inhibiting Dgat1, Ldlr, and Nr1h4 expression in a similar degree than 
simvastatin and induced overexpression of Acat1, Srebf1, and Srebf2. 
a) 
 
b) 
 
Figures 2 a) and b). Legend in the next page. 
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c)
 
Figure 3. Relative mRNA expression (Log10) of cholesterol-related genes in a) jejunum, b) cecum and c) 
liver of mice treated for 4 weeks with the P. ostreatus DF-fraction, simvastatin or ezetimibe simultaneously 
with high-cholesterol diet after 4 weeks of high-cholesterol diet alone (sequential supplementation). 
Indicated genes are only those pointed as significant (P<0.05) compared with hypercholesterolemic mice at 
8 week as control. The expression of each gene was measured at least in duplicate and each biological 
group included a minimum of 3 replicates. 
Simultaneous supplementation 
Simvastatin induced overexpression of Abcg8 in the jejunum, while ezetimibe did not 
induce statistically significant changes. P. ostreatus DF-fraction induced Fdft1 overexpression 
(Figure 3a) at similar levels than those for the sequential supplementation (Figure 2a) and Srebf2 
overexpression. In the ileum, significant changes were observed but only when mice were treated 
with the control drugs since DF-fraction supplementation, as occurred in the sequential 
experiment, did not modify the gene expression profile of this tissue (Figure 3b). Simvastatin 
induced an up-regulation on Abca1, Fdft1 and Nr1h3 genes and a down-regulation on ApoB gene 
while ezetimibe induced an up-regulation on Dgat1 and Nr1h3 genes the latter at lower levels than 
simvastatin.  
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In cecum, Soat2 expression was increased by simvastatin and the changes induced by 
the DF-fraction were restricted to overexpression of the Dgat1 gene (Figure 3c) but, it was up-
regulated at higher levels than observed in the sequential supplementation experiment.  
The hepatic expression profile was largely modulated by both DF-fraction and drugs with 
a clear tendency to down-regulate rather than up-regulating of cholesterol-related gene 
expression (Figure 3d). Simvastatin slightly increased expression levels of ApoB and decreased 
expression levels of 9 genes particularly Fdft1 expression. Ezetimibe increased and decreased 
expression levels of respectively 3 and 10 genes. P. ostreatus DF-fraction increased Acat1 and 
Srebf2 expression and decreased expression levels of 8 genes. Down-regulation of Abcg5, Fdft1, 
Ldlr, Nr1h3 and Nr1h4 was observed not only by simvastatin or ezetimibe but also by the P. 
ostreatus DF-fraction. 
a) 
 
b) 
 
Figure 3 a), b) and c). Legend in next page. 
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c) 
 
d) 
 
Figure 4. Relative mRNA expression (Log10) of cholesterol-related genes in a) jejunum, b) ileum, c) cecum 
and d) liver of mice treated for 4 weeks with the P. ostreatus DF-fraction, simvastatin or ezetimibe 
simultaneously with high-cholesterol diet (simultaneous supplementation). Indicated genes are only those 
pointed as significant (P<0.05) compared with hypercholesterolemic mice at 4 week as control. The 
expression of each gene was measured at least in duplicate and each biological group included a minimum 
of 3 replicates. 
 
Discussion 
In order to select the more interesting DF-fraction regarding its potential 
hypocholesterolemic effect, in vitro gene expression studies were carried out previously to in vivo 
studies. The DF-fractions obtained from the white button (A. bisporus), oyster (P. ostreatus) and 
shiitake (L. edodes) mushrooms were submitted to in vitro digestion in order to mimic in vivo 
conditions.  
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The expression profiles were different depending on the DF-fraction assayed being          
P. ostreatus the one that showed larger transcriptional changes. Recent evidences suggested 
that DF digestion can induce conformational changes in the β-glucans structure influencing their 
solubility or induces partial liberation of more water-soluble oligosaccharides [18, 25] modifying 
their biological properties [26]. Thus, the different effects noticed within DF-fractions at 
transcriptional level could be due to the different solubility and conformations formed in the           
DF-digestates. P. ostreatus DF-fraction induced more transcriptional changes in the long term 
than after 1 h since the Fdft1 and Npc1l1 genes were significantly up-regulated after 24 h. These 
results might suggest a possible cholesterol-lowering effect because on the one hand, FXR 
activation lowers plasma cholesterol in mice [27] and on the other hand, the retarded activation of 
genes that enhance cholesterol biosynthesis (Fdft1) and cholesterol absorption (Npc1l1) suggests 
a compensatory response to the smaller amount of available cholesterol in the cells 24 h after 
application of P. ostreatus digestate. Taking into account the results together with the fact that 
Pleurotus is one of the genera that have been target of more studies describing its 
hypocholesterolemic properties, P. ostreatus DF-fraction was selected for in vivo studies. Two 
experimental models were used in order to assess the potential palliative (sequential 
supplementation) or preventive effect (simultaneous supplementation) of P. ostreatus DF.  
When P. ostreatus DF-fraction was administrated to mice that were already 
hypercholesterolemic (sequential supplementation) no improvement in plasma and liver 
biochemical data concerning cholesterol was noticed indicating that the extract was not able of 
acting as a palliative agent only a slight reduction in fecal cholesterol mas noticed. However, 
increased plasma and liver cholesterol levels as a consequence of reduced fecal cholesterol 
excretion were also not observed. On the other hand, concomitant overexpression of Npc1l1, 
Abcg5 and Abcg8 in the jejunum makes difficult a clear explanation since Npc1l1 up-regulation 
could be associated with enhanced intestinal cholesterol absorption and therefore reduction of 
fecal cholesterol excretion [28] but not up-regulation of Abcg5 and Abcg8 genes, which indeed 
have opposite effect to Npc1l1. Abca1, Abcg5 and Abcg8 are Nr1h3 (Lxr) target genes and their 
expression is increased upon Nr1h3 activation [29] as observed in the jejunum of mice fed             
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DF-fraction. Thus, the slightly higher overexpression of Abca1 might suggest deviation of 
cholesterol into HDL formation.  Elevation in HDL levels occurs through an increase in liver 
production of ApoAI [30] and correlate with increase and HDL plasma levels in mice [31] thus 
apparently, the induction level was insufficient for the HDL values to reach significance. 
Diet supplementation with P. ostreatus DF-fraction and control drugs decreased 
triglyceride in the liver but not hepatomegaly (measured as liver-to-body-weight ratio) induced by 
high-cholesterol diet. Parallel to that reduction, hepatic Dgat1 down-regulation in the 3 
experimental groups was observed suggesting that the reduced hepatic triglyceride accumulation 
could be induced by inhibition of triglyceride synthesis. Other pathway reducing hepatic 
triglyceride is the one induced by cholic acid. In mouse models of hypertriglyceridemia cholic 
acid reduces hepatic expression of Srebp-1c via Fxr up-regulation and Lxr down-regulation [32]. 
In contrast, Nr1h4 down-regulation  (gene encoding the bile acid receptor Fxr) and Srebf1            
up-regulation were observed in mice fed P. ostreatus DF-fraction which rule out regulation of liver 
triglyceride via that pathway and support the possibility of inhibition of triglyceride synthesis. 
Reduction of liver triglyceride by simvastatin and ezetimibe also was not associated with that 
pathway since simvastatin induced Nr1h4 down-regulation and ezetimibe did not influence Nr1h4 
or Srebf1 gene expression. Therefore, gene expression data suggest a common effect for                
P. ostreatus DF-fraction, simvastatin and ezetimibe reducing liver triglyceride by inhibition of 
triglyceride synthesis mediated via down-regulation of Dgat1 gene. Triglyceride accumulation in 
the liver caused by lifestyle-related diseases such as non-alcoholic fatty liver disease (the most 
common hepatic disease in developed countries) begins with steatosis and can result in more 
serious diseases such as non-alcoholic steatohepatitis and others. Therefore, mushroom extracts 
could be of interest in the development of new therapeutic approaches because of their protective 
effect. In this line, administration of Agaricus bisporus prevents hepatic steatosis in mice [33], and 
Panellus serotinus ameliorates non-alcoholic fatty liver disease in obese, diabetic mice [34, 35]. 
Thus, the P. ostreatus DF-fraction might similarly help preventing hepatic steatosis and lifestyle-
related diseases such as non-alcoholic fatty liver disease.  
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Cholesterol-lowering effect in the liver can be directly induced by inhibition of synthesis 
(statins), or indirectly, decreasing enterohepatic circulation of bile acids (bile acid sequestrants) 
which in turn results in increased bile acid synthesis and then decreased hepatic cholesterol [36]. 
Concerning the first case, neither P. ostreatus DF-fraction nor control drugs influenced Fdft1 or 
Hmgcr expression in the liver suggesting a lack of transcriptional effect on cholesterol synthesis. 
However, mice fed the P. ostreatus DF-fraction showed hepatic over-expression of Srebf-2 (gene 
encoding Srebp2) and Srebp2 over-expression induces up-regulation of Fdft1 and Hmgcr in liver 
of mice fed a high protein/low carbohydrate diet [37]. Differences between the diet used by 
Sakakura et al. and those used in the models of this work could explain that apparent controversy. 
Regarding the second case, the P. ostreatus DF-fraction induced down-regulation of 
jejunal Nr1h4 (Fxr) expression. In this line, the classical mechanism of action for the bile acid 
sequestrants is mediated by blocking apical bile acid uptake in the ileum which results in               
down-regulation of Fxr and its target genes [38] suggesting that the uptake of bile acids in the 
jejunum could be similarly blocked. Further studies assessing intestinal transport of bile acids are 
needed to confirm this possibility. The association between reduced liver cholesterol and reduced 
jejunal Nr1h4 expression was more clearly noticed for ezetimibe but not for simvastatin where 
despite of reduced jejunal Nr1h4 a lack of effect on liver cholesterol was noticed. 
P. ostreatus DF-fraction induced Srebf1 and Srebf2 up-regulation in the liver but not 
changes in plasma cholesterol and LDL levels, which is consistent with the effect of prebiotic fiber 
supplementation on lean rats [6]. 
In contrast with the effect of the P. ostreatus DF-fraction in the sequential 
supplementation, when the fraction was simultaneously administrated no significant changes in 
fecal cholesterol excretion was noticed. Lack of significant influence on cholesterol excretion in 
feces compared with the hypercholesterolemic controls was also previously reported in 
hypercholesterolemic rats given powder of P. ostreatus fruiting bodies [39] although it was not 
directly associated with jejunal regulation of genes involved in cholesterol absorption or reverse 
cholesterol transport. Srebf2 and Fdft1 overexpression induced by the P. ostreatus DF-fraction in 
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the jejunum could be related with a possible enhancing of cholesterol synthesis in the small 
intestine however, no increase of cholesterol levels nor significantly increase of fecal excretion 
were noticed. 
The hypocholesterolemic effect of edible mushrooms, particularly P. ostreatus, have 
been evidenced by animal trials [11, 40, 41] and some of them pointed mushroom dietary fibers 
from other mushrooms as the potential responsible of the observed effects [12, 13, 42] although 
not all [43, 44]. The fiber composition of the P. ostreatus DF-fraction used in this study was more 
similar to those described by [12, 13]. Rats administrated powdered P. ostreatus fruiting bodies 
(including similar amounts of dietary fibers than the P. ostreatus DF-fraction) following similar 
experimental setting than the simultaneous supplementation but for a longer period of time were 
able of lowering plasma and liver cholesterol after 8 [45] and 10 weeks [43]. The lower 
experimental time set for this experiment or different extract concentration could be the reason for 
the lack of hypercholesterolemic activity because in the latter reports, a higher mushroom fiber 
dose (5% vs. 1.5%) and normocholesterolemic condition instead of diet-induced 
hypercholesterolemia were utilized. 
Regarding the tissue-specific transcriptional regulation, no large changes were observed 
except for the liver where administration of the P. ostreatus DF-fraction or the two control drugs 
down-regulated most of the genes. Interestingly, the P. ostreatus DF-fraction, simvastatin and 
ezetimibe coincided down-regulating expression of Abcg5, Fdft1, Ldlr, Nr1h3 and Nr1h4 genes 
in the liver. However, these changes do not mirror those observed in hepatic cholesterol or 
triglyceride levels. Concerning Abcg5 expression in the liver, the heterodimer conformed by 
Abcg5 and Abcg8 is necessary for cholesterol excretion into bile [46, 47] and their overexpression 
promotes this phenomena [48]. Therefore, the physiological significance of down-regulation of 
Abcg5 gene alone by the P. ostreatus DF-fraction is unknown. Simvastatin and ezetimibe           
down-regulated Srebf1 gene and its target gene Fdft1 [37] and the P. ostreatus DF-fraction          
down-regulated Fdft1 too but up to a lower level.  These changes might be associated with 
reduction of hepatic cholesterol levels, although none of them induced significant changes in 
cholesterol levels in the liver. On the other hand, the Ldlr down-regulation observed was neither 
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correlated with that lack of changes in hepatic cholesterol. However, the down-regulation of Dgat2 
gene by simvastatine or ezetimibe or of Dgat1 by P. ostreatus DF-fraction suggested a possible 
association with the reduction of hepatic triglyceride levels observed. 
Conclusions 
The DF-fraction induced a similar down-regulation of Dgat1 mRNA than simvastatin or 
ezetimibe in liver, suggesting a possible relation between their reduced hepatic triglyceride levels 
and inhibition of triglyceride synthesis in the sequential supplementation. Thus, DF-fraction may 
be useful limiting hepatic steatosis and preventing lifestyle-related diseases such as non-alcoholic 
fatty liver disease. 
The biochemical data recorded in plasma and liver for mice treated with the P. ostreatus 
DF-fraction showed no significant changes in the cholesterol levels which could be related to the 
ineffective modulation of the genes involved in its homeostasis. Once the hypercholesterolemia 
was induced in mice, administration of the DF-fraction or simvastatin was unable of revert that 
status. Thus, it seems that doses of fungal DF-fractions similar to those effective in 
normocholesterolemic models for lowering cholesterol levels are ineffective in 
hypercholesterolemic mice. However, a mushroom extract that can modulate the transcription of 
genes involved in the cholesterol homeostasis similarly to hypocholesterolemic drugs encourage 
further in a dose-dependent experimental setting to investigate it more in detail. Those studies are 
at the present being developed. 
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Preface 
Ergosterol and other derivatives such as ergosta-5,8,22-trien-3-ol, fungisterol etc. are 
fungal sterols with certain structural similarity to those from plants. As previously explained, several 
publications pointed phytosterols as compounds capable of displacing cholesterol from DMMs 
during digestion impairing its intestinal absorption. Other studies demonstrated the modulatory 
effect of dietary phytostanols and phytosterols on the mRNA expression levels of several genes 
involved on cholesterol metabolism in both hepatic and intestinal tissues. Therefore, the lowering-
cholesterol properties described for several edible mushrooms might be due to the presence of 
these fungal compounds (beside the fungal β-glucans activities described in previous chapter). 
Thus, in this chapter, the procedures to obtain specific sterol-enriched fractions from a selected 
mushroom are described. The influence of those extracts on the cholesterol absorption 
mechanism is studied and their effect on the expression of genes related with the cholesterol 
metabolism is evaluated using cell cultures and animal models. 
According to the results obtained in the preliminary screening previously described 
(preliminary studies section) and as expected, ergosterol and their derivatives were present in all 
the selected mushrooms, because they are compounds constitutive of their hyphal membranes. 
Thus, since cultivated mushrooms were easier to obtain showing less variability due to 
environmental conditions, Agaricus bisporus was selected as raw material to obtain sterol-
enriched fractions because it showed similar sterol levels than other cultivated mushrooms and its 
production for commercialization is higher than any other edible specie (representing almost 70% 
of the total Spanish mushroom market). 
Firstly, in the work titled Sterol enriched fractions obtained from Agaricus bisporus 
fruiting bodies and by-products by compressed fluid technologies (PLE and SFE), a screening 
within several A. bisporus commercial varieties was carried out in order to define the optimal 
starting material for the sterols extraction. However, besides genetic influences, sterol contents 
within the fruiting bodies are also highly dependent on environmental factors i.e. cultivation 
conditions. Thus, the fungal sterol concentrations were also quantified in fruiting bodies obtained 
from different flushes, different developmental stages and from compost beds covered with 
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different casing layers. Moreover, the sterol levels were also determined within the fruiting bodies 
tissues including the lower part of the stipe (which is usually discarded during harvesting) to point 
out whether it was convenient to use only a specific part of the mushroom or the whole fruiting 
body. The lower part of the stipe was also studied as an attempt to investigate its further 
revalorization as a potential source of these compounds. Thus, the two innovative environmentally 
friendly technologies (SFE and PLE) were compared to select the most convenient method to 
obtain fractions with a high content of fungal sterols. Several extractions of ergosterol and 
derivatives were carried out using a range of different parameters and solvent combinations (that 
could be modified depending on the device) until the optimal extraction conditions were 
established.  
Using the optimized extraction conditions (for both PLE and SFE technologies), two 
extracts were prepared and tested together with a commercially available ergosterol as 
cholesterol displacers from dietary mixed micelles (DMMs). The bioavailability of the preparations 
was also estimated with transport experiments using Caco2 cell cultures. The results of the latter 
experiments are described in detail in the work entitled Effect of ergosterol-enriched extracts 
obtained from Agaricus bisporus on cholesterol absorption using an in vitro digestion model. 
Ergosterol and the sterol-enriched extracts were mixed with several lipid-rich food matrices and 
submitted to an optimized in vitro digestion process that mimicked the physiological conditions of 
human digestion. However, after digestion a wide range of emulsified lipid structures with different 
sizes were produced (from oily droplets, vesicles, etc to DMMs) as occurred in vivo. Thus, in order 
to isolate those structures with the proper size to be assimilated by enterocytes (DMMs) an 
isolation procedure was optimized using chromatographic columns. 
As previously mentioned, dietary fibers (DF) lower cholesterol levels partially because of 
their ability to scavenge bile acids during digestion process. Mushrooms contain β-glucans that 
are also considered as DF and can also modulate cholesterol metabolism (see chapter 1). The 
aim of this thesis is to investigate whether a functional food can be designed including a mixture 
of all the fungal extracts with potential hypocholesterolemic properties. However, if mushroom       
β-glucans could bind to bile acids and sterols are structurally similar, perhaps they might also be 
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scavenged by the β-glucans impairing their ability to displace cholesterol from the DMMs. Thus, 
the digestion of the sterol-enriched preparations was also carried out in the presence of                     
β-glucan-enriched extracts from P. ostreatus mixed with a lipid-rich food matrix. Afterwards, the 
isolated DMM fractions including cholesterol and ergosterol or one of the extracts were applied to 
Caco2 monolayers grown on specific membranes to investigate whether they were able to pass 
through the cells from the apical to the basolateral compartment.  
The cholesterol included in the food matrix was not only displaced from the    ergosterol- 
containing-DMMs but its Caco2 absorption mechanism was also altered thus, a more detailed 
study was carried out to investigate the effect of the above described DMM fractions on the 
transcription levels of cholesterol-related genes. Results were presented in the work entitled 
Modulation of cholesterol-related gene expression by ergosterol and ergosterol-enriched extracts 
obtained from Agaricus bisporus. DMMs (containing ergosterol or the  ergosterol-enriched extract 
obtained by SFE (SFE-extract)) applied to Caco2 cells induced (after 1 and 24h) up- and down-
regulation of mRNAs from genes involved in the cholesterol biosynthesis, in its absorption 
mechanism and from regulatory genes responsible for maintaining cholesterol homeostasis. Thus, 
the lower compartments of the Caco2 transport assays (potentially containing those compounds 
able to pass through the cells) were also applied to HepG2 cell cultures and since these solutions 
were also able of modulating cholesterol-related gene expression, in vivo studies with animal 
models were carried out.  
Male C57BL/6JRj mice were fed an hypercholesterolemic diet for 4 weeks and afterwards 
treated during 4 weeks more with simvastatin or ezetimibe (as hypocholesterolemic drugs) or 
administrated ergosterol, the SFE-extract or an extract containing ergosterol and  β-glucans  
(EβG-extract) to study the possible β-glucans interferences for the reasons before explained.  
After the 8 weeks, biochemical parameters (hypocholesterolemia biomarkers from serum and liver 
and sterols fecal excretion) were determined and their mRNA expression pattern in four tissues 
(jejunum, ileum, cecum and liver) compared.  
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Abstract 
Ergosterol, ergosta7,22 dienol, ergosta 5,7 dienol, fungisterol, ergosta-4,7,2-trien-3-ona 
and ergosta-4,6,8(14),22tetraen-3-ona were the fungal sterols detected in Agaricus bisporus 
mushrooms after optimization of a sterol extraction method. Their concentration ranged from        
3.1 to 11.2 mg/g dw depending on the strain, casing soil, flush number, developmental stage and 
sporophore tissue analyzed. Two methods were optimized to obtain sterol enriched extracts from 
A. bisporus fruiting bodies using pressurized liquid extraction (PLE) and supercritical fluid 
extraction (SFE). PLE using ethanol as solvent at 10.7 MPa (50 °C and 100 °C) after 5 cycles of    
5 min extraction (mixing in the extraction cell the sample with sand in a ratio 1:4) yielded extracts 
with respectively 5 and 2.9% sterols. Using SFE-CO2 at 40 °C and 9 to 30 MPa fractions containing 
60% of sterols were obtained. Both technologies could be also utilized to extract sterols from 
mushroom by-products (the lower part of the stipe) as a method for their valorization.  
Industrial relevance: In this work, two environmentally friendly methods (SFE and PLE) to 
obtain sterol enriched fractions from Agaricus bisporus mushrooms were optimized. Extractions 
from both the complete fruiting body and the lower part of the stipe (usually discarded as a            
by-product during harvesting) yielded extracts with high ergosterol (and derivatives) content that 
could be used as functional ingredients to design novel foods with hypocholesterolemic properties 
since fungal sterols are able to reduce cholesterol levels in serum as plant phytosterols. Moreover, 
if the mushroom by-products are utilized as starting material, this application can be an interesting 
alternative method for the commercial valorization of this residue.  
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Introduction 
Cardiovascular diseases (CVD) are one of the leading causes of death in industrialized 
countries. Although, up to 80% of the cases could be prevented by changing style life, advertises 
of public agencies do not have the impact they should. Nowadays, only the consumption of 
functional foods with hypocholesterolemic properties seems to be better accepted by the CVD 
risk population than other changes. The functional foods, available at the markets, bearing the 
claim ‘able to reduce cholesterol levels in serum‘ contain mainly plant phytosterols [1, 2], or cereal 
β-glucans. The mechanism of action of the hypocholesterolemic β-glucans is not completely 
elucidated [3] while apparently the phytosterols are able to impair cholesterol absorption by 
displacing it from the dietary mixed micelles (DMMs) formed during digestion [4]. Phytosterols 
share structural similarity with cholesterol balancing their competitive equilibrium for the DMMs 
toward their inclusion enhancing cholesterol precipitation and excretion [5]. Other mechanisms of 
action mentioned for some phytosterols included the inhibition of the ACAT (acyl-CoA: cholesterol 
acyltransferase) a key enzyme involved in the cholesterol absorption by intestinal enterocytes and 
modification at the mRNA and protein expression levels of NPC1L1 and ABC transporters (proteins 
involved in cholesterol transport mechanisms) [6]. 
Edible mushrooms also contain sterols with structural similarities to phytosterols and 
cholesterol. Thus, these fungal molecules might also act as phytosterols displacing cholesterol 
from the DMMs. Ergosterol (ergosta-5,7,22-trien-3β-ol) is the major sterol of their hyphal            
membranes (approx. 80% of the sterols w/w) followed by other derivatives such as                             
ergosta-5,8,22-trien-3-ol, ergosta-7,22-dien-3-ol, ergosta-5,7-dien-3-ol and ergosta-7-en-3-ol 
(fungisterol). Their presence and con-centration are specie dependent influenced by many other 
environmental factors [7-11].  
Pressurized liquid extraction (PLE) and supercritical fluids extraction (SFE) are 
environmentally-friendly advance technologies utilized for the extraction or removal of specific 
fractions of interest for the food industry [12]. These technologies are nowadays encouraged 
because of ecological concerns and be-cause they share the advantage of using nontoxic and/or 
GRAS solvents such as water, ethanol or CO2. The latter can easily evaporate after the extraction 
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and depressurization leaving no solvent trace in the extract. Compressed fluid technologies such 
as SFE with CO2 were utilized to obtain triterpenoids (with similar rings than ergosterol molecules) 
from reishi mushrooms (Ganoderma lucidum), carboxylic and fatty acids from Agaricus spp., 
antioxidant and antimicrobial compounds from the fruiting bodies of shiitake mushrooms 
(Lentinula edodes) and antitumoral fractions from Cordyceps sinensis mycelia    [13-17]. SFE and 
supercritical fluid chromatography were also utilized in flour and moldy bread for ergosterol 
detection as indicator of fungal contamination [18]. PLE was utilized for the selective isolation of 
polysaccharides from several fungal species [19-22] and certain fatty acids from               
Cordyceps spp.[23]. 
In this work, ergosterol and derivatives were measured in several Agaricus bisporus 
varieties during different cultivation parameters, developmental stages, sporophore tissues etc. 
The sterols were extracted by both SFE and PLE technologies in order to compare them and define 
the optimal method and extraction parameters to obtain sterol-enriched fractions. Extractions were 
carried out using the complete fruiting body or the lower part of the stipe usually discarded as a 
by-product during harvesting to investigate the possible revalorization of this by-product as 
starting material to generate ergosterol-enriched fractions for novel functional ingredients with 
hypocholesterolemic properties. 
Materials and Methods 
 Biological material  
Commercialized spawns of A. bisporus L. (Imbach) were cultivated under controlled 
conditions (temperature, H.R. and CO2) at CTICH (Centro Tecnológico de Investigación del 
Champiñón de La Rioja, Autol, Spain). Fruiting bodies obtained from different flushes (1st to 3rd 
flush) or cultivated under different conditions (the same substrate but with 2 different casing 
layers) were harvested at developmental stages 2–3 according to Hammond (1979) [24] (except 
when the influence of the developmental stage was studied). In some cases, the different 
sporophore tissues, including the lower part of the stipe, were separately collected and treated as 
below described for fruiting bodies.  
Chapter 2- Influence of fungal sterols… 
 
183 
 
The fruiting bodies were sliced, lyophilized and ground using a Grindomix GM200 Retsch 
mill, (VERDER Group, The Netherland) as described by Ramírez-Anguiano, Santoyo, Reglero, and 
Soler-Rivas (2007)[25]. Mushroom powders were stored at -20 °C and in darkness until further 
use. 
Standards and reagents 
Solvents as hexane (95%), cyclohexane (HPLC grade), chloroform (HPLC grade) and 
methanol (HLPC grade) were obtained from LAB-SCAN (Gliwice, Polland) and absolute ethanol 
and sea sand from Panreac (Barcelona, Spain). Potassium hydroxide, ascorbic acid and BHT 
(2,6-Di-tert-butyl-p-cresol) as well as hexadecane, and (22E)-ergosta-5,7,22-trien-3β were 
purchased from Sigma-Aldrich Química (Madrid, Spain). Ergosterol (96% purity) was obtained 
from Alfa Aesar GmbH & Co (Karlsruhe, Germany). CO2 was supplied by Air-Liquid España, S.A. 
(Madrid, Spain). All other reagents and solvents were used of analytical grade. 
Pressurized liquid extraction (PLE)  
A. bisporus mushroom powder (1 g) was mixed with washed sea sand (4 g) and 
submitted to pressurized solvent extraction using an Accelerated Solvent Extractor (ASE) (Dionex 
Corporation, ASE 350, USA). The sea sand was selected as an inert material to hold the sample 
inside the extraction cell and to improve efficiency avoiding formation of preferential flow paths. 
Extraction procedure (per cycle) was carried out at 10.68 MPa (1500 psi) as follows: firstly, the 
sample was loaded into 11 ml extraction cell, then, the cell was filled with ethanol, heated-up and 
static extraction was carried out during the selected minutes with all system valves closed. When 
a cycle was finished, the cell was rinsed, the solvent was purged out of the cell with N2 gas and 
the cell remained depressurized. Then, fresh solvent was again added to the extraction cell to 
carry out another extraction cycle until the programmed number of cycles was finished. The 
fractions collected after the selected cycles were pooled together in a vial as a single extract.  
Several parameters such as static extraction time, number of cycles, ratio mushroom 
powder/sand and temperature were changed in order to optimize the extraction method to obtain 
fractions enriched in fungal sterols.  
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After collection, the extracts were immediately placed on a rotary vacuum extractor (Ika 
RV10 — VWR, PA, United States), concentrated until dryness (at 30 °C) and stored at -20 °C until 
further analysis. Extracted dry matter content was measured to calculate the extraction yields.  All 
the experiments were carried out in duplicate. 
Supercritical fluid extractions (SFE)  
Supercritical fluid extractions with CO2 (pilot-plant scale) were carried out in a plant 
(TharTechnology, Pittsburgh, PA, USA, model SF2000) comprising a 2 l cylinder extraction cell 
and two different separators each of 0.5 l capacity (S1 and S2) with independent control of 
temperature and pressure. The extraction vessel has a ratio of 5.5 height/diameter. A detailed 
explanation of the experimental device can be found elsewhere [26]. Extraction cell was filled with 
80 g of mushroom powder and 900 g of washed sea sand. In order to optimize the extraction 
method to obtain fractions enriched in fungal sterols, parameters such as extraction pressure     
(30, 18 and 9 MPa) and the use of a co-solvent (ethanol, 10% w/w) were tested. Extraction 
temperature as well as temperature of separators 1 and 2 was set to 40 °C for all the experimental 
assays. Pressure of separator 1 and separator 2 using ethanol as co-solvent was maintained at   
6 and 0.1 MPa respectively, however during CO2 extraction both separators were kept at 6 MPa 
pressure. The CO2 flow was set at 3.4 kg/h and the total extraction time was 3 h. Extracted 
compounds were precipitated in separator 1 in all assays. In the extractions with the co-solvent, 
separators were emptied every half hour. At the end of extraction process, the fractions were 
dragged with ethanol and immediately submitted to concentration until dryness on a rotary 
vacuum evaporator. Dried extract was stored at -20 °C until further analysis. Extracted dry matter 
content was measured to calculate the extraction yields. All the experiments were carried out in 
duplicate. 
Fungal sterols extraction method  
Fungal sterols from mushrooms were extracted following the procedure described by 
Mattila et al. (2002)[8] with modifications. Briefly, the mushroom samples or extracts (0.2 g) and 
0.3 g of ascorbic acid were mixed with 15 ml of 11.5% KOH in methanol:water (55:45 v/v) and 
vigorously stirred for 15 min at 80 °C. Afterwards, the mixture was cooled down and 10 ml of 0.01% 
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(w/v) BHT in hexane was added. The mixture was shacked during 2 min and left at room 
temperature (5 min) until complete separation of the phases. Organic fraction was collected and 
5 ml BHT solution were added to the aqueous fraction for a second extraction. Both organic 
phases were pooled together in a round bottom flask and evaporated on a rotary vacuum extractor 
at 30 °C until dryness. Dry extracts were dissolved in a ClCH3:MeOH (2:1 v/v) solution including 
hexadecane as internal standard and submitted to GC–MS– FID analysis. 
GC-MS-FID analysis  
The unsaponifiable fraction obtained from the mushroom extracts was injected                     
(2 mg/ml) into an Agilent 19091S-433 capillary column (30m×0.25mm ID and 0.25 μm phase 
thickness). The column was connected to a 7890A System gas chromatograph (Agilent 
Technologies, USA) equipped with an electronic pressure control, G4513A Auto Injector, a 5975C 
Triple-Axis Mass Spectrometer detector, and GC–MS Solution software. The injector was set at 
260 °C, the detector at 350 °C and the oven temperature program followed the method described 
by Teichmann et al. (2007)[10] with modifications: 60 °C for 1 min, at a rate of  40 °C/min, to a final 
temperature of 310 °C, and held for 30 min. Helium was used as carrier gas at a flow of                  
29.4 ml/min and inlet pressure of 0.19 MPa.  
Ergosterol was used as standard to develop and validate the GC method, using 
hexadecane (10% v/v) as internal standard. Linearity, LOD, LOQ, precision and reproducibility 
were determined following the ICH guidelines (1996) and IUPAC technical report of 2002 [27].  
According to the GC–MS database, the identified the peaks were in concordance with 
previous studies [10, 28]. The detected sterols were ergosterol (ergosta-5,7,22-trien3β-ol) as the 
major sterol (RT=13.3 min) being 83% of the total sterol content followed by ergosta-7,22-dienol 
(RT=13.6 min), ergosta-5,7dienol (RT=14.0 min) and ergosta-7-enol (fungisterol) (RT=14.3 min). 
Two other derivatives ergosta-4,7,2-trien-3-ona (RT=14.9 min) and ergosta-4,6,8(14),22-tetraen-
3-ona (RT=15.7 min) were also detected but in very low concentration. 
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Statistical data analysis 
Significance differences between variables were determined by the Fisher test                    
(α =0.05) using Statgraphics Plus (Statistical Graphics Corporation, Manugistics Inc., MD, USA 
1997). 
Results and discussion 
Selection of the starting material for sterols extractions 
A screening within several commercial A. bisporus strains was carried out in order to 
define the optimal starting material for the sterol extractions. Similarly, the influence of other 
cultivation parameters (casing soil, flush number, developmental stage and tissue distribution) in 
their sterol content was also determined. The total fungal sterol content of A. bisporus mushrooms 
using the modified extraction method ranged from 3.1 to 11.2 mg/g dw thus results were in 
concordance with previous reports [8, 10].  
Firstly, the fungal sterol content was measured in the fruiting bodies harvested from 
substrates inoculated with different spawn varieties (Table 1). Two of the A. bisporus strains 
(Fungisem H15 and Mispaj 365) showed significantly higher ergosterol levels than the others 
although the levels of the minor sterols were similar.  
No significant differences in sterol content were found within fruiting bodies (Fungsiem 
H15) obtained from the first, second or third flush when the mushrooms were cultivated using as 
casing layer a mixture of 70% black and 30% blonde peat. However, when only black peat was 
utilized, lower sterol levels were observed in mushrooms from the third flush. Mushrooms from the 
third flush are usually of lower quality than the previous flushes because when the third flush arises 
almost all nutrients from the substrate have been consumed thus, their hyphae grow less, they are 
weaker and their levels of ergosterol are reduced (as this molecule is considered as a maker for 
the fungal biomass and nutrition status [29]).  
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Table 1. Sterols distribution (mg/g) in different A. bisporus samples. 
 
The sterol content was also measured during the development of the fruiting bodies (from 
the first flush). Results indicated that the largest sterol content occurred during the faster growth 
phase of the sporophore formation (Table 1). At the initial primordial stage, pin heads readjust 
their metabolic mechanisms in order to synthesize the fruiting bodies, then, their hyphal extension 
 Ergosterol Ergosta-7, 22-dienol Ergosta-5,7-dienol Fungisterol 
Commercial varieties (spawns) 
Fungisem H5 5.61 ± 0.76 0.29 ± 0.03 0.70 ± 0.09 0.38 ± 0.04 
Fungisem H15 8.65 ± 0.69 0.42 ± 0.17 1.51 ± 0.20 0.64 ± 0.11 
Mispaj 365 7.40 ± 0.38 0.29 ± 0.03 1.23 ± 0.36 0.47 ± 0.10 
Gurelan 60 5.94 ± 0.14 0.27 ± 0.01 0.86 ± 0.03 0.37 ± 0.03 
Somycel A15 5.15 ± 0.12 0.30 ± 0.00 0.99 ± 0.02 0.50 ± 0.01 
 
Flushes in casing soil 1 (70% black 30% blonde peat) 
1st flush 4.08 ± 1.12 0.30 ± 0.02 0.58 ± 0.10 0.38 ± 0.04 
2nd flush 4.20 ± 0.94 0.30 ± 0.02 0.60 ± 0.10 0.37 ± 0.04 
3rd flush 3.56 ± 0.20 0.30 ± 0.01 0.50 ± 0.03 0.38 ± 0.01 
 
Flushes in casing soil 2 (100% black peat) 
1st flush 3.36 ± 0.02 0.33 ± 0.01 0.53 ± 0.03 0.43 ± 0.01 
2nd flush 3.64 ± 0.12 0.33 ± 0.01 0.58 ± 0.00 0.44 ± 0.03 
3rd flush 2.13 ± 1.04 0.28 ± 0.06 0.39 ± 0.14 0.34 ± 0.08 
 
Developmental stages 
Primordia (Stage 1) 4.12 ± 0.56 nd 0.81 ± 0.10 0.35 ± 0.03 
Immature (stage 2-3) 6.20 ± 0.11 0.26 ± 0.01 1.00 ± 0.02 0.41 ± 0.04 
Intermediate (stage 4-5) 4.51 ± 0.17 0.25 ± 0.00 0.96 ± 0.03 0.40 ± 0.00 
Mature (stage 6-7) 3.87±0.23 0.24±0.01 0.81±0.06 0.38±0.02 
 
Tissue distribution 
Veil 8.72 ± 1.09 0.32 ± 0.01 0.29 ± 0.02 0.19 ± 0.01 
Skin 3.66 ± 0.28 0.18 ± 0.02 0.31 ± 0.05 0.15 ± 0.02 
Gills 6.04 ± 0.29 0.29 ± 0.02 0.28 ± 0.03 0.26 ± 0.02 
Flesh 3.07 ± 0.12 0.25 ± 0.01 0.35 ± 0.01 0.20 ± 0.01 
Stipe 3.91 ± 0.99 0.18 ± 0.04 0.15 ± 0.02 0.13 ± 0.02 
Lower stipe (by-product) 4.7 ± 0.96 0.59 ± 0.01 0.6 ± 0.05 0.53 ± 0.01 
Whole fruiting body 5.9 ± 0.95 0.49 ± 0.15 0.64 ± 0.14 0.44 ± 0.19 
   nd: not detected 
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is not very significant. However immediately after, they start their exponential growth (immature 
stage), mushrooms almost double their size in a few hours indicating large development of hyphal 
membranes and therefore large ergosterol biosynthesis. Afterwards, senescence processes 
begins to open their caps and expose their gills therefore the hyphal as well as ergosterol 
synthesis stopped.  
The sterol distribution within the different sporophore tissues was also evaluated           
(Table 1). Results indicated that ergosterol levels were higher in the veil and gills than in other cap 
tissues. Interestingly, the lower part of the stipe usually discarded as by-product also showed high 
sterol levels. The distribution of the other minor sterols was similar than for ergosterol except for 
the levels of ergosta-5,7 dienol that were slightly higher in skin and flesh than in the other tissues.  
Thus, A. bisporus (Fungisem H15) fruiting bodies from the first flush and harvested at the 
stages 2–3 according to Hammond (1979)[24] were selected as starting material to obtain fungal 
sterol enriched fractions by PLE and SFE. 
Sterols enriched fractions by Pressurized Liquid Extraction (PLE) 
Several parameters such as extraction temperature, static extraction time, number of 
cycles or amount of sample inserted in the extraction cell (ratio mushroom:sand (w/w)) were tested 
in order to optimize the ASE conditions to obtain sterol-enriched extracts using ethanol as 
pressurized liquid (10.7 MPa). 
Influence of extraction temperature 
Accelerated solvent extractions carried out to obtain polysaccharide enriched fractions 
from A. bisporus fruiting bodies were largely influenced, beside the type of solvent, by the 
extraction temperature [22]. Thus, in order to investigate the influence of the temperature in the 
sterol extraction yields, ASE extractions were performed maintaining fixed other parameters            
(5 cycles of 5 min each one with a ratio 1:4 mushroom:sand (w/w)) and changing temperature 
from 25 °C up to 200 °C. Results indicated that the extraction yield (%) increased with the 
temperature from approx. 5% at 25 °C to almost 52% of the total dry matter at 200 °C (Table 2). 
Thus, extractions at 200 °C were less selective for total sterols since only 1% of the obtained 
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fractions were sterols while at lower temperatures (25 and 50 °C) less material was obtained but 
they accounted for almost 5–6% of the extracted material.  
Table 2. Dry matter content and total sterol concentrations in the ASE extracts obtained at different 
temperatures. 
  
However, in terms of quantitative amounts of sterols obtained from the mushroom 
powder, increasing of temperature generated higher sterol recovery rates (mg/g sample). In the 
samples carried out at 25 °C four folds less sterols were extracted that the amount present in the 
fruiting body (7.5 mg/g) and temperatures higher than 100 °C were necessary to extract most of 
them. Thus, extraction temperatures of 50 °C and 100 °C were selected for further testing since 
fraction obtained at 50 °C showed the highest sterol concentration (6%) and at 100 °C almost all 
the extractable sterols present in the mushroom were obtained.  
When the influence of the extraction temperature was evaluated within the individual 
sterols, no specific temperature could be selected to preferentially extract one of the sterol 
derivatives more than the others. Apparently, temperature similarly influenced the extraction of 
ergosterol and the other derivatives. 
Influence of extraction time 
Total extraction time can be adjusted by modifying two parameters: by changing the time 
in which the sample remains in the extraction cell (static time) or the number of extraction cycles. 
Both conditions were studied.  
Temperature  Extracted dry matter Total sterols in extract Total sterols from fruiting bodies 
(ºC) mg/g % mg/g % mg/g % 
25 47.75 ± 9.00 4.77 49.7 ± 22.20 4.98 1.91 ± 0.60 0.19 
50 82.67 ± 11.90 8.26 59.68 ± 20.32 5.97 4.53 ± 0.50 0.45 
100 194.00 ± 27.00 19.40 28.64 ± 1.31 2.86 5.39 ± 0.76 0.53 
150 365.60 ± 29.01 36.56 14.80 ± 4.63 1.48 5.40 ± 1.70 0.54 
200 517.80 ± 76.6 51.78 11.94 ± 1.61 1.19 6.47 ± 0.77 0.64 
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Thus firstly parameters such as temperature (50 and 100 °C), ratio mushroom:sand         
1:4 (w/w) and 5 cycles were set and extractions were carried out at 1, 5, 10 and 15 min per cycle 
(total extraction times were respectively 5, 25, 50 and 95 min). Results indicated that at 50 °C the 
extraction yields were higher after 5 min; further increase of the extraction time did not increase 
the extracted dry matter (Table 3). However, if the extractions were carried out at 100 °C shorter 
extraction time was required. The total sterol concentration of the obtained extracts was more 
influenced by the extraction temperature than by the extraction time. 
Table 3. Extraction yields (%) and sterol content of extracted fractions from A. bisporus using ASE under 
different extractions parameters.     
            
When results were compared in terms of sterol concentrations extracted per gram of 
mushroom powder, only extractions carried out at 100 °C and 1 min per cycle were able to extract 
all the sterols present in the mushroom (Figure 1a). In the fractions obtained from the extractions 
carried out during 10 or 15 min (per cycle) at 100 °C and in those carried out during 15 min at    
 
  50ºC  100ºC 
  
Extraction 
yield (%) 
Sterol yield 
(% in the 
extract) 
 
Extraction 
yield (%) 
Sterol yield 
(% in the 
extract) 
Time per 
cycle 
(5 cycles) 
1 min 6.14 ± 0.55 4.99 ± 0.17  24.36 ± 8.55 2.66 ± 1.39 
5 min 10.05 ± 2.18 4.99 ± 1.46  18.41 ± 4.04 2.71 ± 0.20 
10 min 7.07 ± 0.54 5.53 ± 0.20  19.89 ± 4.09 2.68 ± 0.38 
15 min 7.71 ± 3.13 5.56 ± 1.20  19.83 ± 0.01 2.84 ± 1.32 
Number of 
cycles 
(5 min. each 
one) 
1 cycle 5.14 ± 0.46 4.77 ± 0.90  19.2 ± 3.00 1.34 ± 0.30 
5  cycles 9.38 ± 3.13 4.99 ± 0.80  18.28 ± 3.81 2.71 ± 0.26 
10  cycles 9.68 ± 0.13 2.72 ± 0.18  25.95 ± 11.32 1.63 ± 0.53 
15  cycles 12.87 ± 4.75 2.86 ± 0.40  27.34 ± 6.20 1.47 ± 0.42 
Ratio 
mushroom: 
sand (w/w) 
1:19 4.26 ± 1.40 4.18 ± 0.74  9.72 ± 0.80 1.36 ± 0.42 
1:9 4.36 ± 0.18 6.01 ± 2.04  14.6 ± 1.62 2.11 ± 0.57 
1: 4 9.37 ± 2.13 6.02 ± 1.46  18.28 ± 3.85 2.71 ± 0.26 
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50 °C, a slightly increase of ergosta-5,7-dienol could be noticed suggesting that long extraction 
times, beside sterols degradation, might also induce transformation between them.  
The influence of changing the number of extraction cycles instead of the static extraction 
time (that was set at 5 min per cycle) was also studied at 50 and 100 °C maintaining the same 
total extraction times (5, 25, 50 and 90 min). Results showed that extraction yields increased with 
the number of cycles at both temperatures however, differences were only significant between     
1 and 5 cycles at 50 °C and further increase in the number of cycles did not result in significantly 
higher extraction yield (Table 3). Thus, the extractions carried out during 5 cycles of 5 min yielded 
the ASE extracts with higher sterol concentrations reaching almost 5% of the extract at 50 °C. 
Extractions of 5 cycles were also pointed as the condition to extract more sterols from the 
mushroom at both 50 and 100 °C (Figure 1b). As observed with the increasing of the static 
extraction time, more extraction cycles also induced shifting of some sterols into others (at           
100 °C). Particularly if the 10 cycles extractions were compared with those of 15 cycles, the total 
sterol concentrations were in both cases similar but a small reduction in the ergosterol content 
was noticed in the latter toward a slight increase of the other three identified sterol derivatives.  
The sterol yields of the obtained ASE fractions collected after 50 and 95 min (total time) 
were different depending on the condition changed (static time or number of extraction cycles) 
(Table 3). Apparently, longer contact time between the sample and the solvent is a more effective 
extraction process than extracting using more solvent (as occurred if the number of cycles is 
increased). 
Influence of ratio mushroom/sand 
The amount of sample placed into the extraction cell was another of the tested 
parameters to ensure that the cell was not saturated and that the sample is homogeneously 
distributed forming no aggregates. Several ratios mushroom:sand (w/w) were tested fixing the 
total material weight inside the cell (5 g) and the rest of extraction parameters (5 extraction cycles 
of 5 min at 50º and 100 °C). As expected, the ASE extraction yield was increasing with the amount 
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of sample utilized at both temperatures (Table 3). However, the sterol content in the extracted 
samples showed no significant differences in the ratios 1:9 and 1:4 mushroom:sand (w/w).  
     
  
 
Figure 1. Sterols content (mg/g dw) of ASE extracted fractions from A. bisporus at 50 ºC (dark color) and 
100 ºC (light color) changing a) extraction time per cycle, b) the number of cycles and c) mushroom:sand 
ratio. Full bars indicate ergosterol content, dotted bars ergosta-7,22-dienol, diamonds bars ergosta-5,7-
dienol and vertical lines fungisterol. 
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When results were expressed as amount of sterols extracted from the amount of 
mushroom powder loaded in the cell, no significant differences were observed if the total sterol 
concentrations were compared indicating that the cell was not saturated. However, extractions 
using a ratio 1:19 (mushroom:sand) contained higher levels of fungisterol, ergosta 5,7-dienol and 
ergosta-7,22-dienol than using two or four folds higher amount of sample where ergosterol was in 
these cases between 80 and 95% of the total sterols (Figure 1c). Differences were observed at 
the two selected temperatures being more significant at 100 °C. Apparently, if lower amount of 
sample is utilized for ASE extractions, the extraction times should be again properly adjusted 
because 25 min (total extraction time) provoked similar transformation effects between sterols than 
the one observed at longer extraction times (95 min) when the ratio 1:4 (mushroom:sand) was 
utilized. 
Sterols enriched fractions by supercritical fluid extraction (SFE) 
A. bisporus fruiting bodies were also submitted to supercritical fluids extractions (SFE) 
with CO2 to evaluate whether they were more effective for fungal sterol extraction than PLE. 
Several extraction conditions were tested such as pressure (9, 18 and 30 MPa) and use of 10% 
(v/v) ethanol as co-solvent. Previous studies stated that an in-crease of temperature (from 40 up 
to 60 °C) did not enhance the extraction yield as remarkably as it did when using PLE [30] 
therefore; the extraction temperature was set to 40 °C for the entire set of experiments.  
Results indicated that extraction yields were more influenced by the presence of ethanol 
as co-solvent than by the extraction pressure (Figure 2a). The highest extraction yields were 
obtained using CO2 with ethanol as co-solvent. This was due to the fact that, regardless of the 
pressure tested, the mixture widened the extracting polarity range leading to an increase in the 
amount of extracted compounds. Similar extraction yields were reported in previous studies 
carried out using other mushroom species such as L. edodes (approx. 0.5% and 2.5% with 10% 
ethanol), Agaricus brasiliensis (also known as Agaricus blazei) (0.85–0.98% at 10– 30 MPa and 
up to 4% with 10% ethanol as co-solvent) and G. lucidum (1.3–1.6%) [13, 15, 30]. Opposite to 
what was expected, differences between the extraction yields resulting from different extraction 
pressures were not significant. This might be explained because at 9 MPa all possible extractable 
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matter was already extracted. These results were also in agreement with those above mentioned 
reports using other mushroom species.  
However, sterol concentrations were higher in the SFE extracts where only CO2 was used 
as extraction solvent than in those extracts obtained with CO2 modified with 10% ethanol (Figure 
2b). These differences might be due to the higher extraction yield obtained with ethanol addition. 
When only CO2 was used, no significant differences in the sterol concentration were found. Within 
the extracts obtained at different pressures however, the fraction obtained at 30 MPa with CO2 
and 10% ethanol showed a significantly lower sterol content than the extracts obtained at lower 
pressures.  
The amount of sterols extracted with SFE using CO2 and ethanol as co-solvent 
represented the 80% of the total sterols present in A. bisporus fruiting bodies however, only 50% 
of the sterols were extracted when only CO2 was used.  
Figure 2. a) Extraction yields and b) sterol content in the SFE extracted fractions from A. bisporus          
fruiting bodies. 
When the influence of the extraction conditions were evaluated within the individual sterol 
content, the use of the ethanol as co-solvent appeared to extract a significantly higher amount of 
ergosta-7,22-dienol (6.57% of the total sterols) than without it (3.61%) (Figure 3). Particularly in the 
extractions carried out at 30 MPa, the higher levels of this sterol (9.2% of the total sterols) appeared 
to correlate with the lower ergosterol level (74% while on average, in the rest of the extractions 
was 77.8%) indicating that perhaps shifting between sterol structures might also take place with 
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increasing pressures as observed in PLE extractions. Moreover, the ratio of the minor sterols within 
the total sterol levels seemed higher in SFE than in PLE obtained extracts. 
 
Figure 3. Sterol content (mg/g dw) of SFE fractions extracted from A. bisporus. Dark bars indicate no co-
solvent extraction and light one corresponds to an extraction with co-solvent. Full bars indicate ergosterol 
content, dotted bars ergosta-7,22-dienol, diamonds bars ergosta-5,7-dienol and vertical lines fungisterol. 
Sterols enriched fractions from A.bisporus by-products  
The lower part of the stipe of the A. bisporus sporophore is usually cut and discarded 
during harvesting because it is stained with the attached casing soil and depreciates the quality 
of the fruiting bodies during storage [31]. Then, this part is wasted and considered as a                    
by-product. This by-product was submitted to PLE and SFE extractions to investigate whether it 
could be used as starting material to obtain similar sterol enriched fractions as with the fruiting 
bodies. 
PLE extractions 
The A. bisporus by-product was submitted to PLE using ethanol as the pressurized 
solvent and selecting the optimal extraction conditions (10.7 MPa at 50 °C, 5 cycles of 5 min,       
1:4 mushroom/sand) that according to the obtained results using fruiting bodies, they were 
appropriated to extract high sterol enriched fractions.  
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Results indicated that the extraction yields obtained using the stipes (93.0 ± 4.2 mg/g) 
were similar than when the whole fruiting body was used (82.6 ± 11.9 mg/g) under the same 
conditions. However, the percentage of sterols in the ASE extracts obtained from the by-product 
was lower than when fruiting body was utilized (respectively 3.3% and 6%). The ASE extraction 
process using the by-product extracted approx. 47.5% of the sterols present in that part of the 
stipe (6.4 ± 0.5 mg/g) while submission of the fruiting body to PLE yielded 60% of the sterols from 
the whole sporophore. Certain selectivity within the extracted sterols was also observed 
depending on the selected starting material since ergosterol was almost 93% of the sterols present 
in the extracts obtained from the by-product while in the extracts obtained from the fruiting body 
it represented 85% of the measured sterols. These differences were probably due to the lower 
concentration of the minor sterols in the lower part of A. bisporus stipe (Table 1). 
SFE extractions 
The A. bisporus by-product was also subjected to SFE extraction at 40 °C and 30 MPa 
during 3 h using CO2 modified with ethanol (10% v/v). Results indicated that extraction yield 
obtained when the by-product was used as starting material was lower than when the 
commercialized fruiting body was utilized since 2.1% w/w dry matter was extracted from the 
fruiting bodies while 1.4% was extracted from the discarded stipes. However, the amount of sterols 
in the extracts obtained from the by-product was 37.25% while 23.6% sterols were found in the 
extracts obtained from the fruiting body. Moreover, the total sterol content of the SFE extract 
obtained from the mushroom by-product was 5.3 ± 0.4 mg sterols/g stipes, a slightly higher value 
than the one observed in the SFE extracts obtained from the commercial fruiting bodies                 
(4.4 ± 0.8 mg/g) indicating that the sterol recovery rate from the stipes was higher (82.8%) than 
from whole sporophore (59%).  
As occurred during PLE, preferential extraction of ergosterol instead of the other 
derivatives was observed when the starting material was the by-product (84% of the total extracted 
sterols) because when the whole sporophore was utilized, ergosterol was only the 74% of the total 
extracted sterols.  
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Thus, it could be concluded that ergosterol might also be extracted from these mushroom 
by-products using PLE and SFE technologies making this application an interesting alternative 
method for the commercial valorization of this residue. 
 
Conclusions 
Ergosterol and other minor sterols can be extracted from A. bisporus fruiting bodies and 
by-products (such as the lower part of the stipe) using PLE and SFE technologies. SFE extractions 
extracted less material than PLE but the sterol concentration of the obtained fractions was higher 
(approx. 50% of the extract) than the PLE obtained fractions (approx. 5%) thus, SFE was a more 
selective method and the obtained extracts could be used, for instance, as sterol concentrates or 
supplements to functionalize foods. However, if the aim of the process is to extract all the sterols 
from the mushroom, by selecting the proper parameters, PLE is more recommended. 
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Abstract 
Ergosterol-enriched extracts obtained from Agaricus bisporus were incorporated into 
lard, butter and white chocolate as food carriers to study their potential as ingredients with 
hypocholesterolemic properties to design functional foods. Lard was selected and supplemented 
with several concentrations of cholesterol and ergosterol, beta-sitosterol (as control) and two types 
of ergosterol-enriched extracts obtained by supercritical fluid extraction (SFE) and accelerated 
solvent extraction (ASE). The prepared food combinations were submitted to a specific in vitro 
digestion model, their dietary mixed micelle (DMM) fractions isolated and administrated to Caco2 
cell cultures. Ergosterol was as effective as some phytosterols such as sitosterol, in the 
displacement of cholesterol from the DMMs when applied to the food matrix in a ratio (1:2, w/w, 
cholesterol:sterol). The ASE extract was not effective but addition of the SFE extract provoked a 
67% reduction in the DMM cholesterol content. Lard supplementation with fungal beta-glucans 
able to bind bile-acids enhanced the cholesterol displacement from the DMMs induced by the 
sterols although it also reduced ergosterol incorporation. Fungal sterols also impaired proper 
cholesterol transport through Caco2 monolayers.  
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Introduction 
At the present, two types of functional foods can be found in the market bearing the 
European Food Safety Authority (EFSA) approved health claim “able to lower cholesterol levels in 
serum”. One contains phytosterols or derivatives and the other specific cereal β-glucans. Both 
types of compounds impair cholesterol absorption from the diet but through different mechanisms 
of action [1-3].  
Although the mechanism by which phytosterols interfere with cholesterol absorption is 
not completely clear, they appear to modulate it at different levels. They are able to compete with 
the cholesterol molecules for their incorporation in the dietary mixed micelles (DMM) during 
digestion because of their structural similarity provoking its displacement, precipitation and 
excretion [4]. They were also able to compete at the epithelial brush border of the enterocytes for 
their transport, cause the suppression of the acyl-CoA:cholesterol acyltransferase (ACAT) activity 
(a key enzyme involved in the cholesterol absorption by intestinal enterocytes) and reduce 
chylomicron secretion (measured by apoB48) into the lymph [5, 6].  
Cereal dietary fiber (β-glucans) showed cholesterol-lowering properties apparently 
because they were able to scavenge bile acids during digestion via direct-binding to their 
structure as occurred with the water-insoluble fiber or via the gel formation properties of the water-
soluble polysaccharides [7]. Then, the binding of bile acids might stimulate plasma and liver 
cholesterol conversion to additional bile acids for digestion [8]. However, these mechanisms 
appear not to be the only ones involved and other possible mechanisms are being investigated 
[9, 10].  
The white button mushroom (Agaricus bisporus) and other edible mushrooms could be 
novel sources of molecules such as sterols to design hypocholesterolemic functional foods        
[11-16]. They contain ergosterol (ergosta-5,7,22-trien-3β-ol), the major sterol of their hyphae 
membranes (approx. 80% of the sterols w/w), and other derivatives with chemical structures 
similar to cholesterol and phytosterols. Their concentration ranged from 3.1 to 11.2 mg/g dw 
depending on spawn varieties, developmental stage and cultivation parameters [11]. But, their 
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sporophores or by-products can be submitted to traditional or more advance extraction 
technologies such as accelerated solvent extraction (ASE) or supercritical fluid extraction (SFE), 
yielding fungal extracts containing from 3 to 60% fungal sterols [11, 17]. However, the ability of 
ergosterol or ergosterol enriched extracts to act as plant phytosterols has not been studied in 
detail, neither the possibility of combining sterol-enriched with β-glucan-enriched extracts to 
design a more effective hypocholesterolemic functional food. The latter possibility should be 
carefully evaluated because addition of β-glucans could be detrimental since they might also 
scavenge the beneficial sterols because of their structural similarity with cholesterol.  
In this work, firstly three food products were tested in order to select the most suitable 
matrix (depending on the sterol stability and extractability) to incorporate the                         
ergosterol-containing extracts to study whether they were able to act as plant phytosterols as 
preliminary experiments before designing hypocholesterolemic functional foods. Some of the food 
mixtures included, beside the fungal-sterols, a β-glucan-enriched extract obtained from Pleurotus 
ostreatus (Oyster mushrooms) with bile-acid binding capacity [18]. Afterwards, the specific 
ergosterol-enriched extracts mixed with the selected cholesterol-rich food matrix (and with or 
without fungal β-glucans) were submitted to an in vitro digestion model to investigate whether they 
were able to displace cholesterol from the dietary mixed micelles. The bioavailability of the sterols 
integrated into the DMMs generated after digestion of the   ergosterol-enriched foods was also 
monitorized using Caco2-transport assays.  
Materials and Methods 
 Biological material  
Lyophilized mushroom powders obtained from Agaricus bisporus L. (Imbach) Fungisem 
H-15 and Pleurotus ostreatus (Jacq. Ex.Fr. Kummer) Gurelan H-107 fruiting bodies from the first 
flush were obtained as described by [11, 12] and utilized as starting material for respectively 
sterols and β-glucan extractions.  
Commercially available lard (Iberian pork lard (100 g fat/ 100 g food)), BHT (butylated 
hydroxytoluene), BHA (butylated hydroxyanisole), butter (83 g fat, 1.5 g protein,                                   
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0.3 carbohydrates/100 g food, vitamins A (0.67 mg), D (1 µg) and B12 (0.65 µg)) and white 
chocolate (31.5 g fat, 7.1 g protein, 58.3 g carbohydrates, 0.25 g salt, 0.24 g calcium/100 g food) 
were purchased from a local supermarket and maintained at 4 °C until use. All the experiments 
were performed from the same lotus.  
White chocolate contained sugar, powdered milk (26.4%), cocoa butter, powdered whey 
milk, sunflower lecithin and natural vanilla aroma.  
Accelerated solvent extraction (ASE) 
Agaricus bisporus mushroom powder (1 g) was mixed with washed sea sand (4 g) and 
submitted to pressurized solvent extraction using an Accelerated Solvent Extractor (ASE) (Dionex 
Corporation, ASE 350, Bannockburn, IL, USA) as described in [11]. Five extraction cycles of 5 min 
each were carried out using ethanol as solvent pressurized at 10.7 MPa (1500 psi) and maintained 
at 50 °C. After collection, the ASE extracts were immediately placed on a rotary vacuum extractor 
(Ika RV10 – VWR, Bridgeport, NJ, USA), concentrated until dryness at 30 °C, and stored at -20 °C 
until further analysis.  
Supercritical fluid extractions (SFE)  
Agaricus bisporus mushroom powder (80 g) were mixed with washed sea sand (900 g) 
and submitted to supercritical fluid extraction with CO2 in a pilot-plant (TharTechnology, 
Pittsburgh, PA, USA, model SF2000) as described in [19]. Extraction was carried out at 40 °C and 
30 MPa for 3 h. Obtained fractions were dragged with ethanol and immediately submitted to 
concentration until dryness on a rotary vacuum evaporator at 30 °C. Dried SFE extract was stored 
at -20 °C until further analysis.  
Preparation of the β-glucan-enriched fraction  
Pleurotus ostreatus mushroom powder (10 g) was mixed with distilled water (1 L) and 
treated following the procedure of [20] to obtain a polysaccharide crude extract containing 36% 
(w/w) β-glucans (determined as described in [18]. The β-glucan-containing fraction was stored at 
-18 °C until further use.  
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Sterol incorporation in the food matrices  
Butter, lard, and white chocolate were supplemented with cholesterol (50 mg/g) and 
ergosterol (50 mg/g) and gently stirred at their melting temperature until complete incorporation 
of the standard compounds into the lipidic matrices. The same supplemented products were 
mixed with 133 mg/g of the β-glucan-enriched extract obtained from P. ostreatus.  
Similarly, lard was supplemented with several concentrations of cholesterol (2.5–10%), 
cholesterol and ergosterol (2.5–10%) or mixed with cholesterol (2.5%) and the ergosterol-enriched 
extracts (SFE or ASE) added until a concentration of 5% ergosterol was reached. Depending on 
the assay, β-glucans were also incorporated into the supplemented lards maintaining in all cases 
the same sterols:β-glucans ratio.  
In vitro digestion  
The supplemented food matrices (1 g) were mixed with 5 mL human saliva from volunteer 
and 5 mL tap water in a mortar and stirred with the pestle for 2 min simulating the mastication 
process. Acidified water (54 g) (pH 2 adjusted with 6 M HCl) was added and solution was 
transferred to a thermostatic vessel at 37 °C and stirred at level 8 in a titrator device (Titrino plus 
Metrohm 877, Switzerland) to simulate stomach digestion by adding a 0.275 g pepsin (equiv.        
0.5 g pepsin/100 mL homogenized) and incubated for 15 min at 37 °C. Intestinal digestion was 
started by adding 5 mM CaCl2 and 150 mM NaCl before pH adjustment up to 6, then 6 ml of a 
pancreatic solution (pancreatin (20 mg, 4 × USP), bile extract (633 mg) and phosphatidylcholine 
(228 mg) in 50 mM trizma-maleate buffer pH 7.5) was added. Afterwards, pH was adjusted and 
maintained up to 7.5 (with 1 M NaOH) using a viscotrode (Metrohm, Herisau, Switzerland) placed 
in the titrator device for 1 h, at similar temperature and stirring conditions than those of the gastric 
digestion.  
Determination of the IMBC of the micellar phase  
Immediately after digestion, an aliquot was taken and filtered through a 0.45 µm filter to 
obtain a minimum of 500 µl. Then, the filtrated was centrifuged using a centrifugal filter unit             
(10 kDa cut off, Microcom filters; Millipore, Madrid, Spain) for 30 min to separate vesicles and 
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micelles from the soluble micellar phase. Afterwards, the intermicellar bile salt concentration 
(IMBC) was calculated using the 3-α hydroxysteroid dehydrogenase (3-α HSD) assay (Spinreact, 
Madrid, Spain). The filtrate (10 µl) were placed in a cuvette containing 750 µl of Thio-NAD  (1 g/l), 
triton-100 (0.1% v/v) and sodium azide (0.2% w/v) in Goods buffer pH 4 and 250 µl of NADH (6 
g/l), 3-αHSD (12 kU/l) and sodium azide (0.5% w/v) in Goods buffer pH 9.3 and its absorbance at 
405 nm was measured with a spectrophotometer (Evolution 600 Thermoscientific, England) 
following kit manual’s instructions.  
The IMBC was also determined in the micelles fraction once they were isolated following 
the same procedure as described for digestion samples to check their stability. Significance 
differences between variables were determined by the Fisher test (α=0.05) using Statgraphics 
Plus (Statistical Graphics Corporation, Manugistics Inc., MD, USA 1997). 
Isolation of the DMM fraction  
Separation of dietary mixed micelles (DMM) from vesicles and other lipidic drops of 
higher size and from the major water-soluble fraction was carried out on a Sepharose®4B column 
(Sigma-Aldrich, Madrid, Spain) using as mobile phase 0.15 M NaCl and bile salts (Sigma) at the 
IMBC calculated as described earlier. The solutions resulting after the in vitro digestion (5 ml) 
were passed through a fine paper tissue to eliminate possible clumps and applied to the column. 
The fractions corresponding with the DMM with higher cholesterol and lecithin levels were pooled 
together (12 ml) and immediately utilized for further analysis or applied to Caco-2 cells for 
citotoxicity or transport studies.  
The cholesterol concentration of the fractions eluting from the Sepharose®4B column was 
determined according to the instruction manual of the enzymatic kit for cholesterol quantification 
(Spinreact SAU, Girona, Spain). Each fraction eluting from the column (400 µl) were mixed with 
the indicated reagents and the mixture absorbance was determined at 505 nm and compared 
with a cholesterol standard curve.  
Quantification of phospholipids present in the DMM fractions was carried out using an 
enzymatic kit (Wako, Madrid). Samples (4 µl) were mixed at the concentrations indicated in the 
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user’s manual with the reagents in wells from a 96-wells plate. Absorbance change was followed 
by a microplate reader (Tecan Group Lt, Switzerland) at 37 °C and lecithin concentration 
calculated using a provided standard solution (choline chloride).  
In vitro cell transport assay in Caco2 cell cultures  
Human colorectal adenocarcinoma cell line Caco2 (ATCC HTB¬37) obtained from the 
American Type Culture Collection (Rockville, MD, USA) were maintained in Dulbecco’s modified 
eagle’s medium (DMEM) with high glucose content (4.5 g/l) and supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin–streptomycin, 1% L-glutamine, 1% hydroxyethyl 
piperazineethanesulfonic acid solution (HEPES) and 1% non-essential amino acids at 37 °C in at 
humidified atmosphere containing 5% CO2.  
Firstly, the cytotoxicity was evaluated using 3-(4,5-dimethylthiazol)-2,5-diphenyl 
tetrazolium bromide (MTT) according the method published by [21]. For absorption assays, cells 
were seeded onto a 44 cm2 insert membrane with 0.4 µm pore size (Corning Incorporated Life 
Sciences,Tewksbury, MA, USA) at a density of 5 × 105 cell per insert. Culture medium was 
replaced every 3 days and cells were allowed to differentiate for 21 days before experiments. The 
integrity of the cell layer was evaluated by measuring the transepithelial electrical resistance 
(TEER) (Evon, Sarasota, FL, USA) and cell differentiation was determined by measuring alkaline 
phosphatase activity (ALP) as described by [22] and [23]. Only inserts with values above 400 Ω 
and ALP values of approximately 78 mUI/mg protein were utilized. The DMM fractions were 
applied to Caco2 cell monolayers at subtoxic concentrations in 975 µl of incomplete medium 
(medium described earlier without FBS) to the apical (upper) compartment and left incubating in 
incomplete medium at 37 °C and 5% CO2 for 1 h. The apical and basolateral (lower) compartments 
and the cell monolayer obtained on the membrane were collected and their sterol concentrations 
were analyzed by GC–FID–MS.  
Sterols quantification  
Sterols were extracted from the samples and quantified following the procedure 
described by [19] using a 7890A System gas chromatograph (Agilent Technologies, Las Rozas, 
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Madrid, Spain) equipped with an Agilent 19091S433 capillary column (30 m × 0.25 mm ID and 
0.25 µm phase thickness), an electronic pressure control, G4513A autoinjector, a 5975C triple-
axis mass spectrometer detector. Under the programmed conditions, cholesterol was detected 
after 12.6 min and ergosterol and β-sitosterol appeared after respectively 13.3 min and 14.3 min.  
Results and discussion 
Selection of the food matrix  
Three types of food matrices were tested to select the most appropriate carrier to 
properly integrate the ergosterol-enriched extracts ensuring their complete incorporation in the 
food product. They were matrices with high lipid content due to the apolar nature of the obtained 
extracts and their sterols.  According to GC–MS analysis, none of the food matrices contained 
ergosterol but cholesterol. These results were not surprising since they are animal products (butter 
and lard) and white chocolate, besides cocoa butter also contained animal milk derivatives.  
Although white chocolate was selected instead of normal chocolate to avoid large concentrations 
of cocoa phytosterols and flavonoids, campesterol, stigmasterol and β-sitosterol were also 
detected in white chocolate. However, the cholesterol levels of the three selected products were 
too low (≤0.6 mg/g) to be later detected in the DMM fraction isolated after digestion therefore, the 
food matrices were supplemented with 5% cholesterol apart from the fungal sterol 
supplementation (5% ergosterol, 50 mg/g food matrix).  
Before sterols addition, the matrices were gently melted to avoid lipid degradations but 
although temperature was maintained below caseins critical point (65 °C) a white precipitated 
could be observed in butter indicating emulsion destabilization. Moreover, if a mild extraction 
procedure was followed to partially re-extract the sterols from the three matrices after their 
integration, sterols from the white chocolate were more easily extracted than from the other 
matrices suggesting that sterols were less stabilized in the cocoa butter than in the other two fats 
(Table 1). When the three preparations were submitted to the in vitro digestion model, both 
cholesterol and ergosterol could be easier extracted from the digested mixtures. Ergosterol levels 
were significantly higher in digested butter than white chocolate and in this one higher than lard 
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but differences were not so clear for cholesterol levels. Moreover, when the β-glucan extract was 
added to the same supplemented foods no changes were observed before digestion but 
afterwards a lower recovery rate (or higher degradation, or binding of the sterols, particularly 
cholesterol) was observed in butter and white chocolate while no significant influence was noticed 
if lard was used as matrix carrier.  
Table 1. Sterol recovery rate of the supplemented food matrices before and after the digestion process with 
or without addition of the fungal β-glucans extract. 
 
Thus, lard was selected as food matrix for further experiments avoiding the possible 
phytosterol interferences that might occur if white chocolate was utilized, to ensure carrier stability 
during sterol supplementation avoiding the protein precipitation observed with butter and because 
the observed β-glucan interferences during digestion (perhaps binding of the molecules occurred 
that reduced their bioaccesibility/ extractability or enhanced their degradation) were lower in this 
matrix.  
Isolation of the DMM fractions from the digested supplemented food matrices  
In order to study the reduction of cholesterol solubility in micelles by β-sitosterol, Jesch 
and Carr (2006)[4]  prepared synthetic emulsions including mixed micelles or vesicles depending 
on the bile salt concentration added.  A digestion model, although it is still an in vitro experiment, 
might better reproduce the events occurring during human digestion than synthetically formulated 
mixtures. However, it will also generate many different lipidic structures with a wider range of size 
distribution and different chemical compositions including DMM, vesicles or larger oil droplets that 
will impair the proper evaluation of the events occurring only in those DMM with the correct size 
 Food matrix Cholesterol (%) Ergosterol (%) 
Before digestion 
 
Lard 26.47    2.43 31.06    7.26 
White chocolate 44.86    4.19 47.55     5.28 
Butter 27.36    2.23 29.52    3.45 
After digestion 
(without β-glucans) 
 
Lard 48.15    1.82 55.01    3.30 
White chocolate 61.83    7.87 66.15    5.48 
Butter 62.18    6.05 79.48    4.27 
After digestion 
(with β-glucans) 
 
Lard 45.18    0.97 53.68    2.86 
White chocolate 52.50    0.53 59.27    7.31 
Butter 52.00    3.77 57.38    4.38 
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to be absorbed by the enterocytes. Nevertheless, the micellar fraction (containing the DMM) can 
be isolated from vesicles and larger size lipidic structures by gel filtration columns in both simple 
synthetic preparations and more complex physiological mixtures such as lumenal aspirates          
[4, 24]. Thus, a method to isolate the DMM containing fraction from the digestate obtained after 
the in vitro digestion was optimized.  
Under the conditions described in the previous section, lard digestion (1 g) yielded a 
greenish-turbid emulsion where no macroscopic fat particles were visible since the pancreatic 
lipases (and co-lipase etc. from a pancreas extract) were in the presence of sufficient NaCl and 
CaCl2 to be active during the selected incubation time [25] and had the physiological 
concentrations of lecithin and bile acids (from a bile extract) to form lipidic droplets, vesicles and 
micelles [26]. However, the equilibrium of the micellated bile salts and the so called intermicellar 
bile acid concentration (IMBC) is critical to maintain stable the micelles avoiding their aggregation 
and transformation into larger vesicles during their isolation. The digestate IMBC was determined 
and established in 16 mM and therefore, the buffer required to perform the chromatographic 
separation was prepared including 16 mM bile salts and 0.15 M NaCl since under unphysiological 
saline conditions, the micelles can also be converted to vesicles [24].  Indeed, if the lard digestate 
was applied to the gel filtration column and eluted with a buffer with lower bile salt concentration 
(3 mM) than the determined IMBC, an eluted peak at approximately 40 mL appeared 
indicatingthat larger size vesicles were being formed (Figure 1a).  
The elution peak of the DMM fraction resulting from the lard digestion could not be easily 
detected neither by monitoring its absorbance nor cholesterol content using the kit since the 
utilized lard contained approximately 0.6 mg/g cholesterol. Thus, the food matrix was mixed with 
10% cholesterol before digestion and the chromatographic profile of the obtained digestate 
showed a high cholesterol-containing peak appearing after the vesicles and before the soluble 
components (Abs 260 nm) and coinciding with the fraction containing the larger phospholipid 
composition (Figure 1b) indicating that it was the DMM fraction since phospholipids can only be 
“solubilized” into aqueous solutions when they are micellated [27]. Moreover, the eluting profile of 
the digestates obtained from food preparations containing cholesterol and other sterols or extracts 
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was also monitorized in case that addition of these sterols or sterol-containing extracts could 
modify the size of the formed micelles displacing the DMM fraction from the determined elution 
volume (Figure 1c). Results indicated that the DMM fractions formed after digestion of the 
cholesterol-enriched lard (CH-lard) supplemented with the tested standard compounds               
(5% ergosterol or β-sitosterol as control) eluted at similar volume than the lard containing only 
cholesterol (only 3 or 4 mL before or after) while a slightly broader peak was obtained after 
application of the digestate from the CH-lard supplemented with the SFE extract obtained from   
A. bisporus (an ergosterol-enriched extract, see later). Therefore, for each tested preparation the 
chromatographic profile was determined by measuring the cholesterol and phospholipid levels 
and the fractions (16 mL) containing the higher values were considered as the DMM fraction. 
Several parameters such as extraction temperature, static extraction time, number of cycles or 
amount of sample inserted in the extraction cell (ratio mushroom:sand (w/w)) were tested in order 
to optimize the ASE conditions to obtain sterol-enriched extracts using ethanol as pressurized 
liquid (10.7 MPa). 
Cholesterol displacement from the DMM by ergosterol  
The lipidic composition of lard facilitated the integration in high levels of the liposoluble 
sterols (cholesterol and fungal sterols). However, the use of sterol-enriched preparations does not 
guarantee that they will be fully incorporated in the micelles. Sterols will be micellated until they 
reach their saturating concentration and above that level the excess will precipitate                        
(and in vivo it would be eliminated through the feces) [28]. Thus, in order to study the maximum 
amount of cholesterol and other sterols that can be incorporated in the DMM fraction generated 
by the in vitro digestion model, lard was supplemented with few sterol mixtures and submitted to 
digestion. Afterwards, the DMM fractions were collected and their cholesterol levels were 
determined by GC–MS.  
Results indicated that 10 or 5% (w/w) addition of only cholesterol to lard (CH-lard) was 
excessive since their micelles contained similar cholesterol concentrations (Figure 2) and 
although significant reduction of cholesterol levels were observed when 5% ergosterol was added 
(CH + ERG-lard), the reduction in both cases (10 or 5% CH) was similar and in the first case the 
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ratio cholesterol:ergosterol was 2:1 (w/w) and in the other 1:1 (CH:ERG). Nevertheless, addition of 
higher ergosterol concentrations (10%, ratio 1:2) also showed interesting cholesterol 
displacement in the DMM fraction.  
 
Figure 1. Chromatographic profiles of a) digested lard eluted with 0.15 M NaCl + two biliar salts (SB) 
concentrations, b) digested lard supplemented with 10% cholesterol (CH-lard) eluted with 0.15 M NaCl + 16 
mM SB and c) digested CH-lard supplemented with 5% ergosterol (CH+ERG-lard), β-sitosterol (CH+SIT-
lard) or the SFE extract (CH+SFE-lard). 
a) 
b) 
c) 
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Figure 2. Cholesterol concentration in the isolated DMM fraction after digestion of lard enriched with different 
cholesterol (CH): ergosterol (ERG) ratios (w/w). 
When the enriched lard was prepared with 2.5% cholesterol and supplemented with 
increasing concentrations of ergosterol, significantly less cholesterol was incorporated in the 
generated DMMs and this reduction correlated with the in-crease of ergosterol added up to 5% 
(ratios 1:1, 1:2 CH:ERG showed a cholesterol reduction of 32 and 49%, respectively). However, 
further increase in ergosterol concentration (ratios 1:3 and 1:4 CH:ERG) did not result in larger 
cholesterol displacement, because at these concentrations the saturation level was reached and 
no more ergosterol could be incorporate in the micelles. Thus, results indicated that under the 
experimental conditions, the optimal cholesterol concentration to supplement lard was 2.5% and 
ergosterol was able to displace it from the DMM but up to certain level (ratio 1:2, CH:ERG).  
Cholesterol displacement from the DMM by ergosterol-enriched fractions  
Two ergosterol-containing extracts were evaluated as cholesterol-displacers from DMM 
and compared with ergosterol and a plant phytosterol (β-sitosterol) as controls to study their 
potential as hypocholesterolemic extracts to design new functional foods. Both extracts were 
obtained from the fruiting bodies of the white button mushroom (Agaricus bisporus). The ASE 
extract contained 5.99% (w/w) sterols being ergosterol the major constituent (86.28%), followed 
by other derivatives such as ergosta-5,7-dienol (5.47%), fungisterol (4.29%) and                           
ergosta-7,22-dienol (3.96%). However, SFE was a more selective technology to obtain high sterol-
enriched fractions since 57.73% (w/w) of the obtained extract were sterols. SFE extract 
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composition was also a slightly different than the ASE extract because a lower ergosterol 
concentration (77.55%) was noticed followed by a higher level of ergosta-5,7-dienol (13.89%), 
fungisterol (5.09%) and ergosta-7,22-dienol (3.47%) were also detected. Other compounds were 
also identified such as a few esterified sterols (i.e. 9(11)-dehydroergosteryl benzoate), waxes, 
esterified and free fatty acids and other lipidic molecules. The ASE extract contained more 
phenolic compounds and less fatty acids than SFE extract.  
Both extracts were mixed with CH-lard at specific concentrations in order to have a ratio 
1:2 (CH:ERG) and submitted to in vitro digestion. The resulting DMM fractions were isolated and 
compared to control samples (Figure 3). The DMM fraction obtained after digestion of the sample 
including the ASE extract (CH + ASE-lard) showed the same cholesterol concentration than the 
DMM fraction of a control sample where only cholesterol was added. However, when the SFE 
extract (CH + SFE-lard) was utilized a 67% reduction was observed, a higher cholesterol 
displacement than ergosterol (49%) or β-sitosterol (47%). The different behavior between the two 
types of extracts (although they were applied at the same ergosterol concentrations) could be due 
to the different concentrations of ergosterol derivatives (i.e. ergosta-5,7-dienol) and/or by the 
presence of other compounds which might interact with positive or negative synergy.  
 
Figure 3. Cholesterol concentration in the isolated DMM fraction after digestion of lard enriched with 
cholesterol (2.5%), different ergosterol-containing extracts and ergosterol or β-sitosterol as controls (1:2, 
w/w, cholesterol:sterol ratio). 
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The SFE extract contained more apolar structures than the ASE extract thus, probably 
they were easier included in the micelles together with the fungal sterols and apparently they 
influenced the micelle chemical composition as stated for some lipidic compounds [29].  
On the other hand, the ASE extract might also contain other polar compounds including 
some β-glucans [30] and although, by using lard as food matrix they seemed not to interfere with 
sterols extractability during digestion, they could influence during DMM formation. Thus, the 
possibility of β-glucan interference was further evaluated in the DMM fractions.  
Interference of β-glucans-enriched preparations in the DMM  
CH-lard supplemented with ergosterol (CH + ERG-lard) or SFE extract (CH + SFE-lard) 
were also mixed with a β-glucan enriched fraction showing bile acid-binding activity obtained from 
P. ostreatus [18]. Then, the preparations were submitted to in vitro digestion and the resulting 
DMM fractions were isolated. Results indicated that the fungal β-glucans were able to scavenge 
cholesterol by themselves since when they were mixed with only CH-lard, the digestate generated 
DMM contained approximately threefold lower cholesterol levels (Figure 4). Previous reports also 
suggested that β-glucans can decrease cholesterol solubilization in the DMM besides their bile 
acids-binding capacity [7, 31].  
 
Figure 4. Cholesterol concentration in the isolated DMM fraction after digestion of lard supplemented with 
cholesterol (2.5%), ergosterol and an ergosterol-containing extract (1:2, w/w, CH:ERG ratio) with or without 
addition of a fungal β-glucan-containing extract with bile acid binding activity. 
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When the β-glucan extract was mixed with the CH-lards supplemented with ergosterol 
or the SFE extract and submitted to digestion, the generated DMM also showed significantly lower 
cholesterol levels than the reduction already induced by the presence of the sterol or the SFE 
extract. These results could suggest certain positive synergy between the effect of the                    
β-glucans and the fungal sterols however, if only the three samples including the β-glucans are 
compared, the levels of cholesterol were very similar suggesting that certain scavenging effect of 
the other sterols have also occurred. Moreover, almost two fold lower ergosterol was incorporated 
in DMM fractions generated in the presence of β-glucans thus, the polysaccharide extract was 
able to bind similarly to both types of sterols. It enhanced a higher displacement of cholesterol 
probably because it was added in lower concentration than ergosterol (ratio 1:2 CH:ERG).  
Nevertheless still the cholesterol decrease in the DMMs particularly for those including 
β-glucans and the SFE extract was very high if compared with the control without these extracts.  
Transport through Caco2 cell monolayers  
The DMM fractions obtained from the digestion of CH-lard with or without 
supplementation of ergosterol (CH + ERG-lard) or SFE extract (CH + SFE-lard) were applied at 
subtoxic concentration (25 µL/mL) to Caco2 cell monolayers cultivated in specific inserts to 
measure transport through them. As expected, the applied DMM fraction generated from              
CH-lard showed higher cholesterol levels than those generated from lards containing ergosterol 
(Table 2). After 1 h incubation, cholesterol coming from the applied DMMs was still detected in 
the upper compartment. However, in the cells treated with the DMMs from the digestion of           
CH-lard, a reduction (78.6%) in the intracellular cholesterol was observed, followed by a release 
of 34.8% into the lower compartment while, in the cells treated with the DMMs from CH + ERG-
lard and CH + SFE-lard higher cholesterol levels inside the Caco2 cells were noticed (almost 
doubled the normal cellular levels) liberating only respectively 17.6 and 30.5% of the cholesterol 
from applied DMMs. These different behaviors in the absence or presence of the fungal sterols 
indicated interferences in cholesterol transport. However, phytosterols apparently did not impair 
cholesterol trafficking from the plasma membrane to the endoplasmic reticulum but interfered with 
the uptake of micellar cholesterol [32] and ergosterol seemed to disturb that trafficking more than 
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its absorption since intracellular cholesterol accumulation was observed. On the other hand, both 
phytosterols and ergosterol appeared to decrease levels of cholesteryl ester secreted into the 
basolateral compartments [32] being more effective if ergosterol was directly micellated than 
integrated into an extract.  
Table 2. Sterol concentration of the DMM fractions applied to the apical compartment in the Caco2 transport 
assays. 
       
(ND: no detected) 
 
Ergosterol was absorbed in lower concentrations than cholesterol as occurred with 
phytosterols [5]. However, after (1 h) addition of the DMMs from CH + ERG-lard to the cells only 
23% of the initially applied ergosterol was detected in the upper compartment and only 9.3% was 
found in the lower compartment rising the question whether ergosterol was being transformed into 
cholesterol (as suggested for other organisms [33] contributing to the observed cholesterol 
accumulation or into other ergosterol-derivatives that could not be detected because of the        
GC–MS method utilized. Thus, more detailed studies are needed (at the molecular level), in order 
to further clarify the ergosterol mechanism of action inside Caco2 cells, particularly because in 
the samples containing the SFE extract, ergosterol could not be detected in any of the 
compartments.  
Conclusions 
Ergosterol and ergosterol-enriched extracts obtained from the white button mushroom 
could potentially be used as hypocholesterolemic ingredients to design novel foods because 
when added to lipidic matrices such as lard, they were able to displace cholesterol from DMMs 
following a similar mechanism than the one described for phytosterols. β-Glucans from oyster 
 
 Cholesterol (μg/mL) Ergosterol (μg/mL) 
CH-lard 91.06 ± 0.54 ND 
CH+ERG-lard 46.06 ± 4.99 5.03 ± 1.33 
CH+SFE-lard 29.83 ± 1.54 3.37 ± 2.09 
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mushroom might also be added to the functionalized food because they enhance the cholesterol 
displacement but within controlled concentrations.  
Fungal sterols seemed to hinder the bioavailability of cholesterol but their precise 
mechanism of action still needs to be clarified therefore, the expression of several genes related 
to the cholesterol absorption and metabolism is, at the present, being investigated using Caco2 
cells and also HepG2. Animal studies will be also required to fully confirm the effect of ergosterol 
as hypocholesterolemic compound.  
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Abstract 
Purpose: 
To investigate the effect of two extracts obtained from Agaricus bisporus on the mRNA 
expression of cholesterol-related genes. One of the extracts contained ergosterol and other fungal 
sterols (SFE) and the other contained β-glucans and fungal sterols (EβG). 
Methods: 
Firstly, the dietary mixed micelles (DMM) generated after in vitro digestion of standards 
and SFE were applied to Caco2 cells. Then, the lower compartment after a Caco2-transport 
experiment was applied to HepG2 cells. The mRNA expression was assessed in both cell lines by 
low density arrays (LDA). Mice received the extracts, ergosterol or control drugs after 4 weeks of 
a high-cholesterol diet. The lipid profile of plasma, liver and feces was determined. LDA assays 
were performed in liver and intestines. 
Results: 
The DMM fraction of SFE up-regulated the LDLR mRNA expression in Caco2 cells. The 
lower compartment after Caco2-transport experiments up-regulated LDLR and modulated several 
other lipid-related genes in HepG2 cells. In mice, SFE decreased TC/HDL ratio and reduced 
hepatic triglycerides paralleled with down-regulation of Dgat1 expression while EβG did it without 
transcriptional changes. Addition of SFE or ergosterol induced in jejunum a similar transcriptional 
response to simvastatin and ezetimibe, they all down-regulated Srebf2 and Nr1h4 (FXR) genes. 
Conclusion: 
Ergosterol-containing extracts from A. bisporus lowered hepatic triglyceride and modify 
the mRNA expression of cholesterol-related genes although the transcriptional regulation was 
unrelated to changes in plasma lipid profile. These extracts may be useful limiting hepatic 
steatosis and as bioactive ingredients to design novel functional foods preventing lifestyle-related 
diseases such as non-alcoholic fatty liver disease. 
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Introduction 
Extracts obtained from several edible mushroom species showed hypocholesterolemic 
effects according to in vivo studies with animals and humans [1]. The sporophores of a commonly 
consumed mushroom, the white button mushroom (Agaricus bisporus), were also able to lower 
blood glucose and cholesterol levels in diabetic and hypercholesterolemic rats [2]. However, only 
a few type of molecules have been pointed as potentially responsible for these activities such as 
dietary fibers or β-glucans, lovastatine, eritadenine and, via an indirect mechanism, phenolic 
compounds or antioxidants such as ergothioneine [1]. 
Cholesterol is a water insoluble compound requiring emulsification and micellar 
solubilization during intestinal digestion before it can be absorbed by enterocytes. Uptake of this 
molecule from lumen is carried out by Niemann-Pick C1-like 1 (NPC1L1) protein and perhaps 
other complexes [3]. Depending on the cholesterol intracellular levels, it can also be transported 
back to intestinal lumen by the ABC transporters (ABCG5/8) located on the enterocytes brush 
border or incorporated into plasma HDL by ATP-binding cassette transporter A1 (ABCA1) located 
at the basolateral membrane. The intracellular cholesterol either absorbed or de novo synthesized 
can be esterified by the sterol O-acyltransferases (SOAT), packaged into apolipoproteins (APOB) 
and integrated into nascent chylomicrons with the assistance of the microsomal triglyceride 
transfer protein (MTTP) (an enzyme involved in the chylomicron assembly by transferring neutral 
lipids) and the acetyl-CoA acetyltransferases (ACAT, involved in the fatty acid biosynthetic 
pathway) in order to be transferred to lymph as chylomicrons (or packaged into APOA to release 
them as HDLs) [3, 4]. 
Fungal sterols (such as ergosterol) were able to compete with the cholesterol molecules 
for their incorporation in the dietary mixed micelles (DMM) during in vitro digestion because of 
their structural similarity [5]. This is also one of the generally accepted mechanisms of plant 
phytosterol for lowering cholesterol absorption in vivo [1, 2]. Moreover, supplementation of 
ergosterol extracts with fungal β-glucans induced an even larger cholesterol displacement from 
the DMM although they also partially scavenged the fungal sterols [5].  
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However, phytosterols are able to influence the circulating cholesterol concentration via 
other mechanisms although their precise molecular targets are still not completely defined. 
Studies using Abca1- and Abcg5/8-deficient mice demonstrated that the phytosterol-mediated 
inhibition of intestinal cholesterol absorption was independent of these transporters [3]. Other 
reports suggested that plant sterols were able to modify cholesterol metabolism within the 
enterocyte (with in vivo and in vitro experiments) because of their structural similarity with sterol 
regulatory element-binding protein (SREBP)-signaling ligands (SREBF genes), because of their 
liver X receptor (LXR, NR1H3 gene) agonist activity (in particular ergost-22-ene-1,3-diol) [6] or 
their farnesoid X receptor (FXR, NR1H4 gene) antagonist activity (stigmasterol) [7]. FXR and LXR 
are nuclear receptors also involved in the regulation of cholesterol homeostasis [8]. Cholesterol 
analogs, e.g. phytosterols might also modulate cholesterol esterification by decreasing the SOAT 
activity and inhibiting the NPC1L1 transporter but, although in FHs 74 Int cells reduction of NPC1L1 
mRNA expression levels was observed [9], in vivo it seems unlikely that the observed reduction 
was mediated via transcriptional changes [3]. 
The cholesterol biosynthesis is also regulated at a few key steps such as the 
transformation of hydroxymethylglutaryl coenzyme A into mevalonate by the hydroxymethylglutaryl 
coenzyme A reductase (HMGCR) and downstream at the squalene synthase (farnesyl-
diphosphate farnesyltransferase, FDFT1). Moreover, esterified cholesterol loaded into LDLs can 
be removed from circulation by the low-density lipoprotein receptors (LDLR) located at the cell 
surface that mediate their endocytosis by recognizing the apoprotein B100, which is embedded 
in the outer phospholipid layer of LDL particles.  β-Sitosterol reduced HMGCR gene expression in 
Caco2 cells but not in rats ileum nor mice liver and mononuclear blood cells. Moreover, 
phytostanols ester increased LDLR mRNA expression in human mononuclear blood cells whereas 
1 - 2% phytostanol treatment did not affect Ldlr expression in hypercholesterolemic mice [3].  
In this work, the modulation of mRNA levels of genes related to the cholesterol 
metabolism after supplementation with ergosterol and ergosterol-enriched extracts (with/without 
fungal β-glucans) obtained from A. bisporus is studied using cell cultures and mice fed a           
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high-cholesterol diet by low density arrays (LDA). Biochemical parameters were also determined 
in mouse serum and liver.  
Materials and Methods 
 Fungal material  
Lyophilized mushroom powder obtained from Agaricus bisporus L. (Imbach) Fungisem 
H-15 fruiting bodies (from the first flush) according to Gil-Ramírez et al. (2013) [10] was utilized 
as starting material to obtain ergosterol-enriched fractions. Commercially available lard (Iberian 
pork fat, E-321, E-320), was purchased from a local supermarket. All the experiments were 
performed from the same lotus. 
Standards and reagents 
Solvents as hexane (95%), chloroform and methanol were obtained from LAB-SCAN 
(Gliwice, Polland) and absolute ethanol and sea sand from Panreac (Barcelona, Spain). Potassium 
hydroxide, ascorbic acid, BHT (2,6-Di-tert-butyl-p-cresol), cholesterol, cholic acid, ergosterol, 
congo red as well as hexadecane were purchased from Sigma-Aldrich Química (Madrid, Spain). 
Simvastatin was obtained from Cinfa Laboratories (Spain) and ezetimibe (Ezetrol) from Merck 
Sharp & Dohme (Spain). All other reagents and solvents were used of analytical grade.  
Preparation of SFE extracts (containing sterols) 
Agaricus bisporus mushroom powder (80 g) were mixed with washed sea sand (900 g) 
and submitted to supercritical fluid extraction (SFE) with CO2 in a pilot-plant (TharTechnology, 
Pittsburgh, PA, USA, model SF2000) as described in Gil-Ramírez et al. (2013) [10]. Extraction was 
carried out at 18 MPa and 40 ºC with a total extraction time of 3 h.  Obtained fractions were 
immediately submitted to concentration until dryness on a rotary vacuum evaporator. Dried extract 
(named ´SFE extract´) was stored at -20 ºC until further analysis.  
Preparation of EβG extracts (containing sterols and β-glucans)  
Agaricus bisporus mushroom powder (1 g) was mixed with 100 ml MilliQ water and 
stirred at room temperature for 2 min. Afterwards, suspension was filtered under vacuum using 
Anoia filter paper (Barcelona, Spain) and a Büchner flask. Retained cake was washed with 100 ml 
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distillated water and removed from the filter with the help of 10 ml water into a Falcon tube.  The 
obtained suspension was frozen, lyophilized and the dried extract (called ´EβG extract´) stored at 
-20 ºC until further analysis.  
In vitro digestion and isolation of the DMM  
Ergosterol or SFE extracts (added up to 5% ergosterol, w/w) were dissolved in lard 
supplemented with/without 2.5 % (w/w) cholesterol and submitted to an in vitro digestion model 
as described in Gil-Ramírez et al (2014) [5]. Separation of the dietary mixed micelles (DMM) 
fraction from vesicles was carried out on a Sepharose®4B column (Amersham Pharmacia Biotech, 
madrid) [5]. The DMM fraction was immediately applied to Caco-2 cells grown on specific plates 
depending on the experiments.  
Caco2 cell cultures and transport assay  
Human colorectal adenocarcinoma cell line Caco2 (ATCC HTB-37) obtained from the 
Americam Type Culture Collection (Rockville, MD, USA) were maintained in  Dulbecco´s Modified 
Eagle’s Medium (DMEM) with high glucose content (4.5 g/L) and supplemented with 10% fetal 
bovine serum, 1% penicillin-streptomycin, and 1% non-essential amino acids at 37 ºC in at 
humidified atmosphere containing 5% CO2. Firstly, the cytotoxicity was evaluated using                    
3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium bromide (MTT) method [5]. Then, for the gene 
expression assays, cells were seeded onto a 9.5 cm2 grown area 6 well flat bottom plate (Costar, 
Corning, USA) at a density of 5 ×105 cell per insert (3.3 ×105 cell/ml). Culture medium was replaced 
every three days and cells were allowed to generate a monolayer for 21 days before experiments. 
The DMM fractions were applied at subtoxic concentrations (25 μl/ml [5]) and left incubating at 
37 ºC and 5% CO2 for 1 or 24 h. 
For transport assays, cells were seeded onto a 44 cm2 permeable membrane support 
(0.4 μm pore size, Costar, Corning, USA) at a density of 5.23 ×105 cells per insert (5 ×105 cell/ml). 
Cells were cultivated as above described and allowed to differentiate (21 days before 
experiments). The integrity of the cell layer was evaluated by measuring the transepithelial 
electrical resistance (TEER) (Evon, Sarasota, FL) and alkaline phosphatase activity (ALP) [5].  
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The DMM fractions were applied to Caco2 cell monolayers. Each sample, applied at 
subtoxic concentration (25 μl/ml [5]), was mixed with 8.7 mL medium, applied to the apical (upper) 
compartment and left incubating at 37 ºC and 5% CO2 for 1 h. Afterwards, the lower compartment 
was collected and applied to HepG2 cell cultures. Four replicates per sample were carried out.  
Treatment of HepG2 with the basolateral compartment of the Caco2 monolayers  
Human hepatoma HepG2 cells, obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) were cultured in Dulbecco´s modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), HEPES 1%, Tripsine - EDTA 0.5% (them all from Gibco, Grand 
Island, NY, USA) and 1% of antibiotic solution (containing 10,000 units/mL of penicillin base and 
10,000 µg/mL of streptomycin base, Gibco). The cells were maintained under standard conditions 
of temperature (37 ºC), humidity (95%) and CO2 (5%). 
Firstly, the cytotoxicity was evaluated as above described for the Caco2 cell cultures. 
Then, the HepG2 cell cultures were seeded in 6 wells plates (9.5 cm2) grown to confluence and 
treated with the basolateral compartment obtained after 1 h application of the DMM fractions from 
cholesterol-enriched lard or CH-enriched lard supplemented with ergosterol or the SFE extract 
(applied at subtoxic concentrations, 6.25 μl/ml) and left incubating at 37 ºC, 95% humidity and 
5% CO2 during 1 or 24 h. These experiments were carried out in duplicate.  
Animals and diets  
Male C57BL/6JRj mice (5 weeks old) were purchased from Janvier SAS (Le Genest Saint 
Isle, France). The mice were maintained four per cage in temperature-, humidity- and light-
controlled conditions (24 ± 2 °C, 40%-60% humidity, 12:12 hour light: dark cycle) and had free 
access to water and food. Mice were randomly divided into seven groups, 2 control groups and 
5 treated groups. Normal control group (NC) was fed a standard diet (Safe Rodent Diet A04, Augy, 
France) and the hypercholesterolemic control group (HC) was fed a high-cholesterol diet that 
consisted of A04 supplemented with 2% cholesterol and 1% cholic acid (w/w). NC (n=6) and HC 
(n=8) groups were fed for 8 weeks (from 5 to 13 weeks of age) while the treated groups (n=8) 
received the same diet as HC for the first 4 weeks (from 5 to 9 weeks of age) and that diet together 
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with their corresponding mushroom extract or control drug for the last 4 weeks of the experiments 
(from 10 to 13 weeks of age). The treated groups were named as follows: SFE (SFE extract, extract 
containing fungal sterols), EβG (EβG extract, extract containing fungal sterols and β-glucans), 
ERG (ergosterol-positive control), SV (simvastatin; positive control for inhibition of cholesterol 
biosynthesis), and EZ (ezetimibe; positive control for inhibition of cholesterol absorption). The 
composition of diets, the dose per day of mushroom extract or drug, total sterols, ergosterol, and 
β-glucans, as well as the energy that received the mice daily are shown in Table 1. 
Table 2. Composition of diets.  
 
 Mushroom extracts doses were calculated taking into account the hypocholesterolemic 
minimal daily intake of plant sterols recommended by EFSA [11, 12]. Concerning simvastatin and 
ezetimibe drugs, doses were selected after reviewing literature taking into account studies which 
mouse models were similar to our mouse model, that is, preferably studies where C57BL/6J mouse 
and diet-induced hypercholesterolemia were used [13-16]. According to that works, simvastatin 
Components NC HC SFE EβG ERG SV EZ 
Carbohydrates (%) 59.90 59.90 59.90 59.90 59.90 59.90 59.90 
Proteins (%) 16.10 16.10 16.10 16.10 16.10 16.10 16.10 
Lipids (%) 3.10 3.10 3.10 3.10 3.10 3.10 3.10 
Fibres (%) 3.90 3.90 3.90 3.90 3.90 3.90 3.90 
Mineral mixture* (%) 5.10 5.10 5.10 5.10 5.10 5.10 5.10 
Moisture (%) 11.90 8.90 8.72 3.15 8.82 8.87 8.89 
Cholesterol (%) 0.00 2.00 2.00 2.00 2.00 2.00 2.00 
Cholic acid (%) 0.00 1.00 1.00 1.00 1.00 1.00 1.00 
Mushroom extract or drug (%) 0.00 0.00 0.18 5.76 0.08 0.025 0.005 
Mushroom extract or drug (mg/mouse/day) 0.00 0.00 7.20 230.40 3.20 1.00 0.20 
Total sterols** (%) n.m. n.m. 0.086 0.081 0.080 n.m. n.m. 
Ergosterol (%) n.m. n.m. 0.067 0.081 0.080 n.m. n.m. 
β-Glucans (%) n.m. n.m. 0.00 1.676 n.m. n.m. n.m. 
Total sterols** (mg/Kg/day) n.m. n.m. 173 161 160 n.m. n.m. 
Ergosterol (mg/Kg/day) n.m. n.m. 134 161 160 n.m. n.m. 
β-Glucans (mg/Kg/day) n.m. n.m. 0.000 3352 n.m. n.m. n.m. 
Energy (Kcal/mouse/day) 13.366 14.386 14.450 15.229 14.386 14.386 14.386 
NC: normal control; HC: control fed a high-cholesterol diet; SFE: SFE extract; EβG: EβG extract; ERG: ergosterol; SV: simvastatin; EZ: ezetimibe; 
*A04 mineral mixture; ** cholesterol excluded; n.m.: not measured. 
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daily doses ranged from 0.4 to 1.6 mg/mouse, and ezetimibe ranged from 0.02 to 1.0 mg/mouse. 
As shown in Table 1 daily doses were used encompassed within those mentioned above. Body 
weight was registered for all mice before the experimental feeding period and at the end of the 
experiments. Wet mass of the liver was also registered. Animal studies were approved by our 
institution’s Animal Welfare and Ethics Committee and were carried out according to Spanish and 
European legislation (RD 53/2013, 2010/63/EU, respectively). 
Plasma and liver lipid analyses, tissue and feces collection 
Following the experimental feeding period (8 weeks), mice were sacrificed by 
intracardiac exsanguination under anesthesia with 1.5% isoflurane, and plasma was collected and 
stored at -80 °C before use. Jejunum, ileum, cecum, and liver samples were removed and 
immediately frozen in liquid nitrogen and stored at -80 °C. Feces were collected at the beginning, 
after 4 weeks of high-cholesterol diet and at the end of the experimental feeding period and 
maintained at -20 °C until further use. Plasma levels of total cholesterol, triglyceride,                      
HDL-cholesterol and LDL-cholesterol were measured in duplicate for each sample at 8 weeks 
using a Covas C311 Autoanalyzer (Roche, Spain). Total cholesterol and triglyceride 
concentrations were measured in duplicate for each sample in liver extracts using colorimetric 
enzyme assays (Cholesterol Quantification Kit and Triglyceride Quantification Kit, respectively, 
BioVision Inc., CA, USA). Briefly, liver extracts for total cholesterol quantification were prepared 
by homogenizing a 100-mg sample of liver in 2 mL of CHCl3:isopropanol:NP-40 (7:11:0.1). The 
extract was centrifuged for 5 min at 15,000 × g. The supernatant was air dried at 50 °C and then 
placed it under vacuum for 30 min to remove any remaining solvent. Dried lipids were dissolved 
with 200 μl of Cholesterol Assay Buffer and stirred in a vortex until homogeneous. 5 μl of extract 
per assay were used and volume adjusted to 50 μl/well with Cholesterol Assay Buffer. In the assay, 
free cholesterol is oxidized by cholesterol dehydrogenase to generate NADH. To calculate total 
cholesterol concentration, absorbance at 450 nm was measured after the reaction was incubated 
for 30 min at 37 °C, protected from light. To determine triglycerides contents in liver tissues,          
100 mg of wet liver tissues was homogenized in 1 ml of 5% NP-40. The samples were slowly 
heated up to 100 °C for 5 min and then cooled down to room temperature. The heating was 
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repeated one more time. The tissue homogenates were centrifuged at 15,000 × g for 5 min at room 
temperature and the supernatants were diluted 10 fold with dH2O before the assay. In the assay, 
triglycerides are converted to free fatty acids and glycerol. The glycerol is then oxidized to 
generate a product which reacts with the probe to generate color. To calculate triglycerides 
concentration, absorbance at 570 nm was measured. 
Sterols and β-glucan quantification  
Sterols (cholesterol, ergosterol and derivatives) were extracted from the ergosterol-
enriched extracts or mice feces (300 mg) and further quantified in duplicate for each sample 
(Table 2) by GC-MS-FID following the procedure described in Gil-Ramírez et al. (2013) [10].  
The β-glucan content of both ergosterol-enriched extracts (50 mg) was evaluated in 
duplicate by a β-glucan determination kit specific for mushrooms and yeasts (Megazyme, 
Barcelona, Spain) following the instructions of the user´s manual and as described in Palanisamy 
et al. [17]. The amount of β-(1→3),(1→6)-glucans was also determined following the method of 
Nitschke et al. [18] (Table 2). 
Table 3. Composition of the ergosterol-enriched extracts (% dw). 
  
Statistical analysis for biochemical data 
All values were expressed as mean ± SD. The SPSS software, version 15.0 (Lead 
Technologies, Chicago, IL, USA), was utilized to determine whether the variables differed among 
 SFE extract EβG extract 
Ergosterol 37.3 1.4 
Ergosta-5,7-dienol 6.5 0.02 
Fungisterol 2.6 b.q. 
Ergosta-7,22-dienol 1.5 b.q. 
Total sterols 48 1.4 
Total β-glucans n.d. 29.1 
(1→3),(1→6)-β-glucans n.d. 2.1 
Other fats 51 1.0 
Proteins n.d. 26.3 
Carbohydrates n.d. 68.7 
n.d.: not detected; b.q.: below quantifiable levels  
Chapter 2- Influence of fungal sterols… 
 
233 
 
treatment groups in the in vivo experiments. The effects of treatments were assessed by one-way 
ANOVA. When the ANOVA identified significant treatment effects, the means were evaluated using 
Tukey’s test. Differences with P < 0.05 were considered statistically significant. 
RNA extraction from cells and mice tissues and quantitative real-time PCR 
Total RNA from cell cultures or mice tissues was extracted by magnetic bead technology 
using a pureLinkTM Total RNA kit TRIzol® Plus RNA Kit (Invitrogen, Carlsbad, CA, USA) in an 
iPrepTM Purification Instrument (Invitrogen) programmed with an iPrepTM total RNA card 
(Invitrogen) according to manufacturer instructions. The RNA concentration was determined by 
spectrophotometry at 260 nm and the purity of the extracted RNA was calculated from ratio of 
absorbance at 260:280 nm and 260:230 nm in a NanoDrop ND-1000 (NanoDrop Technologies 
Inc., Wilmington, DE, USA). 
An amount of 400 ng of total RNA from each sample were reversed transcribed using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Framinghan, MA, USA). The 
obtained cDNA (100 μl per port) were loaded into the fluidic cards. Before sealing them, the cards 
were centrifuged twice on a Sorvall centrifugue at 1200 rpm for 1 min. Finally, the micro fluidic 
cards were run in a 7900HT Fast Real-Time PCR system (Applied Biosystems). Amplification 
conditions were 50 ºC for 2 min, 94.5 ºC for 10 min, followed by 40 cycles with 97 ºC with 30 s and 
59.7 ºC for 1 min. 
Low Density Array (LDA) design and gene expression analysis 
A technical and conceptual description of the TaqMan Low Density Array based on 
Applied Biosystems 7900HT Micro-Fluid Cards can be found in the Applied Biosystems TaqMan 
Array Micro-Fluid Cards user guide (http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/ 
generaldocuments/cms_062836.pdf (or 040127). The micro-fluid card was constructed using respectively 
human and mouse commercial available assays (Applied Biosystems) for several genes related 
to the cholesterol metabolism (Table 3) and the internal standard and housekeeping genes. 
Comparative analysis of each of these genes was performed using specialized computer 
programs SDS2.3 and RQ 2.1 (Applied Biosystems).  
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Table 4. ABI (Applied Biosystems) commercial reference and NCBI reference sequence of the selected genes 
from Homo sapiens (cell cultures) and Mus musculus and internal controls used in the LDA design. 
ABI code  for 
Homo sapiens 
ABI code for 
Mus musculus 
Reference sequence/s Gen Description 
Hs01059118_m1 Mm00442646_m1 NM_005502.3 ABCA1 
ATP-Binding Cassette, Sub-Family A (ABC1), 
Member 1 
Hs00223686_m1 Mm00446241_m1 NM_022436.2 ABCG5 
ATP-binding cassette, sub-family G (WHITE), 
member 5 
Hs00223690_m1 Mm00445970_m1 NM_022437.2 ABCG8 
ATP-binding cassette, sub-family G (WHITE), 
member 8 
Hs00608002_m1 Mm00507463_m1 NM_000019.3 ACAT1 Acetyl-CoA acetyltransferase 1 
Hs00255067_m1  NM_005891.2 ACAT2 Acetyl-CoA acetyltransferase 2 
Hs01071209_m1 Mm01545156_m1 NM_000384.2 APOB Apolipoprotein B 
Hs00201385_m1 Mm00515643_m1 NM_012079.4 DGAT1 Diacylglycerol O-acyltransferase 1 
Hs00261438_m1 Mm00499536_m1 NM_001253891.1 NM_032564.4 DGAT2 Diacylglycerol O-acyltransferase 2 
Hs00926054_m1 Mm00815354_s1 NM_004462.3 FDFT1 Farnesyl-diphosphate farnesyltransferase 1 
Hs00168352_m1 Mm01282499_m1 NM_000859.2 NM_001130996.1 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 
Hs00181192_m1 Mm00440169_m1 
NM_000527.4, 
NM_001195798.1NM_001195799.1 
NM_001195800.1 
NM_001195802.1NM_001195803.1 
LDLR Low density lipoprotein receptor 
Hs00165177_m1 Mm00435015_m1 NM_000253.2 MTTP Microsomal triglyceride transfer protein 
Hs00203602_m1 Mm01191972_m1 NM_001101648.1 NM_013389.2 NPC1L1 
NPC1 (Niemann-Pick disease, type C1, gene)-
like 1 
Hs00172885_m1 Mm00443451_m1 
NM_001130101.2 
NM_001130102.2NM_001251934. 
NM_001251935.1 NM_0056933 
NR1H3 
Nuclear receptor subfamily 1, group H, member 
3 (LXRα) 
Hs00231968_m1 Mm00436425_m1 
NM_001206977.1NM_001206978.1 
NM_001206979.1 NM_001206992.1 
NM_001206993.1 NM_005123.3 
NR1H4 
Nuclear receptor subfamily 1, group H, member 
4 (FXRα) 
Hs00162077_m1 Mm00486279_m1 
NM_001252511.1 NM_001252512.1 
NM_003101.5 
SOAT1 Sterol O-acyltransferase 1 
Hs01573878_m1 Mm00448823_m1 NM_003578.3 SOAT2 Sterol O-acyltransferase 2 
Hs01088691_m1 Mm00550338_m1 NM_001005291.2 NM_004176.4 SREBF1 
Sterol regulatory element binding transcription 
factor 1 
Hs01081784_m1 Mm01306292_m1 NM_004599.2 SREBF2 
Sterol regulatory element binding transcription 
factor 2 
Hs99999905_m1  NM_002046.4 GAPDH 
Glyceraldehyde-3-phosphate dehydrogenase       
(internal control) 
 Mm00839493_m1  Polr2a polimerase 
Hs99999908_m1 Mm00446953_m1 NM_000181.3 GUSB Glucuronidase, beta (internal control) 
Hs99999909_m1 Mm00446968_m1 NM_000194.2 HPRT1 
Hypoxanthine phosphoribosyltransferase 1 
(internal control) 
Hs99999901_S1 18S-Hs99999901_s1  RN18S1 RNA, 18S ribosomal 1 (housekeeping gene) 
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Gene expression statistical data analysis 
The expression of each gene was measured at least in duplicate and each biological 
group included a minimum of 3 replicates that were quality controlled using the Median Absolute 
Deviation test (MAD test). Samples of the same biological group with a MAD score higher than     
3 were removed from the analysis. Genorm algorithm [19] was used to identify the most stable 
reference genes for normalization. Genes GUSB and HPRT1 were found to be the most stably 
expressed in Caco2 cell cultures while GAPDH and HPRT1 were more stably expressed in HepG2 
cells. In the mouse tissue samples, genes Hprt1 and Polr2a were most stably expressed in cecum 
and liver, and Gusb and Polr2a in jejunum and ileum. Relative gene expression levels were 
calculated by using the 2-ΔΔCT method [20], using these identified most stable genes as internal 
control genes in each group. Statistical significance of the results was assessed using a Limma 
test, and Benjamini-Hochberg false discovery rate procedure was subsequently applied. Adjusted 
p-values lower than 0.05 were considered significant. All these calculations were carried out 
withReal Time StarMiner 4.5® (Integromics S.L, Spain).  
Results  
Modulation of the mRNA expression pattern in Caco2 cell cultures   
Ergosterol and the ergosterol-enriched SFE extract demonstrated their ability to displace 
cholesterol from DMMs and to interfere with the cholesterol uptake in Caco2 cell monolayers when 
integrated in a high lipid food matrix such as lard [5]. Thus firstly, lard supplemented with 
cholesterol (CH) or ergosterol (ERG) were submitted to digestion, the generated DMM fractions 
were isolated and applied to Caco2 cell cultures to study whether the sterols included in the 
micelles (generated with the in vitro digestion model) could differently modify the transcriptional 
pattern or the lipids from the DMMs (present in higher concentrations) could mask their potential 
modulation. Their molecular answer was evaluated shortly after supplementation (1 h) or after a 
longer period (24 h). 
Results indicated that 1 h after the CH-lard-containing DMMs (CH) were added, only the 
expression of the MTTP mRNA was slightly reduced compared to Caco2 cells with no DMM 
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addition (Figure 1a). On the contrary, application of DMMs obtained from the digestion of lard 
supplemented with ergosterol (ERG) significantly increased levels of MTTP mRNA indicating that 
the different sterols although they were integrated in DMMs they were activating different 
transcriptional mechanisms. Thus, in order to better reproduce in vitro the conditions of mice fed 
hypercholesterolemic diets (see later), lard supplemented with cholesterol (CH) was also mixed 
with ergosterol (ERG) or the ergosterol enriched extract (SFE) and submitted to digestion to 
evaluate their influence in the Caco2 mRNA expression pattern when cholesterol was 
simultaneously present in ergosterol-loaded DMMs as it might occur when a lipid-rich food matrix 
is consumed together with the potentially bioactive extracts. In this case, when the DMMs 
contained both cholesterol and ergosterol (CH+ERG) were applied, no significant differences in 
the mRNA expression could be noticed (Figure 1a). However, the CH+SFE (cholesterol and SFE 
extract) containing DMM fraction induced changes in the mRNA expression levels of many genes 
related to the lipid and cholesterol metabolism. One hour after the addition, the LDLR mRNA 
expression was up-regulated and the expression of others such as ACAT1, DGAT2, NR1H3 and 
SREBF2 was down-regulated. The induced modulation pattern by the latter DMM fraction was 
maintained for a long time (24 h) except for the expression of NR1H3 and particularly LDLR that 
were further respectively repressed and stimulated (Figure 1b). mRNA over-expression of other 
genes such as SREBF1 and APOB and repression of FDFT1 was also noticed. Moreover, the 
expression levels of HMGCR, LDLR and SREBF1 were also up-regulated 24 h after addition of the 
DMMs from CH as well as ERG and CH+ERG.   
Modulation of the mRNA expression pattern in HepG2 cell cultures   
In order to simulate the effect that these extracts might produce at hepatic level, the lower 
compartments after the transport experiments through Caco2 monolayers (potentially containing 
the bioavailable and generated compounds) were applied to HepG2 cell cultures (the DMMs 
would not reach the liver as such) and the modulation of their mRNA expression pattern evaluated 
1 h and 24 h after the application. 
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a) 
 
b) 
 
Figure 5. Relative mRNA expression (Log10) of Caco2 cells cholesterol-related genes after a) 1h and b) 24h 
application of the DMM fraction isolated after digestion of a mixture of lard with cholesterol (CH), with 
ergosterol (ERG) with both cholesterol and ergosterol (CH+ERG) and with cholesterol and the SFE extract 
(CH+SFE). Indicated genes are only those pointed as significant (p< 0.05) compared with their controls 
(Caco2 cells with no DMM fraction addition).  The expression of each gene was measured at least in 
duplicate and each biological group included a minimum of 3 replicates. 
 
Results suggested that the DMMs from the digested extracts were absorbed or induced 
changes in the composition of the lower compartments because when the basolateral solution of 
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non DMM-treated Caco2 cells was applied to HepG2 cell cultures no significant differences in the 
transcription profile was observed when compared with non-treated HepG2 cells used as control 
(Figure 2a). Addition of these potentially modified fractions stimulated the mRNA expression of 
many genes involved in the fatty acids and cholesterol absorption and transformation, a few 
regulators as well as the enzymes involved in biosynthesis and esterification of cholesterol. These 
changes were observed in those cells treated with the basolateral solution obtained after 
application of the DMMs generated from CH and CH+SFE. CH+ERG induced lower changes in 
the mRNA expression profile since no expression of HMGCR or FDFT1 was noticed nor 
overexpression of mRNAs from genes related to the lipidic transport. After a longer incubation 
time, this CH+ERG bioavalilable fraction modulated the mRNA expression pattern differently than 
those obtained from CH and CH+SFE for instance by inhibiting FDFT1 and HMGCR mRNA 
expressions, up-regulating DGAT2, NR1H4 etc. (Figure 2b).     
Modulation of the lipid profile of plasma and liver in the animal intervention 
Since ergosterol and the SFE-extract seemed to significantly modulate the mRNA 
expression of several genes related to the lipid and cholesterol metabolism in specific human 
hepatic and colon cell lines, they were also tested in mice models to further study their in vivo 
significance. According to previous publications, A. bisporus β-glucans (dietary fiber) could be 
involved in the observed lowering of cholesterol levels in serum [2, 21]. Thus, in addition to the 
SFE-extract, another extract administrated at similar sterols concentration (SFE: 0.086%;           
EβG: 0.081%) but including water insoluble β-glucans was also tested (EβG-extract) (Table 2). 
Adding cholesterol to the standard diet significantly increased plasma total cholesterol 
levels 3.3-fold in the HC group compared with NC at the end of the experiment (Table 4). 
Significant reduction was only achieved by ezetimibe or simvastatin treatments and not by extracts 
or ergosterol supplementation. With the high-cholesterol diet, plasma HDL and LDL levels were 
also increased by respectively 1.5 and 6.6 fold. Surprisingly, HDL levels were increased even 
more in the SFE group (22% more than the HC) and in the EβG group (14%) but not in the 
ergosterol group. The LDL levels remained also unchanged in the mice fed SFE extract, EβG 
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extract or ergosterol, while simvastatin produced a 34% reduction and ezetimibe a significant   
85% reduction, achieving normal levels in the ezetimibe group. 
a) 
 
b) 
 
Figure 6. Relative mRNA expression (Log10) of HepG2 cells cholesterol-related genes after a) 1h and b) 24h 
application of the basolateral compartment of Caco2 cell cultures collected 1h after the transport assay was 
performed in which the DMM fraction isolated after digestion of a mixture of lard with cholesterol (CH), with 
both cholesterol and ergosterol (CH+ERG) and with cholesterol and the SFE extract containing ergosterol 
(CH+SFE). The lower compartment of Caco2 cell cultures with no supplementation was also added to 
HepG2 cell cultured as control (Caco2 ST). Indicated genes are only those pointed as significant (p< 0.05) 
compared with their controls (HepG2 cells with no supplementation).  The expression of each gene was 
measured at least in duplicate and each biological group included a minimum of 3 replicates. 
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Table 5. Plasma and liver lipid profile in mice after the experimental feeding period (8 weeks). 
 
In addition to the plasma lipid profile, two atherogenic indexes commonly used in the 
clinic as predictors of cardiovascular disease risk were calculated, total cholesterol/HDL and 
LDL/HDL ratio. Controls fed a high-cholesterol diet significantly increased the TC/HDL ratio by 
2.1-fold as compared to normal controls. This negative balance was improved in mice fed SFE 
extract or ezetimibe, whose TC/HDL ratios were significantly reduced by 19% and 47%, 
respectively. The remaining groups showed insignificant differences compared to HC controls. 
The LDL/HDL ratio was only significantly decreased by supplementation of ezetimibe as 
compared to controls fed a high-cholesterol diet. 
A significant reduction in plasma triglyceride levels was found in mice fed a                    
high-cholesterol diet compared with normal controls. All treated mice showed no differences in 
plasma triglyceride levels compared with controls fed a high-cholesterol diet with a significant 
reduction with respect to normal controls for all of them except for the EβG group. 
Mice fed high-cholesterol diet showed a significant increase in liver total cholesterol by 
5-fold compared to normal controls, those fed the three groups (SFE extract, EβG extract and 
Variable 
Plasma level (mg/dL) 
NC HC SFE EβG ERG SV EZ 
TC 65.3 ± 26.6 214.2 ± 97.3a 204.8 ± 33.6a,e 221.5 ± 43.0a,e 241.1 ± 21.5a,d,e 156.2 ± 31.8a,e 59.4 ± 19.0b 
HDL 59.80 ± 25.0 89.7 ± 27.9 109.2 ± 15.6a,e 102.2 ± 15.8a,e 96.2 ± 10.3e 81.9 ± 21.9e 47.9 ± 10.4b 
LDL 23.4 ± 11.0 155.0 ± 77.3a 145.9 ± 22.3a,e 162 ± 33.27a,d,e 176.8 ± 15.6a,d,e 102.5 ± 24.0a,e 23.4 ± 14.9b 
TC/HDL 1.1 ± 0.07 2.3 ± 0.3a 1.8 ± 0.15a,b,c,e 2.0 ± 0.25a,c,e 2.5 ± 0.2a 1.9 ± 0.2a,c 1.2 ± 0.1b,c,d 
LDL/HDL 0.3 ± 0.13 1.6 ± 0.3a 1.3 ± 0.10a,c,e 1.5 ± 0.22a,e 1.8 ± 0.2a 1.3 ± 0.2a,c 0.4 ± 0.2b,c.d 
TG 72.0 ± 20.0 47.2 ± 8.4a 38.2 ± 10.2a 55.5 ± 13.4 48.2 ± 8.5a 46.2 ± 11.0a 43.4 ± 8.3a 
 Liver level (mg/g tissue) 
TC 0.22 ± 0.09 1.09 ± 0.23a 0.87 ± 0.51 0.71 ± 0.45 0.58 ± 0.50d 1.44 ± 0.43a 0.45 ± 0.20b,d 
TG 4.49 ± 0.87 3.72 ± 0.61 1.41 ± 0.51a,b 1.87 ± 0.24a,b 0.73 ± 0.18a,b 0.78 ± 0.18a,b 0.88 ± 0.52a,b 
NC: normal control; HC: control fed a high-cholesterol diet; SFE: SFE extract; EβG: EβG extract; ERG: ergosterol; SV: simvastatin; EZ: 
ezetimibe. aP<0.05 vs. NC; bP<0.05 vs. HC; cP<0.05 vs. ERG; dP<0.05 vs. SV; eP<0.05 vs. EZ; TC, total cholesterol; HDL, high-density 
lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; TG, triglyceride 
The results are mean ± SD of six (NC) or eight mice on each diet and were analyzed by one-way ANOVA and the Tukey’s procedure. The 
assays were performed in duplicate for each sample.  
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ergosterol) showed insignificant differences respect to both NC and HC control groups. 
Simvastatin increased liver total cholesterol compare to normal control while ezetimibe 
significantly reduced it by 59% respect to HC control. On the other hand, liver triglyceride levels 
were slightly reduced by the high-cholesterol diet, while a significant reduction with respect to NC 
and HC controls was noticed in the liver of all the experimental groups. 
Effect of extracts on body and liver weight and sterol excretion through feces 
No differences were noticed in body weight before the experimental feeding period 
(Table 5). The normal control group gained 5.80±1.18 g over the feeding period while the 
remaining groups showed a slight weight loss (0.30±1.17-1.26±1.12 g) except for the simvastatin 
group that showed a higher weight loss (3.82±1.31 g). No significant differences in final body 
weight of the treated groups were noticed compared with the control group fed a high-cholesterol 
diet, except for SV group where a significantly lower final body weight was recorded compared to 
all other groups, including the control group fed a high-cholesterol diet. Despite the weight loss 
observed, mice seemed healthy all over the study and tolerated well the experimental diets with a 
food intake similar in all groups (3.8-4.0 g/mouse/day from day 4 until the end of the experiments; 
data not shown). The observed weight loss was lower than the one that Ikemoto et al. [22] recorded 
in C57BL/6J mice fed a high-fat diet supplemented with 0.5% sodium cholate and 1% cholesterol 
(final body weight 22.4±0.7 g) as compared with high-fat diet alone (final body weight                     
38.3 ± 1.4 g). The data of liver weight (Table 5) indicated that the absolute liver weight significantly 
increased in the control group fed a high-cholesterol diet and the treated groups, except the 
ergosterol (P=0.052) and simvastatin groups, compared with the normal control group. The same 
tendency was observed when the hepatomegaly was expressed as liver-to-body-weight ratio, with 
a significant increase in all groups with respect to the normal control group. The effect of the     
high-cholesterol diet on liver weight and liver-to-body-weight ratio could not be counteracted by 
the extracts or control drugs with the SFE extract and the simvastatin group showing the highest 
liver-to-body-weight ratio values although in the last case, it was because of its body weight loss 
instead of its increase in liver weight. 
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Before intervention, no cholesterol was found in mouse feces but after 4 weeks             
high-cholesterol diet, 61.5±4.5 mg/g cholesterol (on average) were excreted (Table 5). Similar 
cholesterol levels were observed in the feces after 4 weeks of experimental diets (8 weeks) 
supplemented with the extracts or drugs, only those mice treated with ERG showed a slight 
cholesterol reduction, indicating that their administration did not alter significantly the cholesterol 
excretion compared to the controls fed a high-cholesterol diet. Ergosterol was also detected after 
4 weeks in mice fed with the compound or the extracts.  
Table 6. Effect of extracts on body and liver weight and on the levels of sterols excretion after the 
experimental feeding period (8 weeks). 
 
Modulation of the mRNA expression pattern in mice fed a high-cholesterol diet   
Induction of hypercholesterolemia provoked changes in the mRNA expression of genes 
related with cholesterol metabolism in jejunum and liver although no significant changes were 
noticed in other tissues such as ileum or cecum (Figure 3). Results for ileum were surprising since 
cholesterol absorption in mice takes place within jejunum and ileum [23]. Mice fed a                     
high-cholesterol diet (compared with NC mice) showed in jejunum overexpression of genes 
related to the regulation of cholesterol homeostasis (Srebf’s and Nr1h4) and others such as Fdft1 
and Soat1 involved in the cholesterol biosynthesis and esterification. However, in liver the higher 
mRNA expression levels were those related to cholesterol efflux-related transporters (Abcg5/8) 
Group 
Initial BW 
(g) 
Final BW 
(g) 
Liver weight 
(g) 
Liver weight/BW 
(%) 
Cholesterol 
(mg/g feces) 
Ergosterol 
(mg/g feces) 
NC 19.27 ± 0.84 25.07 ± 0.69 1.25 ± 0.15 4.99 ± 0.62 0.01 ± 0.38 0.0 ± 0.0 
HC 20.06 ± 0.71 18.97 ± 1.07 a 1.62 ± 0.13a 8.54 ± 0.56 a 61.83 ± 0.47a 0.0 ± 0.0 
SFE 19.79 ± 0.87 18.53 ± 0.60 a,d 1.79 ± 0.16a,d 9.66 ± 1.05 a,c,e 60.89 ± 6.60a 0.23 ± 0.06a 
EG 19.69 ± 0.82 19.18 ± 1.19 a,d 1.57 ± 0.18a 8.19 ± 0.67 a 64.83 ± 13.92a 0.18 ± 0.01a 
ERG 19.77 ± 0.81 19.15 ± 0.67 a 1.55 ± 0.07 8.09 ± 0.39 a 54.24 ± 0.99a,b,d 1.99 ± 1.6a 
SV 19.30 ± 0.60 15.48 ± 1.52 a,b,c,e 1.46 ± 0.31 9.43 ± 1.34 a 65.40 ± 7.41a,c 0.0 ± 0.0 
EZ 19.82 ± 0.62 19.52 ± 0.93 a 1.56 ± 0.22a 7.99 ± 1.15 a,d 60.20 ± 14.74a 0.0 ± 0.0 
The results are mean ± SD of six (NC) or eight mice on each diet and were analyzed by one -way ANOVA and the Tukey’s procedure. NC: 
normal control; HC: control  fed a high-cholesterol diet ; SFE: SFE extract; E βG: EβG extract; ERG: ergosterol; SV: simvastatin ; EZ: 
ezetimibe; BW: body weight. aP<0.05 vs. NC; bP<0.05 vs. HC; cP<0.05 vs. ERG; dP<0.05 vs. SV; eP<0.05 vs. EZ.  
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and esterification (Soat). Surprisingly, the mRNA expression of Hmgcr was also up-regulated in 
HC animals compared with normocholesterolemic controls. 
 
Figure 7.  Relative mRNA expression (Log10) of cholesterol-related genes that are modified in mice with the 
induction of hypercholesterolemia for 8 weeks in four different tissues. Indicated genes are only those 
pointed as significant (p< 0.05) compared with normocholesterolemic mice as control.  The expression of 
each gene was measured at least in duplicate and each biological group included a minimum of 3 
replicates. 
The treatment of mice fed high-cholesterol diet with cholesterol-reducing drugs (as 
controls), ergosterol or the ergosterol-enriched extracts during 4 weeks induced different changes 
at the molecular level in all the analyzed mouse tissues. In jejunum, the administration of 
simvastatin decreased the mRNA expression of genes involved in cholesterol synthesis (Hmgcr 
and Fdf1), its blood transport (Ldlr), absorption (Npc1l1) and regulation (Nr1h4, Srebf’s)         
(Figure 4a). However, the treatment with ezetimibe down-regulated the expression of mainly             
2 regulators Nr1h4 (the FXR factor) and Srebf2. Similar decreases in the mRNA expressions were 
also observed when the SFE extract and ERG were administrated. When the mice were treated 
with the EβG extract, no significant changes in the mRNA expression of genes related to the 
cholesterol metabolism was observed. 
In ileum, ezetimibe treatment down-regulated Fdft1 expression as in cecum (Figure 4b 
and c), ergosterol and EβG extract appeared to significantly up-regulate the mRNA expression of 
Nr1h3 gene and ERG down-regulated Apob expression. In cecum besides Fdft1, ezetimibe 
treatment reduced the Apob expression (Figure 4c). However, the modulation induced by 
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ergosterol was, apart from Abcg5 overexpression, different than the drug control (ezetimibe) since 
apparently it was able to stimulate the expression of Mttp and the cholesterol transporter Npc1l1. 
None of the ergosterol-containing extracts were able to modulate mRNA expression in this tissue.  
 
  a) 
 
b) 
 
c) 
 
Figure 4. a), b) and c). Legend in the next page 
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d)     
 
Figure 8.  Relative mRNA expression (Log10) of cholesterol-related genes in a) jejunum, b) ileum, c) cecum 
and d) liver of mice fed high-cholesterol diet that were treated with simvastatin, ezetimibe, ergosterol and 
SFE and EβG extracts. Indicated genes are only those pointed as significant (p< 0.05) compared with 
hypercholesterolemic mice with no treatment (only high-cholesterol diet) as control.  The expression of each 
gene was measured at least in duplicate and each biological group included a minimum of 3 replicates. 
 
Expression of other few genes (Dgat1/2, Nr1h4, etc) was also down-regulated by 
simvastatin in liver being Nr1h4 less influenced than in jejunum (Figure 4d). ERG did not induce 
any changes but, administration of the SFE extract down-regulated the Abcg8 and Dgat1 
expression as ezetimibe or simvastatin did. In animals treated with the SFE extract, Hmgcr gene 
expression was significantly reduced while Fdft1 gene expression was up-regulated. 
Discussion 
The molecular action of non-cholesterol sterols in the cholesterol metabolism remains still 
unclear [3]. Some studies indicated that supplementation of Caco2 cells with phytosterols such 
as β-sitosterol incorporated into synthetic micelles (containing cholesterol) reduced the level of 
HMGCR gene expression [24] but similarly micellated sitostanol induced the expression of the 
ABCA1 gene [25]. However, other publications indicated that addition of β-sitosterol did not alter 
ABCA1, nor ABCG5/8 gene expressions [26], probably because β-sitosterol in that case was 
directly applied and not micellated since apparently the micellar lipid composition profoundly 
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affects cholesterol transport across Caco2 cells [27]. Supplementation of Caco2 cells with 
micelles generated by a less composition-controlled but more physiological-like in vitro digestion, 
also differently modulated cholesterol-related gene expression. Addition of generated DMM 
fractions containing CH+ERG or ERG did not alter HMGCR or transporters gene expression as 
observed for phytosterols, but, particularly the CH+SFE, induced overexpression of LDLR mRNA. 
However, ERG containing DMMs induced for these two genes a similar effect to CH containing 
DMMs (after 24 h) suggesting that the observed LDLR induction might be due to other sterols or 
compounds present in the SFE extract that modified the micelles composition or stimulated a 
synergistic effect because the DMMs including CH+ERG were also unable of inducing its gene 
expression. Moreover, up-regulation of the HMGCR gene after 24 h was also observed in all the 
samples but, it was lower in the one including CH+SFE and it was noticed concomitantly with a 
higher induction of the LDLR mRNA expression and repression of the FDFT1 gene that might be 
considered as a sort of response or compensation mechanism for the stimulated induction of the 
HMGCR mRNA expression. In vivo, increase of LDLR is associate with lowering of cholesterol and 
LDL in serum.  
Further addition to hepatic cells (HepG2) of the potentially bioavailable fractions 
generated after Caco2 absorption of the previously mentioned DMM fractions induced a fast (1 h) 
molecular response stimulating the mRNA expression of most of the selected genes suggesting 
rearrangement in their lipid metabolic pathways in order to assimilate and metabolize the 
absorbed or Caco2-transformed compounds. The fraction generated from CH+SFE (and 
CH+ERG but to a lower extent) induced an expression profile similar to CH (including i.e. 
significant overexpression of the MTTP, DGAT1 (triglyceride synthesis) and NPC1L1 (cholesterol 
absorption) genes)). Previous observations indicated that ergosterol and other sterols integrated 
into the SFE extract showed low bioavailability in in vitro studies and they could also be 
metabolized by Caco2 into other derivatives [5]. Thus, the fraction generated by CH+SFE might 
have a similar composition to the CH fraction or at least a composition able to stimulate initially a 
similar response because as the time passed (24 h), cell transcriptional responses differed 
depending on the sample and although for a few genes the modulation pattern was similar, the 
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bioavailable fraction generated by the CH+SFE extract induced also in hepatic cells 
overexpression of the LDLR mRNA suggesting a potentially beneficial effect but that it might not 
be due to its ergosterol content but to other generated compounds.  
Although the SFE extract induced LDLR mRNA overexpression in Caco2 and HepG2 
cells, no effect was noticed in in vivo studies with mice fed a high-cholesterol diet. In this regard, 
it should be noted that the extracts doses used in mice were calculated considering EFSA 
recommendation on hypocholesterolemic daily minimum intake of plant sterols (0.8 g) [28]. The 
human equivalent dose of sterols, that is, the sterols human dose translated from the sterols mouse 
dose using a body surface area normalization method [29] and considering a normal-weight adult 
(69 kg, 1.81m2) [30] was 0.94 g/day for SFE extract and 0.88 g/day for EβG extract. Although 
EFSA recommendation to achieve significant LDL lowering effect is a daily intake of 2-2.4g of 
phytosterols added to an appropriate food [31], a lower dose was administrated, as a first 
approach, to avoid undesirable potential overdosing because previous in vitro results [5] 
indicated that the SFE extract was 1.5-fold more effective than β-sitosterol as cholesterol displacer 
from DMMs and in the presence of fungal β-glucans this activity was partially enhanced. LDLR 
mRNA expression was also found to be increased in mononuclear blood cells of non-
hypercholesterolemic humans given phytostanol esters [32] but in mice fed a high-cholesterol 
diets, addition of phytosterol [33] did not change Ldlr expression. Moreover, A. bisporus and 
Flammulina velutipes (Enokitake mushroom) fiber extracts (5%) lowered the serum total 
cholesterol level by enhancement of the hepatic Ldlr mRNA in rats fed with a cholesterol-free diet 
[21, 34] but fibers from Grifola frondosa (Maitake mushroom) and Lentinula edodes (Shiitake 
mushroom) [34] did not influence rat Ldlr expression. Similarly, when the mice were fed with the 
EβG-extract (containing similar insoluble fibers) no effect on Ldlr expression was noticed. Despite 
differences between animals and mushroom species, the lack of effect could also be influenced 
by the experimental conditions [1], perhaps overexpression is more noticeable under 
physiological status closer to normocholesterolemia. Further studies using sterols doses closer to 
their human equivalent dose according to EFSA recommendations regarding daily intake of sterols 
Chapter 2- Manuscript 3 
 
248 
 
able of lowering LDL levels might indicate whether the lack of LDL reduction observed in our data 
has been due to the sterols dose used. 
On the other hand, addition of the EβG extract (although a very similar fungal sterols 
concentration than the SFE extract was administrated), did not induce any significant change in 
the expression pattern of genes related to the cholesterol metabolism in the selected mice tissues. 
This result might indicate that, under in vivo conditions, the sterols present in the EβG extract were 
probably not easily absorbed in jejunum and they were transported further in the intestine to ileum 
(where an overexpression of the Nr1h3 gene was induced) suggesting that fungal β-glucans might 
have been able of partially binding the sterols pulling them along the intestine. In a previous study, 
β-glucans from Pleurotus ostreatus (Oyster mushrooms) were able of partially scavenge fungal 
sterols as well as cholesterol in an in vitro digestion model and the amount of β-glucans compared 
to fungal sterols was higher in the EβG extract than in that study [5]. The EβG extract did not 
significantly lowered hepatic total cholesterol as observed in rats fed with β-glucan-rich extracts 
from P. ostreatus [35]. However, EβG extract reduced liver triglyceride levels (p<0.05) compared 
to control fed a high-cholesterol diet, indicating that certain changes at physiological level 
occurred in spite of the lack of transcriptional changes. 
The SFE extract seemed to be more effective than the EβG extract and ERG 
(administrated as standard compound) and absorbed mostly in jejunum since it appeared to 
modulate gene expression in this tissue (and not further in the intestine i.e. ileum, cecum) and its 
effect reached even the liver. Moreover, it was also able to significantly decrease the TC/HDL ratio 
compared to controls fed a high-cholesterol diet mostly because of the HDL increase. The TC/HDL 
ratio is a strong predictor for cardiovascular disease risk and its reduction is associated with 
reduction of cardiovascular mortality. A recent study reported that the TC/HDL ratio decreases 
with an increasing Mediterranean dietary pattern and it is associated with a lower atherothrombotic 
risk [36]. ERG was also partially absorbed in jejunum but apparently not in sufficient amounts to 
affect gene expression in liver but further on in the intestine including ileum and cecum being later 
marginally eliminated (its concentration in the feces was slightly higher than when the mice were 
treated with the ERG-containing extracts).  
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Compared to the two drugs utilized as controls, ERG and the SFE extract induced in 
jejunum an effect more similar to the inhibitor of cholesterol absorption (ezetimibe) than to 
simvastatin, they all down-regulated the expression of Nr1h4 and Srebf2. The latter gene controls 
the expression of numerous genes involved in cholesterol homeostasis including HMGCR,              
3-hydroxy-3-methylglutaril-CoA synthase (HMGCS), LDLR and NPC1L1 [37] while NR1H4 
encodes FXR, a member of the nuclear receptors family such as LXR (NR1H3 gene). Phytosterols 
with an unsaturation within the side chain such as stigmasterol (and ergosterol) were shown to 
disrupt cholesterol biosynthesis because they were endogenous regulators of these two major 
cholesterol regulatory pathways (LXR- and SREBP-sensitive pathways) [38, 39] but their regulatory 
effect was achieved because they were acting as structural analogs of LXR and SREBP-signaling 
ligands and not down-regulating the SREBF2 mRNA expression. Nevertheless, the SREBF2 
repression induced by ergosterol, the SFE extract and the two control drugs might negatively 
influence cholesterol biosynthetic pathway in jejunum (although the biosynthesis ratio in this tissue 
is lower than in liver). 
FXR is the chief sensor of intracellular levels of bile acids, controlling their synthesis and 
transport and in the intestine controls the absorption of bile acids, lipids, vitamins etc., through the 
regulation of expression of important transporters [7]. Stigmasterol was also described as a potent 
antagonist of FXR [37] and these type of compounds can lower serum LDL cholesterol and 
triglycerides levels and increase HDL levels through its regulation of a subset of FXR targets [7]. 
Thus, down-regulation of FXR gene (NR1H4) might also similarly reduce the expression of genes 
that were activated by FXR and enhance those that were inhibited (i.e. the apolipoprotein A1 
(ABCA1) involved in the nascent HDL [40]). Perhaps, this might be the reason for the tendency to 
increase HDL levels found in plasma of mice treated with ergosterol-containing preparations. 
On the other hand, although the target of ezetimibe is Niemann-Pick C1 like 1 [41] 
apparently it did not interact at its transcriptional level but directly on the transporter. Phytosterols 
were also unable to inhibit cholesterol absorption via transcriptional changes in intestinal Npc1l1 
(in mice) [26, 33] and similarly neither ERG nor the SFE-extract affected its expression in mice 
jejunum.  
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Adding cholesterol and cholic acid to a high-fat diet induces a significant triglyceride 
reduction in plasma of mice as compared with high-fat diet alone [18]. Likewise, cholic acid lowers 
hepatic and plasmatic triglyceride levels in mouse models of hypertriglyceridemia. At the 
molecular level, cholic acid decreases hepatic expression of SREBP-1c and its lipogenic target 
genes via a pathway involving FXR (NR1H4) up-regulation and LXR (NR1H3) down-regulation [42]. 
However, the high-cholesterol diet (1% cholic acid) did not change hepatic triglyceride levels 
compared to the normal diet. Despite hepatic overexpression of Nr1h4 mRNA, the concomitant 
overexpression of Dgat1 and Dgat2 (suggesting increase of triglyceride biosynthesis) seemed 
contradictory results difficult to clarify. Differences between the composition of the experimental 
diet used in this mouse model and the one used in that work could likely explain their different 
effects. On the other hand, the diet supplementation with the extracts and control drugs led to a 
significant reduction of hepatic triglyceride in all treated groups as compared with HC controls. 
That reduction was paralleled by a down-regulated Dgat1 expression in the livers of mice fed the 
SFE extract, treated with ezetimibe or treated with simvastatin, suggesting that the lower hepatic 
triglyceride accumulation could be mediated by a reduction of the triglyceride synthesis. 
Concerning the EβG extract and ergosterol they did not change hepatic Dgat1, FXR (Nr1h4) or 
LXR (Nr1h3) mRNA expression suggesting that the hepatic triglyceride-lowering effect observed 
for both was not mediated by inhibition of triglyceride synthesis or via the pathway induced by 
cholic acid.  Hepatic steatosis is an early stage of fatty liver disease that can result in more serious 
liver disease such as non-alcoholic steatohepatitis, fibrosis and cirrhosis, therefore new 
therapeutic approaches are of great interest. Previous studies have demonstrated protective 
effects of several mushrooms against hepatic steatosis. Specifically, the dietary intake of                   
A. bisporus prevents the development of hepatic steatosis in a mouse model of postmenopausal 
women [43], and Panellus serotinus (Mukitake mushroom) consumption alleviates non-alcoholic 
fatty liver disease in obese, diabetic ob/ob mice [44], and in obese, diabetic db/db mice [45]. 
Therefore, the ergosterol-containing fungal extracts might help preventing lifestyle-related 
diseases such as non-alcoholic fatty liver disease, the most common liver disease in developed 
countries. 
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Down-regulation of Hmgcr gene concomitant with up-regulation of the Fdft1 gene was 
also observed in mice treated with the SFE extract.  The reduction of the Hmgcr gene expression 
observed for β-sitosterol in Caco2 was not noticed in livers of hypercholesterolemic mice and 
healthy humans, only in individuals with sitosterolaemia (more than 100 fold β-sitosterol) indicating 
that only large amounts of phytosterols in target tissues may contribute to these characteristics in 
vivo [3, 46]. However, in that study phytosterols were administrated to mice as standard 
compounds and perhaps as part of an extract (such as SFE extract) or because differences in 
absorption have been detected due to specific structural conformations [47], their bioavailability 
in vivo could have been increased having a better chance to reach their target in the liver at lower 
concentrations. Another possibility could be that the compounds responsible from the observed 
modulation of the genes expression were other molecules different than sterols. However, they 
might not be chemically far from sterols since dietary phytosterol supplementations also                 
up-regulated the expression of the hepatic cholesterogenic farnesyl pyrophosphate synthase 
(FPPS) gene in apoE-deficient mice [34] and the SFE extract was able to up-regulate the enzyme 
immediately after in the cholesterol biosynthetic pathway (Fdft1). Nevertheless, the observed 
modulation of the gene expression profile in liver could not explain the reduction in total cholesterol 
observed in the liver of mice fed with i.e. SFE extract (20%) or ezetimibe (59%). 
Conclusions 
In vitro studies indicated that the DMM fraction generated after digestion of the SFE 
extract mixed with lard up-regulated LDLR mRNA expression in Caco2 and HepG2 cells although 
in the latter it also modulated the expression of other genes related to the lipid metabolism. Results 
differed from in vivo studies using mice fed a high-cholesterol diet where no effect on Ldlr 
expression was observed but down-regulation of cholesterol regulatory genes such as Srebf2 and 
Nr1h4 (FXR) (in jejunum). Similar effect was also observed in mice treated with ERG and two 
control drugs (simvastatin and ezetimibe). In addition to other effects, the SFE extract decreased 
the atherogenic index TC/HDL in plasma, which is associated with a reduction of the 
cardiovascular disease risk. Furthermore, the SFE extract induced in liver a similar                      
down-regulation of Dgat1 mRNA than simvastatin or ezetimibe, suggesting that their reduced 
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hepatic triglyceride levels could be produced by inhibition of triglyceride synthesis. In this tissue, 
the effect of the SFE extract differed from the drugs because it induced down-regulation of Hmgcr 
and up-regulation of Fdft1.  
The observed transcriptional modulation was not followed by changes in the biochemical 
parameters analyzed i.e., the treatment with the EβG extract showed no effect at the transcriptional 
level but it reduced hepatic triglyceride in liver suggesting that post-transcriptional regulation 
processes might be also involved. Thus, these mushroom extracts may be useful limiting hepatic 
steatosis and could be a source of bioactive compounds to functionalize foods intended to prevent 
lifestyle-related diseases such as non-alcoholic fatty liver disease. Further studies with higher 
extract doses are, at the present, being carried out to clarify the effect of ergosterol and ergosterol-
containing extracts on the lipid regulatory pathways and to assess their potential applicability in 
humans.  
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 Preface 
One of the hypolipidemic strategies accepted by physicians against cardiovascular 
disease related to obesity is hindering dietary fatty acids release from several structures such as 
triglycerides during digestion process. The inhibition of one of the enzymes involved in this 
process, the pancreatic lipase (PL), results in a non-liberation of fatty acids from triglyceride 
structure in the digestion medium. Thus, inappropriate incorporation of fatty acids into DMMs 
occurs and consequently, their transport thought brush border membrane of the enterocyte is 
impaired. 
 Tetrahidrolipstatin (commonly known as orlistat) is a chemically stabilized structure 
considered as an effective pancreatic lipase inhibitor and isolated from Streptomyces toxytricini. 
Orlistat is a worldwide commercialized compound prescribed against obesity because it impairs 
fatty acid absorption (figure 1).  
 
Figure 1. Orlistat molecule. 
 
Other compounds from several natural sources have been described as molecules able 
of inhibiting this enzyme i.e. saponins from Medicago sativa, polyphenols enriched extracts from 
berry species, a member of the 7-hydroxyisoflavones class isolated from Derris scandens, 
Glycyrrhiza uralensis or Cudrania tricuspidata etc..   
As previously mentioned, although PL inhibition have been observed in a large range of 
mushroom species with 1 till 92% efficiency in in vitro assays, only a couple of singular compounds 
with β-lactones configuration have been isolated from Stereum complicatum and Boreostereum 
vibrans. Despite these interesting in vitro results, the antiobesity effect was only demonstrated in 
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vivo for a few mushrooms species using animal models. The observed reduction in the lipid 
absorption during digestion was due to their PL inhibitory capacity.  
Occasionally, the bioactivity of many compounds determined with in vitro tests can be 
altered during digestion processes due to the degradations and transformations of the initial 
molecules in the presence of gastric, bile and pancreatic juices. Thus, in order to confirm the 
potential PL inhibitory effect of several edible mushrooms, two analytical methods were compared 
in the work entitled Testing edible mushrooms to inhibit the pancreatic lipase activity by an in 
vitro digestion model. One of the in vitro tests utilized was a commercialized enzymatic kit to 
determine PL activity that is frequently used in the literature and the other was an optimized 
method to detect PL activity during in vitro digestion conditions that simulate the physiological 
conditions of human digestion. A screening within several wild and cultivated strains using 
different solvents revealed that results differed depending on the assay utilized.   
 
Although non-promisingly results were obtained, later experiments were carried out to 
confirm several authors published results. As mentioned, it have been described the inhibition 
effect of mushrooms polysaccharides on PL activity. Thus, with the objective confirm those results-
avoiding possible concentration problem- water soluble polysaccharides were extracted from 
Pleurotus eryngii by environmentally friendly technology as described in Additional non-published 
results section. 
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Abstract 
One of the strategies in prevention or treatment of obesity is altering metabolism of lipids 
by inhibition of dietary fat absorption. The extracts obtained with methanol, water and 
methanol:water (1:1) from 21 mushroom species were screened as potential sources of pancreatic 
lipase (PL) inhibitors using a standardized in vitro test. Lepiota procera methanol:water (1:1) 
extracts showed the highest inhibition activity closely followed by Grifola frondosa, Pleurotus 
eryngii and Lyophyllum shimeji. Other mushroom strains such as Morchella conica, Marasmius 
oreades, Lentinula edodes, Amanita ponderosa and Boletus edulis also showed a certain 
inhibitory activity. However, when the PL inhibitory activity was evaluated using an in vitro digestion 
model mimicking gut conditions, none of the selected mushroom extracts were able to inhibit PL 
activity. On the contrary, stimulation of the lipase activity levels was observed and it was not due 
to endogenous mushroom lipases activities.  
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Introduction 
Obesity is the sixth most important risk factor contributing to the overall burden of disease 
worldwide reaching the category of epidemic. Nowadays, pharmacotherapy arises as useful tools 
to approach obesity. So far, there are three major drug options for the long-term treatment of 
obesity: orlistat (a gastric and lipase inhibitor), sibutramine (a monoamine reuptake inhibitor) and 
rimonabant (an endocannabinoid receptor blocker) [1]. However, obese and specially 
overweighed population is reluctant to assume obesity as a medical problem and, before turning 
to a health professional, starts his/her own therapy by using special foods, such as reduced fat 
content (light) products and nutritional supplements (including herbal extracts) and more often, 
diets without scientific evidence. 
Therefore, foods containing active principles with clear metabolic targets and scientific 
evidence of their activity may help in the self-fight against obesity, reaching to a higher number of 
individuals and in an earlier stage of their own obesity. A wide range of natural products (including 
crude extracts) mainly obtained from plants have been reported as effective pancreatic lipase 
(PL) inhibitors. For instance, berry polyphenols [2], triterpenes from Sapindus sp [3], 
monoterpenes from Monarda punctata [4], abietanes from Salvia sp [5] and more than 70 plant 
extracts [6] showed PL inhibitory activity. The list of compounds and sources could be further 
extended with the findings of Birari & Bhutani (2007) and Slanc et al., (2004) [7, 8]. The latter 
publication pointed fungi as a potential new source of PL inhibitors since within 60 edible and non-
edible fungi species, PL inhibitory activities were found ranging from 1% till 97% depending on 
the specie considered.  
Only a few interesting PL inhibitors were isolated from edible fungi, two of them were       
β-lactones with unusual configurations named percyquinin (obtained from Stereum complicatum) 
and vibralactone (Boreostereum vibrans) with similar IC50 (0.4 μg/mL) [7, 9]. For a few mushroom 
species, the observed activities were also effective in vivo according to the results obtained with 
animal models. Ahn et al., (2007) reported the antiobesity effects of Isaria sinclairii fruiting bodies 
[10] and Mizutani et al., (2010) demonstrated the PL inhibitory activity of water extracts 
(polysaccharide-rich fraction) obtained from Pleurotus eryngii fruiting bodies [11].  
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However, most of the former results were obtained from biochemical tests and no further 
studies to evaluate them under gut conditions were carried out. Positive scientific results in dead 
end may be mislead and produce misuse. For instance, a published scientific evidence of lipase 
inhibitory activity in some raw foodstuff or an herb does not mean that will have effect on fat 
absorption but can be interpreted like that, and wrongly used for that purpose. 
Thus, in this work the PL inhibitory activities of several extracts obtained from edible 
mushrooms were determined using a fast and standardized method and compared to the PL 
inhibitory activities obtained using an in vitro digestion model simulating the conditions in which 
the human PL would be involved in order to confirm or reject, in a step ahead, their lipase inhibitory 
capacity before animal testing.   
Materials and Methods 
Biological material  
Mushroom species used in this investigation were Lentinula edodes S. (Berkeley), 
Cantharellus cibarius (Fr.), Lactarius deliciosus (Fr.), Boletus edulis (Bull. Ex Fr.), Pleurotus 
ostreatus (Jacq.Ex Fr.) Kummer,  Agaricus bisporus L. (Imbach), Amanita caesarea (Scop. Ex 
Fri.) Pers. Ex Schw.,  Morchella esculenta (Pers Ex Amans), Agaricus blazei Murill ss. (Heinem), 
Grifola frondosa (Dicks.) Gray, Ganoderma lucidum (Curtis) P.Karst., Flammulina velutipes (Curt. 
Ex Fr.) Singer, Pleurotus eryngii (D.C. Ex Fr.) Quel, Lyophyllum Shimeji (Kawam.), Morchella 
conica (Pers.), Agrocybe aegerita (Briganti) Singer, Auricularia judae (Bull. Ex St.Amans) Berck, 
Amanita ponderosa Malençon & R. Heim, Craterellus cornucopioides (L. Ex Fr.) Pers, Marasmius 
oreades (Bolt. Ex Fr.) Fr. and Lepiota procera (Scop. Ex Fr.) Singer.  Fruiting bodies were 
purchased from the local market in Madrid, Spain. Refined Sunflower oil, milk powder, walnut, 
dehydrated cereals, dried banana were also obtained from local markets. All the experiments 
were performed using the same bottle, box or lotus. 
 Reagents 
Pancreatine (P-1750), lecithin, bile salts, maleic acid, 2,3-Dimercapto-1-propanol 
tributyrate (BALB), sodium dodecyl sulfate, 5,5´-Dithiobis (2-nitrobenzoic acid) (DTNB),                    
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D-mannitol, phenylmethylsulfonyl fluoride (PMSF) were procured from Sigma-Aldrich Co. 
Steinheim, Germany. Orlistat was purchased from Glaxo Group Limited (Middlesex, UK). All other 
reagents and solvents were used of analytical grade.  
Sample preparation 
Dried fruiting bodies dehydrated as described in Ramírez-Anguiano et al., (2007) [12]. 
The fruiting bodies were ground into fine powder using liquid nitrogen in a mortar. The mushroom 
powders (10 mg) were mixed with 1 mL of absolute methanol, a mixture methanol:water (1:1) or 
water, shacked on a Vortex (Heidolph Reax top, Germany) during 3 min and centrifuged (10000 
rpm 2 min) in a mini-centrifuge (Eppendorf, Minispin, Germany). The supernatants were screened 
as source of pancreatic lipase inhibitors. 
Pancreatic lipase activity using an standardized lipase assay kit  
Pancreatic lipase activity in the presence of mushroom extracts was measured using a 
QuantiChromTM Lipase assay kit (DLPS 100) from BioAssay Systems (Hayward, USA). A 
pancreatic lipase solution was prepared by mixing 19 μg porcine pancreatin with 1 ml 50 mM 
trizma-maleate pH 7.5 and it was used as a lipase source. Mushroom supernatants (10 μl) were 
mixed with 40 μl of the pancreatic solution and 100 μl of a mixture including 5 mg DTNB,                      
8 μl BALB in ethanol and 100 μl tris(hydroxymethyl)aminoethane buffer pH 8.5 in a clear flat 
bottom 96-well plate according to the user´s manual. Absorbance increase during 20 min at   412 
nm and 37 ºC was recorded using a microplate reader (Tecan Group Lt, Switzerland). Lipase 
activity was expressed as indicated by the user´s manual. An Orlistat solution (0.75mg/ml) was 
also applied (10 μl) and used as a positive inhibitor control. 
Pancreatic lipase activity using an in vitro digestion model  
The samples (different concentrations of mushroom extracts with/without 1 g sunflower 
oil) were submitted to an in vitro intestinal digestion model carried out following the method 
described by Martín et al., (2010) [13]. The samples were mixed with 54 ml of 50 mM trizma-
maleate buffer pH 7.5 in a titrator device (Titrino plus Metrohm 877, Switzerland) maintaining 
temperature (37 ºC), stirring and pH (7.5) constant for 120 min. Simulation of intestinal digestion 
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was started by addition of 5 mM CaCl2, 150 mM NaCl, and 6 mL of a pancreatin solution                
(1000 IUB m/L, 11.8 mM bile salts and 1.3 mM lecithin in the trizma-maleate buffer). Every 30 
minutes (including time 0 immediately after the mixture of the mushroom sample with the 
pancreatic mixture), 100 μl of the digestion suspension were withdrawn, diluted with 1.8 ml 50 mM 
trizma-maleate buffer pH 7.5 and assayed for lipase activity (50 μl) according to the procedure of 
Furukawa et al., (1982) [14]. Briefly, diluted solutions were mixed with 1 ml of 0.3 mM DTNB and 
20 μl PMSF. The mixture was incubated at 37 ºC for 5 min. Afterwards, 100 μl of a BALB solution 
(20 mM BALB and 20 mM SDS in ethanol) were added and incubated at     37 ºC for 30 min. The 
reaction was stopped by adding 2 ml acetone. Concomitantly, a zero sample of each assay was 
prepared as above described but with no substrate addition. Absorbance increase at 412 nm was 
recorded using a spectrophotometer (Evolution 600 Thermoscintific, England).  In vitro digestions 
of mushroom extracts were also carried out as before described but without lecithin and bile salts 
and the effect of these compounds was also evaluated on the test performance. Orlistat                
(1.48 mg/g oil or 10 mg/ml depending on the type of experiment) was used as a positive inhibitor 
control. 
Mushrooms lipase activities  
Mushroom powders (10 mg/mL) were mixed with methanol:water (1:1) and diluted in 
buffer as described from samples obtained from the in vitro digestion model. Obtained mixtures 
(50 μl) were directly mixed with all the reagents to measure their lipase activity using the protocol 
described above by Furukawa et al., (1982) [15] except for the pancreatin addition in order to 
evaluate the potential residual lipase activity that might occur due to endogenous mushroom 
lipases. 
Results and Discussion 
Screening of pancreatic lipase inhibitory activity  
Several extracts were obtained from mushroom fruiting bodies using methanol, 
methanol:water (1:1) and water as solvents (eight different concentrations ranging from 666 to     
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5.2 μg/ml) screened for pancreatic lipase (PL) inhibitory activity using an standardized lipase 
assay kit and a pancreatin solution.  
Extract concentrations lower than 166 μg/ml (corresponding to an enzyme:inhibitor ratio 
of 1:9 in the final reaction volume) showed no PL inhibitory activity and the percentage of inhibition 
observed for these or higher concentrations was strain and solvent dependent. None of the water 
extracts showed significant PL inhibitory activities compared to controls. The highest inhibitory 
values were found on the methanol:water extracts except for M. oreades (Table 1) and M. conica 
showing higher inhibition on their methanol than methanol:water (1:1) extracts (respect. 19.4% 
and 15.5%). Thus, results were in concordance with those of Slanc et al., (2004) [8] pointing 
methanol:water as the best solvent mixture to extract PL inhibitors.  
Table 1. Pancreatic lipase activity (U/L) using the standardized lipase activity kit of Marasmius oreades  (166 
mg/mL) methanol, methanol:water (1:1, v/v) and water extracts. 
 
The methanol:water (1:1) extracts obtained from the 21 selected mushroom strains were 
screened using the in vitro lipase assay kit for PL inhibitory capacities (Table 2) and many of them 
lacked inhibitory capacity or it was very low. However, B. edulis, A. ponderosa, L. edodes,             
M. oredades, M. conica, Lyophyllum shimeji, P. eryngii and G. frondosa showed between 10% to 
20% and L. procera a PL inhibitory activity equivalent to the 25% of the selected orlistat 
concentration.  
Although, the PL inhibitory activities found in the latter species were four- or five folds 
lower than the selected orlistat concentration (0.75 mg/ml) results might be of high interest. In fact, 
a foodstuff with a quarter of the orlistat activity could be recommended by nutritionists as part of 
 
Control Extract 
Water 252.14 ± 3.34 244.25 ± 6.08  
Methanol: water (1:1) 255.68 ± 0.15  229.22 ± 2.84  
Methanol 294.38 ± 56.76  212.83 ± 7.54  
ORL 
   
44.13 ± 0.73  
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a diet to lose weight. Therefore, the same mushroom extracts were tested under simulated gut 
conditions. 
Table 2. Pancreatic lipase (PL) activity in the presence of methanol:water  (1:1) extracts obtained from several 
fruiting bodies.  
 
 
Mushroom species 
PL activity assessed  
using an enzymatic kit 
(%) 
PL activity assessed using an 
in vitro digestion model 
(%) 
Cantharellus cibarius 106.89 ± 12.03 124.62 ± 1.62  
Lactarius deliciosus 106.55 ± 0.96 123.21 ± 17.32  
Amanita caesarea 105.08 ± 0.80  122.98 ± 7.03  
Flammulina velutipes 103.01 ± 6.55  165.47 ± 11.24  
Morchella esculenta 100.22 ± 0.53  131.12 ± 8.49  
Ganoderma lucidum 100.61 ± 0.80  221.61 ± 9.49  
Agrocybe aegerita 96.16 ± 4.00  121.56 ± 6.67  
Agaricus blazei 96.13 ± 4.58  99.36 ± 12.88  
Craterellus cornucopioides 95.75 ± 0.96  181.04 ± 9.83  
Auricularia judae 93.42 ± 1.28  104.97 ± 6.31  
Agaricus bisporus 93.27 ± 1.01  127.42 ± 5.95  
Pleurotus ostreatus 92.53 ± 2.92  123.98 ± 0.47  
Boletus edulis 87.35 ± 2.74  106.01 ± 16.45  
Amanita ponderosa 86,18 ± 2.74  167.30 ± 24.35  
Lentinula edodes 86.10 ± 3.77  165.71 ± 10.19  
Marasmius oreades 85.81 ± 1.06  159.19 ± 9.81  
Morcella conica 84.46 ± 0.00   96.21 ± 20.70  
Lyophyllum shimeji 83.14 ± 1.01  220.87 ± 14.41  
Pleurotus eryngii 82.69 ± 1.12  95.44 ± 0.94  
Grifola frondosa 82.46 ± 4.00  118.22 ± 19.25  
Lepiota procera 79.07 ± 0.29  152.42 ± 0.23  
Orlistat 16.45 ± 1.33  33.09 ± 15.25  
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Effect of in vitro digestion on the PL inhibitory activity of mushroom extracts 
In order to evaluate whether the mushroom extracts that showed positive PL inhibitory 
activity would still be able to carry out their potential effect on pancreatic lipase during human 
digestion, mushroom extracts were mixed with a fatty food matrix such as oil and submitted to an 
in vitro digestion model mimicking the intestinal digestion. 
The pancreatic lipase activity was monitorised in an in vitro digestion model during 2h 
using a sunflower oil digestion as control (Figure 1). As expected, the lipase activity levels showed 
a constant value of approx. 400 IUB/mL during the selected digestion period and conditions. The 
increasing volume of NaOH added into the digestion vessel by the tritiation device during the 
digestion indicated that the pancreatic lipases were degrading the oil triacylglycerides and 
releasing free fatty acids (provoking a reduction of pH that was compensated by the NaOH) [13]. 
Under the selected in vitro conditions, the lipase reactions followed a hyperbolic curve needing 
approximately one hour to liberate most of the fatty acids although, a slight degradation was still 
observed until 2h digestion. This effect could correspond to the Ca2+ extinction in the media 
needed for the proper lipase activity [15]. When the same digestion was performed in the 
presence of orlistat (1.48 mg/g oil), activity was reduced by approximately six folds during the 
complete digestion time. However, when the oil was mixed with mushroom extracts of G. frondosa 
(51 mg/g oil dw), M. oreades (91 mg/g), and L. procera (189 mg/g) and submitted to in vitro 
digestion during 2 h no inhibitory effect similar to orlistat was observed. A slightly but significantly 
lower PL activity was noticed at the beginning of the digestion when the samples containing the 
M. oreades and L. procera extracts were analyzed.  
However, as the digestion proceeded, in the samples containing M. oreades extracts, 
after 1h PL activity reached values similar to control and in those samples containing L. procera 
(applied in higher concentration) the PL activity values increased up to levels even higher than 
control. Thus, the PL inhibitory capacity detected for some mushroom species using the lipase 
activity kit might not have significant relevance when the lipase assay is performed simulating the 
digestion conditions in which pancreatic lipase might be involved in vivo. Therefore, the PL 
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inhibitory capacity of all the selected mushroom strains was measured again but adding the 
mushroom extracts into a pancreatic lipase solution simulating the in vitro digestion conditions.  
Figure 1.  Pancreatic lipase activity during an in vitro digestion model of mushroom extracts mixed with 
sunflower oil. Digestion of sunflower oil was used as not inhibited control and orlistat digestion as inhibited 
control. 
Screening for pancreatic lipase inhibitors under simulated digestion conditions 
The methanol:water extracts of the selected edible mushrooms were screened again 
against pancreatic lipase activity but maintaining the in vitro digestion conditions and adjusting 
the inhibitor concentrations to similar conditions than those of the kit (enzyme:inhibitor ratio 1:8 in 
the final reaction volume).   
Results differed from those obtained when the enzymatic assay was performed using the 
lipase standardized kit (Table 2). Only P. eryngii extract showed an almost insignificant PL 
inhibitory activity under the simulated gut conditions, being lower than 7% of the orlistat inhibitory 
capacity. Those methanol:water extracts that showed PL inhibitory activity using the in vitro 
biochemical kit did not show activity when assayed simulating the gut conditions.  Wise to mention 
was the fact that many of the mushroom species showed higher lipase activity than the negative 
control (methanol: water (1:1) solution instead of the extract).  
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Since the obtained results appeared so different than those obtained using the 
standardized lipase assay and because practically none of the prepared mushroom extracts 
seemed to contain PL inhibitors, extractions with other solvents were assessed again. Therefore, 
some mushroom extracts were obtained using 100% methanol or water as a second attempt to 
screen for PL inhibitors under simulated digestion conditions (Table 3). Also in this case, none of 
the samples showed any interesting PL inhibitory activity except for orlistat and P. eryngii methanol 
extracts (with an almost insignificant inhibition) and on the contrary, some of the mushroom 
extracts showed lipase activity values higher than their control including only water, methanol or 
a methanol:water (1:1) mixture. 
Table 3. Pancreatic lipase activity (IUB/mL) in the presence of several mushroom extracts (using water, 
methanol and methanol: water (1:1)) simulating the in vitro digestion conditions.   
 
Moreover, if the extracts were applied doubling the concentration, as it was tested for M. 
conica methanol extracts, P. eryngii water extracts and G. lucidum methanol:water extracts, the 
lipase activity was increasing and not decreasing as it would have been expected if the extracts 
would have contained any inhibitory compound. After the above described results it could be 
concluded that none of the tested mushroom extracts contained compounds in sufficient 
quantities able to reduce the pancreatic lipase activity under the simulated gut conditions. 
However, still remains unexplained the reason for increasing PL values in the presence 
of some of the mushroom extracts. Thus, further studies were carried out in order to clarify this 
unexpected behavior. The pancreatic lipase source used to carry out this experiments was not an 
isolated enzyme but a porcine pancreas extract (including co-lipases and other enzymes) so it 
Mush.extracts Water Methanol:water (1:1) Methanol 
Control 961.38 ±  99.79    1076.04 ±  23.11 1253.91 ± 45.74 
G. lucidum 979.02 ±  112.26   1362.69 ±  130.97     1772.82 ± 128.90 
M. conica 1290.66 ±  66.52   1858.08 ±  274.41 1571.43 ± 68.60 
P. eryngii 1121.83 ±  174.13     997.89 ±  64.11 892.61 ± 158.11 
L. edodes 1646.40 ±  332.62   1166.89 ±  26.19 1073.69 ± 205.81 
ORL 247.62 ±  48.39     161.41 ±  71.59 155.11 ± 5.27 
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could be hypothesized that the presence of lipids, lipid-related or lipidic fractions from the 
mushroom extracts might activate, induce or enhance the lipase activity as it was described for 
compounds such as triacylglicerides, etc. [15] since the presence or absence of lecithin nor bile 
salt in the reaction medium influenced the PL activity values. Another possible explanation could 
be that the mushroom extracts might also contain endogenous lipases that might interfere with the 
reaction since fungal lipases have been previously described in some of the mushroom strains 
[16]. 
Thus, in order to further clarify the obtained results, the lipase activity of the mushroom 
extracts was measured and on the other hand, the pancreatic lipase assay mimicking the gut 
conditions was carried out in the presence of various food extracts and pure compounds with 
different lipidic composition. 
Methanol:water mushroom extracts were submitted to the lipase activity test under similar 
conditions than the in vitro digestion assay but without pancreatin addition. Thus, the observed 
activity could be only due to fungal lipases. As expected, results indicated that none of the 
selected strains showed significant lipase activity compared to the control with pancreatin (Table 
4) since the extraction solvent contained methanol and mushroom enzymes (mainly exoenzymes), 
although they can tolerate certain level of organic solvents, they exert their activity using water or 
specific buffer.  
Table 4. Endogenous lipase activity determined in several mushroom extracts using the in vitro digestion 
conditions but in absence of pancreatin. 
 
Mushroom species    PL (IUB/mL) 
Control (MeOH:water,1:1) 126.4 ± 8.3 
Lyophillum shimeji 132.3 ± 8.3  
Craterellus cornucopioides 117.6 ± 12.5  
Pleurotus eryngii 111.7 ± 8.3  
Agaricus blazeii 123.5 ± 8.3  
Amanita caesarea 147.0 ± 8.3  
Morchella conica 113.2 ± 10.4 
Control (with pancreatin) 1123.1 ± 198.4  
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Moreover, their lipase activity values did not correlate with the mushroom species which 
showed higher PL activity (in Table 2). Thus, the endogenous mushroom lipases were not the 
responsible for the increasing of lipase activity observed during in vitro digestion of the extracts. 
Sucrose, starch or dehydrated wheat (as breakfast cereals) was selected as example of 
carbohydrates-rich foodstuff. Serum bovine albumin (BSA) and defatted milk powder were 
selected as protein rich sources. When the methanol:water (1:1) extracts were obtained from these 
poor lipid-containing samples and assayed for lipase activity no significant differences in PL 
activity levels were observed compared to control (Table 5). 
However, when dehydrated banana and walnut extracts (selected as example of    lipid-
containing foodstuff) were tested, pancreatic lipase activities increased up to similar levels than 
those observed for some of the mushroom extracts (for instance M. conica). Moreover, when the 
powdered walnut or M. conica were mixed with a drop of sunflower oil (285mg/g) an even higher 
PL activity increase was observed suggesting that the enhancing of lipase activity is related to 
lipidic compounds. 
Table 5. Pancreatic lipase activity of some lipidic and non-lipidic food matrices and pure compounds using 
the simulated in vitro digestion conditions. 
 
Food extracts     PL activity (IUB/mL) 
Control  1123.08 ± 198.42 
Sugar 1261.26 ± 41.58 
Starch 1149.54 ± 158.00  
BSA 1145.13 ± 172.55 
Dehydrated wheat (Cereal) 1056.93 ± 81.08  
Defatted milk powder 1331.08 ± 76.90  
Dehydrated banana 1718.59 ± 2.08  
Walnut 1822.80 ± 49.90  
Walnut with oil 2335.83 ± 76.90 
Morchella conica 1858.08 ± 274.41  
Morchella conica with oil 2475.48 ± 241.15  
ORL 155.11 ± 5.27  
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Edible mushrooms are highly recommended in diets for overweighed people particularly 
because they are considered as low-fat food [17]. Thus, a minor compound or group of 
compounds (of lipidic nature) could be the responsible for the stimulation of PL activity, perhaps 
sterols since cholesterol was described as compound able to mediate pancreatic lipase 
activity[18]. Mushroom fruiting bodies contain ergosterol as the major sterol constituent of the 
fungal membrane and it was present in the selected mushroom strains in a concentration range 
between 5.69 to 0.69 mg/g [19]. However, when the ergosterol levels were plotted toward PL 
activity measured by the in vitro digestion model no correlation was found leaving the responsible 
compound / group of compounds still unidentified. Other compounds such as saponins have been 
described as stimulating compounds of pancreatic lipases; however, edible mushrooms do not 
contain this type of compounds [20]. 
Conclusions 
Thus, it could be concluded that, although some mushroom extracts showed PL inhibitory 
activity in an in vitro test, under the in vitro digestion model utilized mimicking the intestinal human 
conditions, the selected mushroom species were not able to effectively inhibit the pancreatic 
lipase when mixed with a food matrix as sunflower oil or directly applied as mushroom extract. 
These results strengthen the need of more detailed studies before concluding the ability of natural 
extracts to perform certain biological activities by using only in vitro biochemical tests. Therefore, 
the use of mushroom extracts i.e. as ingredient to formulate functional foods able to act as orlistat 
is, in any case, of limited significance. On the other hand, further studies are, at the present, being 
conducted to clarify the stimulation of PL activity observed.  
 
Acknowledgments 
The research was supported by the European Union within the 7th framework programme 
(7FM-PEOPLE-2009-IIF project 251285), ALIBIRD-CM S2009/AGR-1469 regional program from 
the Community of Madrid (Spain) and AGL2010-21537 national R+D program from the Spanish 
Ministry of Science and Innovation 
Chapter 3- Inhibition of pancreatic lipase… 
 
277 
 
References 
[1]. Ahn, M.Y., S.D. Jee, and B.M. Lee, Antiobesity effects of Isaria sinclairii by repeated oral treatment in obese 
Zucker rats over a 4-month period. Journal of Toxicology and Environmental Health, Part A, 2007. 70(15-16): p. 
1395-1401. 
[2]. Birari, R.B. and K.K. Bhutani, Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug 
Discovery Today, 2007. 12(19–20): p. 879-889. 
[3]. Furukawa, I., et al., Assays of serum lipase by the "BALB-DTNB method" mechanized for use with discrete and 
continuous-flow analyzers. Clinical Chemistry, 1982. 28(1): p. 110-3. 
[4]. Gil-Ramirez, A., et al. Edible mushrooms as potential sources of new hypocholesterolemic compounds in 7th 
International Conference on Mushroom Biology and Mushroom Products. 2011. Arcachon, France. 
[5]. Kalač, P., Chemical composition and nutritional value of European species of wild growing mushrooms: A review. 
Food Chemistry, 2009. 113(1): p. 9-16. 
[6]. Krügener, S., et al., Heterologous expression of an extra-cellular lipase from the basidiomycete Pleurotus sapidus. 
Journal of Molecular Catalysis B: Enzymatic, 2009. 57(1–4): p. 16-21. 
[7]. Liu, D.-Z., et al., Vibralactone:  A lipase inhibitor with an unusual fused β-Lactone produced by cultures of the 
Basidiomycete Boreostereum vibrans. Organic Letters, 2006. 8(25): p. 5749-5752. 
[8]. Martin, D., et al., Intestinal digestion of fish oils and ω-3 concentrates under in vitro conditions. European Journal 
of Lipid Science and Technology, 2010. 112(12): p. 1315-1322. 
[9]. McDougall, G.J., N.N. Kulkarni, and D. Stewart, Berry polyphenols inhibit pancreatic lipase activity in vitro. Food 
Chemistry, 2009. 115(1): p. 193-199. 
[10]. Mizutani, T., et al., Hypolipidemic effect of Pleurotus eryngii extract in fat-loaded mice. Journal of Nutritional 
Science and Vitaminology, 2010. 56(1): p. 48-53. 
[11]. Morikawa, T., et al., Oleanane-type triterpene oligoglycosides with pancreatic lipase inhibitory activity from the 
pericarps of Sapindus rarak. Phytochemistry, 2009. 70(9): p. 1166-1172. 
[12]. Ninomiya, K., et al., Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorganic & Medicinal 
Chemistry Letters, 2004. 14(8): p. 1943-1946. 
[13]. Padwal, R.S. and S.R. Majumdar, Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet. 
369(9555): p. 71-77. 
[14]. Porter, C.J.H., et al., Enhancing intestinal drug solubilisation using lipid-based delivery systems. Advanced Drug 
Delivery Reviews, 2008. 60(6): p. 673-691. 
[15]. Ramírez-Anguiano, A.C., et al., Radical scavenging activities, endogenous oxidative enzymes and total phenols 
in edible mushrooms commonly consumed in Europe. Journal of the Science of Food and Agriculture, 2007. 
87(12): p. 2272-2278. 
[16]. Ros, E., Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce 
cardiovascular risk. Atherosclerosis, 2000. 151(2): p. 357-379. 
Chapter 3- Manuscript 1 
 
278 
 
[17]. Sharma, N., V.K. Sharma, and S.-Y. Seo, Screening of some medicinal plants for anti-lipase activity. Journal of 
Ethnopharmacology, 2005. 97(3): p. 453-456. 
[18]. Slanc, P., et al., Screening of wood damaging fungi and macrofungi for inhibitors of pancreatic lipase. 
Phytotherapy Research, 2004. 18(9): p. 758-762. 
[19]. Sroka, Z., et al., Stimulation of pancreatic lipase activity by saponins isolated from Medicago sativa L. Z 
Naturforsch C, 1997. 52(3-4): p. 235-9. 
[20]. Yamada, K., et al., A lipase inhibitor monoterpene and monoterpene glycosides from Monarda punctata. 
Phytochemistry, 2010. 71(16): p. 1884-1891. 
 
 
 
Chapter 3- Inhibition of pancreatic lipase… 
 
279 
 
Additional non-published results 
Although results presented in the manuscript were discouraging, Pleurotus eryngii 
extracts showed a slight PL inhibitory activity after in vitro digestion assay. This mushroom specie 
has been pointed by several authors as strain capable of acting as PL inhibitor in vivo because of 
certain water soluble polysaccharides. Thus, since PLE could extract fungal polysaccharides as 
previously demonstrated, a last attempt to try to obtain PL inhibitors-enriched fractions was carried 
out using both water and ethanol solvents as well as optimized PLE conditions for other fungal 
polysaccharides. 
Table 1.  PLE extraction yield of Pleurotus eryngii fractions obtained after 5 cycles of 5 min each at different 
temperatures using two different pressurized solvents. 
PLE temp  
(ºC) 
Water extraction  
(mg/g) 
Ethanol extraction 
 (mg/g) 
25 417 18.7 
50 510 45.1 
100 494 153.3 
150 611 NC 
200 778 NC 
                                      NC: not considered 
Extractions yields were different than those previously indicated for the polysaccharide 
extraction from other mushroom species (see chapter 1). Water at 25 ºC extracted larger amount 
of material than the other mushrooms and the extraction increase with the temperature was not so 
steep when water was used as pressurized solvent than for other species. If ethanol was utilized, 
lower amount of material was extracted although it was increasing with the temperature selected.  
However, when both water and ethanol extracted samples were tested as inhibitors of 
the pancreatic lipase, none of the performed extraction showed PL inhibitory activity compared 
with the control (Figure 1) after in vitro digestion assay. Therefore, no further extractions or studies 
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were carried out since results were not so promising as the other compounds investigated and 
described in other chapters. 
 
Figure 1. Pancreatic lipase activity (IUB/ml) in digested P. eryngii mushroom extracts obtained 
from by PLE using ethanol or water as pressurized solvents. 
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Preface  
 Statins are the most frequently prescribed drugs to decrease blood LDL-cholesterol 
levels. These molecules are acting as competitive inhibitors of 3-hydroxy-3-methylglutaryl CoA 
reductase (HMGCR) substrate, leading to a lower activity of this key enzyme involved in the 
cholesterol biosynthesis. However, in order to maintain cholesterol homeostasis, HMGCR 
inhibition stimulate diet cholesterol absorption and vice versa, if its absorption is limited (i.e. by 
any of the mechanisms previously mentioned), liver cholesterol biosynthesis is enhanced. Thus, 
an effective lowering-cholesterol therapy for people with hypercholesterolemia should combine 
statins with low cholesterol-containing diets or intake of food including compounds with the ability 
of reducing cholesterol absorption (as previously demonstrated in other chapters for instance for 
fungal sterols and β-glucans). However, although statins are widely used, they induce negative 
interactions with other therapies (i.e. those for Alzheimer disease) as well as undesirable 
secondary effects after prolonged administrations.  
Besides statins and other pharmacological compounds, a wide range of natural extracts 
and molecules from different sources have been described as HMGCR inhibitors and gene 
modulators affecting not only to HMGCR mRNA but also to collateral cholesterol-related genes 
expression according to in vitro and in vivo studies (as mentioned in Introduction section). 
Moreover, a few extracts obtained from a mushroom strain (Pleurotus ostreatus) also showed 
interesting HMGCR inhibitory activities although no statins were detected as demonstrated by the 
HPLC-MS analysis described in the Preliminary studies section. Thus, in this chapter a wider 
screening through many mushroom species and the extraction of HMGCR inhibitors-enriched 
fractions from specific edible mushrooms using pressurized solvent technologies is described. In 
addition, the use of isolation procedures to identify the inhibitors of the enzyme present in 
particular fractions from specific mushrooms is detailed and then, in vitro and in vivo experiments 
were carried out with the extract from one mushroom to establish its ability to lower cholesterol 
levels and to modulate cholesterol-related genes. 
After the preliminary studies carried out with P. ostreatus, the presence of HMGCR 
inhibitors was investigated in several edible mushroom species. These results are described in 
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the works entitled Screening of edible mushrooms and extraction by pressurized water (PWE) of 
3-hydroxy-3-methyl-glutaryl CoA reductase inhibitors and Study on the 3-hydroxy-3-methyl-
glutaryl CoA reductase inhibitory properties of Agaricus bisporus and extraction of bioactive 
fractions using pressurized solvent technologies. Firstly, two types of solid:liquid extractions were 
performed from powdered fruiting bodies obtained from 26 edible mushrooms species in order to 
determine the presence/absence of HMGCR inhibitors. After the screening, three species were 
selected (P. ostreatus, L. edodes and A. bisporus) and more detailed studies of their HMGCR 
inhibitory properties were carried out such as the influence of cultivation parameters (i.e. different 
spawns, developmental stages, flushes or selenite addition to cultivation substrates), the tissue 
distribution of the HMGCR inhibitors (as previously elucidated for others compounds i.e. 
ergosterol) or the advantages of PWE or SFE as extraction methods to obtain fractions with high 
HMGCR inhibitory activities depending on their extraction parameters i.e. static extraction times, 
number of cycles or temperature etc., compared with the use of supercritical CO2 with or without 
co-solvents (depending on the mushroom strain).  
In the work previously mentioned concerning A.bisporus, an attempt to further determine 
the nature of the HMGCR inhibitors was carried out and results indicated that no statins but other 
compounds with higher molecular weight might be the responsible for the observed inhibitory 
activities. Thus, there were low probabilities that such a large molecules could exert their observed 
inhibitory effect in vivo and therefore, efforts were focused in the study of the HMGCR inhibitors 
detected in the other two mushroom species. 
 The HMGCR-inhibitors were different depending of the mushroom specie, thus the most 
interesting inhibitors, those obtained from P. ostretaus and L. edodes, were individually studied. 
The work entitled Water-soluble polysaccharides from Pleurotus ostreatus with HMGRC (3-
hydroxy-3-methyl-glutaryl-CoA reductase) inhibitory activity describes the experiments carried 
out to point out the compounds present in P. ostreatus water-extracts capable of inhibiting the 
HMGCR. FITR spectroscopy, GC-MS and MNR analysis of specific fractions at different 
purification steps were correlated with the determination of their HMGCR inhibitory activities to 
direct the isolation procedure toward the identification of the compounds responsible for the 
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inhibitory activity. Moreover, the HMGCR inhibitory extracts from P. ostreatus were submitted to 
an in vitro digestion model to find out whether they could be at least partially bioaccesible. 
Afterwards, digestates were submitted to a bioavailability tests using Caco2 cells transport 
assays. 
The last work of this chapter, Water-soluble compounds from Lentinula edodes 
influencing the HMGCoA-reductase activity and the expressions of genes involved in the 
cholesterol metabolism, includes the results obtained after a similar isolation procedure than the 
one described for P. ostreatus but directed toward the identification of the HMGCR inhibitors 
present in L. edodes. The effect on the gene expression showing HMGCR inhibitor of HMGCR 
and other cholesterol-related genes of a water-soluble extract (containing no statins but 
eritadenine) was also reported for Caco2 and HepG2 cell lines. Moreover, the 
hypocholesterolemic properties of the L.edodes water extract are compared with simvastatin or 
ezetimibe in animal studies using normo- and hypercholesterolemic mice models. Their effect on 
the transcription profiles after the different dietary interventions are also described. 
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Abstract 
The methanol/water and particularly the water extracts obtained from 26 mushroom 
species were able to inhibit the 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) activity to 
different extent (10 to 76%). Cultivated mushrooms such as Pleurotus sp. and Lentinula edodes 
were among the strains which showed higher HMGCR inhibitory capacities. Their inhibitory 
properties were not largely influenced by cultivation parameters, mushroom developmental stage 
or flush number. The HMGCR inhibitory activity of L. edodes was concentrated in the cap 
excluding the gills while in P. ostreatus it was distributed through all the different tissues. A method 
to obtain aqueous fractions with high HMGCR inhibitory activity was optimized using an 
accelerated solvent extractor (ASE) by selecting 10.7 MPa and 25 ºC as common extraction 
conditions and 5 cycles of 5 min each for P. ostreatus fruiting bodies and 15 cycles of 5 min for L. 
edodes suggesting that the potential HMGCR inhibitors are different in the two selected 
mushrooms. 
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Introduction 
Coronary heart disease (CHD) is the leading cause of death in the Western world after 
cancer according to the World Health Organization. Many studies have established that high total-
cholesterol and low-density lipoprotein (LDL) cholesterol levels are risk factors for CHD and 
mortality. Several in vivo studies have demonstrated the ability of certain edible mushrooms to 
lower cholesterol levels in serum. Species such as Pleurotus spp. [1-4], Agaricus bisporus [5], 
Ganoderma lucidum [6], Lentinula edodes, Grifola frondosa, Flammulina velutipes [7], Auricularia 
auricular and Tremella fuciformis [8], among others [9], have been investigated in animals and 
human studies. 
Apparently, the hypocholesterolemic effect of the mushroom fruiting bodies and several 
types of their extracts is reached by different mechanisms of action such as impairing dietary 
cholesterol absorption or inhibiting the endogenous cholesterol metabolism [10]. Mushrooms are 
rich in chitin (dietary fibre) and specific β-glucans which might inhibit cholesterol absorption by 
increasing the faecal excretion of bile acids and reducing the amount of serum LDL-cholesterol 
[10, 11]. 
Eritadenine (an adenosine analogue alkaloid) is another compound isolated from 
Lentinula edodes (shiitake mushroom) which is able to lower cholesterol levels. This molecule 
inhibits S-adenosylhomocysteine hydrolase and modifies the hepatic phospholipid metabolism 
[12-14].   
According to previous reports, oyster mushrooms (Pleurotus spp.) contained lovastatin, 
a compound able to lower cholesterol levels inhibiting 3-hydroxy-3-methyl-glutaryl CoA reductase 
(HMGCR) [15, 16], the key-enzyme in the cholesterol metabolism. Statins are the most potent 
drugs available for reducing plasma low density lipoproteins (LDL) in cholesterol concentrations 
[17]. However, other reports found no detectable statins levels in Pleurotus sp. fruiting bodies 
although high HMGCR inhibition activities were recorded [4, 18]. Other compounds (obtained 
from Ganoderma lucidum) were also described as being able to impair the proper function of the 
enzyme [6]. 
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Thus, in this work a preliminary screening of HMGCR inhibitors was carried out using 
several edible mushroom species and varieties. The screening was also performed in cultivated 
mushrooms harvested from cultivation rooms with different cultivation parameters in an attempt to 
define the conditions required for the synthesis of the effective inhibitors. Once the mushrooms 
varieties containing higher HMGCR inhibitory activity were defined, they were submitted to 
pressurized solvent extractions (accelerated solvent extractions, ASE) in order to optimize 
environmentally friendly and GRAS methods able to obtain fungal fractions with high HMGCR 
inhibitory activity to further functionalize foods with potentially hypocholesterolemic properties 
[19]. 
Materials and Methods 
Biological material and samples preparation 
Mushroom strains used in this investigation were Lentinus edodes S. (Berkeley), 
Cantharellus cibarius (Fr.), Lactarius deliciosus (Fr.), Boletus edulis (Bull. Ex Fr.), Pleurotus 
ostreatus (Jacq.Ex Fr.) Kummer, Agaricus bisporus L. (Imbach), Amanita caesarea (Scop. Ex Fri.) 
Pers. Ex Schw., Morchella esculenta (Pers Ex Amans), Agaricus blazei Murill ss. (Heinem), Grifola 
frondosa (Dicks.) Gray, Ganoderma lucidum (Curtis) P.Karst., Flammulina velutipes (Curt. Ex Fr.) 
Singer, Pleurotus eryngii (D.C. Ex Fr.) Quel, Lyophyllum shimeji (Kawam.), Morchella conica 
(Pers.), Agrocybe aegerita (Briganti) Singer, Auricularia judea (Bull. Ex St.Amans) Berck, Amanita 
ponderosa Malençon & R. Heim, Craterellus cornucopioides (L. Ex Fr.) Pers, Marasmius oreades 
(Bolt. Ex Fr.) Fr., Lepiota procera (Scop. Ex Fr.) Singer., Pholiota nameko (T. Itô) S. Imai, Calocybe 
gambosa (Fr.) Donk, Hydnum repandum (Linné Ex Fr.), Cantharellus lutescens (Pers.), Pleurotus 
pulmonarius (Fr.) Quel. 
Fruiting bodies from wild mushrooms were purchased from a local market in Madrid 
(Spain). The cultivable strains were grown in cultivation rooms with automatic control of cultivation 
parameters (temperature, R.H., CO2) at CTICH (Centro Tecnológico de Investigación del 
Champiñón de La Rioja, Autol, Spain) or at the cultivation facilities of some mushroom growers 
belonging to the La Rioja´s mushroom association using commercially available substrates 
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depending on the mushroom specie to cultivate. Fruiting bodies were harvested at the usual 
developmental stage prior to commercialization except in those experiments when the effect of 
the developmental stage was studied. The recorded parameters are described in  Table 1. 
Table 11. Cultivation parameters recorded and correlated with the HMGCR inhibitory activity values 
obtained within the analyzed samples (P. ostreatus and L. edodes). 
 
 
Complete fruiting bodies or their separated tissues were immediately frozen,              
freeze-dried, ground and sieved until the particle size smaller than 0.3 mm as described [20] and 
stored at -20 ºC until further use.  
To extract the potential inhibitors from the spores allowing the breaking down of the spore 
walls, they were first treated with methanol as described by [15]. 
Determination of HMGCoA-red inhibitors in mushrooms 
Mushroom powders (50 mg/ml) were mixed with water, methanol/water (1:1 v/v) or 
methanol. Suspensions were shaken in a Vortex for 1 min and centrifuged at 12000 rpm               
Parameter Different type of samples 
Commercial spawn 
5 different commercial varieties per specie: 
P. ostreatus K15 Fungisem, HK35 Sylvean, K40 Fungisem, 
S-300 Mispaj and H9 Gurelan and L. edodes4312 Sylvan, 
S05 Mispaj, 3710 Mycelia, Le Lion L8 and 4012 Amycel. 
Substrate 
Pasteurized straw (for P. ostreatus) and 
sterilized/pasteurized sawdust (for L. edodes) 
Disease influence Healthy, brown blotch, thrichoderma, pests 
Developmental stage Primordia, small, medium, large 
Flush number First, second, third and fourth flush 
Mushroom growers CTICH and 12 mushroom growers 
Modern controlled chambers Yes/No 
 1 
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(8,854 x g) for 2min (Eppendorf mini-spin, Madrid, Spain) according to the user´s manual. 
Supernatants were used as source of HMGCR inhibitors. 
HMGCR activity was measured using the commercial HMG-CoA Reductase Assay 
(Sigma, Madrid) according to the user´s manual. The assay is based on the spectrophotometric 
measurement of the decrease in absorbance at 340 nm, which represents the oxidation of NADPH 
by the catalytic subunit of HMGCR in the presence of the substrate HMG-CoA according to the 
reaction: 
HMG-CoA + 2NADPH + 2H+ →mevalonate + 2NADP+ + CoA-SH 
Mushroom supernatants (20 µl) were applied into a 96 wells-plate and their absorbance 
change was monitorized at 37 ºC using a microplate reader (Tecan Group Lt, Männedorf, 
Switzerland). 
Pravastatin was utilized as a control for positive inhibition. Other control samples were 
prepared in each assay by substituting the mushroom extract by the same solvent solution utilized 
in the extract. These controls were considered as 100% activity and tested samples were referred 
to them as percentage of inhibition or activity. Assays were performed in duplicate. 
Pressurized water extractions to obtain fractions with HMGCR inhibitory activity 
Mushroom powders (1g) were mixed with sea sand (Sigma, Madrid, Spain) (4g) and 
submitted to pressurized solvent extraction at 1500 psi (10.68 MPa) using an accelerated solvent 
extractor (ASE) (Dionex, ASE 350, Sunnyvale, CA, USA). Several parameters such as extraction 
time or cycle’s number and temperature were changed in order to optimize the extraction method 
to obtain fractions with high HMGCR inhibitory activity.  
Obtained fractions were immediately frozen, lyophilized and stored at -18 ºC until further 
analysis. Extracted dry matter content was measured to calculate the extraction yields.  
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Statistical analysis 
One way analysis of variance (ANOVA) was performed using a Statgraphics® Plus 3.1 
for Windows software (Statistical Graphics Corporation, Rockville, MD, USA). The mean 
comparison test used was Fisher’s least significant differences procedure (LSD). 
Results and Discussion 
Screening of mushrooms species as a source of HMGCR inhibitors 
Several wild and cultivated mushroom species were submitted to water and 
methanol/water (1:1, v/v) extraction since both type of solvents were previously described as able 
to extract compounds with HMGCR inhibitory activity [18]. Methanol was also tested with a few 
strains but no interesting HMGCR inhibitory activity was found in any of the selected samples. 
Results indicated a wide variability within the different mushroom species (Figure 1). The water 
extracts of 8 species showed no significant HMGCR inhibitory activity and many showed inhibitory 
activities from 10 to 50%. However, strains such as Pleurotus sp., Cratharellus cornucopiodes, 
Amanita ponderosa and particularly Lentinula edodes showed inhibitory capacities ranging from 
52 up to 76%. In most of the cases except for Agaricus bisporus and Cantharellus lutescens, the 
water extracts showed higher inhibitory activity than the methanol/water extracts. Surprisingly,       
A. bisporus methanol/water extracts showed almost 2 fold more capacity than the water extracts. 
No similar distribution was found between genera belonging to the same family, for 
instance, within the Pleurotaceae family (P. ostreatus, P. pulmonarius and P. eryngii) two species 
showed similar and high HMGCR inhibitory capacities but P. eryngii showed only 20.7% inhibitory 
capacity. On the contrary, the Agaricaceae family included two species (A. bisporus and                  
A. blazeii) with low inhibition in their water extracts while L. procera was able to inhibit almost 50% 
of the enzyme. The Cantharellaceae family (C. lutescens, C. Cibarius and C. cornucopioides) as 
well as other families such as Marasmiaceae (M. oreades and L. edodes), Morchellaceae           
(M. conica and M. esculenta) and Amanitaceae (A. caesarea and A. ponderosa) included species 
with no, middle and high inhibitory capacities. 
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Figure 9. HMGCR inhibitory activities of several mushrooms extracts obtained in water or            
methanol/water (1:1, v/v). 
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Influence of the cultivation parameters on the HMGCR inhibitory activity of cultivated 
mushrooms 
The water extracts from cultivated mushrooms such as Pleurotus sp. and L. edodes 
showed very interesting inhibitory activities and their growth can be more easily controlled than 
wild mushrooms. Environmental parameters usually influence the presence/absence of many 
compounds therefore; a more detailed study was carried out in those cultivated mushrooms in 
order to determine the effect of the cultivation parameters in their HMGCR inhibitory activities. 
Substrates were inoculated with commercial spawns from several P. ostreatus and            
L. edodes varieties in a minimum of three independent trials but performed under similar 
conditions. After cultivation, the obtained fruiting bodies from the first flush were harvested and 
their water extracts analyzed. Results showed no significant differences between Fungisem K15 
and Sylvan HK35 but they were significantly higher in Fungisem K15 than the other analyzed 
varieties (Figure 2a). Similar results were obtained when the different L. edodes spawns were 
studied (Figure 2b); significant differences were found between Sylvan 4312 and Mycelia 3710 or 
Le Lion L8 but the standard deviation observed within similar trials suggested that other 
parameters different than variety are involved in the HMGCR inhibitory activity observed. 
Therefore, other parameters were investigated such as mushroom grower, automatic 
control of cultivation conditions (or traditional cultivation system), presence of bacterial blotch 
infection, pests (flies, mosquitoes etc.), good or poor quality fruiting bodies or mushroom picked 
from places close to a Trichoderma sp. spot. However, no correlation was found within the 
detected HMGCR inhibitory activities and any of the indicated parameters. 
Developmental and tissue distribution of the HMGCR inhibitory activity of cultivated 
mushrooms 
P. ostreatus and L. edodes fruiting bodies from the same cultivation trial were harvested 
at different developmental stages including from primordia until cap was open and gills exposed 
(mature). The harvesting was repeated in the second and third flush. No significant differences 
were observed between flushes or developmental stages in the HMGCR inhibitory activity of the 
water extracts obtained from P. ostreatus mushrooms. In L. edodes mushrooms a slight decrease 
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of the inhibitory capacity was observed with the increase of the flush number but no significant 
differences were found between young or mature fruiting bodies. 
a) 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
This suggest that the compounds responsible for the HMGCR inhibitory activity are 
present through the whole sporophore life cycle and that they might be different between the two 
studied mushroom strains. This view was further supported by the fact that compounds potentially 
responsible for the inhibitory activity showed a different tissue distribution within the fruiting 
bodies. The water extracts obtained from different tissues of P. ostreatus showed similar HMGCR 
inhibitory activity indicating a homogeneous distribution (Figure 3a) thought the whole body while 
Figure 2. HMGCR inhibitory activities of water extracts from the fruiting bodies obtained by 
cultivating different commercial spawns fron a) Pleurotus ostreatus and b) Lentinula edodes. 
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in the selected L. edodes variety the inhibitory activity was concentrated in the dermis and 
epidermis excluding the gills and the stipe (Figure 3b).  
a)  
 
 
 
 
b) 
 
 
 
 
 
 
 
Worth to take into consideration was the HMGCR inhibitory activity levels found in the 
discarded parts of the stipes, this part correspond to the lower stipe which is bound to the 
mycelium and the substrate, at the base of the fruiting body. Usually, this part of the mushroom is 
cut during harvesting because it might contain traces of substrate or it is deformed and not 
commercialized. The HMGCR inhibition values of the discarded by-product obtained from                
L. edodes varied depending on the strain since Amycell 4012 showed no HMGCR inhibitory 
activity but Sylvan 4312 showed a 37.1% inhibition, higher values than the 10.8% inhibition found 
in the discarded stipe of P. ostreatus. 
Figure 3. HMGCR inhibitory activities of water extracts from different tissues from fruiting bodies from 
the first flush of a) Pleurotus ostreatus Sylvan HK35 and b) Lentinula edodes Amycell 4012. 
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Pressurized water extraction of the cultivated mushrooms to obtain fractions with HMGCR 
inhibitory activity 
Pressurized water extractions are economically sustainable processes that are 
increasingly being developed as a response to the demand (by the food and other industries) of 
environmentally clean extraction processes to produce new extracts or compounds with a 
potential use as functional ingredients or nutraceuticals [21]. Water is a non-toxic and naturally 
occurring solvent that can replace organic solvents when used at higher temperatures and 
pressures. Accelerated solvent extraction using water has been used to extract i.e. 
polysaccharides with different structures and biological activities from edible mushrooms  [22, 23] 
and they are, at the present, being scaled up for industrial applications [24].  
P. ostreatus and L. edodes fruiting bodies were submitted to extraction with pressurized 
water in order to obtain mushroom extracts with high HMGCR inhibitory activity to be in the future 
potentially used as hypocholesterolemic ingredient to functionalize foods. Thus, several 
parameters such as extraction temperature, time and cycles number were changed in order to 
optimize the extraction method. 
A range of temperatures was studied from 25 up to 200 ºC and the obtained dry matter 
increased largely with the temperature, being 200 ºC the best condition to extract almost 60 and 
80% of the material from P. ostreatus and L. edodes, respectively (Figure 4a). However, when the 
HMGCR inhibitory capacity of the extracted fractions was measured, the increase of temperature 
was detrimental suggesting that the compounds responsible for the inhibition were thermolabile 
(Figure 4b). No significant differences were found between extractions at 25 or 50 ºC in both 
mushroom strains neither between these extractions from L. edodes and extractions with plain 
water however, water extraction of P. ostreatus showed a significantly higher inhibitory activity 
(80.1%) than its ASE extractions. Thus, extraction temperature was fixed at 25 ºC and other ASE 
parameters were modified in order to improve extraction yields and inhibitory activities. 
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a)  
 
 
 
 
 
 
b)  
 
 
 
 
 
 
 
 
Extractions carried out by selecting 5 cycles of 1 min each yielded almost half of the dry 
matter than longer extraction times from P. ostreatus mushrooms however, no significant 
differences were observed for L. edodes within 1 to 10 min; apparently all the water soluble 
compounds at 25 ºC are easily extracted after 5 cycles of 5 min from both strains (Figure 5a). The 
ASE extracts obtained from both mushroom strains after 5 cycles of 1 to 10 min each showed high 
HMGCR inhibitory capacity while longer extractions showed a slightly lower inhibitory activity, 
suggesting than the compounds potentially responsible for the inhibition might be unstable if 
extracted for 75 min total extraction time (Figure 5b). The P. ostreatus extract obtained after               
Figure 4. a) ASE extraction yield and b) HMGCR inhibitory activities of Pleurotus ostreatus and 
Lentinula edodes fractions obtained after 5 cycles of 5 min each at different temperatures. 
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5 cycles of 1 min showed similar inhibitory capacity than longer extraction times, however, less 
dry matter was obtained pointing the 5 min extraction as the best extraction time, thus, the optimal 
number of cycles was further studied. 
a)  
 
 
 
 
 
b) 
 
 
 
 
 
 
 
Increase of the extraction cycles (of 5 min each at 25 ºC) from 1 to 15 cycles increased 
the extracts yields almost 3 fold for both mushroom strains (Figure 6a). However, for P. ostreatus, 
the ASE extracts obtained after 5 cycles showed the highest inhibitory activity while no significant 
differences were observed within the HMGCR inhibitory capacity of all the ASE extracts from            
L. edodes obtained independently of the number of cycles (Figure 6b). These results suggested 
once more that the compounds responsible of the inhibitory capacity might be different in both 
Figure 5. a) ASE extraction yield and b) HMGCR inhibitory activities of Pleurotus ostreatus and 
Lentinula edodes fractions obtained at 25 °C but at different extraction times per cycle (5 cycles). 
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mushrooms since 5 cycles should be the optimal to extract the potentially enzyme inhibitors from 
P. ostreatus while higher cycles number can be used to extract higher amount of L. edodes 
extracts. But, both inhibitors are easily extracted with water and their HMGCR inhibitory activity is 
eliminated at temperatures where the typical protein denaturalization takes place suggesting that 
they might share similar chemical nature and it could include a proteic part in its structure. 
Actually, preliminary studies are being carried out suggesting that the inhibitors might be 
proteoglucans.  
a)  
 
 
 
 
 
b)  
 
 
 
 
 
 
 
 
 
Figure 6. a) ASE extraction yield and b) HMGCR inhibitory activities of Pleurotus ostreatus and 
Lentinula edodes fractions obtained at 25 °C but at different number of cycles (5 min each). 
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Conclusions 
Several wild and cultivated mushroom species contain water soluble compounds 
potentially capable of inhibiting the key enzyme of the cholesterol metabolism using in vitro test. 
Two of the cultivated strains, Oyster and Shiitake mushrooms, were particularly interesting. Their 
higher or lower inhibitory capacity was probably dependent on specific requirements since no 
specific influence of the commercial variety, cultivation parameters or developmental stage of the 
mushroom was observed. Tissue distribution within the fruiting bodies was different suggesting 
the presence of different compounds with HMGCR inhibitory activity in both species. The potential 
inhibitory compounds could be easily extracted by using pressurized water extractions at 10.68 
MPa and 25 ºC, 5cycles of 5 min for P. ostreatus and up to 15 cycles of 5 min for L. edodes. Thus, 
by using the optimized extraction methods, higher quantities of the potential inhibitors in will be 
extracted for further identification of the responsible compounds. The purification steps will have 
to be separately carried out for each mushroom since the responsible compounds might be 
different.   
 
Acknowledgments 
The research was supported by the European Union within the 7th framework programme 
(7FM-PEOPLE-2009-IFF project 251285), ALIBIRD-CM S2009/AGR-1469 regional program from 
the Community of Madrid (Spain),AGL2010-21537 national R+D program from the Spanish 
Ministry of Science and Innovation, and 2010-I-ID-00093 project by ADER (Agency for La Rioja´s 
economic development). 
 
 
 
 
Chapter 4- Efect of fungal compounds with HMGCR inhibitory… 
 
305 
 
References 
[1]. Bajaj, M., et al., Role of oyster mushroom (Pleurotus florida) as hypocholesterolemic/antiatherogenic agent. Indian 
Journal of Experimental Biology, 1997. 35(10): p. 1070-5. 
[2]. Bobek, P. and S. Galbavy, The oyster mushroom (Pleurotus ostreatus) effectively prevents the development of 
atherosclerosis in rabbits. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske 
farmaceuticke spolecnosti, 1999. 48(5): p. 226-30. 
[3]. Opletal, L., et al., Evidence for the anti-hyperlipidaemic activity of the edible fungus Pleurotus ostreatus. British 
Journal of Biomedical Science, 1997. 54(4): p. 240-243. 
[4]. Schneider, I., et al., Lipid lowering effects of oyster mushroom (Pleurotus ostreatus) in humans. Journal of 
Functional Foods, 2011. 3(1): p. 17-24. 
[5]. Jeong, S.C., et al., White button mushroom (Agaricus bisporus) lowers blood glucose and cholesterol levels in 
diabetic and hypercholesterolemic rats. Nutrition Research, 2010. 30(1): p. 49-56. 
[6]. Berger, A., et al., Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and 
minipigs. Lipids in Health and Disease, 2004. 3(1): p. 2. 
[7]. Fukushima, M., et al., Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) 
fiber, and enokitake (Flammulina velutipes) fiber in rats. Experimental Biology and Medicine, 2001. 226(8): p. 
758-765. 
[8]. Cheung, P.C.K., The hypocholesterolemic effect of two edible mushrooms: Auricularia auricula (tree-ear) and 
Tremella fuciformis (white jelly-leaf) in hypercholesterolemic rats1. Nutrition Research, 1996. 16(10): p. 1721-
1725. 
[9]. Roupas, P., et al., The role of edible mushrooms in health: Evaluation of the evidence. Journal of Functional Foods, 
2012. 4(4): p. 687-709. 
[10]. Guillamón, E., et al., Edible mushrooms: Role in the prevention of cardiovascular diseases. Fitoterapia, 2010. 
81(7): p. 715-723. 
[11]. Chen, J. and R. Seviour, Medicinal importance of fungal β-(1→3), (1→6)-glucans. Mycological Research, 2007. 
111(6): p. 635-652. 
[12]. Chibata, I., et al., Lentinacin-A new hypocholesterolemic subbstance in Lentinus edodes. Experientia, 1969. 
25(12): p. 1237-&. 
[13]. Sugiyama, K., Hypocholesterolemic action of eritadenine is mediated by a modification of hepatic phospholipid 
metabolism in rats. Journal of Nutrition, 1995. 125(8): p. 2134-2144. 
[14]. Yamada, T., et al., Structure and function of eritadenine and its 3-deaza analogues: Potent inhibitors of S-
adenosylhomocysteine hydrolase and hypocholesterolemic agents. Biochemical Pharmacology, 2007. 73(7): p. 
981-989. 
[15]. Gunde-Cimerman, N., A. Plemenitaš, and A. Cimerman, Pleurotus fungi produce mevinolin, an inhibitor of HMG 
CoA reductase. FEMS Microbiology Letters, 1993. 113(3): p. 333-337. 
Chapter 4- Manuscript 1 
 
306 
 
[16]. Gunde-Cimerman, N., A. Plemenitaš, and A. Cimerman, A hydroxymethylglutaryl-CoA reductase inhibitor 
synthesized by yeasts. FEMS Microbiology Letters, 1995. 132(1–2): p. 39-43. 
[17]. Shitara, Y. and Y. Sugiyama, Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in 
transporter and metabolic enzyme functions. Pharmacology & Therapeutics, 2006. 112(1): p. 71-105. 
[18]. Gil-Ramirez, A., et al. Edible mushrooms as potential sources of new hypocholesterolemic compounds in 7th 
International Conference on Mushroom Biology and Mushroom Products. 2011. Arcachon, France. 
[19]. Chen, Z.-Y., et al., Role and classification of cholesterol-lowering functional foods. Journal of Functional Foods, 
2011. 3(2): p. 61-69. 
[20]. Ramírez-Anguiano, A.C., et al., Radical scavenging activities, endogenous oxidative enzymes and total phenols 
in edible mushrooms commonly consumed in Europe. Journal of the Science of Food and Agriculture, 2007. 
87(12): p. 2272-2278. 
[21]. Sun, H., et al., Application of accelerated solvent extraction in the analysis of organic contaminants, bioactive and 
nutritional compounds in food and feed. Journal of Chromatography A, 2012. 1237(0): p. 1-23. 
[22]. Lo, T.C.T., et al., Pressurized water extraction of polysaccharides as secondary metabolites from Lentinula 
edodes. Journal of Agricultural and Food Chemistry, 2007. 55(10): p. 4196-4201. 
[23]. Di, X., et al., Fingerprint profiling of acid hydrolyzates of polysaccharides extracted from the fruiting bodies and 
spores of Lingzhi by high-performance thin-layer chromatography. Journal of Chromatography A, 2003. 1018(1): 
p. 85-95. 
[24]. Pronyk, C. and G. Mazza, Design and scale-up of pressurized fluid extractors for food and bioproducts. Journal 
of Food Engineering, 2009. 95(2): p. 215-226. 
 
 
Chapter 4- Efect of fungal compounds with HMGCR inhibitory… 
 
307 
 
Manuscript 2 
  
Study on the 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitory 
properties of Agaricus bisporus and extraction of bioactive fractions 
using pressurized solvent technologies (ASE and SFE) 
 
 
Alicia Gil-Ramírez1, Cristina Clavijo2, Marimuthu Palanisamy1, 
Alejandro Ruiz-Rodríguez1, María Navarro-Rubio1, Margarita Pérez2, 
Francisco R. Marín1, Guillermo Reglero3, Cristina Soler-Rivas1  
 
 
1Department of Production and Characterization of Novel Foods, CIAL – Research Institute in Food Science 
(UAM+CSIC), C/ Nicolas Cabrera 9, Campus de Cantoblanco, Universidad Autónoma de Madrid, 28049 
Madrid, Spain. 
2Centro Tecnológico de Investigación del Champiñón de La Rioja (CTICH). Autol. Spain  
3IMDEA-Food Institute. CEI UAM+CSIC. Madrid, Spain. 
 
 
 
 
 
Journal of the Science of Food and Agriculture 
Volume 93, Issue 11, pages 2789–2796, August 2013 
DOI: 10.1002/jsfa.6102 
Chapter 4- Manuscript 2 
 
308 
 
Abstract 
BACKGROUND: Agaricus bisporus mushrooms were able to lower cholesterol levels in 
hypercholesterolemic rats and it was suggested that dietary fibers might inhibit cholesterol 
absorption. However, A. bisporus extracts were also able to inhibit the 3-hydroxy-3-methyl-glutaryl 
CoA reductase (HMGCR, the key enzyme in the cholesterol biosynthetic pathway) and this might 
also contribute to the observed lowering of cholesterol levels in serum.  
RESULTS: The methanol:water extracts obtained from A. bisporus were able to inhibit up 
to 60% the HMGCR activity using an in vitro assay. The HMGCR inhibitory capacities depended 
on cultivation conditions, strains, etc. The potential inhibitors were not statins, they might be β-
glucans able to scavenge the substrate and impair the enzymatic reaction. They were present 
during all mushroom developmental stages and similarly distributed through all the tissues 
including the parts discarded as a by-product. Accelerated solvent extractions using 1:1 
ethanol:water as pressurized solvent (10.7 MPa, 25 ºC, 5 cycles of 5 min) were more effective in 
the extraction of the HMGCiR inhibitor/s than supercritical fluid extractions (9 MPa, 40 ºC) using 
CO2 with 10% ethanol.  
CONCLUSION: A mushroom cultivation and two extraction procedures were optimized 
to obtain fractions from A. bisporus with high HMGCR inhibitory activities to design novel 
ingredients for hypocholesterolemic functional foodstuffs.  
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Introduction 
High cholesterol or low-density lipoprotein levels in serum increases the risk of 
cardiovascular diseases.  In public health terms, achieving a reduction in cholesterol by dietary 
advice (increase consumption of vegetable and fruits) is of limited effectiveness [1]. Many 
researchers have been exploring the possibility of increasing components in foodstuff which have 
hypocholesterolemic effects such as i.e. β-glucans or phytosterols [2, 3]. These novel 
functionalized foods reduce serum cholesterol (10 – 20%) because they impair the absorption of 
exogenous cholesterol during digestion [2, 4]. However, depending on genetic variations, many 
consumers cannot reduce their cholesterol levels because, by avoiding cholesterol intake, their 
3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) activity is stimulated, enhancing the 
biosynthesis of endogenous cholesterol [5]. Thus, another approach to the design of novel 
hypocholesterolemic functional foods might be their supplementation with compounds able to 
inhibit the HMGCR activity.   
 It has been shown that edible mushrooms are able to lower cholesterol levels in vivo 
(Pleurotus spp., Lentinula edodes, Ganoderma lucidum, Agaricus bisporus etc.) [6-8] and can 
inhibit HMGCR in vitro. Some reports pointed to lovastatin as the compound responsible for the 
enzyme inhibition [9-11]. Lovastatin (mevinolin) and other statins are drugs usually prescribed to 
hypercholesterolemic patients because they act as competitive inhibitors of the HMGCR, showing 
approx 200-fold more affinity for them than their real substrate [12]. Moreover, selenium 
supplementation combined with statins therapy was proved to be significantly beneficial to lipid 
therapy [13] and mushrooms can be fortified with selenium by addition of sodium selenite to their 
cultivation substrates to modify their biological properties [14]. Thus, if there are statin-producing 
mushroom strains, they might also be fortified with selenium to enhance their hypocholesterolemic 
effect. 
However, other authors found no detectable lovastatin levels but still high HMGCR 
inhibition activities [6, 15]. Other compounds such as lanosteroids, ganoderols etc., were 
described in G. lucidum and apparently they were also able to inhibit the enzyme but through an 
indirect mechanism [6]. 
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A. bisporus basidiomata were able to lower blood glucose and cholesterol levels in 
diabetic and hypercholesterolemic rats and it was suggested that dietary fibre might be involved, 
but via a complex process [8] The mushroom dietary fibre fraction includes mainly chitins and, in 
higher amounts, β-glucans. Fungal β-glucans are polysaccharides of D-glucose monomers linked 
by β-glycosidic bonds showing preference for the β-(1→3),(1→6) bonds instead of the                   
β-(1→3),(1→4), the characteristic pattern of cereals β-glucans [16]. In this study, the HMGCR 
inhibitory properties of A. bisporus extracts are reported as another pathway which might also 
contribute to the observed lowering of cholesterol levels in serum. The distribution of the potential 
inhibitor(s) depending on the cultivation parameters, different strains (including Se-fortified 
strains), developmental stages etc., was also monitored. 
Supercritical fluid extraction (SFE) with CO2 as well as accelerated solvent extraction 
(ASE) are ecologically and economically sustainable processes that are increasingly being 
developed as a response to recent reports concerning the environmental status of our planet [17]. 
Moreover, both methods satisfy the demand of environmentally clean extraction processes to 
produce new extracts or compounds with a potential use as functional ingredients or 
nutraceuticals. The use of supercritical carbon dioxide, with properties such as low viscosity, high 
solvent strength and zero surface tension has been encouraged as a substitute for organic 
solvents. It has been previously used in the extraction of different compounds from mushroom 
strains [18-23]. On the other hand, when water is used at higher temperatures and pressures (as 
occurs in ASE) it can also replace organic solvents. Water can also be used in combination with 
ethanol, a solvent that is classified as generally recognized as safe’ and which is used in the food 
industry, to tailor the extract composition and therefore its beneficial properties. Accelerated 
solvent extraction using water has also been used to extract polysaccharides and compounds 
with different biological activities from L. edodes, P. ostreatus and G. lucidum [15, 24-26]. 
However, to our knowledge there are no studies on the screening of the HMGCR inhibitory 
properties of A. bisporus extracts produced by either SFE or ASE technologies. 
Chapter 4- Efect of fungal compounds with HMGCR inhibitory… 
 
311 
 
Therefore the other aim of this work was to compare these two extraction technologies in 
order to optimize methods to obtain fractions from A. bisporus with high HMGCR inhibitory 
activities to design novel ingredients for hypocholesterolaemic functional foodstuffs. 
Materials and Methods 
Biological material 
Agaricus bisporus L. (Imbach) mushrooms were grown in cultivation rooms with 
automatic control of cultivation parameters (temperature, relative humidity, CO2) at CTICH (Centro 
Tecnológico de Investigación del Champinón de La Rioja, Autol, Spain) or at the cultivation 
facilities of some mushroom growers belonging to La Rioja’s mushroom association using as 
substrate the commonly utilized indoor compost phase II. A more detailed explanation of the 
experimental trials, utilized substrates, casing layers and spawns and Se supplementations can 
be found elsewhere [27]. Basidiomata were harvested at stage 2 –3 according to Hammond and 
Nichols (1975) [28] except in those experiments when the effect of the developmental stage was 
studied. The recorded parameters are described in Table 1. 
Table 7. Cultivation parameters recorded and correlated with the 3-hydroxy-3-methyl-glutaryl CoA reductase 
inhibitory activity values obtained within the Agaricus bisporus samples analyzed. 
 
Basiodiomata or their separate tissues (manually separated with the aid of a knife) were 
dehydrated (lyophilized) and ground into fine powder as described by Ramírez-Anguiano et al. 
(2007) [29]. Dried mushroom powders were stored at -20 °C until further use. 
A minimum of three sporophores were harvested from the same cultivation bed with 
identical conditions for each different type of sample. 
Parameter Different type of samples 
Selenium-enriched mushrooms Low (10.9 ppm)/ high (31.6 ppm)/ control (3.2 ppm) Se content 
Commercial spawn Fungisem H15 and H5,Gurelan 60, Mispaj 365 and Somycel A15 
Developmental stage Primordia(stage 1), small(2), medium(3-4), large(5-6) 
Flush number First, second and third flush 
 1 
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 Determination of selenium 
The digestion procedure and hydride generation atomic absorption spectrometry (HG-
AAS) method was optimized at CTICH based on previous reports [30, 31]. Briefly, mushroom 
powders (0.4 g) were introduced into a Teflon microwave digestion vessel and HNO3 7.7 M was 
added to a final volume of 8 mL. The vessel was closed and fastened into the rotor. The rotor with 
six loaded vessels was placed into the microwave oven (Milestone Ethos Touch control; Sorisole, 
Italy). The applied microwave digestion program was as follows: 0 – 100 °C (3 min), 100 – 150 °C 
(7 min), 150 – 180 °C (6 min) and 180 °C (15 min). The digested samples were adjusted to 20 mL 
with HCl 4M and heated at 95 °C for 20 min to ensure reduction of Se(VI) to Se(IV). Once the 
mixture had cooled, it was diluted with 50 ml HCl 4F. Selenium was determined by HG-AAS with 
optimized parameters. Detection was performed by an HG-AAS system (Solaar M6 MK2 Dualz; 
Thermo Scientific, Cambridge, UK). The peak areas of the absorbance were used for calculation 
of selenium content. The HG-AAS technique requires a selenium hollow cathode lamp to operate 
at a wavelength of 196.0 nm with a slit width set to 0.5 nm and an electrode-less discharge lamp 
set at 10 mA current without background corrector. Aspiration time was 45 s, measuring time 5 s, 
the height signal evaluation and argon flow 314 ml/min. The atomizing environment was a silicous 
cell heated to 900 °C, floated solution HCl (10 mol/l) and reducers were 0.3% NaBH4 and 0.4% 
NaOH. Selenium determination was performed in duplicate and quantified according to a Se 
calibration curve. 
Accelerated solvent extractions 
Mushroom powder (1 g) were mixed with washed sea sand (4 g) (Panreac, Madrid, 
Spain) and submitted to pressurized solvent extraction using an accelerated solvent extractor 
(ASE 350; Dionex Corporation, Sunnyvale, CA, USA). The sea sand was selected as an inert 
material to hold the sample inside the extraction cell and to improve efficiency avoiding formation 
of preferential flow paths. The extraction procedure (per cycle) was carried out at 10.68 MPa (1500 
psi) as follows. First, the sample was loaded into an 11 ml extraction cell. Then, the cell was filled 
with ethanol and heated. Static extraction was carried out during the selected time (in minutes) 
with all system valves closed. When a cycle had finished, the cell was rinsed, the solvent was 
Chapter 4- Efect of fungal compounds with HMGCR inhibitory… 
 
313 
 
purged from the cell with N2 gas and the cell remained depressurized. Then, fresh solvent was 
again added to the extraction cell to carry out another extraction cycle until the programmed 
number of cycles was finished. The fractions collected after the selected cycles were pooled in a 
vial as a single extract. 
Several parameters, such as solvent, static extraction time or number of cycles, and 
temperature were changed in order to optimize the extraction method to obtain fractions with high 
HMGCR inhibitory activity. 
After collection, fractions were immediately concentrated with a rotary evaporator (40 
°C), frozen and lyophilized. Dried samples were stored at -18 °C until further analysis. Extracted 
dry matter content was measured to calculate the extraction yields. Extractions were carried out 
in duplicate. 
Supercritical fluid extractions 
Supercritical fluid extractions (pilot-plant scale) with CO2 (Air-Liquid España, S.A., 
Madrid, Spain) were carried out in a plant (model SF2000; Thar Technology, Pittsburgh, PA, USA) 
comprising a 2 L cylinder extraction cell and two different separators (S1 and S2), each of 0.5 L 
capacity, with independent control of temperature and pressure. The extraction vessel has a 
height:diameter ratio of 5.5 (0.42 m height, 0.076 m internal diameter). A detailed explanation of 
the experimental device can be found elsewhere [32]. For each experiment, the extraction cell 
was filled with 80 g of mushroom powder and 900 g of washed sea sand (Panreac). In order to 
optimize the extraction method to obtain fractions with high HMGCR inhibitory activity, parameters 
such as the use of a co-solvent (ethanol, 10% w/w) and extraction pressure (30, 18 and 9 MPa) 
were tested. Extraction temperature as well as the temperature of separators 1 and 2 was set to 
40 °C for all the experimental assays. The pressure of separator 1 and separator 2 using ethanol 
as co-solvent was maintained at 6 and 0.1 MPa, respectively; however in CO2 extraction both 
separators were kept at a pressure of 6 MPa. The CO2 flow was set to 2.4 kg/h and the total 
extraction time was 3 h. For each experiment, extracts collected in separators 1 and 2 were mixed 
together, concentrated to dryness with a rotary evaporator and stored at -18 °C until further 
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analysis. Extracted dry matter content was measured to calculate the extraction yields. All the 
experiments were carried out in duplicate. 
Determination of HMGCR inhibitory activity 
Mushroom powders or the mushroom extracts obtained (50 mg/ml) were mixed with 
water (heated at 50 °C or room temperature) or with methanol:water (1:1 v/v). Suspensions were 
shacked in a vortex for 1 min and centrifuged at 9659 × g for 2 min. Supernatants (20 µl) were 
applied to a 96-well plate (Corning Incorporated Life Sciences, Tewksbury, MA, USA) according 
to the user’s manual of the 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) assay (Sigma, 
Madrid, Spain). Absorbance at 340 nm was monitored at 37 °C using a microplate reader (Tecan 
Group, Mannedorf,¨ Switzerland). Determinations were carried out in duplicate. 
HPLC-MS/MS analysis of the extracts 
Mushroom extracts (3 mg/mL) showing HMGCR inhibitory capacity were injected (20 µL) 
into an Accela HPLC-MS/MS (Thermo Electron Corporation, San Jose, CA, USA) equipped with 
an ACE 3 C18-AR column 150 × 4.6 mm, 3 µm particle size (Advanced Chromatography 
Technologies, Aberdeen, UK). The mobile phase was a mixture of acetonitrile:0.5% acetic acid in 
water (60:40 v/v) running isocratically for 30 min. The flow rate was 0.5 ml/min. Detection was 
accomplished by using photodiode array detector (200 – 700 nm) and a mass spectrometer (triple 
quadrupole) (TSQ-Quantum; Thermo Electron Corporation, San Jose, CA, USA) with an 
electrospray ionization interface. 
For mass spectrometry analysis the spray voltage was set at 3500 V in positive mode, 
nitrogen was used as sheath gas at 350 °C and 35 arbitrary flow/pressure units. The mass analyzer 
was set simultaneously in full scan and single reaction monitoring (SRM) modes; in this case SRM 
experiments were done using one precursor ion and one daughter as recommended by the 
relevant European Union regulation (Comision Decission 657/2002 regarding performance of 
analytical methods and the interpretation of results). SRM filters were set for a better quantification 
of statins, precursor and product ions. Moreover, a full scan mode was used within a mass range 
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of 200 – 800 m/z. Statins including pravastatin, lovastatin, simvastatin and atorvastatin (Cinfa, 
Pamplona, Spain) were used as standards. Determinations were carried out in duplicate. 
 
Determination of the chemical nature of the HMGCR inhibitors 
Agaricus bisporus dry powder (50 mg/mL) showing HMGCR inhibitory activity was mixed 
with methanol:water (1:1) the vigorously shaken in a vortex for 1 min, centrifuged at 9659 × g in a 
microfuge for 2 min and the obtained supernatant separated. The supernatant was filtrated 
through a 0.45 µm filter and the filtrate was submitted to several filtrations using centrifugal filters 
(VWR, Barcelona, Spain) with cut-off of 10 and 3 kDa (Microcom filters; Millipore, Madrid, Spain) 
using a microfuge. Fractionated samples were then applied to the HMGCR activity test in order to 
estimate the molecular weight of the potential HMGCR inhibitors. 
The mushroom samples in methanol:water (1:1) were also prepared by mixing them with 
enzymatic preparations such as: (1) a mixture of exo-1,3-β-glucanase (100 U/ml) and β- 
glucosidase (20 U/ml); (2) a mixture of invertase (500 U/ml) and amyloglucosidase (1630 U/ml); 
and (3) pepsin (536 U/ml). Treated samples where incubated for 1 min and centrifuged (9659 × g 
for 2 min.). Supernatants were submitted to filtration using the 10 kDa filters and the microfuge (13 
147 × g for 30 min) in order to separate the enzymes avoiding interference. Then, the HMGCR 
inhibitory activity of the separated fractions was determined. 
The same methanol:water extracts showing HMGCR inhibitory activity where applied to 
the HMGCR activity test but altering the application procedure. Usually, in this test, solutions are 
applied following the sequence: first the buffer, then NADPH, substrate, standard inhibitor 
(pravastatin) as control or sample (potential inhibitory preparation) and, finally, the HMGCoA 
reductase. Then, the test was performed by mixing the sample and substrate separately and 
applying the mixture when substrate should be added or mixing the sample with the enzyme and 
applied at the end. Moreover, similar mixtures were also prepared and applied but mixing the 
sample with a diluted solution (1/2) of pravastatin or with the enzyme but in the presence of the 
diluted pravastatin concentration. All the experiments were carried out in duplicate. 
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Statistical analysis 
One way analysis of variance was performed using a Statgraphics Plus 3.1 for Windows 
software (Statistical Graphics Corporation, Rockville, MD, USA). The mean comparison test used 
was Fisher’s least significant difference procedure. 
Results and Discussion 
Influence of the cultivation systems 
According to preliminary results [27, 33], cultivation parameters influence the HMGCR 
inhibitory activity found in A. bisporus basidiomata because, when different growers cultivate the 
same mushroom variety, large differences in the percentage inhibition are observed [33]. 
However, some of those parameters, such as the casing layer utilized to induce fructification, did 
not significantly affect the presence of HMGCR inhibitory compounds and neither was any 
correlation observed with other parameters, such as crop quality or infections (bacterial, fungal 
and pests)[33]. Other reports also indicated that water was the best solvent to extract HMGCR 
inhibitors from several mushrooms except for A. bisporus, which showed higher HMGCR inhibitory 
activity in methanol:water extracts [15]. Thus, A. bisporus basidiomata from the same spawn 
variety (Fungisem H-15) were cultivated in the same cultivation room in three different batches 
and harvested to investigate the variability from trial to trial and between the first three flushes.  
The mushroom powders obtained from the collected basidiomata were mixed with both 
solvents to compare and results indicated that there were no significant differences between trials. 
The methanol:water extracts obtained from mushrooms harvested in the first and second flush 
showed a lower HMGCR inhibitory capacity (respectively, 14.4 and 11.2%) than those harvested 
from the third flush (29.5%). Thus, the potential inhibitor(s) might be compounds related to the 
secondary metabolism (i.e. statins) since in the third flush, mushrooms obtain fewer nutrients from 
the substrate than during the first and second flushes. On the other hand, it might also suggest 
that the HMGCR inhibitory activity of the basidiomata might be modulated by the 
presence/absence of specific compounds. 
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Mushrooms can be fortified with selenium by the addition of sodium selenite to their 
cultivation substrates and this supplementation can modify their biological properties [14]. 
Moreover, selenium supplementation combined with statins was proved to enhance the effect of 
statins on the reduction of cholesterol levels [13]. Thus, if these A. bisporus strains were able to 
produce statins or related compounds, Se-fortified mushroom strains could perhaps enhance their 
HMGCR inhibitory activity. Therefore, A. bisporus mushrooms (Fungisem H15) were cultivated in 
substrates supplemented with a low and a high dose of selenite. The selenium absorbed by the 
Se-fortified basidioma was also measured and the HMGCR inhibitory activity evaluated. However, 
no correlation was found between the selenium supplementation or the levels of selenium 
absorbed by the basidioma and the inhibitory capacity. Selenium content in the basidiomata 
ranged from an average value of 3.2 ppm in control samples, 10.9 ppm in the lower selenium 
application up to 31.6 ppm in the highest applied dose and the HMGCR inhibitory activity ranged 
from 5.7 to 48.9% independently of the selenium content evaluated. These inhibition values were 
in the range of those usually found for mushrooms that had not been fortified with selenium. 
Therefore, no synergistic effect or enhancing of the HMGCR inhibitory activities was observed by 
selenium supplementation. 
Variability within the Agaricus bisporus commercial strains 
Spawns from several commercial A. bisporus varieties were cultivated and the 
basiodiomata obtained from the first flush were harvested. Only the methanol:water (1:1 v/v) 
extracts obtained from Somycel A-15 showed a significantly lower HMGCR inhibitory activity 
compared to the others varieties (Figure 1).  
No differences were found between summer varieties such as Gurelan 60 and the other 
strains preferentially cultivated in winter. It is worth mentioning that water extracts obtained from 
Fungisem H15 also showed inhibitory capacities opposite to the rest of the varieties, suggesting 
the presence of different inhibitory compounds within the strains. 
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Developmental and tissue distribution of the HMGCoA-reductase inhibitors 
A. bisporus basidiomata (Fungisem H15 from the third flush) from the same cultivation 
tray were harvested at different developmental stages including from primordia until the veil was 
broken and the gills were visible (stage 5). However, the HMGCR inhibitory activity did not 
correlate with the basidioma developmental stage since primordia showed a slightly higher 
inhibitory activity (37.8%), stages 3 and 4 showed 30.8% inhibition and mature mushrooms (stages 
5 – 6) an insignificant increase (32.7%). Therefore, the HMGCR inhibitory capacity was always 
present through the complete sporophore life cycle. 
Similarly, the tissue distribution showed no preferential location of the potential inhibitor(s) 
within the basidioma. Epidermis, dermis, gills, veil, stipe and lower part of the stipe were analyzed 
and only gill extracts appeared to have a slightly lower inhibitory capacity compared to the other 
tissues (Figure 2). These results disagree [9] with those pointing to gills as the tissue with higher 
lovastatin concentration, indicating that perhaps this compound was not in this case the 
responsible for the observed HMGCR inhibitory activity. Interestingly, the lower part of the stipe, 
usually removed during harvesting and discarded, showed 56.9% inhibitory capacity, indicating 
that these mushroom by-products could be valorized and utilized to extract HMGCR inhibitors. 
Figure 3. HMGCR inhibitory activity of A. bisporus extracts obtained from different 
commercial varieties. a,bDenotes statistically significant differences (P<0.05) among the 
values from the same extraction solvent. 
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Accelerated solvent extraction to obtain fractions with high HMGCR inhibitory activity 
A. bisporus basidiomata were submitted to extraction with pressurized solvents in order 
to obtain mushroom fractions with high HMGCR inhibitory activity. Two advanced extraction 
methodologies were tested, supercritical fluid extraction (SFE) and accelerated solvent extraction 
(ASE). 
According to recent studies [15] the extraction yield of HMGCR inhibitors was highly 
influenced by the extraction temperature (for other mushroom species such as Pleurotus ostreatus 
and Lentinula edodes), while other parameters, such as extraction time and number of cycles, did 
not remarkably improve the extraction of the potential inhibitors. Thus, A. bisporus extractions 
were carried out selecting five cycles of 5 min (optimal conditions for the two other species) but 
at different temperatures and using water (as used for the other mushroom species) and a mixture 
of ethanol:water (1:1 v/v). The same extraction procedures were applied to two of the mushroom 
varieties which showed more interesting HMGCR inhibitory activities (Fungisem H15 and Gurelan 
60). 
Increasing the temperature from 25 to 200 °C resulted in a higher yield (higher 
percentage of extracted compounds) with the temperature. Similar results and extraction yields 
 
 
Casing layer and 
substrate (mycelium) 
Wasted 
 
Commercialized 
a 
a 
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b 
c 
Figure 2. Tissue distribution of the HMGCR inhibitory activity observed within the A. bisporus 
basidioma. The dotted line delimits the tissues that are usually commercialized (above the line) 
or discarded during harvesting (lower part of the stipe and mycelium).a,b,c Denotes statistically 
significant differences (P<0.05) among the values. 
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were obtained for both Gurelan 60 (ranging from 243 to 787 mg/g mushroom dry weight) and 
Fungisem H15 (Table 2) varieties being 200◦ C the best condition to extract approx. 80% of the 
material using water as pressurized solvent.  
Table 8. Extraction yields obtained after submission of Agaricus bisporus (Fungisem H15) basidiomata to 
accelerated solvent extraction (ASE) at different temperatures using two different pressurized solvent mixtures. 
 
When ethanol:water (1:1) was used as the extraction solvent a slightly lower yield than 
with plain water was obtained when the extraction was performed at 25 °C. But, increasing 
temperatures resulted in increasing extraction yields up to similar percentages than using 100% 
water. Higher temperatures were not considered because, at 150 and 200 °C, the presence of the 
organic solvent induced a remarkable browning in the extracts provoking colour interferences 
when analyzing their HMGCR inhibitory activities. Moreover, the increase of temperature was 
detrimental for the HMGCR inhibitory capacity of the fractions suggesting that the compounds 
responsible for the inhibition were thermolabile (Figure 3). 
Water extracts obtained at room temperature (with or without pressure) did not show 
interesting HMGCR inhibitory activity. Temperatures higher than room temperature should be used 
in order to increase the extraction of the potential HMGCR inhibitor(s) being the extracts obtained 
at 50 °C the fractions which showed higher inhibitory activities (ASE and standard extractions). 
However, the extractions carried out with ethanol:water as pressurized solvent showed higher 
HMGCR inhibitory activities than water extracts and, in this case, the use of temperatures higher 
than 25 °C was detrimental. Standard solvent extraction using a mixture of ethanol:water at 50 °C 
could not be carried out because of discolouration. In contrast to the situation in ASE extractions, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 NC: not considered 9 
                 a,b,c Denotes statistically significant differences (P < 0.05) among values from the same column 10 
ASE 
temperatures 
100% water 
 
Ethanol:water (1:1) 
(ºC) (mg/g dw) %  (mg/g dw) % 
25 185 ± 94.75a 18.5  62 ± 13.11a 6.2 
50 261 ± 127.99a 26.1  181 ± 29.70b 18.1 
100 283 ± 70.71a 28.3  333 ± 25.71c 33.3 
150 484 ± 44.55b 48.4  NC - 
200 749 ± 156.98c 74.9  NC - 
Chapter 4- Efect of fungal compounds with HMGCR inhibitory… 
 
321 
 
the oxygen present in the solution and the organic solvent induces activation of the mushroom 
polyphenol oxidases [34], impairing the proper determination of the HMGCR inhibitory activity. 
 
 
 
 
 
 
 
These results indicate that A. bisporus might contain compounds able to interfere with 
the extraction process or that the compounds responsible of the inhibitory capacity of A. bisporus 
extracts might be different than those extracted by ASE from P. ostreatus and L. edodes since in 
the latter mushrooms pressurized water was a more effective solvent to extract fractions with high 
HMGCR inhibitory activities [15]. 
Supercritical fluid extraction to obtain fractions with high HMGCR inhibitory activity 
Results obtained from the ASE experiments showed that the extraction of potential 
HMGCR inhibitor(s) detected in A. bisporus basidioma was enhanced when using a mixture of 
water:organic solvent instead of plain water, indicating a certain apolarity in the compounds of 
interest and suggesting that they might also be susceptible to SFE extraction. Then, A. bisporus 
basidiomata were submitted to extraction with pressurized CO2 and CO2 combined with 10% 
ethanol as modifier. Results showed that the highest extraction yields were obtained when ethanol 
was added to the CO2 but higher extraction pressure did not significantly increased the extraction 
yield (Table 3). In terms of HMGCR inhibition, fractions obtained with the aid of ethanol and at 9 
MPa showed a slightly higher inhibitory activity than those obtained at higher pressures (Figure 
4). However, no significant differences were found in samples extracted without modifier indicating 
Figure 3. HMGCR inhibitory activity of the ASE fractions obtained using two pressurized solvents at 
different temperatures from A. bisporus (Fungisem H15) compared with standardized solid:liquid 
extractions. a,b Denotes statistically significant differences (P<0.05) among the values from the same 
extraction solvent. 
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that the fractions obtained with ethanol and low pressure were more selective to isolate the 
potential HMGCR inhibitor(s).  
Table 3. Extraction yields obtained after submission of Agaricus bisporus (Fungisem H15) basidioma to SFE 
at different pressures with or without ethanol as co-solvent. 
 
 
These results can be explained in terms of CO2 density: at higher pressures the density 
– and hence the extracting power – of supercritical CO2 increases at constant temperature, so 
higher extraction yields were expected when working at 30 MPa. Nevertheless, the higher number 
of compounds present in the fractions obtained at higher pressures could have caused a dilution 
effect on the compounds responsible of the HMGCR inhibition leading to better results in fractions 
recovered under lower extraction pressures (9 MPa). 
Since it was previously indicated that the lower part of the A. bisporus stipes (which are 
usually discarded) showed interesting HMGCR inhibitory activities, SFE extractions were also 
performed using these by-products. Extractions carried out at 30 MPa with ethanol as co-solvent 
showed 82.74% inhibition, two-fold higher inhibitory activity than the same SFE extract obtained 
from the basidioma, pointing to these by-products as an interesting source of HMGCR inhibitor(s). 
 1 
 2 
 3 
 4 
 5 
 6 
                                a,b Denotes statistically significant differences (P < 0.05) among values from the same column 7 
SFE 
pressures 
(MPa) 
With 10% ethanol  Without 10% ethanol 
Extracted 
weight (g) 
% 
 Extracted 
weight (g) 
% 
9 1.24 ± 0.1a 1.55  0.50 ± 0.13a 0.62 
18 1.36 ± 0.22a 1.70  0.60 ± 0.20a 0.75 
30 1.50 ± 0.31a 2.08  0.56 ± 0.16a 0.70 
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Figure 4. HMGCR inhibitory activity of the SFE fractions obtained using different pressures with or without 
ethanol as modifier from A. bisporus (Fungisem H15). a,b,c Denotes statistically significant differences 
(P<0.05) among the values from the same extraction solvent. 
However, direct extractions with methanol:water (1:1) from the powdered by-product 
applied at the same concentration than the SFE extract showed already 56.9% inhibition and 80 
g of mushroom powder were necessary to obtain 1.42 g SFE extract with only 1.5-fold higher 
activity than the mushroom powder; thus, SFE was not a method highly selective to obtain fractions 
with high HMGCR inhibitory activity. In contrast, ASE extractions at 25 °C showed 1.6-fold higher 
inhibitory activity than did direct extraction when the same amount of starting material (1 g) was 
used. Thus, the latter method was more suitable than SFE for the extraction of potential HMGCR 
inhibitor(s). 
Presence of statins in the Agaricus bisporus extracts 
A. bisporus extracts with HMGCR inhibitory activity were injected into an HPLC-MS/MS 
system to investigate whether the observed inhibition was due to the presence of statins, as 
described by other authors [10, 11] since they also observed higher inhibitory capacity in samples 
obtained with methanol:water rather than with water [9]. However, no detectable peak at the 
retention time of pravastatin (3.82 min), atorvastatin (8.06 min), simvastatin (9.83 min) or lovastatin 
(20.26 min) was observed. 
A. bisporus extracts showed three peaks – at 4.8, 8.8 and 13.2 min – with 567, 459 and 
520 m/z different from those of the utilized standard statins (Table 4). The SRM transitions of the 
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statins were similar to those used previously by other authors [35], therefore, statins were not in 
this case responsible for the observed HMGCR inhibitory activity.  
Table 4. Single reaction monitoring transitions and energies used for analysis of statins. 
 
Determination of the chemical nature of the HMGCR inhibitors 
Since statins were not present in the A. bisporus extracts showing HMGCR inhibitory 
activity, a preliminary attempt to identify the nature of the inhibitors was carried out. Thus, the 
methanol:water extracts (showing 47.2% inhibitory activity) were fractionated by molecular weight 
using specific filtering devices with cut-offs of 10 and 3 kDa. The fraction obtained, including 
compounds with a molecular weight higher than 10 kDa, showed 61.5% inhibitory activity. 
However, the fraction with molecular weight lower than 10 kDa also showed high inhibitory 
capacity (50.4%). Thus, the latter fraction was further fractionated using a 3 kDa filter and the 
higher inhibitory activity was found in the fraction with a molecular weight between 10 and 3 kDa 
(44.2%) being lower than 23% in the filtrate corresponding to the low molecular weight fraction. 
Results indicated that the potential HMGCR inhibitors might be molecules of high molecular 
weight, higher than 10 kDa. However, the fact that the fractions with molecular weight higher than 
3 kDa also showed interesting inhibitory activity could indicate, on the one hand, that the possible 
degradation products obtained from the molecules with molecular weight higher than 10 kDa 
might still acts as inhibitors or, on the other hand, that the inhibitors were not a single compound 
but molecules with a wide range of molecular weights. In both cases, results suggested that the 
inhibitor(s) were macromolecules, thus they could be proteins or polysaccharides (or a mixture of 
both types of structure, proteoglucans etc.). 
Compound Parent ion 
Parent ion  
(m/z) 
Product ion  
(m/z) 
Collision Energy  
(V) 
Lovastatin M+Na+ 427.101  324.921 24 
Simvastatin M+Na+ 441.106  324.812 24 
Pravastatin M+Na+ 447.099  326.924 18 
Atorvastatin M+H+ 559.114  439.998 24 
 1 
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Therefore, in order to define furthermore the chemical nature of the inhibitors, the 
mushroom extracts showing HMGCR inhibitory activities were treated with specific enzymes 
mixtures. When pepsin was applied to the mushroom extract only a slight reduction of the initial 
inhibitory capacity was observed (from 48 to 41% inhibition). The mushroom extracts mixed with 
enzymes able to hydrolyze β-linked glucans (exo-1,3-β-glucanase and β-glucosidase) showed 
only a 24.3% of HMGCR inhibition, indicating that almost half of the inhibitory capacity was lost in 
the presence of β-hydrolytic enzymes. When the extract was mixed with amyloglucosidase 
(hydrolyse α-linked polysaccharides) and invertase still 34.1% inhibitory activity was observed 
indicating that α-glucans (such as starch or glycogen) might not have as much involvement in the 
inhibitory effect as β-glucans. 
Study of the potential in vitro mechanism of action of the HMGCR inhibitors 
If, as above suggested, certain β-glucans might be the com-pounds responsible of the 
observed inhibition, their mechanism of action cannot be similar to that of statins. The latter are 
small molecules acting as competitive inhibitors for which the enzyme showed 1000-fold more 
affinity (KI in the nanomolar range) than for its substrate (KM in the micromolar range) HMGCoA (3-
hydroxy-3-methulglutaryl-CoA).12 However, fungal β-glucans showed gel-forming properties able 
to scavenge small molecules within their complex structures [26] thus, perhaps these 
water:methanol-soluble mushroom β-glucans might be able to inhibit the enzyme by scavenging 
its substrate. Moreover, these polysaccharides can also bind proteins and if they form linkages 
close to the catalytic center they might also impair the enzymatic reaction. 
Thus, the HMGCR inhibitory test was carried out by mixing first the mushroom extract 
with the substrate or with the enzyme and then performing the standard procedure. As expected, 
addition of the mushroom extract inhibited the activity; however, no significant differences were 
found if the sample was first mixed with the substrate or with the enzyme. Thus, the same 
procedure was carried out by mixing the samples first with pravastatin instead of the substrate 
and with the enzyme in the presence of pravastatin. The selected statin dilution was able to inhibit 
87.8% of the HMGCR activity; however, if the pravastatin was mixed with the mushroom extract 
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and added to the test 71.5% inhibition was recorded suggesting that pravastatin might have been 
partially scavenged because of the decrease (approx. 16%) of its inhibitory effect. But, when the 
sample was first mixed with the enzyme, 11% reduction in the pravastatin inhibitory activity was 
observed suggesting that the sample was also impairing the proper binding of the inhibitor into 
the catalytic site (since the enzyme has more affinity for pravastatin than for the substrate). 
Results indicated that both proposed mechanisms could be possible and might take 
place simultaneously at least in the well of the in vitro test since the same mushroom extract was 
acting as HMGCR inhibitor or as inhibitor of the pravastatin inhibitory action depending on the 
testing conditions. However, in order to test whether these mechanisms have real significance in 
vivo, animal models should be utilized. Moreover, it is wise to mention that not all the β-glucans 
present in A. bisporus were able to inhibit the HMGCR activity since, for instance, the ASE extracts 
obtained using pressurized water at 150 °C (Figure 3) contained large amounts of β-glucans [26] 
but they showed very low HMGCR inhibitory activity. 
Conclusions 
Agaricus bisporus extracts able to inhibit the 3-hydroxy-3-methyl-glutaryl CoA reductase 
(HMGCR) activity could be obtained by environmentally friendly advanced technologies such as 
supercritical fluid extraction (SFE) with CO2 and 10% ethanol and accelerated solvent extraction 
(ASE) using methanol:water (1:1 v/v) as pressurized solvent, the latter being more effective than 
SFE or standard extraction methods. Cultivation parameters, flush, strain and tissue type could 
modulate the higher or lower HMGCR inhibitory activity but not the substrate supplementation with 
selenium. LC-MS analysis confirmed the absence of statins in the inhibitory fractions obtained. 
Instead, certain β-glucans that were easily extracted with methanol:water at moderate 
temperatures (lower than 100 °C) and which had molecular weights higher than 10 kDa, were 
considered as the compounds that might be responsible for the observed activity. They might 
scavenge the HMGCR substrate and bind to the enzyme impairing the enzymatic reaction in the 
in vitro HMGCR activity test. 
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Abstract 
Water extracts from Pleurotus ostreatus containing no statins showed HMGCR inhibitory 
activity (in vitro) that could be due to specific water soluble polysaccharides (WSP) because when 
isolated and deproteinized, increasing concentrations of WSP induced higher inhibition. The WSP 
extract contained mainly β-glucans, mannogalactans and glycogen like α-glucans although 
derivatives or fragments with lower molecular weight (between 14–3.5 kDa) were present and were 
able of inducing the inhibitory activity. The extract contained more β-(1→3)-glucans than                
β-(1→3),(1→6)-glucans and they partially survived digestion and managed to pass through 
Caco2 cell monolayers to the lower compartment after in vitro digestion and transport 
experiments. The WSP might also exert a protective effect on the cell membranes. 
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Introduction 
The hypocholesterolemic properties of Oyster mushrooms (Pleurotus sp.) were 
demonstrated long ago using animal models and now even with clinical trials [1]. Diabetic subjects 
administrated Pleurotus ostreatus for 24 days significantly reduced blood glucose, blood 
pressure, triglycerides and total cholesterol leaving unaffected the HDL levels [2]. Similar results 
were obtained using healthy volunteers drinking an oyster mushroom soup as part of a diet during 
21 days [3]. The beneficial effects of such mushrooms were attributed to the presence of linoleic 
acid, ergosterol and ergosta-derivatives because of their antioxidant activities. 
Animal studies using Wistar rats, Syrian hamsters and Chinchilla rabbits also 
demonstrated P. ostreatus ability to lower the cholesterol levels. When they were fed with 4–10 % 
fruiting bodies in specific diets, they lowered by 40–70% cholesterolemia compared with control 
animals after 4–7 weeks (depending on the type of animal and testing conditions). This effect was, 
in most of the cases, due to a decrease in the concentrations of very low density lipoproteins 
(VLDL), an increase in the HDL and to an induced delay in cholesterol absorption [4-9]. 
According to several studies, ethanol extracts obtained from the same mushroom were 
less efficient than the administration of the whole fruiting body or its water extract (aqueous extract 
reduced the VLDL fraction too) [5] and apparently, other compounds obtained from its mycelium 
(with dichloromethane and 95% ethanol) were also able of lowering cholesterol levels in liver of 
normocholesterolemic rats [10]. Although, the precise nature of the compounds responsible for 
the hypocholesterolemic properties and their mechanism of action still remains unclear because 
sometimes contradictory results were also obtained. For instance, a β-glucan fraction extracted 
from the fruiting bodies was unable to influence cholesterol levels in both serum and liver [7] 
however, specific hot water extracts (containing polysaccharides) managed to decrease the 
oxidative damage related to hypercholesterolemia [11, 12].  
Similarly, a few publications identified a naturally occurring statin (lovastatin) as one of 
the potential compounds involved in the hypocholesterolemic effect by acting as inhibitor of the 
3-hydroxy-3-methyl-glutaryl-CoA-reductase (HMGCR), the key enzyme in the biosynthetic 
cholesterol pathway [13-17]. Although, statins were not always detected in mushroom extracts 
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showing high HMGCR inhibitory activity [3, 18, 19]. In other species such as Agaricus bisporus, 
the polysaccharide fraction was pointed as responsible for the inhibition observed in vitro [20]. 
However, fungal polysaccharides are large molecules that usually survive digestion and are 
eliminated through the faeces (as dietary fibres) reducing the potentially of their use as HMGCR 
inhibitors as they might not enter in the human body as such in large amounts enough for reaching 
easily the liver. Nevertheless, recent reports suggest that both insoluble and water-soluble β-
glucans might bypass the enterocyte barrier entering via M-cells or Payer´s patches. Particularly 
water-soluble β-glucans might be partially bioavailable because of their large solubility in 
physiological fluids [21, 22]. 
Thus in order to bring more light into one of the possible several mechanisms influencing 
the cholesterol lowering properties of P. ostreatus, an attempt to further identify those compounds 
with HMGCR inhibitory activities is described. Their potential bioavailability was estimated using 
an in vitro digestion model and transport assays with Caco2 cell cultures. 
Materials and Methods 
Fungal material and preparation of a water extract 
Fresh fruiting bodies Pleurotus ostreatus (Jacq.Ex Fr.) Kummer strain Gurelan H-107 from 
the first flush were harvested, cut in slices, lyophilized and ground until a dry powder was obtained 
following the procedure described by Gil-Ramirez et al. (2013) [23]. Resulting mushroom powders 
were utilized as starting material to extract the water-soluble compounds and the polysaccharide-
containing fractions.  
Pleurotus ostreatus dry powder (50 mg/ml) was mixed with MilliQ water and stirred gently 
during 1 min in a Vortex at room temperature. Afterwards, the solution was centrifuged at 12000 
rpm during 2 min (Eppendorf mini-spin, Madrid, Spain), the supernatant collected and freeze-
dried. Dried extract (named ´lyophilized water extract´ (LWE)) was stored at -20 ºC until further 
analysis.  
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Determination of HMGCR inhibitory activity 
Pleurotus ostreatus extracts (obtained at different purification steps or submitted to 
different treatments) and other commercially available standard compounds were solubilized in 
water and applied (20 µl) into a 96 wells-plate.  Their HMGCR inhibitory activity was measured 
using the commercial HMGCR activity assay (Sigma-Aldrich, Madrid) according to the user´s 
manual by monitoring their absorbance change (340 nm) at 37 ºC using a 96-wells microplate 
reader (Tecan Group Lt, Männedorf, Switzerland). Pravastatin was utilized as a control for positive 
inhibition.  
Determination of β-glucans 
The total β-glucan content of the extracts (50 mg) was evaluated by a β-glucan 
determination kit specific for mushrooms and yeasts (Megazyme, Barcelona, Spain) following the 
instructions of the user´s manual. Absorbance at 510 nm was measured using a 
spectrophotometer (Evolution 600, Fisher scientific, Madrid, Spain). The amounts of β-(1→3)-
glucans and β-(1→3),(1→6)-glucans cans were also quantified using respectively the methods 
described by Ko and Lin (2004) and Nitschke et al. (2011) [24, 25] with modifications. Briefly, the 
polysaccharide extracts (4.7 mg/ml) dissolved in Tris-maleate buffer pH 6.5 (300 µl) (NaOH was 
not necessary since the PSC were completely solubilized and their chains allowed perfect 
integration of the fluorophore) were mixed with 30 µl of 6N NaOH and 630 µl of a dye solution 
(40:21:59 (v/v/v) 0.1% w/v aniline blue, 1N HCl, 1M glycine/NaOH buffer). The mixture was 
incubated at 50 ºC during 30 min in a water bath and cooled down at room temperature for 30 
min. Afterwards, samples were placed (300 µl) in 96-wells black microplates specific to measure 
fluorescence. The fluorescence of the β-(1→3)-glucans-aniline blue complex was measured at 
an emission wavelength of 502 nm (20 nm slit width) with an excitation wavelength of 398 nm (20 
nm slit width) and quantified using a curdlan standard curve.   
Polysaccharide extracts (4.7 mg/ml) were also dissolved in Tris-maleate buffer pH 6.5 
(1.3 ml) (buffer change did not significantly modify the determinations and allowed better 
comparison with digested samples (see later)) and mixed with 100 µl of a dye solution (0.08% w/v 
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congo red in buffer) up to 1.4 ml total volume. Absorbance of the mixtures at 516 nm was 
determined and the β-(1→3),(1→6)-glucans quantified using an schizophyllan standard curve.   
Determination of the chemical nature of the HMGCR inhibitors 
P. ostreatus lyophilized water extract (50 mg/ml) showing HMGCR inhibitory activity was 
treated as described by Gil-Ramirez et al. (2013b) [20] in order to define the molecular weight 
and chemical nature of the inhibitors but using water instead of the methanol:water mixture 
described in the report to solubilize the extract. 
Moreover, the aqueous extract of P. ostreatus (15 ml of 50 mg/ml) was also submitted to 
a double-membrane dialysis to separate two fractions including compounds with different 
molecular weight. Firstly, dialysis membranes were activated by placing them in boiling 1% EDTA 
(0.5 M) solution for 30 min. Then, a cellulose membrane tubing with 14 kDa cut off was inserted 
inside an outer membrane (3.5 kDa cut off) with the assistance of a 1.7 mm  (22.5 cm long) 
spring. The double-membrane system was dialyzed against MilliQ water under gentle stirring at 4 
ºC for 24 h with frequent renewing of the water. The inner fraction (IN) included compounds with 
a molecular weight higher than 14 kDa plus traces of compounds with molecular weight higher 
than 3.5 kDa and the fraction obtained between the two membranes (OUT) included most of the 
compounds with molecular weights lower than 14 kDa but higher than 3.5 kDa. Thus, OUT and IN 
fractions were collected, lyophilized and stored at -20 ºC until further use. 
Isolation of water-soluble polysaccharides 
Pleurotus ostreatus dry powder (10 g) was mixed with 700 ml ethanol:water (1:1,  v/v) 
and stirred at 4 ºC for 20 h under darkness to remove phenolic compounds. Then, the mixture was 
centrifuged at 4600 rpm during 20 min at 4 ºC, the pellet collected and submitted to phenol 
extraction again. Afterwards, pellet was dissolved in 700 ml MilliQ water, stirred at 4 ºC for 20 h 
under darkness and centrifuged (at 4600 rpm during 20 min at 4 ºC). Pellet was submitted twice 
to extraction and supernatants were pooled together and lyophilized. The remained pellets were 
submitted to hot water extraction (100 ºC, 8 h) and obtained supernatant and pellet separately 
collected (centrifugation) and lyophilized for FT-IR comparison with the water soluble fraction. The 
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obtained lyophilized water soluble fraction (WSP) was mixed with 20% TCA (w/v), maintained on 
ice for 30 min and centrifuged until a clear deproteinized supernatant was obtained (4000 rpm for 
5 min). Then, supernatant was collected, mixed with 1% NaCl and 2 volumes of absolute ethanol 
and incubated overnight at 4 ºC. The precipitated water-soluble polysaccharides (WSP) were 
collected by centrifugation (4000 rpm for 5 min), the supernatant was discarded and the pellet 
washed with acetone (2 ml) and dried under a N2 stream. Obtained extract (WSP) was stored at    
-20 ºC until further analysis. 
 IR analysis of fractionated extracts 
Pleurotus ostreatus fractions such as mushroom powder (MP), lyophilized water extract 
(LWE), dialyzed fractions (IN and OUT) as well as the water-soluble polysaccharides (WSP) were 
monitorized by FT-IR spectroscopy. Dry fractions (1mg) were mixed with 300 mg of KBr FT-IR 
grade (Erba Lachema, Praha, Czech Republic) and compressed. Then, samples were analyzed 
in a Nicolete 6700 FT-IR spectrophotometer (Thermo Scientific, Praha, Czech Republic) in a 
spectral region 4000-400 cm-1 (resolution of 2cm-1) with a laser power set at 100 mW and 256 
measure scans per sample. Obtained data were recorded and analyzed by respectively OMNIC 
and Origin 6.0 s software (Thermo Scientific). 
Monosaccharide composition analysis of water-soluble polysaccharides  
The WSP fraction (1 mg) was hydrolyzed with 2 M TFA at 100 ºC for 8 h, followed by 
evaporation to dryness. The dried carbohydrate samples were dissolved in distilled water            
(100 µl), held at room temperature for 10–15 min in reinforced 4 ml Pyrex tubes with Teflon lined 
screw caps. NaBH4 (1 mg) was added to reach pH 8.0-9.0, and the solution was kept overnight 
at room temperature, in order to reduce aldoses to alditols [26]. The excess of NaBH4 was 
neutralized by adding acetic acid (30 µl), and removed by the addition of methanol (x 2) under a 
N2 stream in a fume hood. The reduced product was dried and acetylation of the Me-alditols was 
performed in pyridine–Ac2O (200 µl; 1:1, v/v), for 30 min at 100 ºC. The resulting alditol acetates 
were analyzed by GC-MS. The analysis was performed using a Varian (model 3300) gas 
chromatograph linked to a Finnigan Ion-Trap model 810 R-12 mass spectrometer, with He as 
carrier gas. A capillary column (30 m x 0.25 mm i.d.) of DB-225, held at 50 ºC during injection and 
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then programmed at 40 ºC /min to 220 ºC (constant temperature) was used for qualitative and 
quantitative analysis of alditol acetates. The sugars were identified by their typical retention times 
and electron impact profiles [27]. 
NMR analysis of water-soluble polysaccharides  
The WSP fraction (30 mg) was solubilized in 400 µl of D2O and added to a 5 mm thin wall 
NMR sample tube. NMR spectra (1H-, 13C-, and HSQC) were obtained using a 400MHz Bruker 
Avance III spectrometer with a 5 mm inverse probe. The analyses were performed at 50 ºC in D2O, 
and the chemical shifts are expressed in  ppm relative to external standard of acetone at  30.2 
(13C) and 2.22 (1H). The signals were assigned according to the correlation among the NMR 
spectra and to literature values of similar polysaccharides. 
HPSEC-MALLS analysis of water-soluble polysaccharides  
The WSP fraction (1 mg) was submitted to analysis of high performance size-exclusion 
chromatography (HPSEC), using a refractive index (RI) detector and a Wyatt Technology Dawn-F 
Multi-Angle Laser Light Scattering detector (MALLS). The eluent was 0.1 M NaNO3, containing 0.5 
g/l NaN3. The sample was solubilized on the eluent solution and filtered through a membrane of 
0.22 µm pore size (Millipore). The chromatogram was analyzed using Astra software 4.70. 
In vitro digestion 
Extracts were submitted to an in vitro digestion according to Palanisamy et al. (2014)[28] 
with modifications. Briefly, the extracts were digested in 3 mL of 0.01 M HCl for 1 h at 37 ºC with 
gentle agitation (Orbital incubator S150, Stuart, Stone, UK). Afterwards, the sample pH was 
adjusted to 6.3 with 0.3 ml of 0.1 M NaOH. Then, 12 ml of bile extract (14.3 mg in Tris-maleate 
buffer pH 6.3) and 15 ml of pancreatin (10 mg in tris-maleate buffer pH 6.3) were added, the 
mixture was incubated for 1 h at 37 ºC and then, filtrated through filter paper. A control sample 
was prepared following the same digestion protocol but without the addition of polysaccharide 
extracts. After digestion, both control and samples were applied to Caco2 fully differentiated 
monolayers. 
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Caco2 cell cultures and transport assay  
Human colorectal adenocarcinoma cell line Caco-2 (ATCC HTB-37) (Rockville, MD, USA) 
were maintained in Dulbecco´s Modified Eagle’s Medium (DMEM) with high glucose content (4.5 
g/l) and supplemented with 10% fetal bovine serum at 37 ºC under a humidified atmosphere 
containing 5% CO2. At 70% of cell confluence, the cells were treated with 0.25% trypsine-EDTA 
and further seeded onto a 33.6 mm2 translucent PET-membrane support (0.4 μm pore size, 
Greiner, Bio-one Kremsmunster, Austria) at a density of 2.25 x 105 cells. Afterwards, they were 
incubated under similar conditions changing the medium every second day until brush-border 
differentiation (21 days later) for both cytotoxicity and transport assays.  
Firstly, the cytotoxicity was evaluated following CellTiter-Glo® Luminescent Cell Viability 
Assay instructions (Promega, Leiden, The Netherlands). Then, digested and non-digested WSP 
extracts were mixed with no-phenolic medium (1:1, v/v ratio) and applied at subtoxic 
concentrations (160 μl) to the upper compartment of Caco2 cell monolayers. Afterwards, plates 
were incubated at 37 ºC and 5% CO2 during 24 h and the lower compartments were collected to 
determine the amount of β-(1→3)-glucans. During the incubation time, the integrity of the cell 
membranes was evaluated by measuring the transepithelial electrical resistance (TEER) (Evon, 
Sarasota, FL) at 0, 1, 3, 6, 9 and 24 h.   
Results and Discussion 
Previous studies indicated that extracts from Pleurotus ostreatus were able of inhibiting 
the activity of the HMGCoA reductase because they contained lovastatin [15]. However, the statin 
was not always detected [3, 18] and still inhibition of the enzyme was recorded [19] therefore, 
other compounds could also be involved in the observed inhibition and an attempt to further 
identify those potential inhibitors was made.  
Screening of specific compounds with potentially HMGCR inhibitory activity 
Water extracts obtained from P. ostreatus fruiting bodies showed higher HMGCR 
inhibitory capacity than others such as methanol, methanol:water or other solvent combinations 
[19] but no statins were detected after HPLC-MS analysis [19]. Thus, other standard compounds 
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potentially present in the water extract such as ergothioneine and laccase were tested because 
they or the laccase oxidation products could be involved in redox reactions (oxidative/antioxidant 
activities) interfering the assay. However, none of the tested compounds inhibited or reduced the 
enzyme activity at concentrations higher than they are usually present in the water extract (Table 
1). Ergosterol (ergosta-5,7,22-trien-3-β-ol) was also tested since a compound analog to lanosterol 
(15α-fluorolanost-7-en-3-β-ol) appeared to decrease the HMGCR activity in cultured cells [29] and 
ergosterol structure resembles lanosterol too. Moreover, specific extracts obtained from A. 
bisporus with pressurized solvent technologies containing not only ergosterol but also other fungal 
sterols such as ergosta-7,22-dienol, ergosta-5,7-dienol and fungisterol were also able of inhibiting 
the enzyme [20]. However, these sterols are lipids integrated in the hyphae membranes with 
reduced water solubility. Thus, ergosterol was dissolved in methanol:water (1:1) and approx. 20% 
reduction was observed but mostly due to the methanol used to enable sterol solubilization since 
a control with only methanol showed similar inhibition percentage.   
Table 1. HMGCR Inhibitory activity of specific standard compounds. 
 
Extract fractionation to determine the molecular size of the potential inhibitors 
Firstly, a preliminary fractionation of LWE was carried out by molecular weight using 
specific filtering devices with cut-off of 10 and 3 kDa and the fractions including compounds with 
a molecular weight lower than 10 kDa and higher than 3 kDa showed high HMGCR inhibitory 
activity (Table 2). Thus, the compounds responsible for the HMGCR inhibition could be molecules 
Standard compounds Concentration applied (mg/ml) HMGR inhibition (%) 
Ergothioneine 1 0 
Lacasse 1 8.45 ± 6.7 
Ergosterol (dissolved in MeOH:H2O,1:1, v/v) 
(MeOH reduced by 20% activity) 
27.47 22.9 ±15.6 
Agar-Agar 10 32 ± 14.3 
Xanthan  10 14.8 ± 1.0 
Alginate 10 19.8 ± 2.48 
Pravastatin (Cinfa, Pamplona, Spain) 
0.5 100 ± 0.9 
0.01 40 ± 5.6 
0.001 7.6 ± 2.9 
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such as proteins, small polysaccharides or oligosaccharides (or proteo-glucans as observed for 
another mushroom species such as Agaricus bisporus [20]). However, P. ostreatus inhibitory 
compounds could be smaller than for A. bisporus since the compounds responsible for the 
inhibition in the latter mushroom showed a molecular weight higher than 10 kDa.  
Then, the LWE was also fractionated using a dialysis system to separate the fractions 
containing those compounds with a molecular weight higher than 14 kDa (IN fraction) and those 
with a molecular weight lower than 14 but higher than 3.5 kDa (OUT fraction) in sufficient amounts 
to monitor their composition using FT-IR spectroscopy.  
Dialyzed fractions lacked small molecules present in the mushroom powder and LWE 
(i.e. simple sugars) as they were removed with the dialysis system (Figure 1a). They also showed 
a lower protein/phenol ratio than LWE and higher carbohydrate content. However, both IN and 
OUT fractions contained similar compositions including proteins, phenols and polysaccharides. 
   
Table 2. HMGCR inhibitory activity of P. ostreatus extracts obtained using different fractionation procedures 
 
Fractionation 
procedure 
Isolated fraction Concentration applied 
(mg/ml) 
HMGR inhibition 
(%) 
Filtration  
P. ostreatus water extract  
(directly obtained from the mushroom powder) 
50 
80.51 ± 0.91 
 
Water fraction < 10 kDa 50* 82.69 ± 2.71 
10 kDa > fraction > 3 kDa 50* 70.72 ± 2.98 
Water fraction < 3 kDa 50* 0.0 ± 3.47 
Dialysis 
P. ostreatus water extract  
(directly obtained from the mushroom powder) 
50 39.35 ± 0.14 
Lyophilized water extract  50 31.92 ± 18.06 
IN fraction (fraction > 14 kDa) 50 41.94 ± 10.32 
OUT fraction (14 kDa > fraction > 3.5 kDa) 50 36.30 ± 18.10 
*Initial mushroom concentration before fractionation process 
Chapter 4- Manuscript 3 
 
342 
 
        a) 
        
       b) 
    
Figure 1. FTIR spectra from P. ostreatus extracts obtained using a) the double-membrane dialysis system 
and b) the procedure to isolate water soluble polysaccharides. 
The LWE showed similar inhibition capacity than the initial mushroom powder and its 
activity was not lost with the dialysis process because the obtained IN and OUT fractions still 
showed HMGCR inhibitory capacities (Table 2). However, the inhibitory activity of the fraction 
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corresponding to molecular weights between 14 and 3.5 kDa was not significantly different than 
the one with a molecular weight higher than 14 kDa suggesting than both larger size 
polysaccharides and those between 14 to 3.5 kDa were able of inhibiting the enzyme. Since both 
fractions showed similar composition (according to FT-IR spectra) the OUT fraction could contain 
smaller fragments generated from the higher molecular weight polysaccharides (derivatives, 
partially degraded polysaccharides, broken fibers, partially synthetized pieces etc). This 
observation could be of interest because it suggest that the compounds responsible for the 
HMGCR inhibitory activity could still be acting as inhibitors when they are partially degraded as it 
might occur during digestion.  
Moreover, the HMGCR inhibitory activity observed using the filtration devices was higher 
than using dialysis. The observed differences could be due to the different P. ostreatus batch 
utilized for fractionation (since its initial activity was also lower). However, it could also be due to 
the followed procedures because dialysis requested longer time and the phenolic compounds 
present in the fractions (particularly in the OUT fraction) could polymerize interfering in the 
inhibitory activity as noticed by a slightly browning of the obtained fractions. Edible mushrooms 
contain phenolic compounds that can be oxidized by fungal polyphenol oxidases and 
peroxidases into quinones [30]. The latter are very reactive molecules able to spontaneously 
polymerize with themselves and with almost any high molecular weight compound including 
polysaccharides or proteins interfering in many reactions.  
Therefore, a procedure to separate the phenolic compounds from the water-soluble 
polysaccharides was followed. 
Isolation of water-soluble polysaccharides with potentially HMGCR inhibitory activity   
Phenolic compounds and simple sugars were removed after washing the mushroom 
powder with 50% ethanol (Figure 1b). Further extraction with cold water yielded a higher protein-
rich fraction than carbohydrate fraction.  
The profile was different than the typical signals from 1500 to 1200 cm-1 corresponding 
to more water insoluble polysaccharide mixture that is usually obtained when hot water is utilized 
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to extract polysaccharides from P. ostreatus or those insoluble polymers such as chitins, chitin 
degradation products, α- and β-glucans, mannans and other complex heteroglucans. 
Interestingly, the isolated water-soluble fraction (WSP) showed a dose-increasing HMGCR 
inhibitory activity (Figure 2). Thus, it was further processed to separate proteins from 
polysaccharides in order to elucidate the nature of the inhibitors.  
 WSP deproteinization with TCA yielded a higher purified WSP fraction showing an even 
higher HMGCR inhibitory activity than before protein removal (Figure 2). The deproteinized WSP 
fraction showed mainly mannose (14.8%), galactose (24.9%), glucose (58.6%), and traces of 
arabinose, and fucose by the GC-MS analysis. 
 
Figure 2. HMGCR inhibitory activity of WSP before and after phenols and protein removal applied at two 
different concentrations. 
The HPSEC-MALLS indicated that this fraction was a mixture of polysaccharides (by the 
refractive index) of different molecular weight (by the light scattering) ranging from approximately 
20 kDa to 650 kDa (Figure 3), although it is well known that polysaccharides may form complexes 
by hydrogen bonds and other weak interactions between them and other molecules therefore, 
there is also the possibility of the presence of smaller polysaccharides [31].  
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Figure 3. Elution profile of WSP fraction on HPSEC-MALLS, using refractive index detectors and light 
scattering (0.1 M NaNO3 as eluent). 
NMR analyses confirmed the total removal of proteins by the absence of signals at 
regions  10-40 and  120-180 ppm in 13C spectrum (data not shown). The HSQC experiment 
(Figure 4) indicated only signals of carbohydrates and, based on the correlation among the NMR 
spectra besides comparison with literature data, it was possible to identify anomeric signals 
referent to β-glucans ( 102.7/4.73;  102.8/4.51), α-glucans ( 99.7/5.34), and a mannogalactan 
( 98.4/5.13;  98.1/4.98;  101.7/4.80). The β-glucans are common in mushrooms, especially in 
Pleurotus spp. and the β-(1→3)-linkages are usually observed, which is confirmed by the signal 
observed at  84.7/3.74 [32-35]. Small shifts can be observed depending on the branching degree 
of the β-glucans and also according to the temperature and calibration used for the NMR 
experiment. Glycogen-like glucans were also reported and the normal shifts for the glucopyranose 
units in α-configuration are between ~99.0-100.0 ppm. Such polysaccharides usually present 
(1→4)- and (1→6)-linkages and these signals were observed at HSQC spectrum, although they 
were not clearly identified due to the great overlapping on region  65-80 ppm [36, 37]. 
Mannogalactans seems to be common to Pleurotus spp. and were already isolated from                       
P. ostreatoroseus, P. ostreatus [38], P. geesteranus [39], and P. pulmonarius [40]. Such 
heteropolysaccharides present a natural methyl group linked to O-3 of some of the 
galactopyranose units. The signal of methyl group was also observed in the spectrum at  
56.3/3.45. Moreover, the signals of reducing units were observed ( 92.0/5.22;  95.0/4.64), 
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indicating that low molecular weight carbohydrates are present in the WSP fraction. By the 
integration of the areas of the anomeric signals it was possible to quantify the four main classes 
of molecules observed in this fraction totalizing 34% of mannogalactans, 38% of β-glucans, 25.7% 
of α-glucans, and 2.3% of low molecular weight carbohydrates.  
Thus, other polysaccharides were also tested as HMGCR inhibitors in order to discard possible 
interferences that could be common for scavenging/binding molecules such as complex 
polysaccharides. Results indicated that anionic polysaccharides such as alginate (a linear               
β-(1→4)-linked polymer of n-mannuronic and L-guluronic acid) and xanthan (a β-(1→4)-D-
glucopyranose glucan backbone with side chains of (1→3)-α-linked D-mannopyranose-(2→1)-
β-D-glucuronic acid-(4→1)-β-D-mannopyranose on alternating residues) showed marginally 
interference (Table 1), only the presence of agar-agar (a partially neutral and anionic 
polysaccharide complex constituted by agarose (chains of repeating alternate units of β-(1→3)-
linked- D-galactose and α-(1→4)-linked 3,6-anhydro-L-galactose) and agaropectin (a sulfated 
polysaccharide (3% to 10% sulfate), showed a 30.5% inhibition but significantly lower than the 
inhibition observed by the isolated water-soluble polysaccharide fraction isolated from                         
P. ostreatus taking into consideration that they were applied at 10 fold higher concentrations              
(50 mg/ml).  
In vitro bioavailability of the WSP with HMGCR inhibitory properties 
NMR analysis indicated that the WSP extract contained higher amount of glucans (63.7%) 
than mannogalactans (34%) and the other tested polysaccharides including galactose in their 
backbones and mannopyranose residues in their side chains (although different linkage patterns) 
did not show HMGCR inhibitory activity (Table 1).  Moreover, many reports pointed β-glucans as 
the polysaccharides with hypocholesterolemic properties thus, these compounds might 
potentially be the inhibitors of the HMGCR. However, in order to reach their target, they should 
firstly resist digestion and pass through the intestinal barrier therefore, the WSP extract was 
submitted to an in vitro digestion and absorption model as a preliminary attempt to investigate 
whether its β-glucans might be bioaccesible and bioavailable. 
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Figure 4. HSQC spectrum of the WSP fraction isolated from P. ostreatus, in D2O at 50 ºC (chemical shifts are 
expressed in ppm). 
Spectrophotometrical determinations indicated that 41.4% of the WSP glucans showed 
an β-linkage while 58.6% of them were β-glucans coinciding with NMR analysis. Moreover, the 
WSP extract contained more β-(1→3)- than β-(1→3),(1→6)-glucans (Table 3) suggesting than 
their structural configuration might be linear more than the usual triple helix form typical for 
branched polysaccharides. This might explain their large solubility in water since complex folding 
and chains aggregations increases water insolubility. Digestion affected more to β-(1→3)-
glucans than β-(1→3),(1→6)-glucans which was also expected as the complex conformation of 
the latter polysaccharides should protect them from the enzymatic degradation more than a linear 
chain. Nevertheless, part of the β-(1→3)-glucans also survived the digestive process indicating 
that they might be partially bioaccesible.  
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Table 9. Effect of in vitro digestion on the β-(1→3)- and β-(1→3),(1→6)-glucans present in the WPS. 
 
However, the degree of β-glucans degradation during digestion might also be highly 
influenced by the presence of other food matrix in the digestive track since it might protect them 
reducing the access of degradative enzymes to the polysaccharide thus, the bioavailability of the 
WSP β-(1→3)-glucans (present in higher amounts) was studied using non-digested and digested 
WSP extracts. Surprisingly, results indicated than the non-digested β-(1→3)-glucans were able 
to pass through the Caco2 cells in larger amounts than after digestion (Table 4) although it might 
also indicate than digested β-glucans might be easier further processed by the cells during the 
24h incubation than the non-digested since they should have lower molecular weights because of 
the previous digestion process liberating into the lower compartment more monosaccharides than 
higher polymers that are no longer detectable with the method utilized since the fluorophore 
specifically binds β-(1→3)-linkages. Nevertheless, WSP β-(1→3)-glucans were observed in the 
lower compartment suggesting that they could be bioavailable thus, in vivo studies should be 
carried out to further investigate the significance of these results.  
Table 4. β-(1→3)-Glucans applied to the Caco2 cells. 
 
Wise to mention was the fact than when the TEER was measured to control the membrane 
integrity during the 24h cells incubation in the presence of digested and non-digested WSP, the 
obtained values were higher than the controls with no β-glucan addition (Figure 5).  
β-Glucans concentration  
(g/100mg) 
Before WSP 
digestion 
After WSP 
digestion 
Bioaccesible  
(%) 
β-(1→3),(1→6)-Glucans  4.012 2.854 71.1 
β-(1→3)-Glucans  394.7 85.4 21.6 
 
Sample applied β-Glucans applied 
 (g/mL) 
β-Glucans lower compart. 
 (g/mL) 
Bioavailable β-Glucans 
(%) 
Non digested WSP 2.3 0.38 16.7 
Digested WSP 2 0.14 7 
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Figure 5. Relative TEER during Caco2 cells incubation in the presence of digested and non-digested WSP 
compared to respective control cells where a digestion mixture including no extract or only medium and 
buffer were used. 
The TEER of the cells treated with the digested WSP increased already after 1h 
application and continued to increase until 6h later while the TEER increase induced by the non-
digested WSP was not noticed until 3h later and it was less pronounced than the digested one. 
Recent studies indicated that dietary fibres and β-glucans might have a protective effect on 
enterocytic membranes [41] these results might support that possibility. On the other hand, the 
lower β-(1→3)-glucan concentration found in the lower compartment of cells treated with the 
digested WSP extract compared to the non-digested WSP could perhaps be because these 
possibly smaller polysaccharides might be better retained or attached to the Caco2 luminal 
membranes (upper compartment) acting as protective layer more efficiently than higher size 
polysaccharides (non-digested). However, further experiments are needed to confirm this 
hypothesis.   
Conclusions 
The HMGCR inhibitory activity observed in the water extracts from Pleurotus ostreatus 
was not due to the presence of statins but to other compounds with higher molecular weight 
because when the water soluble polysaccharide fraction (WSP) was isolated, inhibition of the 
HMGCR was also observed. According to NMR analysis this fraction contained β-glucans, 
mannogalactans, α-glucans and a small amount of low molecular weight (MW) compounds. 
Compounds with MW lower than 3.5 kDa showed no HMGCR inhibitory activity but those with MW 
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lower than 14 but higher than 3.5 kDa did suggesting that derivatives or fragments of the indicated 
polysaccharides were still retaining the inhibitory activity. This could be interesting because lower 
MW compounds are easier absorbed by the intestine than large and complex polymers. 
Apparently, there were more β-glucans showing linear (β-(1→3)-glucans) than triple helix 
configuration enhancing their solubility in physiological fluids and their possibility of being 
bioavailable. In fact, the in vitro model utilized suggested that they could be not only partially 
bioaccesible but also partially absorbed by the enteric barrier reaching the blood stream since 
they were detected in the lower compartment of Caco2 cell transport experiments. However, 
further studies are necessary to confirm these indications and to investigate whether the HMGCR 
inhibitory polysaccharides are also able of performing such an inhibition under in vivo real 
situations therefore, animal dietary interventions are being carried out at the present to confirm the 
presented results.  
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Abstract 
The water extracts from Lentinula edodes (Shiitake mushroom) (LWE) able of reducing 
the HMG-CoA reductase in vitro contained no lovastatin but a mixture of water soluble α- and        
β-glucans and fucomannogalactans. Fragments or derivatives of these polysaccharides with 
molecular weight down to approx. 1 kDa still retained their inhibitory activity. The extract also 
contained eritadenine although it was not the compound responsible for the inhibitory activity. 
When digested and applied to Caco2 cells no significant effect was noticed on the modulation of 
cholesterol-related gene expression. But, when the lower compartment of Caco2 cell monolayer 
(where LWE digestates were added) was applied to HepG2 modulation of some genes were 
noticed after 24 h incubation. The LWE extract was also administrated to normo- and 
hypercholesterolemic mice (4 weeks) and no significant lowering of serum cholesterol levels was 
observed but reduction of triglycerides in liver. However, LWE supplementation modulated the 
transcriptional profile of the genes involved in the cholesterol metabolism similarly to simvastatin 
suggesting that it could hold a potential as hypolipidemic /hypocholesterolemic extract although 
further dose-dependent studies should be carried out.   
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Introduction 
Cardiovascular diseases (CVD) are the major cause of death in industrialized countries 
and high cholesterol levels in serum increases CVD risk. Nowadays, natural or synthetic statins 
are commonly prescribed to lower cholesterol levels since they are inhibitors of the HMGCR (3-
hydroxy-3-methyl-glutaryl-Co A reductase), the key enzyme in the endogenous cholesterol 
biosynthesis [1]. However, frequent and prolonged administration of these drugs induce 
secondary undesirable effects therefore, other alternative are being followed such as the 
prescription of drugs impairing cholesterol absorption (ezetimibe) or other formulations able of 
inhibiting enzymes downstream the cholesterol metabolic pathway (squalene synthetase,  24-
dehydrocholesterol reductase, etc. ) [2, 3].  
People still with low or moderate hypercholesterolemia might choose for a less drastic 
alternative to drug treatment: the regular consumption of functional foods with 
hypocholesterolemic activity such as those including phytosterols or cereal β-glucans as 
compounds able to reduce mainly cholesterol absorption [4]. However, these products are not 
effective for everyone because if cholesterol is not absorbed, the liver synthetizes it by increasing 
up to 3 folds the activity of the HMGCR (observed in regular β-glucan consumers) [5]. Thus, 
another strategy might be designing of functional foods able to impair the endogenous cholesterol 
biosynthesis by disrupting the HMGCR activity or inhibiting other enzymes involved in that 
metabolic pathway.     
Shiitake mushrooms (Lentinula edodes) and other edible mushroom species showed 
hypocholesterolemic effects according to in vivo tests with animals and clinical trials [6]. 
Apparently, their dietary fiber content [7] and eritadenine (2(R), 3(R),-dihydroxy-4-(9-adenyl)-
butyric acid, lentinacin or lentysine) [8] contents were involved in their cholesterol lowering 
properties by different mechanisms.  
Fractions enriched in water-insoluble fibers obtained from L. edodes administrated to 
rats for 4 weeks were able to significantly lower VLDL, IDL and LDL levels compared with cellulose 
fed control rats. However, the mRNA transcription levels of genes encoding key enzymes in the 
biosynthesis of cholesterol (HMGCR, gene encoding HMG-CoA reductase) and in the synthesis 
of bile acids from cholesterol (CYP7A1, cholesterol 7α-hydroxylase) and other proteins involved 
Chapter 4- Manuscript 4 
 
358 
 
in cholesterol transport (APOB, apolipoproteins B and LDLR, LDL receptor) were not significantly 
modulated compared to control. Apparently, their hypocholesterolemic effect was exerted by 
enhancement of faecal cholesterol excretion [7] probably because of their ability to scavenge bile 
acids during digestion as suggested after in vitro studies [9]. 
Eritadenine reduced cholesterol and triacylglycerol levels in rats due to its activity as 
inhibitor of the S-adenosylhomocysteine hydrolase (SAHH), a key enzyme in the hepatic 
phospholipid metabolism [8]. The alkaloid decreased in a dose-dependent manner levels of VLDL, 
LDL and HDL, increased the hepatic S-adenosylhomocysteine (SAH) level and decreased the 
ratio of S-adenosylmethionine (SAM) to SAH indicating that its hypocholesterolemic action might 
be elicited through an alteration of the hepatic phospholipid metabolism that resulted from an 
inhibition of phosphatidylethanolamine N-methylalion due to a decreased SMA/SAH ratio in the 
liver [10].  
However, there could be more compounds involved acting via different mechanisms 
because other reports pointed out that the water extracts obtained from this mushroom were able 
of inhibiting the HMGCR activity in vitro [11] and hot water extracts decreased oxidative damage 
related to hypercholesterolemia [12, 13]. They could also contain lovastatin as suggested for other 
mushroom species [14] or different water soluble polysaccharides as suggested for specific 
species such as Agaricus bisporus [15] and Pleurotus ostreatus [16]. Other publications pointed 
compounds such as lanosteroids, ganoderols etc. from Ganoderma lucidum as molecules able 
of reducing the HMGCR mRNA expression [17] although ergosterol and derivatives, the 
compounds from L. edodes with structures similar to those mentioned, showed no HMGCR 
inhibitory activity [16]. 
In this work, a more detailed study about those HMGCR inhibitors is carried out in order 
to further define the compounds responsible for the inhibition as an initial study to investigate the 
possibility of designing new functional foods with hypocholesterolemic properties but following 
different mechanisms of action than those of the actually commercialized products. Molecular 
approaches were also utilized (low-density arrays) in order to broaden the overview of other 
potential action points (other enzymes involved in the cholesterol homeostasis) which might be 
target of fungal compounds. The experiments were firstly conducted in vitro using Caco2 and 
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HepG2 cell cultures and afterwards the effect of a L. edodes extract was tested using normo- and 
hypercholesterolemic mice models.  
Materials and Methods 
Fungal material and preparation of water extracts 
Fresh fruiting bodies from Lentinula edodes S. (Berkeley) strain 4312 Sylvan were 
harvested and processed until a dry powder was obtained as described [18]. Resulting mushroom 
powders were further processed to prepare a lyophilized water extract (LWE) and to isolate a 
water-soluble polysaccharide fraction (WSP) as explained [16]. 
Determination of HMGCR inhibitory activity 
Lentinula edodes extracts (obtained at different purification steps or submitted to 
different treatments) and an eritadenine (Synchem UG & Co. KG, Altenburg, Germany) standard 
preparation were solubilized in water and applied (20 ml) into a 96 wells-plate. Their HMGCR 
inhibitory activity was measured using the commercial HMG-CoA Reductase Assay (Sigma, 
Madrid, Spain) according to the user´s manual by monitoring their absorbance change (340 nm) 
at 37 ºC using a microplate reader (Tecan Group Lt, Männedorf, Switzerland). Pravastatin was 
utilized as a control for positive inhibition.  
Determination of statins  
The presence of statins in L. edodes were determined following the procedure indicated 
by Gil-Ramirez et al. (2011) [19]. 
Determination of eritadenine  
Eritadenine was extracted from the mushroom powder following the procedure of [20] 
with modifications. Briefly, L. edodes dry powder or LWE (5 g) were mixed with 100 ml 
methanol:water (80:20 v/v) and stirred at  25 ºC for 3 h. Then, the suspension was filtered through 
a 14-18 μm pore size paper filter (GE Healthcare Europe GmbH 1240, Barcelona, Spain) and the 
filtrate was dried in a water bath at 60 ºC in darkness. Afterwards, the remaining dry pellet was 
dissolved in 50 ml MilliQ water and washed 3 times with diethyl ether to remove undesirable 
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compounds. This washed aqueous extract was stored at -20 ºC until it was injected in an HPLC 
system for analysis.  
Identification and quantification of eritadenine were carried out using a C18 Spherisorb 
ODS2 4 x 250 mm analytical column with a  5 μm particle size (Waters, Missisagua, Ontario, 
Canada) in an HPLC system (Varian Pro-Star 330, Madrid, Spain) coupled to PDA detector (Varian 
Pro-Star 363 module, Madrid, Spain). Samples (10 ml) were injected and developed under a 
constant flow (0.5 ml/min) and an isocratic mobile phase of water:acetonitrile (98:2, v/v with 1% 
TFA). The alkaloid eluting after 11.6 min showed an UV-spectra similar to previously described 
[20] and to eritadenine thus, it was quantified at 260 nm using a standard curve of the 
commercialized standard. 
Identification of the compounds with HMGCR inhibitory activity 
Firstly, the LWE (50 mg/ml) showing HMGCR inhibitory activity was filtrated as described 
in [16] to fractionate the extract and estimate the molecular weight and chemical nature of the 
inhibitors. Then, they were also fractionated using a double-dialysis system but using membranes 
with smaller cut off (3.5 and 1 kDa). Finally, a water-soluble polysaccharide fraction (WSP) was 
also isolated from L. edodes dry powder (10 g) following the procedure of [16]. 
The composition of the fractions obtained during the isolation procedure was followed by 
FT-IR spectroscopy. The sugar content of the isolated WSP was quantified by GC-MS and the 
compounds identified by NMR as described by [16].  
In vitro digestion and Caco2 cell experiments   
LWE extracts were submitted to an in vitro digestion according to [16]. After digestion, 
the samples were applied to Caco2 cell cultures at subtoxic concentrations. 
Human colorectal adenocarcinoma cell line Caco-2 (ATCC HTB-37) obtained from the 
ATCC (Rockville, MD, USA) were maintained in  Dulbecco´s Modified Eagle’s Medium (DMEM) 
with high glucose content (4.5 g/L) and supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin, and 1% non-essential amino acids at 37 ºC in at humidified atmosphere containing 
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5% CO2. Firstly, the cytotoxicity was evaluated using 3-(4,5-dimethylthiazol)-2,5-diphenyl 
tetrazolium bromide (MTT) method [21]. Then, for the gene expression assays, cells were seeded 
onto a 9.5 cm2 grown area 6 well flat bottom plate (Costar, Corning, USA) at a density of 5 × 105 
cell per well (3.3 × 105 cell/ml) and incubated at 37 ºC and 5% CO2 until confluence. The digested 
extracts were applied at subtoxic concentrations (4 μl/ml) and left incubating for 1 or 24 h. 
For transport assays, cells were seeded at similar densities in a 4.67 cm2 permeable 
membrane support (0.4 μm pore size, Transwell Costar, Corning, USA). Cells were cultivated as 
above described and allowed to differentiate (21 days). The integrity of the cell layer was 
evaluated by measuring the transepithelial electrical resistance (TEER) (Evon, Sarasota, FL) and 
alkaline phosphatase activity (ALP) [22]. The digested extracts were applied to Caco2 cell 
monolayers. Each sample was mixed with medium to a total volume of 1.5 ml per insert and 
applied to the apical (upper) compartment. Then, plates were incubated at 37 ºC and 5% CO2 for 
1 h. Afterwards, the lower compartment was collected and applied to HepG2 cell cultures.  
Treatment of HepG2 with the basolateral compartment of the Caco2 monolayers  
Human hepatoma HepG2 cells, obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) were cultured in Eagle’s Minimum Essential Medium (EMEM) supplemented 
with 10% fetal bovine serum (FBS) and 1% of antibiotic solution (containing 10,000 units/ml of 
penicillin base and 10,000 μg/ml of streptomycin base, Gibco). The cells were maintained under 
standard conditions of temperature (37 ºC), humidity (95%) and CO2 (5%). 
Firstly, the cytotoxicity was evaluated as above described for the Caco2 cell cultures but 
after 3 h incubation. Then, the HepG2 cell cultures were seeded in 6 wells plates (9.5 cm2) and 
cultivated until confluence. Afterwards, cells were treated with the basolateral compartment 
obtained 3 h after the Caco2 transport assay was carried out using as starting material the 
digested extracts or controls. These solutions were applied to HepG2 at subtoxic concentrations 
(6.25 μl/ml) and left incubating at 37 ºC, 95% humidity and 5% CO2 during 1 or 24 h. The medium 
of the basolateral compartment with no addition was also tested as control.  
 
Chapter 4- Manuscript 4 
 
362 
 
Animals and diets  
Animal studies were approved by our institution’s Animal Welfare and Ethics Committee 
and were carried out according to European legislation (2010/63/EU). C57BL/6JRj mice were 
purchased from Janvier SAS (Le Genest Saint Isle, France). They were maintained in a 
temperature-, humidity- and light-controlled room (24 ± 2 ºC, 40-60% humidity, 12:12 hour light: 
dark cycle) and food and water were provided ad libitum. Male mice were randomly divided into 
five groups (n=6-8 per group) and fed with normal diet (Safe Rodent Diet A04, Augy, France; 3% 
fat, NCD) or high-cholesterol diet (NCD diet supplemented with 2% cholesterol, 1% cholic acid, 
HCD). NCD and HCD were also supplemented with 0.67% LWE from L. edodes. HCD groups 
were also treated with 0.025% simvastatin as a positive control for inhibition of cholesterol 
biosynthesis, and HCD plus 0.005% ezetimibe as a positive control for inhibition of cholesterol 
absorption. In order to assess the effects of the mushroom extract in normo- and hyper-
cholesterolemic mice, in the first case, mice were fed NCD for 4 weeks (from 5 to 9 weeks of age) 
supplemented with the LWE. In the second case, mice were fed HCD for 4 weeks to induce 
hypercholesterolemia followed by another 4 weeks of HCD plus LWE (from 10 to 13 weeks of age). 
Plasma and liver lipid analyses, tissue and feces collection 
Mice were sacrificed at the end of experiments by intracardiac exsanguination under 
anesthesia with 1.5% isoflurane, and plasma was collected and stored at -80 ºC. Jejunum, ileum, 
cecum, and liver samples were removed and immediately frozen in liquid nitrogen and stored at   
-80 ºC. Feces were collected at the beginning, after induction of the hypercholesterolemia and at 
the end of the experiments and they were stored at -20 ºC. Cholesterol extraction from feces       
(300 mg) and analysis by GC-MS were carried out as described in [23]. Plasma concentrations of 
total cholesterol, HDL, LDL and triglyceride were measured using a Covas C311 Autoanalyzer 
(Roche, Spain). Total cholesterol and triglyceride concentrations were measured in liver samples 
homogenized according to [23]. 
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RNA extraction, qRT-PCR and gene expression analysis of the low-density array (LDA) 
Total RNA from cell cultures or mice tissues (see later) was extracted and quantified as 
explained in [23].  Total RNA from each sample were reversed, loaded into the micro-fluidic cards 
and run in a 7900HT Fast Real-Time PCR system (Applied Biosystems).  
The micro-fluid card was constructed using respectively human and mouse commercial 
available assays (Applied Biosystems) for several genes related to the cholesterol metabolism, 
some internal standard and housekeeping gene that are described in detail elsewhere [23]. The 
selected cholesterol-related genes were ABCA1 (ATP-Binding Cassette, Sub-Family A, Member 
1), ABCG5 and  ABCG8 (ATP-binding cassette, sub-family G (WHITE), members 5 and 8), ACAT1 
and ACAT2 (Acetyl-CoA acetyltransferase 1 and 2), APOB (Apolipoprotein B), DGAT1 and  
DGAT2 (Diacylglycerol O-acyltransferase 1 and 2), FDFT1 (Farnesyl-diphosphate 
farnesyltransferase 1), HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), LDLR (Low density 
lipoprotein receptor), MTTP (Microsomal triglyceride transfer protein), NPC1L1 (NPC1 (Niemann-
Pick disease, type C1 like 1), NR1H3 and NR1H4 (Nuclear receptor subfamily 1, group H, member 
3 and 4), SOAT1 and  SOAT2 (Sterol O-acyltransferase 1 and 2), SREBF1 and SREBF2 (Sterol 
regulatory element binding transcription factor 1 and 2). Comparative analysis of each of these 
genes was performed using specialized computer programs SDS2.3 and RQ 2.1 (Applied 
Biosystems) [23]. 
Gene expression statistical data analysis 
The expression of each gene was measured at least in triplicate for each sample. In order 
to control for potential outliers, Grubb’s test was applied to technical replicates with a threshold of 
0.05. Biological replicates were quality controlled using the Median Absolute Deviation test (MAD 
test). Samples of the same biological group with a MAD score higher than 3 were removed from 
the analysis. Genorm algorithm [24] was used to identify the most stable reference genes for 
normalization. Genes GUSB (Glucuronidase, beta) and HPRT1 (Hypoxanthine phosphoribosyl 
transferase 1) were found to be the most stably expressed in Caco2 cell cultures while GAPDH 
(Glyceraldehyde-3-phosphate dehydrogenase)and HPRT1 were more stably expressed in HepG2 
cells. In the mouse tissue samples (see later), genes Hprt1 and Polr2a (Polimerase) were the most 
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stably expressed in cecum and liver tissues, Gusb and Polr2a in jejunum and ileum tissues. 
Relative gene expression levels were calculated by using the 2-ΔΔCT method [25]. Statistical 
significance of the results was assessed using a limma test, and Benjamini-Hochberg false 
discovery rate procedure was subsequently applied.  Adjusted p-values lower than 0.05 were 
considered significant. All these calculations were carried out with Real Time StatMiner 4.5® 
(Integromics S.L, Spain).   
 
Results and Discussion 
Water extracts obtained from Lentinula edodes were able of inhibiting the HMG-CoA 
reductase using in vitro tests [11]. However, they did not contain lovastatin as suggested for 
Pleurotus spp. [14] nor pravastatin or simvastatin according to HLPC-MS analysis indicating that 
other compounds might be responsible for the observed inhibition.  Thus, an isolation procedure 
was followed as an attempt to further identify the compounds responsible for the HMGCR inhibitory 
activity found in the water extracts of L. edodes fruiting bodies.  
Identification of the compounds with HMGCR inhibitory activity 
Firstly, a preliminary fractionation of LWE was carried out by molecular weight using 
specific filtering devices with cut-off of 10 and 3 kDa as previously described for other mushroom 
extracts [15, 16]. Opposite to the results observed for A. bisporus or P. ostreatus, the fraction 
obtained from L. edodes including compounds with a molecular weight lower than 3 kDa showed 
higher HMGCR inhibitory activity than those with higher molecular weight (Table 1) suggesting 
that the compounds responsible for the HMGCR inhibition could be small polypeptides or 
oligosaccharides or even lower molecular weight compounds such as specific phenolic 
compounds, acids or alkaloids. The fact that polysaccharides were pointed in the other two 
mushroom species as the compounds responsible for the observed inhibitory activity (and that 
fractions with higher molecular weight also showed interesting inhibitory activities) might also 
suggest that perhaps in this case, the polysaccharides of L. edodes could be smaller or that the 
activity showed at lower molecular weight was due to degradation products or fragments derived 
from larger molecules that might still retain its inhibitory activity when partially degraded. This 
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observation could be interesting because smaller compounds have higher chance of being 
bioavailable and this might suggest that the fragments of larger molecules were still able of acting 
as HMGCR inhibitors.  
On the other hand, L. edodes contains specific bioactive alkaloids with low molecular 
weight such as eritadenine that although its hypocholesterolemic activity was related to the 
inhibition of another enzyme (SAHH) it was not tested whether it could also show HMGCR inhibitory 
activity. The LWE obtained from L. edodes contained 2.07 μg/mg eritadenine (0.41 mg/g dw 
mushroom). However, when commercially available eritadenine was tested using the HMGCR 
activity assay, no inhibitory activity was detected when applied at 10 fold higher concentration 
than in the extract (1 mg/ml).  
Table 1. HMGCR Inhibitory activity of L. edodes fractions before and after certain treatments or isolation 
steps. 
 
 
Process Isolated fraction 
Concentration 
applied (mg/ml) 
HMGR inhibition 
(%) 
Filtration 
L. edodes water extract (directly obtained 
from the mushroom powder) 
50 75.2 ± 1.4 
Fraction < 10 kDa 50* 66.5 ± 6.5 
10 kDa > Fraction > 3 kDa 50* 24.4 ± 1.2 
Fraction < 3 kDa 50* 76.3 ± 1.2 
Dialysis 
L. edodes water extract (directly obtained 
from the mushroom powder) 
50 28.8 ± 6.9 
LWE 50 73.1 ± 3.3 
IN fraction (> 3.5 KDa) 50 53.7 ± 10.2 
OUT fraction (3.5 kDa > fraction > 1KDa) 50 63.3 ± 2.0 
WSP isolation 
L. edodes water extract (directly obtained 
from the mushroom powder) 
10 76 ± 4.1 
WSP fraction after removal of phenolic 
compounds 
5 16.8 ± 4.9 
10 22.6 ± 12 
WSP fraction after removal of phenols and 
proteins 
5 43.6 ± 5.9 
10 89.4 ± 0.5 
*Initial mushroom concentration after fractionation process. 
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Then, the LWE was also fractionated using a double-dialysis system to separate the 
fractions containing those compounds with a molecular weight higher than 3.5 kDa (IN fraction) 
and those with a molecular weight lower than 3.5 but higher than 1 kDa (OUT fraction) in sufficient 
amounts to monitor their composition using FT-IR spectroscopy and to distinguish small 
polypeptides or polysaccharides from lower molecular weight compounds such as phenols, 
monosaccharides, alkaloids etc.  
Dialyzed fractions lacked the mannitol content identified in mushroom fruiting bodies 
(MP) samples by presence of several characteristic signals, peak in the area between 1100-1000 
cm-1 , 860 cm-1 peak and a right shift of water signal (Figure 1a).  Other small molecules present 
in MP and LWE (i.e. simple sugars) were also removed with the dialysis system.  The marked lipid 
band (approx. 1450 cm-1) observed in LWE was also noticed in both dialyzed samples but with 
lower intensity suggesting a possible fractionation of lipid compounds between the IN and OUT 
fractions. Despite different profiles, LWE, IN and OUT fractions contained similar compositions 
including proteins, phenols and polysaccharides but, the ratios between those compounds were 
different. Phenolic compounds were not completely removed with the dialysis in none of the 
isolated fractions. IN fraction showed the highest protein/carbohydrate ratio, followed by OUT and 
LWE fractions. Compared with proteins, a lower phenolic content was found in IN sample, being 
higher and similar for OUT and LWE fractions. Moreover, both IN and OUT fractions showed similar 
HMGCR inhibitory activities (Table 1) reinforcing the possibility that the inhibitors might be 
polysaccharides and that their fragments still retained the inhibitory activity (probably the OUT 
fraction mainly contained smaller fragments from the IN fraction).  
Therefore, further polysaccharide isolation was carried out following the procedure 
utilized for another mushroom specie [16]. The FT-IR analysis of the fractions obtained during the 
purification of the WSP fraction indicated that phenols and monosaccharides were removed after 
washing of the sample with 50% ethanol (Figure 1b) leading to fractions with higher carbohydrate 
and proteins content. The water soluble polysaccharide (WSP) fraction showed a specific signal 
of protein content from amina I and amina II compounds (peaks at 1650 and 1550 cm-1). 
Protein/phenol and protein/carbohydrates ratios of WSP were higher than those from the hot water 
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fraction since WSP fraction contained lower amounts of phenols and carbohydrates. Spectral 
comparison in the range 1500 to 1200 cm-1 between the water soluble fractions (cold/hot) and the 
water insoluble fractions indicated a peak shifting corresponding to the presence in the latter 
fraction of compounds such as chitins, chitins degradation products, α- and β-glucans, mannans 
and other complex polysaccharides. FT-IR analysis showed that although, most of phenols 
seemed to be removed from WSP, some peaks in the phenolic area were still present and that the 
profile in the area from 1200 to 1500 cm-1 could correspond to specific proteo-polysaccharide 
complexes.  
Moreover, when the HMGCR inhibitory activity of the WSP fraction was determined before 
and after a treatment usually applied to remove proteins it could be observed that deproteinization 
increased the inhibitory activity and the inhibition degree was increasing with increasing 
concentrations (Table 1). Therefore, the WSP were also pointed as the compounds responsible 
for the inhibitory activity as observed for A. bisporus and P. ostreatus.  Thus, this fraction was 
injected in GC-MS and NMR to further identify the type of polysaccharides. 
The deproteinized WSP fraction showed a heterogeneous profile when analyzed by 
HPSEC-MALLS and it contains polysaccharides of different molecular weight (data not shown). 
The monosaccharide composition was determined by GC-MS, after total hydrolysis, and it 
presented fucose (8.0%), mannose (13.7%), galactose (36.7%), and glucose (41.6%) as main 
monosaccharides.  
NMR analysis of the deproteinized WSP fraction indicated a great complexity due to the 
presence of high amounts of signals in the anomeric region (Figure 2a), although only 
carbohydrate signals could be observed on the HSQC, 13C and 1H experiments. Based on the 
correlation among the NMR spectra besides comparison with literature data, it was possible to 
identify some anomeric signals referent to β-glucans ( 102.8/4.51), α-glucans ( 99.6/5.36) [26, 
27] and fucomannogalactans ( 101.6/4.79; 101.5/5.13; 101.3/5.07; 98.4/5.21; 98.3/5.12; 
98.0/5.04; 98.0/4.98) [28, 29]. 
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a) 
 
b) 
 
Figure 1. IR spectra from a) the complete L. edodes, the LWE extract and IN and OUT samples and b) from 
the WSP fraction compared to the discarded fraction containing phenolic compounds, a hot water extraction 
and a fraction containing the insoluble polysaccharides. 
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a) 
 
b) 
 
 
Figure 2. a) Anomeric region of the HSQC spectrum of the WSP fraction isolated from L. edodes, in D2O at 
50 ºC (chemical shifts are expressed in ppm). b) HSQC and insert of 13C spectra of the WSP fraction isolated 
from L. edodes, in D2O at 50 ºC (chemical shifts are expressed in ppm). 
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The presence of fucose was confirmed by the signal at  15.6/1.24 ppm (Figure 2b). 
Furthermore, other signals could be observed that confirmed the result of FTIR, and are related to 
the presence of chitin or fragments of chitin. The signals at  20.3/2.15 and 20.4/2.08 ppm (Figure 
2b) are related to the methyl group linked to carbonyl, and the signal at  173.7 ppm is related to 
the carbon of carbonyl group, which is common of N-acetyl-b-D-glucosamine [30, 31]. The β-
glucans are common in mushrooms and their presence in L. edodes has already been reported 
by [29], being described some different molecular weight β-glucans, with (1→3)- and (1→6)-
linkages. In WSP the signal at  84.7/3.73 confirm the presence of (1→3)-linkages. 
Fucomannogalactans were also observed in the same species and also in Amanita muscaria [32]. 
Some variations on the NMR shifts can be observed depending on the calibration, solvent, and 
temperature that was used for the experiment, although the pattern is the same. Furthermore, fungi 
present α-glucans as storage carbohydrate and chitin as structural component, which is probably 
present in WSP as fragments considering it high insolubility in water [33]. 
Modulation of the gene expression pattern in Caco2 and HepG2 cell cultures   
The LWE showing HMGCR inhibitory activity was submitted to in vitro digestion and 
added to Caco2 cell cultures as an attempt to further study the bioavailability of the HMGCR 
inhibitors. However, the enzymes used for digestion and the complex media mixture used to 
carried out the transport experiments impaired the proper HMGCR activity determination. Thus, 
the influence of the LWE in the expression of genes related to the cholesterol metabolism was 
measured after a sort (1 h) and a longer (24 h) incubation periods as another strategy to further 
study the extract effect on the cholesterol metabolism (and indirectly its bioavailability).  
Results indicated that no significant differences were found between the modulation 
induced by a digestion control with no L. edodes extract and the digested LWE in any of the 
selected genes. HMGCR inhibitory extracts obtained from other mushrooms (A. bisporus and P. 
ostreatus [15, 16] were similarly ineffective (data not shown) thus, the inhibitors were not 
influencing transcriptional responses in Caco2 cells (or were not bioavailable).  
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However, when the basolateral compartment of the Caco2 monolayer where the 
digestate of the L. edodes extract was added (containing those compounds able of passing 
through the cells) was applied to HepG2 cell cultures, a significantly different modulation of the 
expression was observed after 24 h compared to the control (Figure 3). The genes involved in the 
biosynthesis of cholesterol such as HMGCR and, downstream the pathway, the FDFT1 (squalene 
synthethase) were significantly overexpressed as well as the SOAT1 (sterol O-acyltransferase). 
Two cholesterol homeostasis regulators: SREBF1 and NR1H4 (nuclear factor FXR) were also 
inversely modulated while a cholesterol carrier was slightly down-regulated (APOB). Other 
enzymes involved in the lipid metabolism such as ACAT (acetyl-CoA acetyltransferases) and 
DGAT1 (diacylglycerol O-acyltransferase) were also up-regulated.  
Results suggested that the compounds from the water extracts were not affecting the 
intestinal-like cell cultures but affected the hepatic cells. Thus, the responsible compounds might 
be bioavailable or might be transformed into something able to modulate, at the molecular level, 
not only cholesterol homeostasis but also the lipid metabolism.  
Previous reports indicated that L. edodes was able of inducing hypocholesterolemia and 
reducing the triacylglycerol levels in rats due to its content in eritadenine via modifications in the 
hepatic phospholipid metabolism [8, 10]. Thus perhaps, eritadenine could also be involved in the 
observed molecular changes although it was never related to the HMGCR mRNA transcription nor 
activity levels. Moreover, the fact that the HMGCR and FDFT1 mRNAs were not modified shortly 
after application (1 h) but up-regulated (together with other cholesterol biosynthetic genes) after 
certain time could suggest certain response mechanism to a previous lack or insufficient HMGCR 
activity.  
Perhaps eritadenine or the compounds derivatives from the HMGCR inhibitory 
polysaccharides might show certain involvement in cholesterol metabolism but at post-
transcriptional level. Thus, in order to further clarify this effect in vivo studies were carried out. 
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Figure 3. Relative mRNA expression (Log10) of LDA gene expression pattern of HepG2 cells after 24 h 
application of the basolateral compartment of Caco2 cell cultures collected 1 h after the transport assay was 
performed in which the fraction isolated after digestion of the LWE obtained from L. edodes mushroom was 
applied. Indicated genes were those pointed as statistically significant (p< 0.05) compared with their 
controls (HepG2 cells with no supplementation).   
Modulation of the gene expression pattern in normocholesterolemic animal studies   
LWE showing HMGCR inhibitory activity (92.2 ± 1.9 % inhibition when applied at 50 
mg/ml) was administrated to normocholesterolemic mice for 4 weeks and its effects on serum and 
liver cholesterol levels and genes expression were recorded. Levels of total cholesterol (TC), 
triglycerides (TG), LDL and HLD in serum of normocholesterolemic mice administrated with the 
LWE were respectively 75.32 ± 15.88, 48.78 ± 4.41, 27.77 ± 5.49 and 52.31 ± 11.69 mg/dl values 
that were not significantly different than the NCD control mice (Table 2). No cholesterol was 
observed in the feces at the beginning of the experiment but two weeks after LWE administration 
a slight cholesterol amount was significantly noticed (3.63 ± 1.93 mg/g feces) although after 4 
weeks their levels were again reduced (1.08 ± 1.42 mg/g feces) until they were no significantly 
different than the control. However, the LWE significantly modified the transcription profile of the 
supplemented mice, particularly in liver.  
Inclusion of the L. edodes extract in mouse diet induced up-regulation of the Fdft1 gene 
and down-regulation of the Apob gene in jejunum, the tissue where cholesterol is mainly absorbed 
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(Figure 4). The observed increase in the mRNA levels of the squalene synthetase might involve 
stimulation of the cholesterol biosynthesis however, in that case probably the Hmgcr and Soat1 
mRNA should have also been induced (as observed for HepG2 in the in vitro study). Since the 
squalene synthetase is located in the intersection of a few metabolic branches, perhaps in this 
case it is stimulated to generate other intermediate metabolites yielding steroids or other 
triterpenoids. Apob gene encode for apolipoproteins (Apolipoprotein B-48 in intestine and B-100 
in liver) which are lipid and cholesterol carriers to transport them through the blood. Thus, a 
reduction in the Apob mRNA transcription in jejunum might negatively affect the intestinal 
chylomicrons formation since apoliproteins B-48 are building blocks of these particles.   
Table 12. Plasma, liver and feces lipid profile in normocholesterolemic and hypercholesterolemic mice 
treated with a water extract from Lentinula edodes, simvastatin or ezetimibe. 
 
As noticed in vitro, hepatic cells in mice were more affected by the L. edodes extract 
than intestinal cells (no significant modulation of the gene expression was neither noticed in ileum 
or cecum) and showed similar modulation profiles for genes such as Hmgcr, Acat1 and Nr1h4 
(FXR), they were in both cases overexpressed. Moreover, similar modulation of the transcription 
Variable 
Plasma level (mg/dL) 
NC HC LWE SV EZ 
TC 65.3 ± 26.6 214.2 ± 97.3a 206.0 ± 47.3a,d 156.2 ± 31.8a,d 59.4 ± 19.0b 
HDL 59.8 ± 25.0 89.7 ± 27.9 91.6 ± 19.4d 81.9 ± 21.9d 47.9 ± 10.4b 
LDL 23.4 ± 11.0 155.0 ± 77.3a 133.5 ± 36.6a,d 102.5 ± 24.0a,d 23.40± 14.9b 
TC/HDL 1.1 ± 0.0 2.3 ± 0.3a 2.2 ± 0.2a,d 1.9 ± 0.2a 1.22 ± 0.16b,c 
LDL/HDL 0.3 ± 0.1 1.6 ± 0.3a 1.4 ± 0.2a,d 1.3 ± 0.2a 0.46 ± 0.23b,c 
TG 72.0 ± 20.0 47.2 ± 8.4a 32.5 ± 9.6a 46.2 ± 11.0a 43.4 ± 8.3a 
 Liver level (mg/g tissue) 
TC 0.22 ± 0.09 1.09 ± 0.23
a 1.20 ± 0.28a,d 1.44 ± 0.43a 0.45 ± 0.20b,c 
TG 4.49 ± 0.87 3.72 ± 0.61 0.63 ± 0.20a,b 0.78 ± 0.18a,b 0.88 ± 0.52a,b 
 
Fecal level after 4 weeks (mg/g feces) 
TC nd 61.83 ± 0.46a 49.33 ± 7.37a,b 65.40 ± 7.41 60.20 ± 14.7 
NC, normal control; HC, hypercholesterolemic control; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low density lipoprotein 
cholesterol; TG, triglyceride. aP<0.05 vs. NC; bP<0.05 vs. HC; cP<0.05 vs. SV; dP<0.05 vs. EZ;  nd, non-detected. 
The results are mean ± SD of six-eight mice on each diet and were analyzed by one-way ANOVA and the Bonferroni’s procedure.. 
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of the Srebfs regulators was observed but, in vitro the Srebf1 gene was significantly down-
regulated (Figure 3) while in vivo the influenced gene was Srebf2.  
 
 
Figure 4. Relative mRNA expression (Log10) of cholesterol-related genes in jejunum, ileum, cecum and liver 
of normocholesterolemic mice fed for 4 weeks with normal diet plus LWE. Indicated genes are only those 
pointed as statistically significant (p< 0.05) compared with normocholesterolemic mice with only NC diet as 
control.  Few genes did not pass the quality control either in the target or the control group, and therefore 
their expression level was omitted in the figure. 
The effect on the Apob gene expression was opposite to the one observed in HepG2 
since overexpression of this mRNA was recorded in liver of normocholesterolemic mice. Perhaps 
it was a type of compensating mechanism for the down-regulation observed in jejunum, 
suggesting that the potential reduction of the ApoB-48 biosynthesis was compensated by 
induction of ApoB-100 synthesis in liver. This might influence the lack of noticeable changes in 
the biochemical cholesterol parameters in plasma. 
Nevertheless, the fact that in vivo the Hmgcr transcription was also stimulated (and 
perhaps also the Fdft1 in jejunum) could, as before suggested for the in vitro results, indicate that 
the mice liver was noticing certain lack of cholesterol that could be due to a possible enzyme 
inhibition (at the post-translational level) or due to certain cholesterol excretion (noticed after 2 
weeks) which should have activated correcting mechanisms (after 4 weeks no excretion was 
noticed) to maintain the homeostasis thus, another in vivo experiment was carried out to 
investigate the effect of the extract when the cholesterol homeostasis is altered such as under 
hypercholesterolemic conditions.     
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Modulation of the gene expression pattern in hypercholesterolemic animal studies   
Feeding of mice with the hypercholesterolemic diet increased the cholesterol levels in 
plasma 3.3 folds although levels of triglycerides were reduced (Table 2). The increase was mainly 
due to higher LDL concentrations in serum. Treatment with ezetimibe or simvastatin, two drugs 
utilized to impair respectively cholesterol absorption and biosynthesis affected differently the 
cholesterol levels in serum since only ezetimibe was able to significantly induce reduction in TC, 
HDL and LDL concentrations in serum compared to HC mice. Administration of the LWE obtained 
from L. edodes showed biochemical values similar to those observed after the treatment with 
simvastatin since they both were unable to significantly reduce cholesterol levels in plasma but 
reduce TG levels in liver compared to hypercholesterolemic mice.  Surprisingly, cholesterol fecal 
excretion in mice fed LWE extract was significantly lower than HC. 
Similarities between the effect of the LWE from L. edodes and simvastatin were also 
noticed at the molecular level (Figure 5). For instance, in both cases the Abcg8 and Acat1 genes 
were upregulated and the Srebf2 down-regulated in jejunum (Figure 5a and 5b). In liver, also in 
both cases down-regulation of the Dgat1 gene was recorded. The expression of Nr1h4 (FXR) was 
in both type of samples also down-regulated but in mice treated with simvastatin the effect was 
noticed in liver while in the mice supplemented with the mushroom extract the effect was noticed 
in jejunum. In this case, the modulation was more similar to the other drug since inhibition of the 
Nr1h4 transcription was also noticed in the jejunum of mice treated with ezetimibe (Figure 5c). 
The administration of the mushroom extract showed also certain similarities at the 
molecular level with the effect of ezetimibe but in other tissues such as in cecum in both cases 
overexpression of the Abcg5 gene was observed and inhibition of the Ffdt1 gene was noticed in 
ileum. Moreover, ezetimibe treatment was also able of inhibiting transcription of the Srebf2 gene 
in jejunum as observed after simvastatin treatment or extract administration. This treatment also 
up-regulated the Npc1l1 gene, probably because its translation product, the Niemann-Pick C1-
like 1 protein is the ezetimibe target and therefore, an inhibition of the cholesterol transporter would 
trigger a response mechanism such as increasing its transcription, particularly after 4 weeks of 
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treatment when the biochemical parameters showed a correction for the induced 
hypercholesterolemia. 
Wise to mention is the completely different transcription profile generated by the same 
mushroom extract in normo (Figure 4) or hypercholesterolemic (Figure 5a) mice. Particularly in 
liver, genes such as Soat2 and Dgat1 in one case were up-regulated and in the other down-
regulated. Opposite behaviors were also found (but within different tissues) for the expression of 
other genes such as Fdft1 and Nr1h4. The inhibition of Dgat1 transcription in hypercholesterolemic 
mice administrated LWE or simvastatin might be related to the lower hepatic TG levels noticed in 
these cases as it would inhibit triglyceride biosynthetic pathway (perhaps due to the eritadenine 
content of the extract as it was previously described as the metabolite able of altering this 
mechanism). 
SREBPs (Sterol Regulatory Element-Binding Proteins) directly activate the expression of 
more than 30 genes dedicated to the synthesis and uptake of cholesterol, fatty acids, triglycerides, 
and phospholipids, as well as the NADPH cofactor required to synthesize these molecules. Both 
SREBP-1a and -1c are derived from a single gene (SREBF1) by alternative transcription and 
SREBP2 is encoded by the SREBF2 gene. SREBP-1a is a potent activator of all SREBP-responsive 
genes, including those that mediate the synthesis of cholesterol, fatty acids, and triglycerides. The 
roles of SREBP-1c and SREBP-2 are more restricted than that of SREBP-1a. SREBP-1c 
preferentially enhances transcription of genes required for fatty acid synthesis but not cholesterol 
synthesis. Like SREBP-1a, SREBP-2 preferentially activates cholesterol synthesis. SREBP-1a and 
SREBP-2 are the predominant isoforms of SREBP in most cultured cell lines, whereas SREBP-1c 
and SREBP-2 predominate in the liver and most other intact tissues. Thus, the down-regulation of 
Srebf2 mRNA observed in the animals treated with the two drugs and the mushroom extract might 
indicate inhibition of cholesterol synthesis in jejunum.  
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a) 
 
b) 
 
c) 
 
 
Figure 10. Relative mRNA expression (Log10) of cholesterol-related genes in jejunum, ileum, cecum and 
liver of hypercholesterolemic mice fed for 4 weeks with HCD supplemented with a) the LWE extract b) 
simvastatin or c) ezetimibe. Indicated genes are only those pointed as significant (p< 0.05) compared with 
hypercholesterolemic mice fed only HCD as control.  Few genes did not pass the quality control either in the 
target or the control group, and therefore their expression level was omitted in the figure. 
However, FXR (the nuclear receptor encoded by NR1H4) regulates not only a wide 
variety of genes involved in bile acid synthesis, metabolism, and transport but is also critically 
involved in triglyceride, cholesterol and glucose metabolism [34]. Activation of FXR by bile acids 
(or nonsteroidal synthetic FXR agonists) lowers plasma triglycerides by a mechanism that may 
involve the repression of hepatic SREBP-1c expression and/or the modulation of glucose-induced 
lipogenic genes. Thus, FXR activation improved hyperglycemia and dyslipidemia in diabetic 
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mice.  Thus, the inhibition of Nr1h4 transcription observed in the animals treated with the drugs 
and the extract would suggest an opposite effect than above described. Moreover, FXR-deficient 
(FXR-/-) mice displayed elevated serum levels of triglycerides and high-density lipoprotein 
cholesterol. 
On the other hand, overexpression of the mRNAs of both ABC carriers (ABCG5/8) was 
related to stimulatory effects of the cholesterol intestinal efflux although in this case the activation 
was noticed in cecum and not in jejunum were might be expected. The fact that non-digestible 
polysaccharides passes along the small intestine and get accumulated in cecum and colon might 
be related with this observation. 
However, the real significance of all these changes at the molecular level at this moment 
is a bit speculative since many genes belonging to different metabolic pathways were modified 
including two genes (encoding the regulatory molecules SREBP2 and FXR) that should activate 
opposite mechanisms. However, an extract showing similar modulatory effects than two 
commercial drugs utilized against hypercholesterolemia and reduced TG content in liver seemed 
quite interesting, therefore at the present further studies are being conducted using higher doses 
of the LWE in order to light up the real significance of the results.    
 
Conclusions 
The water extracts of L. edodes contained specific polysaccharides able of inhibiting the 
HMGCoA reductase in vitro. The extracts also modified the expression of genes related to the 
cholesterol homeostasis in HepG2 cell cultures and similarly in normocholesterolemic mice. 
Extract administration to hypercholesterolemic mice induced a complete different expression 
profile but it was similar to the modulation observed when mice where treated with drugs utilized 
to lower cholesterol levels in serum, particularly to simvastatin however, neither LWE nor 
simvastatin were able of lowering cholesterol levels in plasma. They reduced the triglyceride 
content in livers which might be related to the Dgat1 down-regulation observed. Therefore, this 
mushroom extract might have potential to be used as functional ingredient to design 
hypolipidemic / hypocholesterolemic foods acting via a different mechanism that the compounds 
actually commercialized. The lack of statistical significance in the plasmatic biochemical 
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parameters encouraged further dose-related experiments since modulation of key genes involved 
in the cholesterol metabolism are being modulated.   
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 Preface  
 As previously mentioned, the normal activity of cholesterol metabolism could be altered 
by certain modulatory compounds able to modify one of the two major pathways regulating 
cholesterol levels: the exogenous cholesterol absorption or the endogenous cholesterol 
biosynthesis. Thus, if one of these pathways is impair/stimulated the human body compensate it 
by enhancing/inhibiting the activity of the other to maintain cholesterol homeostasis and bring 
back normal cholesterol blood levels. Thus, lower cholesterol absorption rates induce higher 
activities of cholesterol biosynthetic enzymes and vice versa. 
Apparently, ergosterol and ergosterol-derivatives and dietary fibers such as β-glucans 
or chitins-derivatives products were modulators more oriented toward the cholesterol absorption 
pathway while other mushroom polysaccharides (with HMGCR inhibitory activity), also pointed as 
modulators, might probably be more involved in the cholesterol biosynthetic pathway although all 
these compounds were also capable of modulating the expression of some genes involved in both 
and other regulatory pathways related to the cholesterol metabolism. Therefore, the next logic step 
to follow was to prepare a specific mixture of all the investigated compounds and study whether 
it could lower cholesterol levels in mice by interfering at both cholesterol-generating pathways 
acting then as a double targeting hypocholesterolemic mixture.  
 Thus, the extracts detailed in preceding chapters were individually and jointly introduced 
in a specific food matrix simulating a specifically supplemented food product. Lard was selected 
as ideal food matrix because of its high cholesterol and saturated lipid levels, mimicking unhealthy 
eating habits related with cardiovascular diseases to evaluate whether the fungal extracts were 
able to overcome its negative influence for mice health. Mice were fed a hypercholesterolemic 
diet simultaneously with the supplemented food products and their influence on cholesterol 
metabolism was studied by measuring cholesterol- and triglyceride-related parameters in plasma, 
liver and feces. Furthermore, cholesterol-related gene expression profiles were studied in several 
mice tissues (jejunum, cecum, liver).The most relevant results are summarized in the work titled 
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The cholesterol-lowering effects of food products supplemented with specific fungal extracts are 
independent of Niemann-Pick C1-like 1 protein and ABC sterol transporters gene expression in 
mice fed an hypercholesterolemic diet. 
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Abstract 
Mushrooms are a source of β-glucans and ergosterol, which have been shown to 
significantly lower cholesterol. However, food matrices functionalized with mushroom extracts 
have been less widely studied and their underlying mechanisms remain still unclear. An animal 
model was used to investigate the effect of lard supplemented with mushroom extracts on the 
cholesterol metabolism and the transcriptional changes of cholesterol-related genes. Mice were 
fed a hypercholesterolemic diet, and concomitantly lard functionalized with mushroom extracts at 
0% HC, 2.77% BGF, 1.23% WPF, 0.44% EGF, or 4.44% (w/w) MIF for 4 weeks. BGF was a                 
β-glucan enriched extract, WPF was an extract containing specific water-soluble polysaccharides 
with HMGCR inhibitory activity and EGF was an ergosterol-enriched extract. MIF was a mixture of 
BGF, WPF and EGF. Functionalized foods significantly reduced plasma cholesterol levels by 22% 
to 42%, HDL by 18% to 40%, and LDL by 25% to 51% and they led to different tissue-specific 
expression profiles with a higher regulation in the intestine than in the liver. BGF and MIF 
significantly increased jejunal mRNA levels of Npc1l1 and Abcg5 genes and hepatic mRNA levels 
of Npc1l1 gene. None of the tested foods significantly modify the expression of other cholesterol-
related genes. In conclusion, lard functionalized with mushroom extracts may help limiting 
cholesterol levels when consuming hypercholesterolemic diets and show good prospect to be 
developed into functional foods. Their cholesterol-lowering effect was not mediated via 
transcriptional changes of Npc1l1 or ABC sterol transporters. Further studies to determine 
mechanisms of action are needed. 
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Introduction 
Consumption of edible/medicinal mushrooms such as Pleurotus spp. and Lentinula 
edodes has beneficial effects on cardiovascular diseases [1, 2] mainly because they were able of 
decreasing hypercholesterolemia, one of the major risk factor for coronary heart disease. 
Pleurotus ostreatus decreases plasma cholesterol levels in both humans [3] and animals [4, 5] 
and cholesterol-lowering effect of Lentinula edodes has also showed in rats [6]. Concerning their 
bioactive compounds, most evidence pointed to β-glucans [7], ergosterol and derivatives [8], 
lovastatin [9], eritadenine [10] and phenolic compounds [11]. However, the underlying 
mechanisms of these effects are only partially understood. 
Hypocholesterolemic effect can take place by decreasing intestinal cholesterol 
absorption, where Niemann-Pick C1-Like 1 (NPC1L1) protein is essential [12]. In fact, ezetimibe, 
a potent cholesterol absorption inhibitor acting through NPC1L1, it is used in the clinics for 
management of dyslipidemias [13]. On the other hand, cholesterol absorption is mainly regulated 
by the sterol efflux transporters Abcg5 and Abcg8 in the small intestine of mice [14]. ABCG5 and 
ABCG8 form a complex that transport cholesterol from the enterocyte back into the intestinal 
lumen counteracting cholesterol absorption and is also expressed in liver where it promotes the 
excretion of cholesterol into bile. Increased expression of Abcg5 and Abcg8 in mice decreases 
dietary cholesterol absorption and increases biliary cholesterol secretion [15]. 
Competition and displacement of cholesterol by other molecules for incorporation into 
dietary mixed micelles decreasing intestinal cholesterol absorption have been pointed as one of 
the possible mechanisms underlying cholesterol-lowering effect of plant stanols, phytosterols and 
fungal sterols such as ergosterol [16-18]. 
The hypocholesterolemic mechanism of β-glucans are also still unclear, some studies 
pointed their ability to bind to bile acids within micelles in the intestine, preventing the entry of bile 
acids into blood and therefore removing them from the enterohepatic circulation as one of the 
potential mechanisms [19]. The decreased bile acids returned to the liver in turn activates 
cholesterol 7α-hydroxylase that catalyze the conversion of cholesterol into bile acids leads a 
compensatory increase in hepatic LDLR expression which results in reduced LDL and cholesterol 
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levels.  Bile-acid binding capacities for fungal β-glucans have been described but using in vitro 
assays [20, 21]. Moreover, the subsequent addition of mushroom β-glucans to ergosterol enriched 
extracts increased cholesterol displacement from the DMM [18].  
Statins are a class of drugs that reduce synthesis of cholesterol in the liver by 
competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), leading to 
decreased plasma cholesterol levels. Moreover, the reduction in intracellular cholesterol 
concentration induces low-density lipoprotein receptor (LDLR) expression on the hepatocyte cell 
surface, which results in a decreased concentration of circulating LDL-cholesterol [22]. However, 
the presence of lovastatin or other statins in mushroom is actually under discussion, some 
publications monitored their presence in several mushroom strains [23, 24] and other found no 
statins [3, 25, 26] but other compounds such as lanosteroids, ganoderols etc. able of reducing 
the mRNA expression of the HMG-CoA reductase or specific water-soluble polysaccharides 
showing HMGCR inhibitory activity with in vitro tests [26-29].  
The studies carried out to demonstrate the hypocholesterolemic effects of edible 
mushrooms have mostly been performed using powdered fruiting bodies, broth cultured mycelia 
or specific water/organic extracts. However, their bioavailability and efficacy when added into a 
food matrix are still not studied in detail and food nature may influence the efficiency of the 
bioactive compounds when integrated into food matrices [18]. Therefore, in this study, in order to 
emulate usual inadequate eating habits related with dyslipidemia, lard was chosen as a food 
matrix and it was supplemented with 3 different mushrooms extracts. The extracts contained very 
different bioactive compounds such as β-glucans, ergosterol and derivatives and a water extract 
containing polysaccharides with HMGCR inhibitory capacity and eritadenine. A mixture of the 3 
extracts was also integrated into the food matrix to detect possible positive or negative synergies 
and their hypocholesterolemic effects studied. The influence of lard supplemented with mushroom 
extracts was examined on plasma lipids and fecal cholesterol in mice fed a high-cholesterol diet. 
In addition, low-density arrays were used in order to identify genes regulated by mushroom foods 
in the small intestine, liver and cecum. 
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Materials and Methods 
Biological material  
Fresh fruiting bodies of Pleurotus ostreatus (Jacq.Ex Fr.) Kummer strain ¨Gurelan H-
107¨ and Lentinula edodes S. (Berkeley) from ¨Sylvan 4312¨ from the first flush were harvested, 
cut in slices, lyophilized and ground until a dry powder was obtained following the procedure 
described by [30]. Resulting mushroom powders were utilized as starting material to prepare a 
dietary fiber extract rich in β-glucans, an extract containing eritadenine and water soluble 
polysaccharides with HMGCR inhibitory activity and an ergosterol-enriched extract.  
Commercially available lard (Iberian pork lard (100 g fat/100 g food), BHT, BHA) was 
purchased from a local supermarket and maintained at 4 ºC until use. All the experiments were 
performed from the same lotus. 
Preparation of a food product containing a β-glucans-enriched extract (BGF) 
 A β-glucan-enriched fraction from Pleurotus ostreatus was prepared according to the 
method of [31]. This fraction contained 39.87 mg/100mg (dw) β-glucans, 7.70 mg/100mg α-
glucans and 6.10 mg/100mg chitins [32]. The extract (2.77%) was mixed with lard (12%) by slightly 
melting of the lipid matrix and the resulting supplemented food product (BGF) was utilized for 
animal feeding. 
Preparation of a food product containing an extract with water-soluble polysaccharides (WPF) 
Lentinula edodes dry powder was mixed with MilliQ water and stirred gently during 1 min 
in a Vortex at room temperature. Afterwards, the solution was centrifuged at 12000 rpm during 2 
min and supernatant collected and freeze-dried [29]. The obtained extract contained no statins 
but 0.21 mg/100mg eritadenine, 26.49 mg/100mg proteins and 31.51 mg/100mg of 
polysaccharides of which only 9.74 mg/100mg were β-glucans but it also contained α-glucans 
and fucomannogalactans. The polysaccharides were able of inhibiting the HMGCR activity [29]. 
The extract (1.23%) was mixed with lard (12%) by slightly melting of the lipid matrix and the 
resulting supplemented food product (WPF) was utilized for animal feeding.  
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Preparation of a food product containing an ergosterol-enriched extract (EGF) 
A fungal sterols-enriched fraction from Lentinula edodes was prepared according to the 
method of [30]. Mushroom powder (80 g) were mixed with washed sea sand (900 g) and submitted 
to supercritical fluid extraction (SFE) with CO2. Extraction was carried out at 18 MPa and 40 ºC 
with a total extraction time of 3 h.  Obtained fractions were immediately dried on a rotary vacuum 
evaporator and stored at -20 ºC. This fraction contained 37.3 mg/100mg ergosterol, 6.5 mg/100 
mg ergosta-5,7-dienol, 2.6 mg/100 mg fungisterol and 1.5 mg/100 mg ergosta-7,22-dienol [33]. 
The extract (0.44%) was mixed with lard (12%) by slightly melting of the lipid matrix and the 
resulting supplemented food product (EGF) was utilized for animal feeding.  
Preparation of a food product containing a mixture of BGF, WPF and EGF (MIF) 
A mixture of the 3 above described extracts (4.44%) was prepared and added to lard 
(12%) by slightly melting of the lipid matrix and the resulting supplemented food product (MIF) 
containing 2.77% BGF + 1.23% WPF + 0.44% EGF was utilized for animal feeding. 
Experimental design 
Male C57BL/6JRj mice (9 weeks old), were purchased from Janvier SAS (Le Genest Saint 
Isle, France). The mice were maintained in temperature-, humidity- and light-controlled conditions 
(24 ± 2 ºC, 40-60% humidity, 12:12 hour light: dark cycle) and had free access to water and food. 
The experimental protocol was approved by our institution’s Animal Welfare and Ethics Committee 
and was carried out according to internationally approved guidelines (2010/63/EU). Animals were 
randomly divided into six groups (n=8 per group). Mice fed a high-cholesterol diet used as control 
(HC) were administrated a standard diet (Safe Rodent Diet A04, Augy, France) supplemented with 
2% cholesterol, 1% cholic acid and 12% lard (w/w). The other groups were fed the same diet as 
HC but lard was substituted by BGF, WPF, EGF or MIF. Mice were fed for 4 weeks and fasted 12 
hours before harvesting blood for subsequent lipid measurements, and jejunum, liver and cecum 
for RNA isolation. Both the mice and the food were regularly weighed to determine changes in 
body weight and food intake. 
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Blood and feces biochemistry 
Blood samples were obtained from retromandibular vein before the administration of 
experimental diets (baseline samples) or intracardiac exsanguination under isoflurane anesthesia 
(1.5%) at the end of the study. Plasma was collected and stored at -80 ºC before use. Plasma 
levels of total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were measured 
using an Automated Analyzer (Covas C311, Roche, Spain). Cholesterol extraction from the stored 
feces (300 mg) and analysis by GC-MS were carried out as described in [33].  
Statistical Analysis of biochemical data 
To determine statistically significant differences among dietary groups, the data were 
analyzed at P<0.05 by one-way ANOVA, followed by Tukey’s test, using SPSS software (LEAD 
Technologies, Chicago, IL, USA). Data are expressed as means ± SEM. 
RNA extraction and quantitative real-time PCR 
Total RNA from cell cultures or mice tissues was extracted by magnetic bead technology 
using a pureLinkTM Total RNA kit TRIzol® Plus RNA Kit (Invitrogen, Carlsbad, CA, USA) in an 
iPrepTM Purification Instrument (Invitrogen) programmed with an iPrepTM total RNA card 
(Invitrogen) according to manufacturer instructions. The RNA concentration was determined by 
spectrophotometry at 260 nm and the purity of the extracted RNA was calculated from ratio of 
absorbance at 260:280 nm and 260:230 nm in a NanoDrop ND-1000 (NanoDrop Technologies 
Inc., Wilmington, DE, USA).An amount of 400 ng of total RNA from each sample were reversed 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Framinghan, MA, USA). The obtained cDNA (100 µl per port) were loaded into the fluidic cards. 
Before sealing them, the cards were centrifuged twice on a Sorvall centrifuge at 1200 rpm for 1 
min. Finally, the micro fluidic cards were run in a 7900HT Fast Real-Time PCR system (Applied 
Biosystems). Amplification conditions were 50 ºC for 2 min, 94.5 ºC for 10 min, followed by 40 
cycles with 97 ºC with 30 s and 59.7 ºC for 1 min. 
Gene expression by Low Density Array (LDA) procedures 
The micro-fluid card (Applied Biosystems TaqMan Array Micro-Fluid Cards) was 
constructed using respectively human and mouse commercial available assays (Applied 
Chapter 5- Manuscript 1 
 
396 
 
Biosystems) for several genes related to the cholesterol metabolism (Table 1) and the internal 
standard and housekeeping genes.Comparative analysis of each of these genes was performed 
using specialized computer programs SDS2.3 and RQ 2.1 (Applied Biosystems). 
Gene expression statistical data analysis 
The expression of each gene was measured at least in triplicate for each sample. In order 
to control for potential outliers, Grubb’s test was applied to technical replicates with a threshold of 
0.05. Biological replicates were quality controlled using the Median Absolute Deviation test (MAD 
test). Samples of the same biological group with a MAD score higher than 3 were removed from 
the analysis. Genorm algorithm [34] was used to identify the most stable reference genes for 
normalization. Genes Gusb and Hprt1 were found to be the most stably expressed in the mouse 
tissue samples. Relative gene expression levels were calculated by using the 2-ΔΔCT method [35]. 
Statistical significance of the results was assessed using a Limma test, and Benjamini-Hochberg 
false discovery rate procedure was subsequently applied.  Adjusted p-values lower than 0.05 
were considered significant. All these calculations were carried out with Real Time StarMiner 4.5® 
(Integromics S.L, Spain).   
Results 
Functionalized foods lower plasma levels of cholesterol, HDL and LDL 
Diets with or without supplemented foods were well tolerated by mice. There were no 
significant differences in final body weights or dietary intake among groups (data not shown). 
Plasma total cholesterol, HDL, LDL and triglycerides were determined at baseline and at the end 
of the experiments (week 4). Total cholesterol and LDL were markedly increased in mice controls 
fed a high-cholesterol diet (HC) at the end of the dietary period with respect their own baseline 
levels (2.9, 26 fold, P<0.05, respectively), while HDL slightly increased (1.43 fold). Compared with 
HC, 22-42% reduction of plasma total cholesterol was observed in mice fed supplemented foods 
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Table 1. ABI (Applied Biosystems) commercial reference and NCBI reference sequence of the selected genes 
from Mus musculus and internal controls used in the LDA design. 
ABI code for 
Mus musculus 
Reference sequence/s Gen Description 
Mm00442646_m1 NM_005502.3 Abca1 
ATP-Binding Cassette, Sub-Family A (ABC1), Member 
1 
Mm00446241_m1 NM_022436.2 Abcg5 
ATP-binding cassette, sub-family G (WHITE), member 
5 
Mm00445970_m1 NM_022437.2 Abcg8 
ATP-binding cassette, sub-family G (WHITE), member 
8 
Mm00507463_m1 NM_000019.3 Acat1 Acetyl-CoA acetyltransferase 1 
 NM_005891.2 Acat2 Acetyl-CoA acetyltransferase 2 
Mm01545156_m1 NM_000384.2 ApoB Apolipoprotein B 
Mm00815354_s1 NM_004462.3 Fdft1 Farnesyl-diphosphate farnesyltransferase 1 
Mm01282499_m1 NM_000859.2 NM_001130996.1 Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase 
Mm00440169_m1 
NM_000527.4, 
NM_001195798.1NM_001195799.1N
M_001195800.1 
NM_001195802.1NM_001195803.1 
Ldlr Low density lipoprotein receptor 
Mm01191972_m1 NM_001101648.1 NM_013389.2 Npc1l1 NPC1 (Niemann-Pick disease, type C1, gene)-like 1 
Mm00443451_m1 
NM_001130101.2 
NM_001130102.2NM_001251934. 
NM_001251935.1 NM_0056933 
Nr1h3 
(Lxrα) 
Nuclear receptor subfamily 1, group H, member 3 
(LXRα) 
Mm00436425_m1 
NM_001206977.1NM_001206978.1 
NM_001206979.1 NM_001206992.1 
NM_001206993.1 NM_005123.3 
Nr1h4 
(Fxrα) 
Nuclear receptor subfamily 1, group H, member 4 
(FXRα) 
Mm00486279_m1 
NM_001252511.1 NM_001252512.1 
NM_003101.5 
Soat1 Sterol O-acyltransferase 1 
Mm00448823_m1 NM_003578.3 Soat2 Sterol O-acyltransferase 2 
Mm00550338_m1 NM_001005291.2 NM_004176.4 Srebf1 Sterol regulatory element binding transcription factor 1 
Mm01306292_m1 NM_004599.2 Srebf2 Sterol regulatory element binding transcription factor 2 
Mm00839493_m1 NM_002046.4 Polr2a polimerase 
Mm00446953_m1 NM_000181.3 Gusb Glucuronidase, beta (internal control) 
Mm00446968_m1 NM_000194.2 Hprt1 
Hypoxanthine phosphoribosyltransferase 1 (internal 
control) 
18S-Hs99999901_s1  Rn18s1 RNA, 18S ribosomal 1 (housekeeping gene) 
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for 4 weeks, with a significant reduction for BGF, WPF and MIF (Figure 1a). HDL levels were 
reduced by 18-40% compared with HC, with a significant reduction for WPF (Figure 1b). LDL 
levels were markedly increased due to the high cholesterol diet from day 0 to the end of the 
experimental period. A higher reduction in LDL levels (27-51%) compared with that of HDL was 
observed, with a significant reduction in LDL levels for BGF and WPF mushroom foods (Figure 
1c). 
 a)                                                 b)                                                 c) 
 
Figure 11. Supplemented foods lower plasma levels of cholesterol, HDL, and LDL. Plasma total cholesterol 
(a), HDL (b), and LDL (c) levels in mice at 0 and 4 weeks of feeding with supplemented foods. 
Hypercholesterolemic control (HC), -glucan containing food (BGF), water-soluble polysaccharides 
containing food (WPF), ergosterol containing food (EGF), and mixture containing food (MIF). Values are 
expressed as mean ± SEM of eight mice per group. *P<0.05 vs. HC. 
 Plasma triglycerides levels showed no differences between HC and mice fed mushroom 
foods at the end of the dietary period (HC, BGF, WPF, EGF and MIF: 0.43 ± 0.03, 0.49 ± 0.04, 0.44 
± 0.01, 0.39 ± 0.03, and 0.38 ± 0.03 mmol/l, respectively). 
Effect of mushroom foods on cholesterol excretion 
Before the experimental feeding period no cholesterol was detected in mice feces 
whereas at the end of the experiments, WPF and MIF groups showed a significant reduction 
compared with HC (Table 2). BGF and EGF groups showed no significant differences with respect 
HC. MIF group also showed a significant reduction with respect BGF and EGF groups. 
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Table 2. Fecal cholesterol concentrations in mice fed supplemented foods for 4 weeks. 
 
Ergosterol was not detected in the faces neither at the beginning or after 4 weeks in mice 
fed BGF or WPF as expected. However, it was also not found at significant levels in mice fed EGF 
food and only traces in some samples of mice fed MIF foods. 
Effects of mushroom foods on Npc1l1, Abcg5, and Abcg8 gene expression 
To examine responses of major tissues involved in cholesterol homeostasis after the 
different diets, the mRNA expression levels of cholesterol-related genes were studied in jejunum, 
liver and cecum using low density arrays. No significant differences were observed at 
transcriptional level of genes involved in the cholesterol biosynthesis such as Hmgcr, Fdft1 or in 
those related to cholesterol transport (Ldlr), to the maintenance of cholesterol homeostasis (such 
as Nr1h3 (Lxr), Nr1h4 (Fxr), Srebf1/2) or to the cholesterol incorporation into the blood circulation 
(Apob, Abca1). However, changes in cholesterol absorption, cholesterol efflux and biliary 
cholesterol excretion were noticed since consumption of supplemented foods produced 
significant changes in the expression of Npc1l1 gene and ABC transporters (Abcg5/8) in jejunum, 
liver, and cecum although the intensity of these changes was tissue dependent. Compared with 
HC, feeding BGF and MIF significantly increased expression levels of Npc1l1 and Abcg5 genes 
in the jejunum with a higher regulation on Abcg5, while no changes of Abcg8 gene were observed 
(Figure 2). WPF and EGF did not produce changes on the expression of Npc1l1, Abcg5 and 
Abcg8 genes in jejunum. 
 Diet group 
 HC BGF WPF EGF MIF 
Time on diet (mg cholesterol/g feces) 
0 weeks ND ND ND ND ND 
2 weeks 43.56 ± 4.28 58.98 ± 8.13* 46.92 ± 9.95 51.76 ± 18.49 44.91 ± 0.96 
4 weeks 59.53 ± 2.27 54.87 ± 2.43 46.18 ± 2.55* 48.99 ± 3.07* 33.01 ± 0.16*,#,§ 
HC: hypercholesterolemic control; BGF: -glucan containing food; WPF: water-soluble polysaccharides containing food; EGF: ergosterol containing 
food; MIF: mixture containing food; ND: no detected. Values are expressed as means ± SEM for eight mice per group. *P<0.05 vs. HC, #P<0.05 vs. 
BGF, §P<0.05 vs. EGF. 
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In liver, Npc1l1 gene expression was significantly increased by BGF and MIF as 
compared with HC, whereas expression of Abcg5 and Abcg8 genes were not modified by those 
foods. 
EGF did not induce any transcriptional answer in the jejunum or liver but in cecum, it 
stimulated a significant overexpression of Abcg5 and Abcg8 genes while MIF induced a 
significant down-regulation on Npc1l1 gene in cecum. BGF and WPF did not induce significant 
changes on gene expression of Npc1l1, Abcg5 and Abcg8 genes. 
 
                   Npc1l1        Abcg5        Abcg8                    Npc1l1        Abcg5         Abcg8                  Npc1l1         Abcg5        Abcg8  
Figure 12. Effects of supplemented foods on Npc1l1, Abcg5, and Abcg8 gene expression in jejunum, liver, 
and cecum. Mice were fed each diet for 4 weeks and thereafter, mRNA expression levels were determined 
using low-density arrays. Data are relative to the hypercholesterolemic control (HC) and presented as mean 
± SEM of three mice per group. *P<0.05 vs. HC. See legend of groups in Figure 1. 
 
Discussion 
Diets supplemented with cholesterol and cholic acid facilitates cholesterol absorption 
resulting in increased plasma cholesterol [36]. However, when mice were given these high 
cholesterol and cholic diets including specific foods supplemented with several mushroom 
extracts a notable decrease in plasma cholesterol as compared with controls was recorded mainly 
due to a higher LDL reduction than HDL reduction. The food matrix enriched with β-glucans (BGF), 
was probably the most beneficial of the 4 tested food formulations since it induced a significant 
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reduction of cholesterol and LDL with respect to controls and no changes of HDL compared with 
its baseline levels. The fungal β-glucans included in the BGF are considered as dietary fiber (DF) 
because with their β-(1→3) and β-(1→3),(1→6) linkages generate complex polymers that 
cannot be digested and previous in vitro studies indicated that they could scavenge bile acids 
during digestion [20] suggesting that these properties might contribute to the observed 
hypocholesterolemic activity. Indeed significantly higher cholesterol excretion was observed after 
only 2 weeks BGF supplementation compare to HC controls, although this effect was not kept until 
the end of the feeding period. Dietary fiber extracts obtained from other mushroom strains such 
as Agaricus bisporus, Grifola frondosa, and Flammulina velutipes were also able of lowering LDL 
[6, 37] although, DF fractions from L. edodes and A. bisporus also induced a significant HDL 
reduction. However, these extracts were given to rats fed a cholesterol-free diet thus, the results 
obtained using BGF might suggest that apparently fungal DF fractions could even exert their 
beneficial influence when unhealthy diets are followed (high-cholesterol diet). But, a previous 
report indicated that when an alkali-insoluble β-glucan extract obtained from Pleurotus ostreatus 
was administrated concomitant with a cholesterol-enriched (0.3%) diet, no cholesterol lowering 
effect was observed [38]. Perhaps, the higher isolation degree of the specific polysaccharide 
(higher than BGF and those previously reported DF extracts) might explain its lack of activity 
because when fed the complete mushroom powder from which the purified extract was obtained, 
cholesterol levels were reduced [38]. 
Likewise, the consumption of WPF also induced cholesterol and LDL levels significantly 
reduced but taking into account its effect on HDL, which reached levels below baseline levels, it 
seems less beneficial than BGF. This extract contained water soluble polysaccharides, such as 
glucans and fucomannogalactans with the ability of inhibiting the HMGCR (3-hydroxy-3-methyl-
glutaryl-Co A reductase) in vitro and eritadenine [29]. The ability of the small alkaloid to decrease 
levels of LDL and HDL was associated with modifications in hepatic phospholipid metabolism 
[10]. Moreover, ergosterol and β-glucan-enriched extracts were also able of reducing hepatic 
triglyceride levels in mice [33]. Therefore, the observed results might be partially due to 
modifications on the lipid metabolism in liver in combination with the inhibition of the HMGCR if 
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the water-soluble polysaccharides (or their degradation products) were also able of inhibiting the 
enzyme in vivo. In fact, the reduction in the excreted cholesterol that was noticed in this samples 
could reinforce this hypothesis since this observation suggest that the cholesterol-lowering effect 
of the supplemented food is not mediated via inhibition of intestinal cholesterol absorption or 
enhanced biliary cholesterol excretion. 
The ergosterol enriched food (EGF) trended to reduce cholesterol, HDL and LDL but 
these changes did not reach statistical significance. Previous studies carried out using female 
hamster rats indicated that ergosterol-containing extracts obtained from Pleurotus citrinopileatus 
lowered cholesterol but increased HDL. Differences between results could be, despite differences 
in extract composition, due to the different experimental settings since in that case 
hypercholesterolemia was firstly induced in rats and then treated with the extract [8]. Significant 
cholesterol reduction was also observed in another study using apoE (-/-) mice fed a normal diet 
containing ergosterol [39]. Compared to phytosterols, 2% supplementations were needed to 
observe a slight cholesterol decrease in C57BL/6J mice fed a Western diet for 4 weeks [40] while 
apparently 0.44% fungal sterols were also able of stimulate a similar reduction. Perhaps this low 
concentration also explains their absence in the feces. The traces found in MIF foods could be 
due to certain scavenging degree due to the presence of β-glucans in the same food matrix [18]. 
The MIF containing a mix of the 3 mushroom extracts lowered cholesterol without 
significant reduction of HDL and LDL. The observed effects were not quantitatively higher than 
those induced by each individually administrated food and therefore, no synergy was observed. 
Its biochemical parameters (and gene expression data, see later) were more similar to BGF than 
to the others, which it seems reasonable taking into account that the β-glucan-enriched extract 
was the extract with the highest concentration in MIF. 
The cholesterol-lowering effects observed after administration of supplemented foods 
did not correlated with changes in the expression of cholesterol-related genes. Genes were 
selected taking into account that cholesterol homeostasis is a highly regulated balance of dietary 
cholesterol absorption, biliary excretion, and de novo synthesis. Concerning cholesterol 
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absorption, which occurs in jejunum both in humans and mice, Npc1l1 [12], Abcg5 and Abcg8 
genes [14] play a key role. Intestinal expression of Npc1l1 is down regulated by diets containing 
high levels of cholesterol [41].  Thus, the overexpression of the Npc1l1 gene noticed in the jejunum 
of mice fed BGF or MIF might indicate that higher levels of Npc1l1 mRNAs than the HC are found 
in this tissue as a response to the noticeable lower cholesterol levels in serum. The cholesterol 
levels in serum are lower so more Npc1l1 protein can be synthesized to absorb it.  
Beside down-regulation of Npc1l1, inhibition of cholesterol absorption can also take 
place by up-regulation of intestinal Abcg5/8 [15]. Administration of BGF and MIF supplemented 
foods significantly increased Abcg5 mRNA levels in the intestine while Abcg8 mRNA levels and 
Lxr (liver X receptor), a transcription factor regulating ABCG5 and ABCG8 genes [42], remained 
unchanged (data not shown). Thus, it seems unlikely that the observed over-expression is of 
relevance for the cholesterol efflux mechanism or the hypocholesterolemic effect of these foods 
although, the possibility of post-transcriptional or activity regulation mechanisms should not be 
excluded. Moreover, inhibition of cholesterol absorption is associated with increased fecal 
cholesterol levels [43] but no changes or decrease in fecal cholesterol levels was found in mice 
fed supplemented foods as compared with controls. Similar transcriptional responses were also 
recorded in mice fed a phytosterol enriched diet where intestinal overexpression of Npc1l1, Abcg5 
and Abcg8 was observed concomitant with a hypocholesterolemic effect indicating that the 
inhibition of cholesterol absorption by phytosterols was not mediated via transcriptional changes 
of these genes [40]. In other study, reduction of cholesterol absorption also did not correlate with 
transcriptional changes of Npc1l1, Abcg5 or Abcg8 in jejunum of mice fed a phytosterol enriched 
diet since no significant differences compare to control were observed after the dietary period 
[44]. If the cholesterol absorption pathway was not transcriptionally modulated, the supplemented 
foods could influence the endogenous cholesterol biosynthetic pathway. In fact that was the 
response that could be expected for the mice supplemented with WPF because of its HMGCR 
inhibitors content. However, no significant changes at the transcriptional level were found for 
genes such as Hmgcr, Fdft1, Srebf1/2 etc. confirming previous in vitro studies using Caco2 cell 
cultures [29] where no significant modulation of cholesterol-related genes was found for water-
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soluble extracts similar to the one included in WPF. These results suggested again that the 
modulation of cholesterol metabolism induced by supplemented foods might took place via post-
transcriptional mechanisms. 
The balance between hepatic transcriptional regulation of NPC1L1, and ABCG5/8 genes 
is involved in the cholesterol excretion into bile. Taking into account Npc1l1 is almost not 
expressed in mouse liver [12] it is noticeable the marked enhancement of Npc1l1 expression in 
liver of mice fed BGF and MIF supplemented foods. Hepatic overexpression of Npc1l1 markedly 
decreases biliary cholesterol concentration in transgenic mice expressing human Npc1l1 in liver 
[45, 46] which in turn decreases fecal cholesterol levels and increases plasma cholesterol. Lower 
fecal cholesterol excretion was recorded in mice fed the supplemented foods (after 4 weeks) than 
the HC control suggesting a lower biliary cholesterol concentration associated to their increased 
hepatic Npc1l1 mRNA levels. However, mice fed WPF or EGF also showed decreased feces 
cholesterol levels even though their no effect on hepatic Npc1l1 expression. On the other hand, 
decreased instead of increased plasma cholesterol levels were observed in mice fed 
supplemented foods. Therefore, no correlation between hepatic Npc1l1 gene expression and 
biliary and plasma cholesterol levels could be established. 
The amount of cholesterol that circulates in the plasma as lipoproteins can be affected 
by the balance of cholesterol metabolism within and between the intestines and liver. Lowering 
LDL by ezetimibe has been proven to be associated with increase of hepatic LDLR expression 
[13]. Ezetimibe inhibits intestinal cholesterol absorption which in turn leads to a reduced amount 
of lipoprotein cholesterol circulated to the liver. The reduction of cholesterol delivery induces an 
up-regulation of LDLR in the liver and as a consequence, a reduction of plasma LDL levels [47]. 
However, hepatic Ldlr mRNA levels in mice fed supplemented foods were not different than HC 
control (data not shown) indicating that the plasmatic LDL decrease was not related to 
transcriptional changes at the LDLR. Hepatic Ldlr up-regulation was also noticed after 
administration of dietary fiber extracts from A. bisporus or Flammulina velutipes to 
normocholesterolemic rats [6, 37] but it was not significant for the fiber extracts from other 
mushrooms such as L. edodes and Grifola frondosa. LDLR up-regulation was also found in Caco2 
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and HepG2 cell cultures after administration of an ergosterol-enriched extract but in vivo it was 
unable of reproducing the observed modulation [33]. 
Hypocholesterolemic effect as a secondary reaction of microbial fermentation of oat β-
glucans has also been proposed as β-glucans can be transformed into short-chain fatty acids 
(SCFAs) in the colon [48, 49] and they might lower plasma cholesterol levels by inhibiting hepatic 
cholesterol synthesis in humans [50, 51] and rats [52]. This inhibition was observed at enzymatic 
level instead of transcriptional level as some of the generated SCFAs were able of acting as 
competitive inhibitors of mevalonate [52]. This observation is in line with the results found for the 
BGF and MIF foods which β-glucans could exert their hypocholesterolemic effect via post-
transcriptional modifications rather than by modifying the mRNAs levels of genes involved in the 
synthesis of cholesterol since no different transcriptional profiles were found compare to HC 
controls. 
The cholesterol-lowering effect of ergosterol has been previously demonstrated in 
hamster rats [8], rat liver microsomes [53] and mice [54]. In the latter study, an ergosterol 
derivative ((22E)-ergost-22-ene-1,3-diol) but not ergosterol, was found to be a potent agonist for 
LXR and inhibited intestinal cholesterol absorption by up-regulation of Abcg5 and Abcg8 genes 
in the small intestine but not in liver of mice. EGF also induced overexpression of Abcg5 and 
Abcg8 in cecum but not in the small intestine or liver. Moreover, a significant down-regulation of 
the Npc1L1 was observed also in cecum for the MIF, perhaps as combination of the tendency 
observed for the 2 extracts containing polysaccharides (BGF and WPF). More studies are needed 
in order to assess whether these transcriptional changes might be involved in cholesterol 
absorption or in other processes. 
Conclusions 
A considered unhealthy food matrix such as lard (because of its high cholesterol and fat 
contents) can be functionalized with specific mushroom extracts to generate food products 
showing hypocholesterolemic properties. They all similarly modified the biochemical cholesterol-
related parameters despite their differences in their compositions suggesting that probably 
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several mechanisms are involved. Effects appeared not to be due to inhibition of intestinal 
cholesterol absorption or increase of cholesterol excretion through feces or into bile. The ability of 
β-glucans to bind to bile acids, preventing their entry into blood and forcing the cholesterol 
transformation into bile acids to maintain the levels needed for digestion [19] might not be the in 
vivo mechanism of action for fungal β-glucans extracts. The ability of sterols for competing and 
displacing cholesterol from dietary mixed micelles seemed not to be the main mechanism for 
fungal sterols. Thus, the hypocholesterolemic effect might be more related to the inhibition of the 
cholesterol biosynthetic pathway (although via post-translational changes) perhaps by the 
generation of SCFAs (from β-glucans) or other compounds (from water-soluble polysaccharides 
or sterols) acting as inhibitors of enzymes involved in the pathway. Nevertheless, the cholesterol-
lowering effect was independent of transcriptional changes in Npc1l1 or ABC transporters as well 
as in other genes involved in its regulation, biosynthesis, absorption, processing or transport. 
Thus, the prepared functional foods may be useful in limiting hypercholesterolemia under a high-
cholesterol diet. Furthermore, they could be a source for the development of novel functional foods 
although further studies to determine mechanisms of action are needed. 
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The following conclusions can be drawn from the obtained results concerning the 
different hypocholesterolemic compounds obtained from edible mushrooms. They have been 
organized as responses to each of the initially proposed objectives. 
Objective 1. Evaluation of mushrooms polysaccharides as compounds able of impairing 
exogenous cholesterol absorption. 
- The amount of total β-glucans in mushroom fruiting bodies is specie-dependent. They also 
showed different structural conformations and degree of branching (ratio β-(1→3) vs β-
(1→3),(1→6)). 
 
- Environmentally friendly technologies (PWE) can be used to extract polysaccharide-enriched 
fractions from L. edodes, P.ostreatus and A. bisporus. Extracts contents differed depending 
on the selected extraction parameters and specie but in general, they included mainly β-
glucans, chitins (also chitooligosaccharides) and α-glucans. 
 
- PWE obtained extracts and fractions obtained by standardized methods showed similar bile 
acids scavenging capacities during an in vitro digestion model. They showed a slightly lower 
activity than β-glucans from marketed cereals products claiming cholesterol lowering 
properties.  
 
- The digested fractions of L. edodes, A. bisporus and P. ostreatus induced on Caco2 cultures 
different short (1 h) and long (24 h) transcriptomic responses of genes involved in the 
cholesterol metabolism depending on the specie.  
 
- No significant hypocholesterolemic effect of P. ostreatus fraction was noticed in mice serum 
when administrated together with a high-cholesterol diet using two experimental settings. 
However, reduction of hepatic total triglycerides were recorded concomitant with down-
regulation of Dgat1 mRNA. Modulation of other genes was similar to simvastatin or ezetimibe 
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therefore, the lack of effect in serum could be because higher doses are needed when 
hypercholesterolemic models are used compared with normocholesterolemic mice.  
Objective 2. Evaluation of fungal sterols as compounds able of impairing exogenous cholesterol 
absorption. 
- Ergosterol was present in all the mushrooms (around a 80% of sterols) together with ergosta-
7,22-dienol, ergosta 5,7-dienol and fungisterol but at different concentrations depending on 
the specie considered. 
 
- Within the same strain (A. bisporus), sterol levels were modulated depending on their spawn 
variety, flush, casing soil composition, developmental stage and tissue.  
 
- PLE and SFE could be used to obtain fungal sterols-enriched extracts from fruiting bodies and 
by-products with recovery rates of respectively 5-12% and 30-50%. The use of 10% ethanol 
as co-solvent in SFE extractions was detrimental decreasing 20-30% the sterol yield 
depending of selected conditions. 
 
- Ergosterol (49%) and SFE-extracts (67%) were able of displacing cholesterol from DMMs 
isolated after an in vitro digestion process. They were more effective than β-sitosterol (47%). 
When sterols were digested in the presence of fungal β-glucans the cholesterol displacement 
from DMMs was even larger. 
 
- DMM fraction generated after digestion of the SFE-extract induced up-regulation of LDLR 
mRNA expression Caco2. The bioavailable fraction obtained after transport experiments from 
that sample also stimulated LDLR transcription in HepG2 and modulated a few more genes 
related to the cholesterol metabolism. 
 
- The atherogenic index TC/HDL was significantly lower in hypercholesterolemic mice 
administrated the SFE extract than hypercholesterolemic controls due to increased HDL values 
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but no significant HDL/LDL reduction was recorded. However, down-regulation of two 
important genes involved in the regulation of cholesterol homeostasis (Srebf2 and Nr1h4 
(FXR)) was observed similarly for SFE extracts, ergosterol and two hypocholesterolemic drugs 
(simvastatin and enzetimibe). Therefore, the lack of significance in the biochemical parameters 
might be due to the low sterol concentration utilized. 
Objective 3. Evaluation of mushroom extracts as pancreatic lipase inhibitors influencing diet lipid 
absoption. 
- Soli-liquid extracts from several mushrooms species showed PL inhibitory activity (up to 21% 
inhibition) using an in vitro enzymatic test. Except for some species, the methanol:water (1:1, 
v/v) extracts were more effective than others obtained only with methanol. 
 
- The attempt to extract PL inhibitory compounds from Pleurotus eryngii with PLE using different 
solvents and temperatures was unsuccessful since none of the generated extracts showed 
significant inhibitory activity. 
 
- When the extracts of mushrooms showing higher PL inhibitory activity there tested using an in 
vitro digestion model (simulating physiological conditions) no inhibition was noticed indicating 
that the results obtained using the enzymatic test might not have in vivo relevance. 
Objective 4. Evaluation of mushroom extracts with HMGCR inhibitory activity able of impairing 
endogenous cholesterol biosynthesis.  
- The water extracts from several mushrooms species showed higher HMGCR inhibitory 
capacity (up to 80% inhibition) than the methanol:water (1:1, v/v) extracts except for a few 
strains. Differences were also found between commercial varieties within the same strain. 
However, the observed inhibitory activity was not due to lovastatin or any other natural statin. 
 
Conclusions/Conclusiones 
 
416 
 
- HMGCR inhibitorory fractions could be extracted with PLE and SFE technologies from L. 
edodes , P. ostreatus and A. bisporus taking into consideration that increasing of temperature 
is detrimental since the inhibitors were thermolabile. 
 
- The compounds responsibles for the HMGCR inhibitory activity were different water soluble 
polysaccharides depending on whether they were extracted from P. ostreatus, L. edodes or 
A. biporus. The inhibitory extracts isolated from P. ostreatus and L. edodes, contained both α- 
and β-glucans and respectively mannogalactans or fucomannogalactans.  
 
- Fragments derived from the polysaccharides retained their inhibitory activity down to certain 
size being L. edodes fractions the smaller (1KDa). The β-(1→3)-glucans from P. ostreatus 
partially passed through enterocitic barrier (7-17%) in Caco2 transport experiments. L. edodes 
polysaccharides did not influence Caco2 gene expression after in vitro digestion but its 
bioavailable fraction activated in HepG2 a retarded transcriptomic response similar to 
intracellular low-cholesterol conditions.   
 
- No significant differences were found in the cholesterol-related biochemical parameters in any 
of the two mice models supplemented with L. edodes water extracts compared with controls. 
The induced modulation affected to some genes belonging to different metabolic pathways 
suggesting that the transcriptomic response was due to indirect influences. Nevertheless, 
modulation for certain genes, i.e. Dgat1 in liver, was similar to simvastatin suggesting that 
higher extract doses might be needed to achieve significance in its hypocholesterolemic 
effect.   
Objective 5. Evaluation of the hypocholesterolemic effect of a food matrix supplemented with 
specific mushroms extracts using animal trials. 
- Administration of lard supplemented with β-glucans (2.77%), sterols (0.44%), water soluble 
fractions (1.23%) or a mixture of the extracts to mice simultaneously fed a high-cholesterol diet 
reduced cholesterol-related serum parameters compared to controls being the β-glucan 
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extract the most effective because it reduced 34% LDL but not HDL levels. No positive 
synergies were noticed in the mixture. 
 
- Modulation of the expression of cholesterol-related genes in mice administrated the 
supplemented food products was completely different than when direct administration of the 
extracts was carried out. The noticed cholesterol-lowering effects were independent of 
Niemann-Pick C1-like 1 protein and ABC sterol transporters gene expression reinforcing the 
premise that the different hypocholesterolemic mechanisms of the mushroom extrats might be 
mainly post-transcriptional being the observed mRNA modulations consecuences of indirect 
effects.  
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A continuación se enumeran las conclusiones más relevantes extraídas del estudio de 
compuestos hipocolesterolemicos de origen fúngico. Dichas conclusiones han sido organizadas 
siguiendo los objetivos inicialmente planteados en este trabajo. 
Objetivo 1. Evaluación de polisacáridos fúngicos como compuestos capaces de impedir la 
absorción de colesterol exógeno.   
- El contenido en β-glucanos totales en los cuerpos fructíferos de hongos es dependiente de 
la especie, mostrando variadas conformaciones estructurales, así como diferentes patrones 
de ramificación (ratio β-(1→3) vs β-(1→3),(1→6)). 
 
- Las tecnologías respetuosas con el medio ambiente, como las extracciones con agua 
presurizada (PWE), son de utilidad para la extracción de fracciones ricas en polisacáridos de 
L. edodes, P.ostreatus y A. bisporus. El contenido de dichos extractos depende tanto de la 
especie como de los parámetros de extracción seleccionados; sin embargo, en general, todo 
ellos incluyen mayoritariamente  β-glucanos, quitinas (así como quito-oligosacáridos) y α-
glucanos.  
 
- Las fracciones obtenidas mediante el empleo de métodos estandarizados y avanzados de 
extracción (i.e. PWE), muestran capacidades similares en cuanto a la captación de ácidos 
biliares durante su digestión in vitro. La actividad de dichos extractos es ligeramente menor 
que la mostrada por β-glucanos comerciales, obtenidos de cereales. y  que alegan ser 
capaces de disminuir los niveles plasmáticos de colesterol. 
 
- La respuesta en la transcripción de genes involucrados en el metabolismo del colesterol de 
células Caco2 tratadas a corto y largo plazo (1 y 24 h) con fracciones digeridas de L. edodes, 
A. bisporus  y P. ostreatus, depende de la especie fúngica utilizada. 
 
- En las condiciones descritas en el presente trabajo, los tratamientos con extractos de P. 
ostreatus administrados, junto a una dieta hipercolesterolémica, no mostraron efecto 
Conclusions/Conclusiones 
 
420 
 
hipocolesterolémico alguno. No obstante, se observó una reducción en los niveles totales de 
triglicéridos en hígado junto con la disminución en la transcripción del gen Dgat1. La 
modulación de otros genes bajo estudio presentó patrones similares a los observados para 
los tratamientos con simvastatina y ezetemiba. Dicha falta de efecto fisiológico queda probada 
en las condiciones del estudio, no pudiendo descartarse que sean necesarias dosis más altas 
cuando se utilizan modelos hipercolesterolémicos, en comparación con ratones 
normocolesterolémicos 
Objetivo 2. Evaluación de esteroles fúngicos como compuestos capaces de impedir la absorción 
de colesterol exógeno. 
- En todas las especies fúngicas estudiadas se detecta ergosterol, siendo este el esterol 
mayoritario en todas ellas; además se encuentran otros como el ergosta-7,22-dienol, ergosta 
5,7-dienol y fungisterol, variando sus concentraciones con las especie analizada. 
 
- La cantidad de esteroles presentes en una especie determinada (v.gr. A bisporus) está sujeta 
a la fenología y al fenotipo, i.e. variedad de las semillas, florada, composición de la tierra de 
cobertura, estado del desarrollo o tipo de tejido, entre otros. 
 
- Determinadas tecnologías de extracción, como PLE y SFE, resultan efectivas para la 
obtención de extractos ricos en esteroles fúngicos, cuando se utilizan como material de 
partida tanto el cuerpo fructífero de los hongos como sus productos de deshecho; en estos 
casos se alcanzan tasas de recuperación de 5-12% y 30-50% respectivamente. Asimismo, el 
uso de etanol (10%) como co-solvente, en las extracciones SFE, disminuye la tasa de 
recuperación de esteroles entre un 20-30% dependiendo de las condiciones seleccionadas. 
 
- Tanto el ergosterol (49%) como los extractos SFE (67%) son capaces de desplazar al 
colesterol de manera más efectiva que el β-sitosterol (47%) en las micelas mixtas de digestión 
(DMMs), aisladas después de un proceso de digestión in vitro. Dicha capacidad es aún mayor 
cuando los esteroles son digeridos en presencia de  β-glucanos de origen fúngico. 
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- Las DMMs obtenidas tras la digestión de los extractos obtenidos mediante SFE estimulan la 
expresión génica de LDLR en células Caco2. Igualmente, se observa un efecto similar en 
células HepG2, como respuesta a la presencia de la fracción biodisponible procedente de 
las células Caco2. 
 
- Los niveles séricos de LDL y HDL en ratones hipercolesterolémicos, alimentados con una 
dieta suplementada con extractos obtenidos mediante SFE, se mantienen o aumentan 
respectivamente en comparación con el control de hipercolesterolemia inducida; lo que se 
traduce en un índice aterogénico TC/HDL significativamente menor que el observado en el 
control de hipercolesterolemia inducida. En contraposición, no se observó una reducción 
significativa en el ratio HDL/LDL registrado después del tratamiento con dicho extracto.  
 
- Los extractos obtenidos mediante SFE, el ergosterol y dos fármacos hipocolesterolemiantes 
(simvastatina y ezetimiba) deprimen, de manera similar, la expresión génica de Srebf2 y Nr1h4 
(FXR).  
Objetivo 3. Evaluación de la influencia de extractos fúngicos en la absorción de lípidos dietéticos 
por su potencial inhibidor de la lipasa pancreática. 
- Extractos sólido-líquido de varias especies de hongos muestran inhibición de la enzima PL 
(lipasa pancreática) en su análisis  in vitro con test enzimáticos (hasta un 21% de inhibición). 
Exceptuando algunas especies, los extractos obtenidos con la mezcla de disolventes 
metanol:agua (1:1, v/v) resultan más efectivos que aquellos extraídos sólo con metanol. 
- El empleo de PLE para la obtención de compuestos inhibidores de Pleurotus eryngii no es la 
técnica más adecuada ya que ninguna de las fracciones obtenidas con diferentes 
disolventes a diversas temperaturas muestra una actividad inhibidora relevante. 
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- La actividad inhibidora de la Lipasa Pancreática, mostrada por los extractos fúngicos 
estudiados, desaparece tras someter estos extractos a una simulación in vitro del proceso 
de digestión fisiológica; de lo que puede inferirse su irrelevancia a nivel fisiológico. 
 
Objetivo 4. Evaluación de extractos fúngicos con actividad inhibidora de la HMGCR capces de 
impedir la biosíntesis endógena de colesterol.  
- Los extractos acuosos de varias especies de hongos presentan una elevada actividad 
inhibidora de la enzima HMGCR, llegando ésta hasta un 80% en condiciones in vitro. 
Asimismo, y en general, los extractos acuosos mostraron mayor actividad inhibidora que los 
extractos obtenidos con mezclas binarias metano-agua, en proporción 1:1 (v:v). 
 
- Los estudios realizados mediante LC-MS descartan que la actividad inhibidora de la enzima 
HMGCR sea debida a estructuras químicas con naturaleza de estatinas. 
 
- Las tecnologías de extracción PLE y SFE resultan adecuadas para la obtención de fracciones 
inhibidoras de la actividad HMGCR a partir de las especies L. edodes , P. ostreatus y A. 
bisporus. Asimismo, los extractos obtenidos a temperaturas altas mostraron menor actividad 
inhibidora que los obtenidos a temperaturas menores. 
 
- Los estudios encaminados a dilucidar la naturaleza de los compoeustos responsables de la 
actividad inhibiora de la HMGCR obtenidos a partir de P. ostreatus, L. edodes o A. biporus, 
permiten concluir que éstos se corresponden con polisacáridos solubles en agua y que estos 
polisacáidos son característicos de cada especie. En particular, para los aislados de P. 
ostreatus y L. edodes se pudo concluir que contienen principalmente α- y β-glucanos, junto 
con manogalactanos y fucomanogalactanos respectivamente. 
- De los procesos de digestión química de polisacáridos de L edodes, se concluye que los 
fragmentos derivados de dichos polisacaridos mantienen su actividad inhibidora hasta un 
determinado peso molecular, desapareciendo la actividad inhibidora para fragmentos 
inferiores a 1 kDa. 
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- Parte de los β-(1→3)-glucanos de P. ostreatus son capaces de atravesar la barrera entérica 
(entre un 7 y un 17%, de los inicales) en experimentos de transporte de membrana con células 
Caco2. Por otra parte, los polisacárdos de L. edodes digeridos mediante un modelo de 
digestion in vitro no modifican el patrón normal de expresión génica de las celulas Caco2. Sin 
embargo, la fracción biodisponible es capaz de generar a largo plazo una respuesta 
trasncriptomica en HepG2 similar a la registrada en condiciones de baja presencia de 
colesterol. 
 
- Los estudios realizados con ratones alimentados con dietas suplementadas, con extractos 
acuosos de L. edodes, no mostraron diferencias significativas, respecto al control, en los 
marcadores bioquímicos relacionados con la hipercolesterolemia. Asimismo, el patrón de 
expresión génica afecta a genes involucrados en varias rutas metabólicas, lo que sugiere un 
efecto pleiotrópico. No obstante, el comportamiento individual de algunos genes, i.e. Dgat1 
en hígado, es consistente con el observado en tratamientos con simvastatina. Asi, un patrón 
transcriptómico acorde con el del fármaco, pero sin manifestación clínica, podría sugerir que 
las dosis utilizadas han sido inferiores a las necesarias para obtener el efecto 
hipocolesterolémico buscado. 
Objectivo 5. Evaluación del efecto hiocolesterolemico de una matriz alimentaria suplementada 
con extractos especificos de hognos mediante el uso de ensayos con animales. 
- La administración de manteca de cerdo suplementada con β-glucanos (2,77 %), esteroles 
(0.44 %), fracciones solubles en agua (1,23 %) o su mezcla, a ratones alimentados con una 
dieta alta en colesterol, reduce los marcadores séricos relacionados con el colesterol en 
comparación con los controles. La alimentación con extractos que contienen β-glucanos 
resultó ser la más eficaz al reducir en un 34% los niveles de LDL manteniendo inalteradas 
las lipoproteínas de elevada densidad (HDL). Por el contrario, no se han detectado  sinergias 
positivas en el grupo de estudio alimentado con la mezcla de extractos. 
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- La modulación en  la expresión de genes relacionados con el metabolismo de colesterol, 
observada en ratones alimentados con productos alimenticios suplementados, sigue un 
patrón totalmente diferente al obtenido tras la administración directa de los extractos. Los 
efectos en la reducción de colesterol son independientes de la expresión génica de los 
transportadores Niemann-Pick C1-like 1 y ABC. Estos resultados descartan un mecanismo 
de regulación transcripcional, en cuanto a transporte del colesterol en el modelo 
experimental estudiado, del efecto hipocolesterolemiante observado, no pudiendo 
descartarse mecanismos post-transcripcionales. 
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